Sunday, September 23, 2018

IASLC CT Screening Symposium: Forefront Advances in Lung Cancer Screening
(Ticketed Session)

Topics: Screening and Early Detection
Moderation: J. Field, UK; J. Mulshine, USA

07:00 - 07:30
S01.01 - Breakfast

07:30 - 07:35
S01.02 - Introductions & Welcome

Session I: The Backbone to our Knowledge on Lung Cancer Screening

07:35 - 07:50
S01.04 - Lung Cancer Screening: 1999 to Date - What Have We Learnt?
David Yankelevitz, NY/USA

07:50 - 08:00
S01.05 - Discussion

Session II: Future Integration of Biomarkers in the Selection of High Risk Individuals for Lung Cancer Screening

08:00 - 08:50
S01.07 - The U19 Plans for Integration of Biomarkers into Future Lung Cancer Screening
Rayjean Hung, Canada; Paul Brennan, France; Christopher Amos, USA

08:50 - 09:00
S01.08 - Discussion

Session III: European Strategy for the Implementation of Lung Cancer Screening

09:00 - 09:20
S01.10 - EU Position Statement on Lung Cancer Screening
Matthijs Oudkerk, Netherlands
09:20 - 09:30  S01.11 - Discussion

09:30 - 09:50  S01.12 - Coffee break

Session IV: Lung Cancer Screening Requires Infra-Structural Organisation and an Integrated Smoking Cessation Plan

09:50 - 10:05  S01.14 - Coordination of the Lung Cancer CT Screening Experience
Joelle Fathi, USA

10:05 - 10:20  S01.15 - Integration of Smoking Cessation into Lung Cancer Screening
Kate Brain, UK

10:20 - 10:30  S01.16 - Discussion

10:30 - 11:30  Session V: Panel Discussion: Next Steps for Lung Screening?
Claudia Henschke, NY/USA; Kwun Fong, Australia; Motoyasu Sagawa, Japan; Matthew Callister, UK; Nasser Altorki, USA; Bruce Pyenson, USA; Andrea Borondy Kitts, USA

11:30 - 11:50  S01.18 - IASLC Leads the International Collaboration on Data Sharing (IASLC- ELIC-CCTRR)
John Field, UK; James Mulshine, IL/USA

11:50 - 12:00  S01.19 - Discussion

12:00  S01.20 - Networking Lunch

JCSE01

07:30 - 11:15  Perspectives for Lung Cancer Early Detection
Topics: Screening and Early Detection
Moderation: F. Hirsch, USA; Y.-L. Wu, China; T. Mok, Hong Kong

07:30 - 08:00  JCSE01.01 - Breakfast and Poster Viewing
08:00 - 08:20  JCSE01.02 - Necessity for Early Detection in Lung Cancer and Initial Attempts for Early Detection  
Annette Mclwilliams, Australia

08:20 - 08:40  JCSE01.03 - CT Screening for Early Detection (NLST, UKLS, NELSON, ITALUNG, DANTE, Others)  
Matthijs Oudkerk, Netherlands

08:40 - 09:00  JCSE01.04 - Risk Modeling for the Early Detection of Tin Miner Lung Cancer in China  
You-ting Qiao, China

09:00 - 09:20  JCSE01.05 - Biomarkers and Liquid Biopsy for Early Detection of Lung Cancer  
K C Allen Chan, China

09:20 - 09:40  JCSE01.06 - Incorporating Artificial Intelligence for Early Detection of Lung Cancer  
Jie Hu, China

09:40 - 09:50  JCSE01.07 - Discussion

09:50 - 10:15  JCSE01.08 - Coffee Break and Poster Viewing

10:15 - 10:25  JCSE01.09 - Cluster Trial: Ph2 Biomarker-Integrated Study of Single Agent Alpelisib, Capmatinib, Ceritinib and Binimetinib in advNSCLC  
Yi-long Wu, China

10:25 - 10:35  JCSE01.10 - A Ph3 Study of Niraparib as Maintenance Therapy in 1L Platinum Responsive Extensive Disease Small Cell Lung Cancer Patients  
Shun Lu, China

10:35 - 10:45  JCSE01.11 - Dynamic ctDNA Monitoring Revealed Novel Resistance Mechanisms and Response Predictors of Osimertinib Treatment in East Asian NSCLC Patients  
Jianhua Chang, China

10:45 - 11:00  JCSE01.12 - Discussant Oral Abstracts  
Daniel Tan, Singapore

11:00 - 11:15  JCSE01.13 - Discussant Poster Abstracts  
Bob Li, NY/USA
Poster Abstracts

JCSE01.14 - Effects of Neoadjuvant Chemotherapy on the Expression of Programmed Death Ligand-1 and Tumor Infiltrating Lymphocytes in Lung Cancer Tissues
Xu Wang, China

JCSE01.15 - Molecular Characteristics of ALK Primary Point Mutations Non-Small-Cell Lung Cancer in Chinese Patients
Chunwei Xu, China

JCSE01.16 - Positive Correlation Between Whole Genomic Copy Number Variant Scoring and the Grading System in Lung Non-Mucinous Invasive Adenocarcinoma
Zheng Wang, China

JCSE01.17 - Weekly Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy for IIIA-N2 Lung Squamous Cell Carcinoma: A Prospective Phase II Study
Changli Wang, China

JCSE01.18 - A Multicenter Survey of One Year Survival Among Chinese Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer (CTONG1506)
Qing Zhou, China

JCSE01.19 - ALTER-0303 Study: Tumor Mutation Index (TMI) For Clinical Response to Anlotinib in Advanced NSCLC Patients at 3rd Line
Baohui Han, China

JCSE01.20 - Outcome in Small Cell Lung Cancer Patients with Cerebral Recurrence After Prior Prophylactic Cranial Irradiation
Lei Zhao, China

JCSE01.21 - Different Responses to Osimertinib in Primary and Acquired EGFR T790M-Mutant NSCLC Patients
Shuyuan Wang, China

JCSE01.22 - Differential Molecular Mechanisms Associated with Dramatic and Gradual Progression in NSCLC Patients with Intrathoracic Dissemination
Ying Chen, China

JCSE01.22a - Tislelizumab Combined with Chemotherapy as First-Line Treatment in Chinese Patients with Advanced Lung Cancer
Jie Wang, China

11:15 - 11:15  JCSE01.23 - Closing Remarks
08:00 - 09:30  IASLC Foundation Walk supported by Lung Cancer Canada (Ticketed Event)  Room 201 F

08:00 - 09:00  Registration Opens

09:00 - 10:30  Shotgun Start

10:30 - 12:00  Celebration and Breakfast/Snacks

WS01

08:00 - 11:15  Cancer Genomics Workshop (Ticketed Session)  Room 201 BD

08:00 - 08:15  WS01.01 - Introduction to the Workshop

08:15 - 09:30  WS01.02 - Exercise 1: Cancer Gene Panels: Methods and Application

09:30 - 09:45  WS01.03 - Break

09:45 - 11:00  WS01.04 - Exercise 2: Cancer Gene Panels: Result Interpretation and Clinical Utility

11:00 - 11:15  WS01.05 - Questions/Panel Discussion

WS02

08:00 - 11:15  Mesothelioma Workshop  Room 205 AC

Topics: Mesothelioma

Session 1: Surgery for Mesothelioma
Harvey Pass, NY/USA
08:00 - 08:15  WS02.02 - What Are the Most Important Unmet Needs in the Surgical Management of Mesothelioma?  
Valerie Rusch, NY/USA

08:15 - 08:30  WS02.03 - Who Are the High-Risk Patients for Surgical Failure in Mesothelioma?  
Harvey Pass, NY/USA

08:30 - 08:45  WS02.04 - SMART, Where It Is Going  
Marc De Perrot, Canada

08:45 - 09:00  WS02.05 - Reliability of MM Diagnosis and Role of BAP1 Staining  
Francoise Galateau-Salle, France

09:00 - 09:05  WS02.06 - Q&A

Session 2: Immunotherapy in Mesothelioma  
Paul Baas, Netherlands

09:05 - 09:20  WS02.08 - The Microenvironment and Mesothelioma  
Prasad Adusumilli, NY/USA

09:20 - 09:35  WS02.09 - PDL-1 and Mesothelioma  
Raphael Bueno, MA/USA

09:35 - 09:50  WS02.10 - An Overview of Present and Future Immunotherapy Trials in Mesothelioma: Progress and Problems  
Aaron Mansfield, MN/USA

09:50 - 10:05  WS02.11 - Window of Opportunity Immunotherapy Trials in Mesothelioma: Design and Translation  
Anne Tsao, TX/USA

10:05 - 10:10  WS02.12 - Q&A

Session 3: Transcriptome Changes and Mutations in Mesothelioma - Somatic, Germline, BAP1 and more  
David Jablons, USA
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:10 - 10:25</td>
<td>WS02.14 - BAP1 Mutations: Mechanisms and Significance</td>
<td>Michele Carbone, HI/USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:25 - 10:40</td>
<td>WS02.15 - Novel Approaches for Targeting BAP1</td>
<td>Marjorie Zauderer, NY/USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:40 - 10:55</td>
<td>WS02.16 - Genome-wide Silencing Screen in Mesothelioma Cells Reveals that Loss of Function of BAP1 Induces Chemoresistance to Ribonucleotide Reductase Inhibition: Implication for Therapy</td>
<td>Emanuela Felley-Bosco, Switzerland</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:55 - 11:10</td>
<td>WS02.17 - A Subset of Mesotheliomas with Improved Survival Occurring in Carriers of BAP1 and of other Germline Mutations</td>
<td>Haining Yang, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:10 - 11:15</td>
<td>WS02.18 - Q&amp;A</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**WS03**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 11:30</td>
<td>Endoscopic Diagnosis and Staging of Lung Cancer - Interventional Pulmonology (Hands-On Workshop (Ticketed Session))</td>
<td>Room 205 B&lt;br&gt;Topics: Interventional Diagnostics/Pulmonology</td>
<td></td>
</tr>
<tr>
<td>08:00 - 08:35</td>
<td>WS03.01 - Welcome and Introduction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:35 - 09:10</td>
<td>WS03.02 - EBUS-TBNA - Role in Invasive Mediastinal Staging</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:10 - 09:45</td>
<td>WS03.03 - Combined EBUS/EUS Mediastinal Staging</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:45 - 10:20</td>
<td>WS03.04 - Radial Probe EBUS - Methods and Results</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:20 - 10:55</td>
<td>WS03.05 - Navigational Bronchoscopy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:55 - 11:30</td>
<td>WS03.06 - Hands-On Session on 6 stations</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### WS04

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 08:15</td>
<td>Welcome &amp; Introduction</td>
<td></td>
</tr>
<tr>
<td>08:15 - 08:45</td>
<td>Protein-based Biomarkers as Tools to Support Clinical Decision Making for Lung Cancer Patients with Results from the Laboratory</td>
<td>Rafael Molina, Spain</td>
</tr>
<tr>
<td>08:45 - 09:15</td>
<td>Using Immunohistochemistry in Differential Diagnosis and Predictive Assessment of Lung Cancer</td>
<td>Mark Kockx, Belgium</td>
</tr>
<tr>
<td>09:15 - 09:45</td>
<td>Clinical Utility of Liquid Biopsy to EGFR Mutation Detection in NSCL</td>
<td>Adrian Sacher, Canada</td>
</tr>
<tr>
<td>09:45 - 10:00</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>10:00 - 10:30</td>
<td>Circulating Tumor DNA: Solid Tumor MRD Detection and Potential Clinical Utility</td>
<td>Aadel Chaudhuri, USA</td>
</tr>
<tr>
<td>10:30 - 11:00</td>
<td>University of Missouri’s Experience with the NAVIFY Tumor Board Solution in HemOnc Tumor Board</td>
<td>Richard Hammer, USA</td>
</tr>
<tr>
<td>11:00 - 11:30</td>
<td>Panel Discussion</td>
<td></td>
</tr>
</tbody>
</table>

### YI01

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 08:10</td>
<td>Introduction to the IASLC - Why You Should be a Member</td>
<td>Clarissa Mathias, Brazil</td>
</tr>
<tr>
<td>Time</td>
<td>Topic</td>
<td>Speaker(s)</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>08:10 - 08:20</td>
<td>Planning a Career in Lung Cancer - Clinical Trials</td>
<td>Roy Herbst, CT/USA</td>
</tr>
<tr>
<td>08:20 - 08:30</td>
<td>Planning a Career in Lung Cancer - Science</td>
<td>Yolonda Colson, USA</td>
</tr>
<tr>
<td>08:30 - 08:40</td>
<td>Planning a Career in Lung Cancer - Bench to Beside</td>
<td>Pasi Jänne, MA/USA</td>
</tr>
<tr>
<td>08:40 - 08:50</td>
<td>Planning a Career in Lung Cancer - Education</td>
<td>Barbara Melosky, Canada</td>
</tr>
<tr>
<td>08:50 - 09:00</td>
<td>Community Oncology</td>
<td>Parneet Cheema, Canada</td>
</tr>
<tr>
<td>09:00 - 09:10</td>
<td>Making the Most of your Cooperative Group</td>
<td>Rolf Stahel, Switzerland</td>
</tr>
<tr>
<td>09:10 - 09:30</td>
<td>Panel Discussion</td>
<td></td>
</tr>
<tr>
<td>09:30 - 09:45</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>09:45 - 10:00</td>
<td>Knowing your Statistics</td>
<td>Mary Redman, WA/USA</td>
</tr>
<tr>
<td>10:00 - 10:15</td>
<td>How to get your Paper Published</td>
<td>Alex Adjei, NY/USA</td>
</tr>
<tr>
<td>10:15 - 10:30</td>
<td>Writing a Successful Abstract</td>
<td>Michael Boyer, ACT/Australia</td>
</tr>
<tr>
<td>10:30 - 10:45</td>
<td>How to give a Great Presentation</td>
<td>Tony Mok, Hong Kong</td>
</tr>
<tr>
<td>10:45 - 11:00</td>
<td>How to write a Successful Grant Application</td>
<td>Dean Fennell, UK</td>
</tr>
<tr>
<td>Time</td>
<td>Event Description</td>
<td></td>
</tr>
<tr>
<td>----------</td>
<td>--------------------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>11:00 - 11:15</td>
<td>YI01.15 - Panel Discussion</td>
<td></td>
</tr>
<tr>
<td>11:15 - 11:20</td>
<td>YI01.16 - Young investigator Experience</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fabio Moraes, Brazil</td>
<td></td>
</tr>
<tr>
<td>11:20 - 11:30</td>
<td>YI01.17 - Getting the most out of WCLC 2018</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Andrea Bezjak, ON/Canada; Gail Darling, ON/Canada; Natasha Leighl ON/Canada</td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td>YI01.18 - Close</td>
<td></td>
</tr>
</tbody>
</table>

**ISS01**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:45 - 11:15</td>
<td>Symposium Supported by Takeda: New Insights and Clinical Implications for the Treatment of ALK+ NSCLC</td>
</tr>
<tr>
<td>09:45 - 11:15</td>
<td>New Insights and Clinical Implications for the Treatment of ALK+ NSCLC</td>
</tr>
</tbody>
</table>

**ISS02**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30 - 13:00</td>
<td>Symposium Supported by Incyte: Novel Immunotherapy Strategies in Lung Cancer</td>
</tr>
<tr>
<td>11:30 - 13:00</td>
<td>Novel Immunotherapy Strategies in Lung Cancer</td>
</tr>
</tbody>
</table>

**WS05**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 - 18:00</td>
<td>ITONF Workshop: Excellence in Thoracic Oncology Care</td>
</tr>
<tr>
<td></td>
<td>Topics: Nursing and Allied Professionals</td>
</tr>
<tr>
<td>12:00 - 12:30</td>
<td>WS05.01 - ITONF Membership Meeting &amp; Luncheon</td>
</tr>
<tr>
<td></td>
<td>Melissa Culligan, PA/USA</td>
</tr>
<tr>
<td>12:30 - 13:00</td>
<td>WS05.02 - Keynote Speaker: Lung Cancer and Mesothelioma Nursing Care in Canada</td>
</tr>
<tr>
<td></td>
<td>Massey Nematollahi, Canada</td>
</tr>
<tr>
<td>13:00 - 13:30</td>
<td>WS05.03 - Panel Discussion: Managing Hope and Expectations in Thoracic Oncology</td>
</tr>
<tr>
<td></td>
<td>Maria Guerin, UK; Bethany Taylor, UK; Beth Eaby-Sandy, PA/USA</td>
</tr>
<tr>
<td>Time</td>
<td>Session Title</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>13:30 - 13:50</td>
<td>WS05.04 - Tag, Tweet or Follow: Top Tips for using Social Media in your Clinical Practice</td>
</tr>
<tr>
<td>13:50 - 14:15</td>
<td>WS05.05 - UPDATE: Immunotherapy, Targeted Therapy and Combination Therapy Clinical Trials in Lung Cancer and Mesothelioma</td>
</tr>
<tr>
<td>14:15 - 14:30</td>
<td>WS05.06 - Break</td>
</tr>
<tr>
<td>14:30 - 15:00</td>
<td>WS05.07 - Global Issues in Lung Cancer and Mesothelioma in 2018</td>
</tr>
<tr>
<td>15:00 - 15:45</td>
<td>WS05.08 - UPDATE: Advances in Local Treatments for Lung Cancer and Mesothelioma (Radiation and Surgery)</td>
</tr>
<tr>
<td>15:45 - 16:00</td>
<td>WS05.09 - Break</td>
</tr>
<tr>
<td>16:00 - 16:30</td>
<td>WS05.10 - Nurse-led TeleHealth in Thoracic Oncology</td>
</tr>
<tr>
<td>16:30 - 17:00</td>
<td>WS05.11 - UPDATE: Toxicity Management of Immunotherapy Treatments in Lung Cancer and Mesothelioma</td>
</tr>
<tr>
<td>17:00 - 17:30</td>
<td>WS05.12 - 2017-18 Year in Review: Scientific Poster Session</td>
</tr>
</tbody>
</table>

ISS03

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00 - 14:30</td>
<td>Symposium Supported by Lilly Oncology: Steering Improved Outcomes in Non-driver Mutation Lung Cancer: Progress and Challenges</td>
<td>Room 106</td>
</tr>
<tr>
<td>13:00 - 14:30</td>
<td>Steering Improved Outcomes in Non-driver Mutation Lung Cancer: Progress and Challenges</td>
<td></td>
</tr>
<tr>
<td>Session</td>
<td>Time</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
<td>------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>ISS04</td>
<td>14:30 - 16:00</td>
<td>Symposium Supported by Bristol-Myers Squibb: Refining the Focus in Lung Cancer: New Data and Emerging Biomarkers</td>
</tr>
<tr>
<td></td>
<td>14:30 - 16:00</td>
<td>Refining the Focus in Lung Cancer: New Data and Emerging Biomarkers</td>
</tr>
<tr>
<td>ISS05</td>
<td>16:00 - 17:30</td>
<td>Symposium provided by Oakstone Publishing, LLC and PeerVoice, supported by an educational grant from AstraZeneca: EGFR-Mutant NSCLC: Evolving Treatment Paradigms and Game Changers for Current and Future Front-Line Care</td>
</tr>
<tr>
<td></td>
<td>16:00 - 17:30</td>
<td>EGFR-Mutant NSCLC: Evolving Treatment Paradigms and Game Changers for Current and Future Front-Line Care</td>
</tr>
<tr>
<td>PR01</td>
<td>16:00 - 17:30</td>
<td>Press Conference</td>
</tr>
<tr>
<td></td>
<td>16:00 - 17:30</td>
<td>Press Conference</td>
</tr>
<tr>
<td></td>
<td>17:45 - 18:45</td>
<td>IASLC Foundation Concert (Ticketed Event)</td>
</tr>
<tr>
<td></td>
<td>17:45 - 18:45</td>
<td>IASLC Foundation Concert (Ticketed Event)</td>
</tr>
<tr>
<td>OC01</td>
<td>19:00 - 20:30</td>
<td>Opening Ceremony</td>
</tr>
<tr>
<td></td>
<td>19:00 - 19:10</td>
<td>OC01.01 - Eradicating Lung Cancer</td>
</tr>
<tr>
<td></td>
<td>20:30 - 22:00</td>
<td>Welcome Reception</td>
</tr>
</tbody>
</table>
20:30 - 22:00    Welcome Reception
### Monday, September 24, 2018

#### ISS06

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00 - 08:00</td>
<td>Symposium Supported by Medscape: NTRK Fusions in NSCLC - Practice Changing in 2018 and Beyond?</td>
<td>Room 106</td>
</tr>
<tr>
<td>07:00 - 08:00</td>
<td>NTRK Fusions in NSCLC - Practice Changing in 2018 and Beyond?</td>
<td></td>
</tr>
</tbody>
</table>

#### ISS07

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00 - 08:00</td>
<td>Symposium Supported by Clinical Care Options, LLC: Strategies to Maximize the Clinical Benefit of EGFR TKIs in Advanced NSCLC</td>
<td>Room 107</td>
</tr>
<tr>
<td>07:00 - 08:00</td>
<td>Strategies to Maximize the Clinical Benefit of EGFR TKIs in Advanced NSCLC</td>
<td></td>
</tr>
</tbody>
</table>

#### ISS08

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00 - 08:00</td>
<td>Symposium Supported by Foundation Medicine: Implementing Liquid Biopsies into Clinical Practice: Challenges, Achievements and Progress</td>
<td>Plenary Hall</td>
</tr>
<tr>
<td>07:00 - 08:00</td>
<td>Implementing Liquid Biopsies into Clinical Practice: Challenges, Achievements and Progress</td>
<td></td>
</tr>
</tbody>
</table>

#### MTE01

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00 - 08:00</td>
<td>Preclinical Models of Lung Cancer (Ticketed Session)</td>
<td>Room 206 F</td>
</tr>
<tr>
<td>07:00 - 07:30</td>
<td>MTE01.01 - GEMM of Lung Cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sarah Best, VIC/Australia</td>
<td></td>
</tr>
<tr>
<td>07:30 - 08:00</td>
<td>MTE01.02 - Lung Patient Derived Xenograft and Organoid</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nadeem Moghal, ON/Canada</td>
<td></td>
</tr>
</tbody>
</table>
MTE02

07:00 - 08:00 Update on WHO Classification and Staging of Lung Cancer (Ticketed Session)  
Topics: Pathology  
Room 203 BD

07:00 - 07:30 MTE02.01 - Update on WHO Classification and Staging of Lung Cancer  
Sanja Dacic, PA/USA

07:30 - 08:00 MTE02.02 - Update on WHO Classification and Staging of Lung Cancer  
Teh-Ying Chou, Taiwan

MTE03

07:00 - 08:00 Clinical Trial Design with Novel Lung Cancer Therapy (Ticketed Session)  
Topics: Targeted Therapy  
Room 105

07:00 - 07:30 MTE03.01 - Inclusion/Exclusion Updates (CNS Mets, Multiple Prior Cancers, Organ Dysfunction)  
Peter Ellis, Canada

07:30 - 08:00 MTE03.02 - Novel Trial Design for Precision Medicine  
Fiona Blackhall, UK

MTE04

07:00 - 08:00 Comparison of Various Risk Models (Ticketed Session)  
Topics: Screening and Early Detection  
Room 205 AC

07:00 - 07:30 MTE04.01 - Comparisons of Risk Models  
Christine Berg, USA

07:30 - 08:00 MTE04.02 - Where Should Health Programs Set Threshold for Tailored Screening?  
James Mulshine, IL/USA

MTE05

07:00 - 08:00 Role of Pneumonectomy in N2 Disease (Ticketed Session)  
Topics: Treatment of Locoregional Disease - NSCLC  
Room 202 BD

07:00 - 07:30 MTE05.01 - Role of Pneumonectomy in N2 Disease  
Jessica Donington, NY/USA
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30 - 08:00</td>
<td><strong>MTE05.02</strong> - Role of Pneumonectomy in N2 Disease</td>
<td>Paula Ugalde, QC/Canada</td>
<td></td>
</tr>
<tr>
<td>07:00 - 08:00</td>
<td><strong>MTE06</strong> - Symptom Management in Mesothelioma (Ticketed Session)</td>
<td></td>
<td>Room 206 BD</td>
</tr>
<tr>
<td>07:00 - 07:30</td>
<td><strong>MTE06.01</strong> - Role of Pleurectomy in Palliation of Symptoms</td>
<td>John Edwards, UK</td>
<td></td>
</tr>
<tr>
<td>07:30 - 08:00</td>
<td><strong>MTE06.02</strong> - How to Register Toxicity and Guide Patients</td>
<td>Liz Darlison, UK</td>
<td></td>
</tr>
<tr>
<td>07:00 - 08:00</td>
<td><strong>MTE07</strong> - Management of Pleural Recurrence (Ticketed Session)</td>
<td></td>
<td>Room 201 F</td>
</tr>
<tr>
<td>07:00 - 07:30</td>
<td><strong>MTE07.01</strong> - From Radiation Oncology Perspective</td>
<td>Andreas Rimner, NY/USA</td>
<td></td>
</tr>
<tr>
<td>07:30 - 08:00</td>
<td><strong>MTE07.02</strong> - From Surgical Perspective</td>
<td>Robert Korst, USA</td>
<td></td>
</tr>
<tr>
<td>07:00 - 08:00</td>
<td><strong>MTE08</strong> - Enhancing the Nurse's Role in Tobacco Prevention and Cessation: New Challenges (Ticketed Session)</td>
<td></td>
<td>Room 205 B</td>
</tr>
<tr>
<td>07:00 - 08:00</td>
<td><strong>MTE08.01</strong> - Enhancing the Nurse's Role in Tobacco Prevention and Cessation: New Challenges</td>
<td>Linda Sarna, CA/USA</td>
<td></td>
</tr>
</tbody>
</table>
### MTE09

**07:00 - 08:00**  
*Management of Advanced Wild-Type Lung Cancer in Special Situations (Ticketed Session)*  
Topics: Advanced NSCLC  
*Room 206 AC*

07:00 - 07:30  
**MTE09.01 - Evidence Based Management of the Patient over 80**  
Elisabeth Quoix, France

07:30 - 08:00  
**MTE09.02 - Management of the PS 2 Patient**  
Joan Schiller, VA/USA

### MTE10

**07:00 - 08:00**  
*Emerging Technologies for Small and Smaller Lesions - Update on Ablation via Endoscopy vs Percutaneous (Ticketed Session)*  
Topics: Interventional Diagnostics/Pulmonology  
*Room 201 BD*

07:00 - 08:00  
**MTE10.01 - Emerging Technologies for Small and Smaller Lesions - Update on Ablation via Endoscopy vs Percutaneous**  
Felix Herth, Germany

### PL01

**08:15 - 09:45**  
*Patients First*  
Moderation: A. Bezjak, Canada; P. Bunn, Jr., USA  
*Plenary Hall*

08:15 - 08:25  
**PL01.01 - When Breath Becomes Air**  
Lucy Kalanithi, USA

08:25 - 08:40  
**PL01.02 - Science that Matters**  
David Carbone, OH/USA

08:40 - 08:55  
**PL01.03 - Trials that Matter!**  
Tony Mok, Hong Kong

08:55 - 09:10  
**PL01.04 - Getting Drugs to Patients Faster: A Global View**  
Solange Peters, Switzerland

09:10 - 09:25  
**PL01.05 - Conquering Lung Cancer - The IASLC Vision**  
Giorgio Scagliotti, Italy
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:25 - 09:40</td>
<td>PL01.06 - Patients First</td>
<td>Tish Vigna, Canada</td>
<td></td>
</tr>
<tr>
<td>10:30 - 12:00</td>
<td>MA01</td>
<td>Early Stage Lung Cancer: Questions and Controversies</td>
<td>Room 202 BD</td>
</tr>
<tr>
<td></td>
<td>MA01.01</td>
<td>Proposal on Incorporating Lymphovascular Invasion as a T-Descriptor for Stage I Non-Small Cell Lung Cancer</td>
<td>Shuyuan Wang, China</td>
</tr>
<tr>
<td>10:30 - 10:35</td>
<td>MA01.02</td>
<td>Histologic Subtyping in Pathologic Stage I Lung Adenocarcinoma Provides Risk-Based Stratification for Surveillance</td>
<td>Yusuke Takahashi, NY/USA</td>
</tr>
<tr>
<td>10:40 - 10:45</td>
<td>MA01.03</td>
<td>An Externally Validated Nomogram for Predicting Distant Metastasis After SBRT for Early Stage Non-Small Cell Lung Cancer</td>
<td>Aditya Juloori, OH/USA</td>
</tr>
<tr>
<td>10:45 - 11:00</td>
<td>MA01.04</td>
<td>Discussant - MA 0.01, MA 0.02, MA 0.03</td>
<td>Deepali Jain, India</td>
</tr>
<tr>
<td>11:00 - 11:05</td>
<td>MA01.05</td>
<td>Opioids and Sleep Medication Use After Surgery for Early Stage Lung Cancer: A SEER-Medicare Analysis</td>
<td>Stephanie Tuminello, USA</td>
</tr>
<tr>
<td>11:05 - 11:10</td>
<td>MA01.06</td>
<td>Evaluation of Safety and Efficacy in Surgical Treatment for Octogenarian Lung Cancer Patients by Multicenter Prospective Study: JACS1303</td>
<td>Tomohiro Haruki, Japan</td>
</tr>
<tr>
<td>11:10 - 11:15</td>
<td>MA01.07</td>
<td>Validation of RTOG 0813 Normal Tissue Constraints for Pulmonary Toxicity in SBRT for Central Non-Small Cell Lung Cancer</td>
<td>Kyle Verdecchia, OH/USA</td>
</tr>
<tr>
<td>11:15 - 11:30</td>
<td>MA01.08</td>
<td>Discussant - MA 01.05, MA 01.06, MA 01.07</td>
<td>Biniam Kidane, MB/Canada</td>
</tr>
</tbody>
</table>
### MA01.09 - Risk Factors of Radiation-Induced Lymphopenia (RIL) and Its Prognostic Significance in Small Lung Cancer Patients Treated with Stereotactic Body Radiation Therapy
Jian He, China

### MA01.10 - Toxicity and Local Control in “Ultra-Central” Lung Tumors Treated With SBRT or High-Dose Hypofractionated RT
Chunyu Wang, USA

### MA01.11 - Salvage SBRT for Local Recurrence After Primary Surgical Resection of Early Stage Non-Small Cell Lung Cancer
Sarah Sittenfeld, USA

### MA01.12 - Discussant - MA 01.09, MA 01.10, MA 01.11
Drew Moghanaki, USA

---

### Improving Outcomes for Patients with Lung Cancer
Room 201 BD

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 - 10:35</td>
<td>MA02.01</td>
<td>ROS1 Gene Rearrangements Are Associated with an Exaggerated Risk of Peri-Diagnosis Thromboembolic Events</td>
<td>Terry Ng, USA</td>
</tr>
<tr>
<td>10:35 - 10:40</td>
<td>MA02.02</td>
<td>Multistate Healthcare Network Underutilizes Valuable End-of-Life Resources in Stage IV Non-Small Cell Lung Cancer</td>
<td>Candice Wilshire, WA/USA</td>
</tr>
<tr>
<td>10:40 - 10:45</td>
<td>MA02.03</td>
<td>ASTRIS: A Real-World Treatment Study of Osimertinib in Patients with EGFR T790M-Positive NSCLC</td>
<td>Yi-Long Wu, China</td>
</tr>
<tr>
<td>10:45 - 11:00</td>
<td>MA02.04</td>
<td>Discussant - MA 02.01, MA 02.02, MA 02.03</td>
<td>Alona Zer, Israel</td>
</tr>
<tr>
<td>11:00 - 11:05</td>
<td>MA02.05</td>
<td>A Double-Blind, Randomized, Placebo-Controlled Phase 3 Noninferiority Study of Darbepoetin Alfa for Anemia in Advanced NSCLC</td>
<td>Rajnish Nagarkar, India</td>
</tr>
</tbody>
</table>
11:05 - 11:10  MA02.06 - A Randomized, Double-Blind, Placebo-Controlled Trial of Chemotherapy Combined with Yangzheng Xiaoji in Advanced NSCLC
Ligang Xing, China

11:10 - 11:15  MA02.07 - Aprepitant for Cough Suppression in Advanced Lung Cancer: A Randomized Trial
Kumar Prabhash, India

11:15 - 11:20  MA02.08 - The Effect of Nabilone on Appetite, Nutritional Status, and Quality of Life in Lung Cancer Patients: A Randomized, Double-Blind Clinical Trial
Jenny Turcott, Mexico

11:20 - 11:35  MA02.09 - Discussant - MA 02.05, MA 02.06, MA 02.07, MA 02.08
Paul Wheatley-Price, Canada

11:35 - 11:40  MA02.10 - The First Year of Implementing a Lung Cancer Screening Program in an Urban Safety-Net Health System
Heidi Hamann, USA

11:40 - 11:45  MA02.11 - Achieving Value in Cancer Diagnostics: Blood Versus Tissue Molecular Profiling - A Prospective Canadian Study (VALUE)
Doreen Ezeife, Canada

11:45 - 12:00  MA02.12 - Discussant - MA 02.10, MA 02.11
William Evans, ON/Canada

MA03

10:30 - 12:00  Lung Cancer Screening - Next Step
Topics: Screening and Early Detection
Moderation: A. Tremblay, Canada; S. Janes, UK
Room 206 AC

10:30 - 10:35  MA03.01 - Manchester Lung Cancer Screening: Results of the First Incidence Screening Round
Haval Balata, UK

10:35 - 10:40  MA03.02 - Prospective Evaluation of the Clinical Utility of the International Lung Screen Trial Lung Nodule Management Protocol
Stephen Lam, Canada

10:40 - 10:45  MA03.03 - Prolonged Low-Dose Computed Tomography (LDCT) Screening Beyond 5 Years Reduces Overall and Lung Cancer Specific Mortality
Ugo Pastorino, Italy
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45 - 11:00</td>
<td><strong>MA03.04</strong> - Discussant - MA 03.01, MA 03.02, MA 03.03&lt;br&gt;Denise Aberle, USA</td>
</tr>
<tr>
<td>11:00 - 11:05</td>
<td><strong>MA03.05</strong> - New Subsolid Pulmonary Nodules in Lung Cancer Screening: The NELSON Trial&lt;br&gt;Marjolein Heuvelmans, Netherlands</td>
</tr>
<tr>
<td>11:05 - 11:10</td>
<td><strong>MA03.06</strong> - Descriptive Epidemiology of Significant Incidental Findings in a Large Clinical Lung Cancer Screening Program&lt;br&gt;Shawn Regis, MA/USA</td>
</tr>
<tr>
<td>11:10 - 11:15</td>
<td><strong>MA03.07</strong> - Development and Validation of Deep Learning Model for Recognition of Histologic Subtype of Lung Adenocarcinoma from CT Images&lt;br&gt;Yunlang She, China</td>
</tr>
<tr>
<td>11:15 - 11:30</td>
<td><strong>MA03.08</strong> - Discussant - MA 03.05, MA 03.06, MA 03.07&lt;br&gt;Richard Booton, UK</td>
</tr>
<tr>
<td>11:30 - 11:35</td>
<td><strong>MA03.10</strong> - Population-Based Relative Risks for Lung Cancer Based on Complete Family History of Lung Cancer&lt;br&gt;Shamus Carr, MD/USA</td>
</tr>
<tr>
<td>11:35 - 11:40</td>
<td><strong>MA03.11</strong> - Trained Dogs Can Identify Malignant Pulmonary Nodules in Exhaled Gas&lt;br&gt;Angela Guirao, Spain</td>
</tr>
<tr>
<td>11:40 - 11:55</td>
<td><strong>MA03.12</strong> - Discussant - MA 03.09, MA 03.10, MA 03.11&lt;br&gt;Luis Montuenga, Spain</td>
</tr>
<tr>
<td>11:55 - 12:00</td>
<td><strong>MA03.12a</strong> - Q&amp;A</td>
</tr>
</tbody>
</table>

**MS01**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 - 12:00</td>
<td><strong>Cancer Pathways, Targeted Therapy and Resistance</strong>&lt;br&gt;Topics: Biology&lt;br&gt;Moderation: G. Riely, USA; W. Lam, Canada</td>
</tr>
<tr>
<td>10:30 - 10:50</td>
<td><strong>MS01.01</strong> - Defects of the SWI/SNF OR MYC/MAX Pathways: Effects in Cell Differentiation and Therapeutic Opportunities&lt;br&gt;Montse Sanchez-Cespedes, Spain</td>
</tr>
<tr>
<td>10:50 - 11:10</td>
<td><strong>MS01.02</strong> - Targeting Negative Feedback Regulators to Hyperactivate Oncogenic Signaling</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>----------</td>
<td>----------------------------------------------</td>
</tr>
<tr>
<td>11:10 - 11:30</td>
<td>MS01.03 - Stimulating Anti-Tumor Immunity Through Enhancing T-Cell Activation</td>
</tr>
<tr>
<td>11:30 - 11:50</td>
<td>MS01.04 - Addressing Drug Resistance Beyond Kinase Domain Mutations</td>
</tr>
<tr>
<td>11:50 - 12:00</td>
<td>MS01.05 - Q&amp;A</td>
</tr>
</tbody>
</table>

**MS02**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 - 12:00</td>
<td>The Future of IO</td>
<td>Topics: Immunooncology</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Moderation: Y. Ohe, Japan; R. Hui, Australia</td>
<td></td>
</tr>
<tr>
<td>10:30 - 10:45</td>
<td>MS02.01 - What Is/Will Be the Optimal Duration of Therapy with IO?</td>
<td>David Spigel, TN/USA</td>
<td></td>
</tr>
<tr>
<td>10:45 - 11:00</td>
<td>MS02.02 - Combination Therapies: Where Are We in 2018?</td>
<td>Martin Reck, Germany</td>
<td></td>
</tr>
<tr>
<td>11:00 - 11:15</td>
<td>MS02.03 - Next Generation IO in Lung Cancer</td>
<td>Solange Peters, Switzerland</td>
<td></td>
</tr>
<tr>
<td>11:15 - 11:30</td>
<td>MS02.04 - Optimizing Clinical Trial Designs in Immunotherapy</td>
<td>Vassiliki Papadimitrakopoulou, TX/USA</td>
<td></td>
</tr>
<tr>
<td>11:30 - 11:45</td>
<td>MS02.05 - Convincing Policy Makers to Afford Immunotherapy</td>
<td>Carlos Gil Ferreira, Brazil</td>
<td></td>
</tr>
<tr>
<td>11:45 - 12:00</td>
<td>MS02.06 - Q&amp;A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Sponsor and Topic</td>
<td>Room</td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>----------------------------------------------------------------------------------</td>
<td>------------------</td>
<td></td>
</tr>
</tbody>
</table>
| 10:30 - 12:00 | **New Frontiers in Oligometastases**  
Topics: Oligometastatic NSCLC  
Moderation: J. Patel, USA; E. Lim, UK | Room 203 BD      |
| 10:30 - 10:45 | **MS03.01 - The Biology of Oligometastases: What Have We learned?**  
David Palma, Canada |                  |
| 10:45 - 11:00 | **MS03.02 - Biomarkers in Oligometastatic Patients i. Monitoring Diseases Response - Imaging vs Serum**  
Max Diehn, CA/USA |                  |
| 11:00 - 11:15 | **MS03.03 - Investigations into Alternative Clinical Endpoints for OM Beyond Survival**  
Alexander Louie, Canada |                  |
| 11:15 - 11:30 | **MS03.04 - Treatment of Oligoprogression: Real Progress or False Hope?**  
Fiona Mcdonald, UK |                  |
| 11:30 - 11:45 | **MS03.05 - Integration of Immunotherapy in the Oligometastatic Paradigm**  
Shankar Siva, VIC/Australia |                  |
| 11:45 - 12:00 | **MS03.06 - Q&A** |                  |

**MS04**

<table>
<thead>
<tr>
<th>Time</th>
<th>Sponsor and Topic</th>
<th>Room</th>
</tr>
</thead>
</table>
| 10:30 - 12:00 | **Joint GLCC/IASLC Session: Exploring Hot Topics for Advocates**  
Topics: Advocacy  
Moderation: C. Aldige, USA; C. Sit, Canada | Room 206 BD      |
| 10:30 - 10:45 | **MS04.01 - Collecting Data in the Real World - How Can Patient Groups Work with Researchers in Defining and Collecting Real-World Evidence?**  
Taofeek Owonikoko, GA/USA |                  |
| 10:45 - 11:00 | **MS04.02 - How Is Lung Cancer Screening Evolving to Be More Efficient and Effective?**  
David Baldwin, UK |                  |
| 11:00 - 11:15 | **MS04.03 - Exploring Smoking Stigma, Negativity and Lung Cancer - What Can Be Done?**  
Stefania Vallone, Italy |                  |
<p>| 11:15 - 11:30 | <strong>MS04.04 - E-Cigarettes - What Do Lung Cancer Advocates Need to Know?</strong> |                  |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 - 12:00</td>
<td>MS04.05</td>
<td>Panel Discussion</td>
<td></td>
</tr>
<tr>
<td>10:30 - 12:00</td>
<td>OA01.01</td>
<td>Improving Outcomes in Locoregional NSCLC I</td>
<td>Room 107</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Topics: Treatment of Locoregional Disease - NSCLC</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Moderation: G. Rocco, Italy; R. Carlson, Canada</td>
<td></td>
</tr>
<tr>
<td>10:30 - 10:40</td>
<td>OA01.01.01</td>
<td>10-Year Updated Analysis of NRG Oncology/RTOG 0214: A Phase III Comparison of PCI vs. Observation in Patients with LA-NSCLC.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Alexander Sun, Canada</td>
<td></td>
</tr>
<tr>
<td>10:40 - 10:50</td>
<td>OA01.02</td>
<td>The Estimate of Shrinking Field and SIB Radiotherapy Guided by 18F-FDG PET/CT in Locally Advanced NSCLC Patients: A Phase 2 Randomized Clinical</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Yaping Xu, China</td>
<td></td>
</tr>
<tr>
<td>10:50 - 11:00</td>
<td>OA01.03</td>
<td>Interaction Between Dose and Calcifications Is a Predictor for Overall Survival in Lung Cancer Patients Receiving Radiotherapy</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Alan Mcwilliam, UK</td>
<td></td>
</tr>
<tr>
<td>11:00 - 11:15</td>
<td>OA01.04</td>
<td>Discussant - OA 01.01, OA 01.02, OA 01.03</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>John Armstrong, Ireland</td>
<td></td>
</tr>
<tr>
<td>11:15 - 11:25</td>
<td>OA01.05</td>
<td>Phase II Study of Neo-Adjuvant Chemo/Immunotherapy for Resectable Stages IIIA Non-Small Cell Lung Cancer- Nadim Study-SLCG</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mariano Provencio, Spain</td>
<td></td>
</tr>
<tr>
<td>11:25 - 11:35</td>
<td>OA01.06</td>
<td>DETERRED: Phase II Trial Combining Atezolizumab Concurrently with Chemoradiation Therapy in Locally Advanced Non-Small Cell Lung Cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Steven Lin, TX/USA</td>
<td></td>
</tr>
<tr>
<td>11:35 - 11:45</td>
<td>OA01.07</td>
<td>Updated Results of a Phase II Trial of Concurrent Chemoradiation with Consolidation Pembrolizumab in Patients with Unresectable Stage III NSCLC</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Greg Durm, IN/USA</td>
<td></td>
</tr>
<tr>
<td>11:45 - 12:00</td>
<td>OA01.08</td>
<td>Discussant - OA 01.05, OA 01.06, OA 01.07</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Corey Langer, PA/USA</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session Title</td>
<td>Presenter and Location</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>--------------------------------------</td>
<td></td>
</tr>
<tr>
<td>10:30 - 12:00</td>
<td>Novel Therapies in ROS1, HER2 and EGFR</td>
<td>Room 105</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Topics: Targeted Therapy</td>
<td>R. Heist, USA; B. Xia, China</td>
<td></td>
</tr>
<tr>
<td>10:30 - 10:40</td>
<td>OA02.01 - Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)</td>
<td>Robert Doebele, CO/USA</td>
<td></td>
</tr>
<tr>
<td>10:40 - 10:50</td>
<td>OA02.02 - Safety and Preliminary Clinical Activity of Ropotrectinib (TPX-0005), a ROS1/TRK/ALK Inhibitor, in Advanced ROS1 Fusion-Positive NSCLC</td>
<td>Jessica Lin, MA/USA</td>
<td></td>
</tr>
<tr>
<td>10:50 - 11:00</td>
<td>OA02.03 - Clinical Activity of Lorlatinib in Patients with ROS1+ Advanced Non-Small Cell Lung Cancer: Phase 2 Study Cohort EXP-6</td>
<td>Sai-Hong Ou, CA/USA</td>
<td></td>
</tr>
<tr>
<td>11:00 - 11:15</td>
<td>OA02.04 - Discussant - OA 02.01, OA 02.02, OA 02.03</td>
<td>Shengxiang Ren, China</td>
<td></td>
</tr>
<tr>
<td>11:15 - 11:25</td>
<td>OA02.05 - CK-101 (RX518), a Third Generation Mutant-Selective Inhibitor of EGFR in NSCLC: Results of an Ongoing Phase I/II Trial</td>
<td>Melissa Johnson, TN/USA</td>
<td></td>
</tr>
<tr>
<td>11:25 - 11:35</td>
<td>OA02.06 - A Phase II Trial of Pozitinib in EGFR and HER2 exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC)</td>
<td>John Heymach, TX/USA</td>
<td></td>
</tr>
<tr>
<td>11:35 - 11:45</td>
<td>OA02.07 - Updated Results of Phase 1 Study of DS-8201a in HER2-Expressing or -Mutated Advanced Non-Small-Cell Lung Cancer</td>
<td>Junji Tsurutani, Japan</td>
<td></td>
</tr>
<tr>
<td>11:45 - 12:00</td>
<td>OA02.08 - Discussant - OA 02.05, OA 02.06, OA 02.07</td>
<td>Daniel Costa, MA/USA</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Title</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>----------------------------------------------------------------------</td>
<td>--------------------</td>
<td></td>
</tr>
<tr>
<td>10:30 - 12:00</td>
<td>Advances in Lung Cancer Pathology</td>
<td>Room 205 B</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Topics:</strong> Pathology</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Moderation:</strong> G. Chen, China; G. Pelosi, Italy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30 - 10:40</td>
<td>OA03.01 - The Immunophenotyping and Genomic Characteristics of Pulmonary Sarcomatoid Carcinoma: Pleomorphic, Spindle Cell and Giant Cell Carcinoma</td>
<td>Chunyan Wu, China</td>
<td></td>
</tr>
<tr>
<td>10:40 - 10:50</td>
<td>OA03.02 - Nationwide Comparative Study Of PD-L1 IHC Assays on Lung Cancer: Initial Report Of LC-SCRUM-IBIS Project</td>
<td>Noriko Motoi, Japan</td>
<td></td>
</tr>
<tr>
<td>10:50 - 11:00</td>
<td>OA03.03 - Phase 2B of Blueprint PD-L1 Immunohistochemistry Assay Comparability Study</td>
<td>Keith Kerr, UK</td>
<td></td>
</tr>
<tr>
<td>11:00 - 11:15</td>
<td>OA03.04 - Discussant - OA 03.01, OA 03.02, OA 03.03</td>
<td>Julien Adam, France</td>
<td></td>
</tr>
<tr>
<td>11:15 - 11:25</td>
<td>OA03.05 - Characterization of the Immunologic Intra-Tumor Heterogeneity in Early Stages of Non-Small Cell Lung Cancer by Multiplex Immunofluorescence</td>
<td>Alejandro Francisco Cruz, USA</td>
<td></td>
</tr>
<tr>
<td>11:25 - 11:35</td>
<td>OA03.06 - Extraction of Radiomic Values from Lung Adenocarcinoma with Near-Pure Histological Subtypes</td>
<td>Mong-Wei Lin, Taiwan</td>
<td></td>
</tr>
<tr>
<td>11:35 - 11:45</td>
<td>OA03.07 - Three-Dimensional Immunofluorescence Analysis of Dynamic Vessel Co-Option of Spread Through Air Spaces (STAS) in Lung Cancer</td>
<td>Yukako Yagi, NY/USA</td>
<td></td>
</tr>
<tr>
<td>11:45 - 12:00</td>
<td>OA03.08 - Discussant - OA 03.05, OA 03.06, OA 03.07</td>
<td>David Rimm, CT/USA</td>
<td></td>
</tr>
</tbody>
</table>

**OA04**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 - 12:00</td>
<td>Improving Access and Outcomes in Lung Cancer Management</td>
<td>Room 201 F</td>
</tr>
<tr>
<td></td>
<td><strong>Topics:</strong> Nursing and Allied Professionals</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Moderation:</strong> M. Culligan, USA; P. Garrido, Spain</td>
<td></td>
</tr>
<tr>
<td>10:30 - 10:40</td>
<td>OA04.01 - What is the Cost of a Strong Evidence for the Treatment of Advanced Non-Small Cell Lung Cancer?</td>
<td></td>
</tr>
</tbody>
</table>

Monday, September 24, 2018
Pedro Aguiar Jr, Brazil

10:40 - 10:50  OA04.02 - Demographic, Psychosocial, and Behavioral Associations with Cancer Screening Among a Homeless Population
Lovoria Williams, USA

10:50 - 11:00  OA04.03 - The Role of Comprehensive Genomic Profiling in the Community Setting
Kimberly Rohan, IL/USA

11:00 - 11:15  OA04.04 - Discussant - OA 04.01, OA 04.02, OA 04.03
Jhanelle Gray, FL/USA

11:15 - 11:25  OA04.05 - An Early Rehabilitation Intervention for Enhancing Oxygenation from Lung Cancer Surgery
Wei Ling Hsiao, Taiwan

11:25 - 11:35  OA04.06 - Perceptions of Non-Participation in a Rehabilitation Intervention After Surgery for Non-Small Cell Lung Cancer
Mai Schoenau, Denmark

11:35 - 11:45  OA04.07 - Early Initiated Postoperative Rehabilitation Reduces Fatigue in Patients with Operable Lung Cancer: A Randomized Trial
Morten Quist, Denmark

11:45 - 12:00  OA04.08 - Discussant - OA 04.05, OA 04.06, OA 04.07
Pippa Labuc, UK

PC01
10:30 - 12:00  Controversies in Mesothelioma
Topics: Mesothelioma
Moderation: N. Bouchard, Canada; N. Van Zandwijk, Australia

10:30 - 10:45  PC01.01 - PRO Intrapleural Chemotherapy Is It the Future?
Isabelle Opitz, Switzerland

10:45 - 11:00  PC01.02 - CON Intrapleural Chemotherapy Is It the Future?
David Rice, TX/USA

11:00 - 11:15  PC01.03 - PRO IO in Mesothelioma Should Only Be Given on Clinical Trials
Penelope Bradbury, ON/Canada
11:15 - 11:30  PC01.04 - CON in Mesothelioma Should Only Be Given on Clinical Trials
Evan Alley, USA

11:30 - 11:45  PC01.05 - PRO Radiation Options: Are We SMART Enough?
John Cho, Canada

11:45 - 12:00  PC01.06 - CON Radiation Options: Are We SMART Enough?
Charles Simone, USA

12:00 - 13:30  Symposium Supported by Merck: Pembrolizumab: The Evolving Standard of Care in Advanced and Early-Stage Lung Cancer

12:00 - 13:30  Pembrolizumab: The Evolving Standard of Care in Advanced and Early-Stage Lung Cancer

12:00 - 13:30  Meet the JTO Editor
Alex Adjei, NY/USA

13:30 - 15:00  Advances in Lung Cancer Screening Through Imaging
Topics: Screening and Early Detection
Moderation: H. Schmidt, Canada; D. Aberle, USA

13:30 - 13:50  ES01.01 - Image Quality Characteristics and Nodule Growth Measurement, Medical Physics and Machine Parameters
Ricardo Avila, USA

13:50 - 14:10  ES01.02 - Image Interpretation and Advances from the Perspective of the Radiologist
David Yankelevitz, NY/USA
14:10 - 14:30  ES01.03 - Deep Machine Learning for Screening LDCT  
Bram Van Ginneken, Netherlands

14:30 - 14:50  ES01.04 - Multi-Phasic Screening - Can We Address Competing Causes of Morbidity * Mortality Such as Coronary Artery Disease and COPD  
Rozemarijn Vliegenthart, Netherlands

14:50 - 15:00  ES01.05 - Q&A

MA04

13:30 - 15:00  Novel Approaches with IO  
Room 107

Topics: Immunooncology
Moderation: T. Montella, Brazil; R. Sangha, Canada

13:30 - 13:35  MA04.01 - Cemiplimab, a Human Monoclonal Anti-PD-1, Alone or in Combination with Radiotherapy: Phase 1 NSCLC Expansion Cohorts  
Victor Moreno, Spain

13:35 - 13:40  MA04.02 - Responses and Durability in NSCLC Treated with Pegilodecakin and Anti-PD-1  
Edward Garon, USA

13:40 - 13:45  MA04.03 - Immunotherapy for Non-Small Cell Lung Cancers (NSCLC) with Oncogenic Driver Mutations: New Results from the Global IMMUNOTARGET Registry  
Oliver Gautschi, Switzerland

13:45 - 14:00  MA04.04 - Discussant - MA 04.01, MA 04.02, MA 04.03  
Jose Pacheco, USA

14:00 - 14:05  MA04.05 - Outcomes in NSCLC Patients Treated with First-Line Pembrolizumab and a PD-L1 TPS of 50-74% vs 75-100% or 50-89% vs 90-100%  
Mark Awad, MA/USA

14:05 - 14:10  MA04.06 - PD-1 Blockade Promotes Hyperprogressive Disease in NSCLC Through Macrophages Activation via Antibody-Fc/FcR Interaction  
Gabriella Sozzi, Italy

14:10 - 14:15  MA04.07 - MicroRNA-Based Liquid Biopsy Combines with PD-L1 Tumor Expression to Predict Response to Immunotherapy in Advance NSCLC Patients
Matthew Boeri, Italy

14:15 - 14:30  MA04.08 - Discussant - MA 04.05, MA 04.06, MA 04.07
Patrick Forde, MD/USA

14:30 - 14:35  MA04.09 - Neoadjuvant Atezolizumab in Resectable Non-Small Cell Lung Cancer (NSCLC): Updated Results from a Multicenter Study (LCMC3)
Valerie Rusch, NY/USA

14:35 - 14:40  MA04.10 - Comprehensive Peripheral Blood Immunophenotyping and T-Cell Clonal Analysis During Neoadjuvant Immunotherapy with Atezolizumab in NSCLC
Filiz Oezkan, USA

14:40 - 14:45  MA04.11 - Neoantigen Targeting and T Cell Reshaping in Resectable NSCLC Patients Treated with Neoadjuvant PD-1 Blockade
Kellie Smith, MD/USA

14:45 - 15:00  MA04.12 - Discussant - MA 04.09, MA 04.10, MA 04.11
Alex Adjei, NY/USA

MA05

13:30 - 15:00   Improving Outcomes in Locoregional NSCLC II
Room 105
Topics: Treatment of Locoregional Disease - NSCLC
Moderation: J. Martin, Canada; D. Schellenberg, Canada

13:30 - 13:35  MA05.01 - E6508: Phase II Study of Immunotherapy with Tecemotide and Bevacizumab after Chemoradiation in Unresectable Stage III NS-NSCLC
Jyoti Patel, IL/USA

13:35 - 13:40  MA05.02 - PACIFIC Subgroup Analysis: Pneumonitis in Stage III, Unresectable NSCLC Patients Treated with Durvalumab vs. Placebo After CRT
Johan Vansteenkiste, Belgium

13:40 - 13:45  MA05.03 - Immune Microenvironment and its Association with Adjuvant Chemotherapy Benefit in Locoregionally Advanced Lung Adenocarcinoma
Raj Vaghjiani, USA

13:45 - 14:00  MA05.04 - Discussant - MA 05.01, MA 05.02, MA 05.03
Scott Gettinger, CT/USA
14:00 - 14:05 MA05.05 - Photon-Based Cardiac Sparing Via Volumetric Modulated Arc Therapy in Thoracic Radiation Therapy for Locally Advanced Non-Small Cell Lung Cancer
Matthew Ferris, USA

14:05 - 14:10 MA05.06 - Locally Advanced Lung Cancer Radiotherapy in Deep Inspiration Breath Hold: Dosimetric Benefits from a Prospective Trial
Mirjana Josipovic, Denmark

14:10 - 14:15 MA05.07 - Dose Escalated Chemo-RT to 84 Gy in Stage III NSCLC Appears Excessively Toxic: Results from a Randomized Phase II Trial
Jan Nyman, Sweden

14:15 - 14:30 MA05.08 - Discussant - MA 05.05, MA 05.06, MA 05.07
Benjamin Lok, Canada

14:30 - 14:35 MA05.09 - PFS and Cardiac-Toxicity-Adjusted-PFS As Predictors of OS in Locally Advanced NSCLC Treated with Concurrent Chemoradiation
Chen Hu, MD/USA

14:35 - 14:40 MA05.10 - The Pathologic Response of Locally Advanced NSCLC Treated with Concomitant Chemoradiation to 60 Gy in Image Guided Radiation Therapy (IGRT)
Sarit Appel, Israel

14:40 - 14:45 MA05.11 - Radiomics Analysis Using SVM Predicts Mediastinal Lymph Nodes Status of Squamous Cell Lung Cancer by Pre-Treatment Chest CT Scan
Wu Nan, China

14:45 - 15:00 MA05.12 - Discussant - MA 05.09, MA 05.10, MA 05.11
Matthew Hatton, UK

MA06

13:30 - 15:00 PDL1, TMB and DNA Repair
Topics: Biology
Moderation: N. Motoi, Japan; J. Adam, France

13:30 - 13:35 MA06.01 - The Intrinsic PD-L1 Promotes Cellular Invasiveness Via their PD-1 Receptor in Lung Adenocarcinoma Cells
Wen-Pin Su, Taiwan

13:35 - 13:40 MA06.02 - Prospective Immunogenomic Profiling of Non-Small Cell Lung Cancer: Genomic and Immune Profiling Updates from Project ICON

Monday, September 24, 18
Marcelo Negrao, USA

13:40 - 13:45  MA06.03 - PD-1 and Id-1 Combined Blockade Impacts Tumor Growth and Survival Through PD-L1 Expression and Tumor Infiltration by Immune-Related Cells
Ignacio Gil-Bazo, Spain

13:45 - 14:00 MA06.04 - Discussant - MA 06.01, MA 06.02, MA 06.03
Akihiko Yoshida, Japan

14:00 - 14:05 MA06.05 - The Micro-Environmental Cross Talk Between Mast Cells and Lung Cancer Cells Through Cell-to-Cell Contact
Rachel Shemesh, Israel

14:05 - 14:10 MA06.06 - An Ex-Vivo Patient-Derived, Immunocompetent (PDI) Culture System to Evaluate Immunotherapeutic Agents’ Anti-Tumor Efficacy
Zachary Tano, NY/USA

14:10 - 14:15 MA06.07 - Genetic and Epigenetic Alterations are Associated with Tumor Mutation Burden in Non-Small Cell Lung Cancer
Liang-Liang Cai, China

14:15 - 14:30 MA06.08 - Discussant - MA 06.05, MA 06.06, MA 06.07
Jyoti Patel, IL/USA

14:30 - 14:35 MA06.09 - XRCC6BP1: A DNA Repair Gene in Cisplatin Resistant Lung Cancer Stem Cells That May Predict Survival Outcomes in Patients
Martin Barr, Ireland

14:35 - 14:40 MA06.10 - Germline Mutation in ATM Affect Lung Cancer Risk with High Effect
Xuemei Ji, NH/USA

14:40 - 14:45 MA06.11 - Distinct Origins of Lymphatic and Brain Metastasis in Lung Cancer
Tao Jiang, China

14:45 - 15:00 MA06.12 - Discussant - MA 06.09, MA 06.10, MA 06.11
Rebecca Heist, USA

MA07

13:30 - 15:00 Towards Survivorship: The Landscape, Supports and Barriers Room 205 AC

Monday, September 24, 18
<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker details</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30 - 13:35</td>
<td>MA07.01 - No Longer Outliers: Understanding the Needs of Long-Term Lung Cancer Survivors</td>
<td>Maureen Rigney, DC/USA</td>
</tr>
<tr>
<td>13:35 - 13:40</td>
<td>MA07.02 - Line of Therapy and Patient Preferences Treating Lung Cancer: A Discrete-Choice Experiment</td>
<td>Andrea Ferris, USA</td>
</tr>
<tr>
<td>13:40 - 13:45</td>
<td>MA07.03 - Attitudes to Lung Cancer in Europe: Findings from a Global Consumer Survey</td>
<td>Jesme Fox, UK</td>
</tr>
<tr>
<td>13:45 - 14:00</td>
<td>MA07.04 - Discussant - MA 07.01, MA 07.02, MA 07.03</td>
<td>Govind Babu Kanakasetty, India</td>
</tr>
<tr>
<td>14:00 - 14:05</td>
<td>MA07.05 - Psychosocial Needs and Programs of Cancer Patients/Survivors and Their Relatives: Unmet Needs from an International Study</td>
<td>Csaba Dégi, Romania</td>
</tr>
<tr>
<td>14:05 - 14:10</td>
<td>MA07.06 - Telephonic Communication In Palliative Care For Better Management Of Terminal Cancer Patients In Rural India - An NGO Based Approach.</td>
<td>Nabanita Mandal, India</td>
</tr>
<tr>
<td>14:10 - 14:15</td>
<td>MA07.07 - Identifying the Severity of Psychosocial Symptoms Among Patients Diagnosed with Lung Cancer. Do We Really Need Emotional Support Groups?</td>
<td>Arooj Fatima, Pakistan</td>
</tr>
<tr>
<td>14:15 - 14:30</td>
<td>MA07.08 - Discussant - MA 07.05, MA 07.06, MA 07.07</td>
<td>Jennifer King, USA</td>
</tr>
<tr>
<td>14:30 - 14:35</td>
<td>MA07.09 - Willingness to Perform Multiple Biopsies to Improve Quality of Lung Cancer Care: Understanding the Oncologists' Perspective</td>
<td>Upal Basu Roy, MD/USA</td>
</tr>
<tr>
<td>14:35 - 14:40</td>
<td>MA07.10 - Utilizing a Personalized Navigation Program to Identify Barriers and Increase Clinical Trial Participation Among Lung Cancer Patients</td>
<td>Andrew Ciupek, USA</td>
</tr>
<tr>
<td>14:40 - 14:45</td>
<td>MA07.11 - Drug Price Comparison in Advanced Lung Cancer - High Cost Prices is Accompanied by Patient Benefits?</td>
<td>Luciene Bonan, Brazil</td>
</tr>
</tbody>
</table>
### MS05 - Diagnostic Dilemma in Lung Cancer

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30</td>
<td>MS05.01 - Staging and Pathology of Multiple Lung Nodules</td>
<td>Alain Borczuk, NY/USA</td>
</tr>
<tr>
<td>13:45</td>
<td>MS05.02 - Defining Invasion in Minimally Invasive Adenocarcinoma</td>
<td>Masayuki Noguchi, Japan</td>
</tr>
<tr>
<td>14:10</td>
<td>MS05.03 - Tumor Heterogeneity in Lung Cancer</td>
<td>Elisabeth Brambilla, France</td>
</tr>
<tr>
<td>14:30</td>
<td>MS05.04 - Diagnosis and Classification in Biopsies</td>
<td>Andre Moreira, NY/USA</td>
</tr>
</tbody>
</table>

### MS06 - Practical Issues in the Management of Oligometastatic NSCLC

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30</td>
<td>MS06.01 - The Role of Radiation in Treating the Mets</td>
<td>Hak Choy, TX/USA</td>
</tr>
<tr>
<td>13:45</td>
<td>MS06.02 - The Role of Interventional Pulmonology and Radiology</td>
<td>Kwun Fong, Australia</td>
</tr>
<tr>
<td>14:00</td>
<td>MS06.03 - The Role of Surgical Resection</td>
<td>Boris Sepesi, TX/USA</td>
</tr>
</tbody>
</table>
14:15 - 14:30 | **MS06.04** - Systemic Therapy for Oligometastases: Before, During, or After Local Therapies?  
Ross Camidge, USA

14:30 - 14:45 | **MS06.05** - The Special Case of Brain Metastases: Systemic Therapy, Radiation or Both?  
Laurie Gaspar, CO/USA

14:45 - 15:00 | **MS06.06** - Q&A

---

**MS07**

**Antibody-Drug Conjugates in Advanced NSCLC**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
</table>
| 13:30 - 15:00 | Topics: Advanced NSCLC  
Moderation: N. Blais, Canada; E. Santos, USA | 

13:30 - 13:50 | **MS07.01** - Basic Science  
David Gerber, TX/USA

13:50 - 14:10 | **MS07.02** - Pharmacology  
Christian Rolfo, Belgium

14:10 - 14:30 | **MS07.03** - Clinical Data  
Thomas Stinchcombe, NC/USA

14:30 - 15:00 | **MS07.04** - Future Directions  
Silvia Novello, Italy

14:50 - 15:00 | **MS07.05** - Q&A

---

**MS08**

**Lung Cancer in the Real World**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
</table>
| 13:30 - 15:00 | Topics: Treatment in the Real World - Support, Survivorship, Systems Research  
Moderation: A. Wozniak, USA; R. Kelly, USA | 

13:30 - 13:45 | **MS08.01** - How Can Real World Data Improve Clinical Evidence Generation and Impact Regulatory Bodies - European Perspective  
Yolande Lievens, Belgium
13:45 - 14:00  MS08.02 - How Can Real World Data Improve Clinical Evidence Generation and Impact Regulatory Bodies - US Perspective  
Gideon Blumenthal, USA

14:00 - 14:15  MS08.03 - Sources of Real World Data: Research Designs, Statistical Modelling and Quality Assurance Requirements  
Mary Redman, WA/USA

14:15 - 14:30  MS08.04 - The ASCO Perspective  
Bruce Johnson, MA/USA

14:30 - 14:45  MS08.05 - The ESTRO Perspective  
Umberto Ricardi, Italy

14:45 - 15:00  MS08.06 - Discussion

OA05

13:30 - 15:00  Clinical Trials in IO  
Room 106  
Topics: Advanced NSCLC  
Moderation: S. Owen, Canada; D. Moro-Sibilot, France

13:30 - 13:40  OA05.01 - Efficacy/Safety of Entinostat (ENT) and Pembrolizumab (PEMBRO) in NSCLC Patients Previously Treated with Anti-PD-(L)1 Therapy  
Matthew Hellmann, USA

13:40 - 13:50  OA05.02 - Epacadostat Plus Pembrolizumab in Patients with Non-Small Cell Lung Cancer: Phase 1/2 Results from ECHO-202/KEYNOTE-037  
Liza Villaruz, PA/USA

13:50 - 14:00  OA05.03 - Safety and Clinical Activity of Adoptive Cell Transfer Using Tumor Infiltrating Lymphocytes (TIL) Combined with Nivolumab in NSCLC  
Ben Creelan, FL/USA

14:00 - 14:15  OA05.04 - Discussant - OA 05.01, OA 05.02, OA 05.03  
Martin Edelman, MD/USA

14:15 - 14:25  OA05.05 - Avelumab vs Docetaxel for Previously Treated Advanced NSCLC: Primary Analysis of the Phase 3 JAVELIN Lung 200 Trial  
Fabrice Barlesi, France
14:25 - 14:35  OA05.06 - CheckMate 227: Patient-Reported Outcomes of First-Line Nivolumab + Ipilimumab in High Tumor Mutational Burden Advanced NSCLC
Julie Brahmer, MD/USA

14:35 - 14:45  OA05.07 - IMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC
Vassiliki Papadimitrakopoulou, TX/USA

14:45 - 15:00  OA05.08 - Discussant - OA 05.05, OA 05.06, OA 05.07
Hossein Borghaei, USA

OA06
13:30 - 15:00  Early Stage Lung Cancer: Outcomes and Interventions
Room 202 BD
Topics: Treatment of Early Stage/Localized Disease
Moderation: P. Van Schil, Belgium; H. Kato, Japan

13:30 - 13:40  OA06.01 - Case-Series Study in Ever- and Never-Smoking Females and Males with NSCLC: Exposures, Tumor Factors, Biology and Survival (SWOG S0424)
Kathy Albain, USA

13:40 - 13:50  OA06.02 - Video-Assisted Thoracoscopic Surgery vs. Thoracotomy for Non-Small Cell Lung Cancer: Oncologic Outcome of a Randomized Trial
Dongrong Situ, China

13:50 - 14:00  OA06.03 - Sublobar Resection is Equivalent to Lobectomy for Screen Detected Lung Cancer
Brendon Stiles, NY/USA

14:00 - 14:15  OA06.04 - Discussant - OA 06.01, OA 06.02, OA 06.03
Valerie Rusch, NY/USA

14:15 - 14:25  OA06.05 - Do SBRT Planning and Delivery Factors Influence Local Control for Early Stage Non-Small Cell Lung Cancer (e-NSCLC)?
Gregory Videtic, OH/USA

14:25 - 14:35  OA06.06 - MISSILE-NSCLC: A Phase II Trial Measuring the Integration of Stereotactic Radiotherapy Plus Surgery in Early-Stage Non-Small Cell Lung Cancer
David Palma, Canada

14:35 - 14:45  OA06.07 - Predictors and Consequences of Refusing Surgery for Clinical Stage I NSCLC: A National Cancer Database Analysis
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:45 - 15:00</td>
<td>QA06.08</td>
<td>Discussant - OA 06.05, OA 06.06, OA 06.07</td>
<td>Steven Lin, TX/USA</td>
</tr>
</tbody>
</table>

**PC02**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30 - 15:00</td>
<td>PC02</td>
<td>Debate on Local Therapies for Limited Small Cell Lung Cancer? Surgery PRO/CON and BID Radiation PRO/CON</td>
<td>Brendon Stiles, NY/USA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Topics: Small Cell Lung Cancer/NET</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Moderation: Q. Chu, Canada; W. Eberhardt, Germany</td>
<td></td>
</tr>
<tr>
<td>13:30 - 13:50</td>
<td>PC02.01</td>
<td>Surgery - PRO</td>
<td>Elliot Wakeam, Canada</td>
</tr>
<tr>
<td>13:50 - 14:10</td>
<td>PC02.02</td>
<td>Surgery - CON</td>
<td>Cecile Le Pechoux, France</td>
</tr>
<tr>
<td>14:10 - 14:30</td>
<td>PC02.03</td>
<td>BID Radiation - CON</td>
<td>Ben Slotman, Netherlands</td>
</tr>
<tr>
<td>14:30 - 14:50</td>
<td>PC02.04</td>
<td>BID Radiation - PRO</td>
<td>Jeffrey Bogart, USA</td>
</tr>
<tr>
<td>14:50 - 15:00</td>
<td>PC02.05</td>
<td>Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>

**MA08**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:15 - 16:45</td>
<td>MA08</td>
<td>Clinical Trials in Brain Metastases</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Topics: Advanced NSCLC</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Moderation: E. Filion, Canada; B. Melosky, Canada</td>
<td></td>
</tr>
<tr>
<td>15:15 - 15:20</td>
<td>MA08.01</td>
<td>Phase 3 Trial of Whole Brain Radiotherapy with Concurrent Erlotinib Versus WBRT Alone for NSCLC with Brain Metastases (ENTER)</td>
<td>Zhen Zhou Yang, China</td>
</tr>
<tr>
<td>15:20 - 15:25</td>
<td>MA08.02</td>
<td>Prophylactic Cranial Irradiation Reduces the Risk of Brain Metastases in High-Risk Lung Cancer Patients: EGFR and ALK Mutations</td>
<td>Oscar Arrieta, Mexico</td>
</tr>
<tr>
<td>Time</td>
<td>Session Description</td>
<td>Speaker(s)</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------------------------------------------------------------------------------------------</td>
<td>-------------------------------------</td>
<td></td>
</tr>
<tr>
<td>15:25 - 15:30</td>
<td>MA08.03 - EGFR-TKI Plus Brain Radiotherapy Versus EGFR-TKI Alone in the Management of EGFR Mutated NSCLC Patients with Brain Metastases: A Meta-Analysis</td>
<td>Wenhua Liang, China</td>
<td></td>
</tr>
<tr>
<td>15:30 - 15:45</td>
<td>MA08.04 - Discussant - MA 08.01, MA 08.02, MA 08.03</td>
<td>Nasser Hanna, IN/USA</td>
<td></td>
</tr>
<tr>
<td>15:45 - 15:50</td>
<td>MA08.05 - Brain Penetration of Lorlatinib and Cumulative Incidence Rates for CNS and Non CNS Progression from a Phase 1/2 Study</td>
<td>Todd Bauer, TN/USA</td>
<td></td>
</tr>
<tr>
<td>15:50 - 15:55</td>
<td>MA08.06 - Outcomes Among Patients with EGFR-Mutant Metastatic NSCLC with and without Brain Metastases</td>
<td>Janet Espirito, TX/USA</td>
<td></td>
</tr>
<tr>
<td>15:55 - 16:00</td>
<td>MA08.07 - Real World Data of Osimertinib in Patients with Central Nervous System (CNS) Metastasis in ASTRIS Korean Subset.</td>
<td>Jin-Hyoung Kang, Republic of Korea</td>
<td></td>
</tr>
<tr>
<td>16:00 - 16:15</td>
<td>MA08.08 - Discussant - MA 08.05, MA 08.06, MA 08.07</td>
<td>Myung-Ju Ahn, Republic of Korea</td>
<td></td>
</tr>
<tr>
<td>16:15 - 16:20</td>
<td>MA08.09 - Impact of Brain Metastases in Immune Checkpoint Inhibitors (ICI) Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients</td>
<td>Lizza Hendriks, Netherlands</td>
<td></td>
</tr>
<tr>
<td>16:20 - 16:25</td>
<td>MA08.10 - Real-Life Intracerebral Efficacy of Nivolumab in Non-Small Cell Lung Cancer Patients with Brain Metastases</td>
<td>Margaux Geier, France</td>
<td></td>
</tr>
<tr>
<td>16:25 - 16:30</td>
<td>MA08.11 - Early Safety Data of a Phase I/II Combining Nivolumab and Stereotactic Brain Radiosurgery for Treatment of Brain Metastases in Patients with NSCLC</td>
<td>Raafat Alameddine, Canada</td>
<td></td>
</tr>
<tr>
<td>16:30 - 16:45</td>
<td>MA08.12 - Discussant - MA 08.09, MA 08.10, MA 08.11</td>
<td>Arjun Sahgal, Canada</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session Title</td>
<td>Speaker(s)</td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>-------------------------------------------------------------------------------</td>
<td>------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>15:15</td>
<td>Lung Cancer Surgical and Molecular Pathology</td>
<td>Room 202 BD</td>
<td></td>
</tr>
<tr>
<td>15:15 - 15:20</td>
<td>MA09.01 - Correlation of Pre-Operative Cancer Imaging Techniques with Post-Operative Macro and Microscopic Lung Pathology Images</td>
<td>Stephen Harrow, UK</td>
<td></td>
</tr>
<tr>
<td>15:20 - 15:25</td>
<td>MA09.02 - Tumor Size and Frozen Section Should Be Considered Jointly to Predict the Final Pathology for Lung Adenocarcinoma</td>
<td>Erjia Zhu, China</td>
<td></td>
</tr>
<tr>
<td>15:25 - 15:30</td>
<td>MA09.03 - Multiple Pathological Variables Predict Efficacy of Adjuvant Chemotherapy in Primary Lung Adenocarcinoma</td>
<td>John Le Quesne, UK</td>
<td></td>
</tr>
<tr>
<td>15:30 - 15:45</td>
<td>MA09.04 - Discussant - MA 09.01, MA 09.02, MA 09.03</td>
<td>Natasha Rekhtman, NY/USA</td>
<td></td>
</tr>
<tr>
<td>15:45 - 15:50</td>
<td>MA09.05 - Can We Predict Radiosensitivity in Non-Small Cell Lung Cancer?</td>
<td>Juvenal Baena, UK</td>
<td></td>
</tr>
<tr>
<td>15:50 - 15:55</td>
<td>MA09.06 - The Newly Recognized Filigree Pattern of Micropapillary (MIP) Lung Adenocarcinoma (LADC) is as Clinically Important as the Classical Pattern</td>
<td>Katsura Emoto, USA</td>
<td></td>
</tr>
<tr>
<td>15:55 - 16:00</td>
<td>MA09.07 - Developing a Pathological Grading System in Predicting Prognosis for Invasive Mucinous Adenocarcinomas</td>
<td>Wei-Chin Chang, Taiwan</td>
<td></td>
</tr>
<tr>
<td>16:00 - 16:15</td>
<td>MA09.08 - Discussant - MA 09.05, MA 09.06, MA 09.07</td>
<td>Lucian Chirieac, MA/USA</td>
<td></td>
</tr>
<tr>
<td>16:15 - 16:20</td>
<td>MA09.09 - EBUS-TBNA in Assessing PD-L1 Expression in NSCLC</td>
<td>Jason Agulnik, Canada</td>
<td></td>
</tr>
<tr>
<td>16:20 - 16:25</td>
<td>MA09.10 - Molecular Profiling and PD-L1 Status in 900 Cases of Surgically Resected Non-Small Cell Lung Cancer with Clinical and Pathological Correlation</td>
<td>Zhaolin Xu, Canada</td>
<td></td>
</tr>
<tr>
<td>16:25 - 16:30</td>
<td>MA09.11 - Genomic Landscape and its Correlation with TMB, CD8 TILs and PD-L1 Expression in Chinese Lung Squamous Cell Carcinoma</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
MS09

15:15 - 16:45

**Tumour Board - Tissue Acquisition and Staging**

Topics: Interventional Diagnostics/Pulmonology
Moderation: S. Murgu, USA; E. Edell, USA

Room 206 BD

15:15 - 15:30

**MS09.01 - Cases Prepared by Drs. Edell/Murgu**

Neal Navani, UK

15:35 - 15:55

**MS09.02 - Cases Prepared by Drs. Edell/Murgu**

Karin Steinke, Australia

15:55 - 16:15

**MS09.03 - Cases Prepared by Drs. Edell/Murgu**

Kazuhiro Yasufuku, ON/Canada

16:15 - 16:35

**MS09.04 - Cases Prepared by Drs. Edell/Murgu**

David Hwang, Canada

16:35 - 16:45

**MS09.05 - Q&A**

---

MS10

15:15 - 16:45

**Part Solid Nodules, GGN and STAS**

Topics: Treatment of Early Stage/Localized Disease
Moderation: P. Van Schil, Belgium; N. Peled, Israel

Room 206 F

15:15 - 15:30

**MS10.01 - Radiographic Differences Between Presumed AIS and MIA**

Mini Pakkal, Canada

15:30 - 15:45

**MS10.02 - Importance of CT in the Pathologic Assessment of Tumor Sized in Subsolid and Part-Solid Adenocarcinoma**

Erik Thunnissen, Netherlands

15:45 - 16:00

**MS10.03 - CT Versus Needle Biopsy Assessment Before Resection of Part Solid Nodules**
Young Tae Kim, Republic of Korea

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00 - 16:15</td>
<td>MS10.04</td>
<td>Therapeutic Implications of Spread Through Air Spaces (STAS)</td>
<td>William Travis, USA</td>
</tr>
<tr>
<td>16:15 - 16:30</td>
<td>MS10.05</td>
<td>Should We Resect GGNs</td>
<td>Kenji Suzuki, Japan</td>
</tr>
<tr>
<td>16:30 - 16:45</td>
<td>MS10.06</td>
<td>Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>

### MS11

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:15 - 16:45</td>
<td></td>
<td>Stigma and Lung Cancer: Unintended Translational Consequences of Effective Tobacco Control</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Topics: Prevention and Tobacco Control</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Moderation: A. Rosell, Spain; L. Zhang, China</td>
<td></td>
</tr>
<tr>
<td>15:15 - 15:35</td>
<td>MS11.01</td>
<td>Identifying Consequences of Stigma on Lung Cancer Care Delivery and Patient Outcomes</td>
<td>Heidi Hamann, USA</td>
</tr>
<tr>
<td>15:35 - 15:55</td>
<td>MS11.02</td>
<td>Stigma of Tobacco and Lung Cancer: A South American Perspective</td>
<td>Clarissa Baldotto, Brazil</td>
</tr>
<tr>
<td>15:55 - 16:15</td>
<td>MS11.03</td>
<td>Prevalence of Perceived Lung Cancer Stigma Among Medical and Nursing Students</td>
<td>Jamie Studts, KY/USA</td>
</tr>
<tr>
<td>16:15 - 16:35</td>
<td>MS11.04</td>
<td>Taking a Smoking History in the Context of Lung Cancer Treatment: Missed Opportunities for Stigma-Reducing Empathic Encounters with Thoracic Oncologists</td>
<td>Peter Harper, USA</td>
</tr>
<tr>
<td>16:35 - 16:45</td>
<td>MS11.05</td>
<td>Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>

### MS12

Monday, September 24, 18
15:15 - 16:45 Immunotherapy and RT
Room 105
Topics: Treatment of Locoregional Disease - NSCLC
Moderation: Y.-L. Wu, China; J. Salama, USA

15:15 - 15:35  MS12.01 - Biology IO+RT
Dirk De Ruysscher, Belgium

15:35 - 15:55  MS12.02 - Clinical Data Available
Feng-Ming (Spring) Kong, AL/USA

15:55 - 16:15  MS12.03 - Ongoing Studies
Francoise Mornex, France

16:15 - 16:35  MS12.04 - Implications for Routine Practice
Paul Mitchell, Australia

16:35 - 16:45  MS12.05 - Q&A

15:15 - 16:45 Oligometastasis: What Should Be the State-Of-The-Art?
Room 107
Topics: Oligometastatic NSCLC
Moderation: Y. Ung, Canada; P. Mulvenna, UK

15:15 - 15:25  OA07.01 - Phase II Study of Pembrolizumab for Oligometastatic Non-Small Cell Lung Cancer (NSCLC) Following Completion of Locally Ablative Therapy (LAT)
Joshua Bauml, PA/USA

15:25 - 15:35  OA07.02 - ATOM: A Phase II Study to Assess Efficacy of Preemptive Local Ablative Therapy to Residual Oligometastases After EGFR TKI
Oscar S H Chan, China

15:35 - 15:45  OA07.03 - Addition of Local Therapy to EGFR TKI Showed Survival Benefit in EGFR-Mutant NSCLC pts with Oligometastatic or Oligoprogressive Liver Metastases
Tao Jiang, China

15:45 - 16:00  OA07.04 - Discussant - OA 07.01, OA 07.02, OA 07.03
Gregory Videtic, OH/USA
16:00 - 16:10  OA07.05 - Local Ablative Therapy Improves Survival in Patients with Synchronous Oligometastatic NSCLC Harboring EGFR Mutation Treated with EGFR-TKIs
Yaping Xu, China

16:10 - 16:20  OA07.06 - Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring EGFR Mutations.
Fang Hu, China

16:20 - 16:30  OA07.07 - PFS and OS Beyond 5 years of NSCLC Patients with Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450)
Dirk De Ruyscher, Belgium

16:30 - 16:45  OA07.08 - Discussant - OA 07.05, OA 07.06, OA 07.07
Sue Yom, CA/USA

OA08

15:15 - 16:45  Mesothelioma: Immunotherapy and microRNA for Diagnosis and Treatment  Room 201 BD
Topics: Mesothelioma
Moderation: D. Fennell, UK; J. Cho, Canada

15:15 - 15:25  OA08.01 - Long-Term Efficacy and Safety of Nivolumab in Second- or Third-Line Japanese Malignant Pleural Mesothelioma Patients (Phase II: MERIT Study)
Takashi Nakano, Japan

15:25 - 15:35  OA08.02 - DREAM - A Phase 2 Trial of Durvalumab with First Line Chemotherapy in Mesothelioma: Final Result
Anna Nowak, Australia

15:35 - 15:45  OA08.03 - Phase II Trial of Pembrolizumab (NCT02399371) In Previously-Treated Malignant Mesothelioma (MM): Final Analysis
Arpita Desai, USA

15:45 - 16:00  OA08.04 - Discussant - OA 08.01, OA 08.02, OA 08.03
Thomas John, Australia

16:00 - 16:10  OA08.05 - Quantifying Tumour Infiltrating Lymphocytes (TILs) in Malignant Pleural Mesothelioma (MPM) -Defining the Hot, the Warm and the Cold Tumours.
Bibhusal Thapa, VIC/Australia
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:10</td>
<td>OA08.06</td>
<td>Tumour Suppressor MicroRNAs Modulate Drug Resistance by Targeting Anti-Apoptotic Pathways in Malignant Pleural Mesothelioma (MPM)</td>
<td>Yuen Yee Cheng, Australia</td>
<td></td>
</tr>
<tr>
<td>16:20</td>
<td>OA08.07</td>
<td>In Silico Discovery of Unannotated miRNAs in Malignant Pleural Mesothelioma Reveals Novel Tissue-of-Origin Markers</td>
<td>Brenda Minatel, BC/Canada</td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td>OA08.08</td>
<td>Discussant - OA 08.05, OA 08.06, OA 08.07</td>
<td>Emanuela Felley-Bosco, Switzerland</td>
<td></td>
</tr>
<tr>
<td>15:15</td>
<td>OA09</td>
<td>Prevention and Cessation</td>
<td></td>
<td>Room 205 B</td>
</tr>
<tr>
<td>15:15</td>
<td>OA09.01</td>
<td>5As to 3As: Evolution of the Systematic Approach to Smoking Cessation in Ontario’s Regional Cancer Centres</td>
<td>William Evans, ON/Canada</td>
<td></td>
</tr>
<tr>
<td>15:25</td>
<td>OA09.02</td>
<td>Acceptance of Smoking Cessation Services in Cancer Care Ontario’s Lung Cancer Screening Pilot for People at High Risk</td>
<td>William Evans, ON/Canada</td>
<td></td>
</tr>
<tr>
<td>15:35</td>
<td>OA09.03</td>
<td>Discussions Between Health Professionals and Smokers About E-Cigarettes: Results from the ITC Policy Evaluation Project</td>
<td>Shannon Gravely, ON/Canada</td>
<td></td>
</tr>
<tr>
<td>15:45</td>
<td>OA09.04</td>
<td>Discussant - OA 09.01, OA 09.02, OA 09.03</td>
<td>Betty Tong, USA</td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td>OA09.05</td>
<td>Potential Reduction in Lung Cancer Mortality in the US from 2015-2065: A Comparative Modeling Approach</td>
<td>Jihyoun Jeon, MI/USA</td>
<td></td>
</tr>
<tr>
<td>16:10</td>
<td>OA09.06</td>
<td>Molecular Alterations and Estimated Indoor Radon in NSCLC Patients from the French National Cancer Institute Registry: Radon France Study</td>
<td>Laura Mezquita, France</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| 16:20 - 16:30 | OA09.07 - Association Between Outdoor Air Pollution and Lung Cancer in Female Never Smokers  
Renelle Myers, MB/Canada |
| 16:30 - 16:45 | OA09.08 - Discussant - OA 09.05, OA 09.06, OA 09.07  
Doug Arenberg, MI/USA |

**PC03**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 15:15 - 16:15 | Controversies in Management of Resectable Thymoma  
Topics: Thymoma/Other Thoracic Malignancies  
Moderation: N. Ikeda, Japan; A. Bezjak, Canada |
| 15:15 - 15:25 | PC03.01 - Post-Operative Radiation Therapy or NOT: PRO  
Conrad Falkson, Canada |
| 15:25 - 15:35 | PC03.02 - Post-Operative Radiation Therapy or NOT: CON  
Daniel Gomez, USA |
| 15:35 - 15:45 | PC03.03 - Discussion |
| 15:45 - 15:55 | PC03.04 - Debate on Standard Surgical Approaches - Minimally Invasive Thymectomy  
Shaf Keshavjee, Canada |
| 15:55 - 16:05 | PC03.05 - Debate on Standard Surgical Approaches - Open Thymectomy  
Meinoshin Okumura, Japan |
| 16:05 - 16:15 | PC03.06 - Discussion |
| 16:15 - 16:25 | PC03.07 - Adjuvant Chemotherapy for Thymic Carcinoma - YES  
Giulia Pasello, Italy |
| 16:25 - 16:35 | PC03.08 - Adjuvant Chemotherapy for Thymic Carcinoma - NO  
Sukhmani Padda, CA/USA |
| 16:35 - 16:45 | PC03.09 - Discussion |
### PC04

**Targeted Therapy for NSCLC**

**Room 106**

**Topics:** Targeted Therapy  
**Moderation:** Z. Piotrowska, USA; B. Solomon, Australia

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:15 - 15:27</td>
<td><strong>PC04.01 - Optimal Sequencing of EGFR TKI Therapy (Gefitinib/Erlotinib/Afatinib First versus Osimertinib First)</strong></td>
<td>James Chih-Hsin Yang, Taiwan</td>
</tr>
<tr>
<td>15:27 - 15:39</td>
<td><strong>PC04.02 - Optimal Sequencing of EGFR TKI Therapy - 3rd Generation First</strong></td>
<td>Karen Reckamp, CA/USA</td>
</tr>
<tr>
<td>15:39 - 15:51</td>
<td><strong>PC04.03 - Adjuvant Targeted Therapy for pts with Genomic Alterations - Yes</strong></td>
<td>Shun Lu, China</td>
</tr>
<tr>
<td>15:51 - 16:03</td>
<td><strong>PC04.04 - Adjuvant Targeted Therapy for pts with Genomic Alterations - No</strong></td>
<td>Lecia Sequist, MA/USA</td>
</tr>
<tr>
<td>16:03 - 16:15</td>
<td><strong>PC04.05 - NGS/Whole Exome Sequencing for Routine Use</strong></td>
<td>Daniel Tan, Singapore</td>
</tr>
<tr>
<td>16:15 - 16:27</td>
<td><strong>PC04.06 - Focused Panels for Molecular Profiling for Routine Use</strong></td>
<td>Fernando Lopez-Rios, Spain</td>
</tr>
<tr>
<td>16:27 - 16:45</td>
<td><strong>PC04.07 - Q&amp;A</strong></td>
<td></td>
</tr>
</tbody>
</table>

**P1.01**

**Advanced NSCLC**

**Exhibit Hall**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:45 - 18:00</td>
<td><strong>P1.01-01 - ROS1-Positive Non-Small Cell Lung Cancer: Real-World Data in Korea</strong></td>
<td>Beung Chul Ahn, Republic of Korea</td>
</tr>
<tr>
<td></td>
<td><strong>P1.01-02 - Long-Term Outcomes with First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up from CheckMate 012</strong></td>
<td>Scott Antonia, FL/USA</td>
</tr>
<tr>
<td></td>
<td><strong>P1.01-03 - Effect of Prophylactic Cranial Irradiation on Cognitive Function and QoL in NSCLC Patients at High Risk of Brain Metastases</strong></td>
<td>Oscar Arrieta, Mexico</td>
</tr>
</tbody>
</table>
P1.01-04 - Treatment Patterns and Overall Survival Following Biomarker Testing in Real-World Advanced NSCLC Patients
Fabrice Barlesi, France

P1.01-05 - Metformin in Combination with Crizotinib for The Treatment of EML4-ALK+ Lung Cancer.
Abigail Bland, New Zealand

P1.01-06 - Plinabulin, a Novel Immuno-Oncology Agent Mitigates Docetaxel Chemotherapy - Induced-Neutropenia and -Thrombocytopenia in NSCLC Patients.
Douglas Blayney, CA/USA

P1.01-07 - Immune-Related Pneumonitis in NSCLC Patients Treated with Immune Checkpoint Inhibitors (ICI): Impact of Previous Thoracic Radiotherapy
Angela Botticella, France

P1.01-08 - Hyperresponsive Disease: A New Pattern of Response in NSCLC Patients Treated by Anti-PD-1/PD-L1
Nicole Bouchard, Canada

P1.01-09 - Pembro litigation Plus Ipilimumab or Placebo in 1L Metastatic NSCLC with PD-L1 Tumor Proportion Score (TPS) ≥50%: KEYNOTE-598
Michael Boyer, ACT/Australia

P1.01-10 - Stage III Non-Small Cell Lung Cancer Clinical Outcomes with Surgical Resection After Definitive Neoadjuvant Chemoradiotherapy
Ilaria Caturegli, USA

P1.01-11 - Named Patient Use Program for Afatinib in Advanced NSCLC with Progression on Prior Therapy: Experience from Asian Centers
Keunchil Park, Republic of Korea

P1.01-12 - SWitch Maintenance PEmbrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (SWIPE)
Haris Charalambous, Cyprus

P1.01-13 - A Study of S-1 Plus Cisplatin in Patients with Advanced Non-Small-Cell Lung Cancer
Yuh-Min Chen, Taiwan

P1.01-14 - Immunotherapy (I) for Advanced, Pre-Treated, Non-Squamous NSCLC (APNS-NSCLC). Preliminary Data of a Pooled Analysis
Lorenza Landi, Italy

P1.01-15 - ROS1-Rearranged Non-Small Cell Lung Cancer Is Associated with High Rate of Venous Thromboembolism: Analysis of The METROS Trial
Biagio Ricciuti, Italy

P1.01-16 - First-Line Pembrolizumab With or Without Chemotherapy in PD-L1 positive NSCLC: A Network Meta-Analysis of Randomized Trials.
Mark Doherty, Canada
P1.01-17 - Immune-Related Adverse Events in Patients with Metastatic Non-Small Cell Lung Cancer: Sex Differences and Response to Therapy.
Narjust Duma, MN/USA

P1.01-18 - Immunosenescence Correlates with Progression upon PD-(L)-1 Blockade (IO) in Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients.
Roberto Ferrara, France

P1.01-19 - Efficacy of Tyrosine Kinase Inhibitors in EGFR Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases.
Ronan Flippot, France

P1.01-20 - Phase III Study Comparing Gefitinib (G) to Gefitinib Combined with Carboplatin and Pemetrexed (GCP) for NSCLC with EGFR Mutations (NEJ009).
Tatsuro Fukuhara, Japan

P1.01-21 - Safety of Durvalumab Retreatment in Advanced NSCLC Patients Who Progressed Following Initial Disease Control In ATLANTIC
Marina Garassino, Italy

P1.01-22 - Effect of Basal Lymphopenia on Outcome of Non-Small Cell Lung Cancer Patients Treated with Immunotherapy
Giulia Galli, Italy

P1.01-23 - High PD-L1 Expression is Less Common Than Expected Among Advanced NSCLC in Brazil. Are We Missing the Target?
Ana Gelatti, Brazil

P1.01-24 - Clinical Efficacy of Immunotherapy in Metastatic Non-Small Cell Lung Cancer Patients Treated with Prior Radiotherapy
Daniel Glick, BC/Canada

P1.01-25 - Carboplatin and Pemetrexed Plus Bevacizumab After Failure of First-Line EGFR-TKI Therapy for NSCLC Harboring EGFR Mutation (CJLSG 0908)
Yasuhiro Goto, Japan

P1.01-26 - Single-Centre Experience of Clinical Outcomes for Advanced Lung Cancer Patients in Phase I Clinical Trials.
Donna Graham, UK
P1.01-27 - Influence of EGFR-TKIs Treatment Lines and PFS on the Emergence of T790M Mutation
Xiaorong Dong, China

P1.01-28 - Impact of Afatinib Dosing on Safety and Efficacy Real-World in Patients with EGFR Mutation-Positive Advanced NSCLC
Balazs Halmos, NY/USA

P1.01-29 - Crizotinib in Advanced Lung Adenocarcinoma Patients with ALK or ROS-1 Rearrangement: Is it the Same?
Baohui Han, China

P1.01-30 - Crizotinib in Advanced Non-Adenocarcinoma, NSCLC (NA-NSCLC) Patients with ALK Rearrangement: A Retrospective Study and Literature Review
Baohui Han, China

P1.01-31 - Weekly Regimen of PAXUS-PM, a Novel Cremophor-Free, with Carboplatin in Patients with Advanced Non-Small-Cell Lung Cancer in Vietnam
Mi-Ryung Jin, Republic of Korea

P1.01-32 - A Multicenter, Open-Label, Phase II Trial of S-1 Plus Carboplatin in Advanced Non-Small Cell Lung Cancer Patients with Interstitial Lung Disease
Masaki Hanibuchi, Japan

P1.01-33 - Randomized Phase 2 Study Comparing CBDCA+PTX+BEV and CDDP+PEM+BEV in Treatment-Naïve Advanced Non-Sq NSCLC (CLEAR study)
Toshiyuki Harada, Japan

P1.01-34 - Docetaxel Plus Ramucirumab with Prophylactic PEG-G-CSF Support for Chemo-Naïve Elderly NSCLC Patients: A Phase II Study (WJOG9416L)
Akito Hata, Japan

P1.01-35 - Tumor Volume Analysis In ALK-Rearranged NSCLC Treated with Crizotinib: Identifying an Early Marker for Clinical Outcome
Tomoyuki Hida, USA

P1.01-36 - Thoracic Surgery in Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutant After Tyrosine Kinase Inhibitor Therapy
Chen-Hao Hsiao, Taiwan

P1.01-37 - BPI-9016M, a Novel c-Met Inhibitor, in Pretreated Advanced Solid Tumor: Results from a First-In-Human, Phase 1, Dose-Escalation Study
Xingsheng Hu, China
P1.01-38 - A Phase II with a Lead-In Phase I Study to Examine Safety and Efficacy of Hydroxychloroquine and Gefitinib in Advanced NSCLC
Yiqing Huang, Singapore

P1.01-39 - Cost-Effectiveness of Crizotinib Versus Chemotherapy as First-Line Treatment of ALK Positive Advanced NSCLC -- A Real World Study
Meijuan Huang, China

P1.01-40 - Randomized Phase II Study of Docetaxel Plus Bevacizumab or Pemetrexed Plus Bevacizumab for Elderly pts with Untreated Advanced NSCLC: TORG1323
Kentaro Ito, Japan

P1.01-41 - A Phase 2 Study of DS-8201a in HER2-Overexpressing or -Mutated Advanced Non-Small-Cell Lung Cancer
Pasi Jänne, MA/USA

P1.01-42 - Real-World Evaluation of Tolerability in Older Adult Patients (≥75 years old) with EGFR-mutated NSCLC
Shirley Jiang, Canada

P1.01-43 - Next-Generation Sequencing in the Exploration of Genetic Heterogeneity for Lung Adenocarcinoma Patients with EGFR Activating Mutations
Ying Jin, China

P1.01-44 - Outcome of Uncommon EGFR Mutation Positive Newly Diagnosed Advanced NSCLC Patients: A Single-Centre Retrospective Analysis
Shruti Kate, India

P1.01-45 - Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience from Turkey
Saadettin Kılıçkap, Turkey

P1.01-46 - Circulating Tumor DNA Analysis for Predicting Response to Osimertinib and Disease Progression in EGFR-Mutant Non-Small-Cell Lung Cancer
Chul Kim, USA

P1.01-47 - Phase I/II Trial of Dasatinib and Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Chul Kim, USA
P1.01-48 - Nab-Paclitaxel Plus Gemcitabine in Advanced NSCLC After Platinum-Based Chemotherapy: Final Results and Caveolin-1 Expression
Tatsunori Kiriu, Japan

P1.01-49 - irAE, Possible Predictive Markers for Immune Checkpoint Inhibitors
Kazutoshi Komiya, Japan

P1.01-50 - Real World Experience of Nivolumab in Patients with Metastatic Nonsmall Cell Lung Cancer (mNSCLC)
Doran Ksienski, BC/Canada

P1.01-51 - Real world Experience of Pembrolizumab in Patients with Metastatic Nonsmall Cell Lung Cancer (mNSCLC)
Doran Ksienski, BC/Canada

P1.01-52 - BR-34- Randomized Trial of Durvalumab & Tremelimumab +/- Platinum Chemotherapy in Patients with Metastatic Squamous or Non-Squamous NSCLC
Swati Kulkarni, ON/Canada

P1.01-53 - Bone Metastases and Efficacy of Immunotherapy in Patients with Pretreated Advanced Non-Small-Cell Lung Cancer (NSCLC)
Lorenza Landi, Italy

P1.01-54 - A Phase I/Ib Study of Binimetinib (MEK162), a MEK Inhibitor Plus Carboplatin/Pemetrexed in Non-Squamous NSCLC
Natasha Leighl, ON/Canada

P1.01-55 - Unique Genetic Profiles from Cerebrospinal Fluid Could Predict Survival of EGFR-Mutant NSCLC with Leptomeningeal Metastases
Yangsi Li, China

P1.01-56 - Concurrent Mutations in Chinese Lung Cancer Patients Carrying HER2 Genomic Aberrations
Xuefang Xia, China

P1.01-58 - Variants Distribution and Heterogeneity of Outcomes to Crizotinib in ALK-Rearranged Chinese Non-Small Cell Lung Cancers
Naixin Liang, China

P1.01-59 - A Better Real-World Practice for ROS1 Positive NSCLC Patients, Driven by the Targeted Next Generation Sequencing (NGS) and the Targeted TKI
Yongchang Zhang, China
P1.01-60 - Preventing and Treating Brain Metastases with Three First-Line EGFR-TKI in Patients with EGFR Mutation Advanced NSCLC
Chien-Chung Lin, Taiwan

P1.01-61 - Clinical Characterization of ERBB2 Exon 20 Insertions and Heterogeneity of Outcomes to Afatinib in Chinese Lung Cancers
Zhefeng Liu, China

P1.01-62 - The Third Generation Irreversible EGFR Inhibitor HS-10296 in Advanced Non-Small Cell Lung Cancer Patients
Shun Lu, China

P1.01-63 - Correlation Between Immune-Related Adverse Events and Efficacy of Immune-Checkpoint Inhibitors in Patients with Non-Small Cell Lung Cancer
Margarita Majem Tarruella, Spain

P1.01-64 - Impact of STK11 Co-Mutation on Outcomes Following Immunotherapy Among Patients with TP53 and KRAS Mutated Stage IV NSCLC
Melina Marmarelis, PA/USA

P1.01-65 - PII of Pemetrexed or Pemetrexed Plus Bevacizumab for Previously Untreated Elderly (>=75) Non-Squamous NSCLC (LOGIK1201)
RIICHIRO Maruyama, Japan

P1.01-66 - Randomized Phase II Evaluating EGFR-TKI Associated with Anti-Estrogen in Women with Non-Squamous Advanced Stage NSCLC: IFCT-1003 LADIE Trial.
Julien Mazieres, France

P1.01-67 - Clinical Relevance of ALK/ROS1 Resistance Mutations and Other Acquired Mutations Detected by Liquid Biopsy in Advanced NSCLC Patients
Laura Mezquita, France

P1.01-68 - Correlation of the Lung Immune Prognostic Index (LIPI) and PDL1 Status with Outcomes for Immune Checkpoint Inhibitors in Advanced NSCLC Patients
Laura Mezquita, France

P1.01-69 - Validation of the Lung Immune Prognostic Index (LIPI): Useful to Identify Resistance to PD-1 Checkpoint Inhibitors in Pretreated Lung Cancer
Xabier Mielgo-Rubio, Spain

P1.01-70 - Efficacy and Safety of Second- or Third-Line Nab-Paclitaxel + Durvalumab in Patients with Advanced NSCLC (ABOUND.2L+)
Daniel Morgensztern, USA

P1.01-71 - Co-Mutations, Natural History, and Outcomes of BRAF-Mutated Non-Small Cell Lung Cancer at a Single Academic Cancer Center
Nathaniel Myall, USA

P1.01-72 - FIND Trial: A Phase II Study to Evaluate the Efficacy of the FGFR-Inhibitor Erdafitinib in FGFR-Mutated and -Translocated Squamous NSCLC
Jürgen Wolf, Germany

P1.01-73 - Preliminary Results of the SENECA (SEcond Line NintEdanib in Non-Small Cell Lung Cancer) Trial: An Italian Experience.
Silvia Novello, Italy

P1.01-74 - MET Exon 14-Altered Lung Cancers: Central Nervous System (CNS) Metastases and Patterns of CNS Progression on MET Inhibition.
Michael Offin, NY/USA

Michael Offin, NY/USA

P1.01-76 - A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers
Paul Paik, NY/USA

P1.01-77 - Osimertinib in the First-Line Treatment of Non-Small Cell Lung Cancer Harboring Activating EGFR Mutation from Circulating Tumor DNA
Cheol-Kyu Park, Republic of Korea

P1.01-78 - The Incidence of Brain Metastases in ROS1-Rearranged Non-Small Cell Lung Cancer at Diagnosis and Following Progression on Crizotinib
Tejas Patil, CO/USA

P1.01-79 - CheckMate 817: Safety of Flat-Dose Nivolumab Plus Weight-Based Ipilimumab for the First-line (1L) Treatment of Advanced NSCLC
Luis Paz-Ares, Spain

P1.01-80 - ELIOS: A Multicenter, Open-Label, Molecular Profiling Study of Patients with EGFRm and NSCLC Treated with Osimertinib
Zosia Piotrowska, MA/USA
P1.01-81 - Phase 3 Study of Pemetrexed-Platinum with or without Pembrolizumab for TKI-Resistant/EGFR-Mutated Advanced NSCLC: KEYNOTE-789
Gregory Riely, NY/USA

P1.01-82 - Risk of Not Receiving 2nd Line Therapy is High in EGFR mt+ pts: Real World Data of Certified Lung Cancer Centers on Treatment Sequence in EGFR mt+ pts
Julia Roeper, Germany

P1.01-83 - IMpower150: Impact of Chemotherapy Cycles in 1L Metastatic NSCLC in Patients Treated with Atezolizumab + Bevacizumab
Jeffrey Rothenstein, ON/Canada

P1.01-84 - High Basal Serum EGF Levels Predicts Response to CIMAavax-EGF, a Therapeutic Vaccine for Advanced NSCLC
Orestes Santos Morales, Cuba

P1.01-85 - The Prevalence of Different EGFR exon20 Mutations in 12,833 Chinese Lung Cancer Patients
Yang W Shao, Canada

P1.01-86 - BTCRC-LUN15-017: Phase-Ib Study of Imprime PGG and Pembrolizumab in Stage IV NSCLC after Progression on Platinum Based Therapy
Ardaman Shergill, IL/USA

P1.01-87 - A Phase 1b Study of TRC105 In Combination with Paclitaxel/Carboplatin and Bevacizumab in Patients with Stage 4 Non-Squamous Cell Lung Cancer
Garrett Sherwood, AL/USA

P1.01-88 - Osimertinib Maintenance After Definitive Chemoradiation in Patients with Unresectable EGFRm-Positive Stage III NSCLC (LAURA)
Lu Shun, China

P1.01-89 - Analysis and Monitoring CTCs and ctDNA in CSF Demonstrates Clinical Concordance in Tesevatinib Treated NSCLC Patients with LM
Veena Singh, CA/USA

P1.01-90 - A Pilot Trial Assessing Apatinib Combined with Docetaxel (DTX) as Second-Line Chemotherapy for EGFR Negative Advanced NSCLC)
Yong Song, China

P1.01-91 - A Phase I Study of Fixed Dose Vinorelbine and Escalating Doses of Ifosfamide in First-Line Advanced Non-Small Cell Lung Cancer
Julian Surujballi, Canada

P1.01-92 - A Phase II Study of Afatinib Treatment for Elderly Patients with Previously Untreated Advanced NSCLC Harboring EGFR Mutations

Kensuke Suzuki, Japan

P1.01-93 - Quality of Life in Patients with Advanced NSCLC Treated in Second- or Third-Line with Nab-Paclitaxel + Durvalumab: ABOUND.2L+

Santiago Ponce Aix, Spain

P1.01-94 - Phase I Trial to Establish Maximum Tolerated Dose Safety and Pharmacokinetic Profile of Oral Paclitaxel

Satheesh Thungappa, India

P1.01-95 - Crizotinib Treatment in 29 Advanced NSCLC Chinese Patients with ROS1 Rearrangement—A Single Chinese Cancer Institute Experience

Jialei Wang, China

P1.01-96 - Concurrent ALK/EGFR Alterations in Chinese Lung Cancers: Frequency, Clinical Features, and Differential Response to Therapy

Da Wu, China

P1.01-97 - Cluster Trial: Ph2 Biomarker-Integrated Study of Single Agent Alpelisib, Capmatinib, Ceritinib and Binimetinib in advNSCLC

Yi-Long Wu, China

P1.01-98 - A Phase IIIb Trial of Afatinib in EGFRm+ NSCLC: Analyses of Outcomes in Patients with Brain Metastases or Dose Reductions

Yi-Long Wu, China

P1.01-99 - Detecting HER2 Alterations by Next Generation Sequencing (NGS) in Patients with Advanced NSCLC from the United States and China

Chong-Rui Xu, China

P1.01-100 - Concurrent Brain Radiotherapy and EGFR-TKI Have Better Survival Benefits in Patients with Brain Metastases from EGFR-Mutant NSCLC

Yaping Xu, China

P1.01-101 - Survival Benefit of Sequential Therapy in ALK Positive Olioprogressive NSCLC Patients After Crizotinib Resistance

Haiyan Xu, China
P1.01-102 - Retrospective Analysis of Immune Checkpoint Inhibitors in Patients with EGFR Mutated Non-Small Cell Lung Cancer in a Japanese Cohort
Tadaaki Yamada, Japan

P1.01-103 - Leukocyte Telomere Length as a Novel Biomarker in Advanced Lung Adenocarcinoma Patients Treated with Gefitinib
Ming Yang, China

P1.01-104 - Updated Phase I Results of Carboplatin, Pemetrexed and Exemestane in Postmenopausal Women with Metastatic Non-Squamous NSCLC
Patricia Young, CA/USA

P1.01-105 - Lung Cancer Patients with Concurrent EGFR and MET Mutations: A Retrospective Analysis of 29 Cases
Zhaoxia Wang, China

P1.01-106 - Pembrolizumab Randomized, Phase 1 Study in Chinese Patients with Advanced NSCLC: KEYNOTE-032.
Li Zhang, China

P1.01-107 - The Impact of Anlotinib on Quality of Life in Patients with Advance NSCLC: Post-Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303)
Li Zhang, China

P1.01-108 - Management of Anlotinib-Related Adverse Events: Data from ALTER 0303
Li Zhang, China

P1.01-109 - Phase I Study of Apatinib Plus Gefitinib as First-Line Therapy in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer
Hongyun Zhao, China

P1.01-110 - Three Specific HER2 Mutations Predict Favorable Outcomes in Advanced Lung Cancer Patients Treated with Afatinib
Shen Zhao, China

P1.01-111 - EGFR exon20 Insertion Patients Treated with First-Line Chemotherapy in Non-Small Cell Lung Cancer
Chao Zhao, China

P1.01-112 - Osimertinib vs Standard of Care (SoC) EGFR-TKI as First-Line Treatment in Chinese Patients with EGFRm Advanced NSCLC
Caicun Zhou, China

P1.01-113 - Analysis of Clinicopathological Features and Clinical Efficacy of Crizotinib in ROS1 Positive Non-Small Cell Lung Cancer
Youcai Zhu, China

P1.02

16:45 - 18:00 Advocacy Exhibit Hall

P1.02-01 - Imaging of Lung Cancer at the University College Hospital, Ibadan, Nigeria: Does Nuclear Medicine Have Anything to Offer?
Olusegun Ayeni, South Africa

P1.02-02 - ‘Listen to Your Lungs’ - An Awareness Campaign from The Marie Keating Foundation
Anne-Marie Baird, Australia

P1.02-04 - The EGFR Resisters Lung Cancer Group: A Patient-Driven Initiative to Understand & Improve Treatments for EGFR+ Lung Cancer
Jill Feldman, USA

P1.02-03 - The Role of Lung Cancer Advocacy Organizations in Biomarker Testing
Winfield Boerckel, USA

P1.02-05 - ALK Positive Lung Cancer: Patient Engagement and Partnership
Shelly Engfer-Triebenbach, NY/USA

P1.02-06 - Usefulness of Workshop to Promote Communication Between Patient and Family
Kazuo Hasegawa, Japan

P1.02-07 - The Role of Volunteers in Quality Palliative Care Delivery for Advance Lung Cancer
Aditya Manna, India

P1.02-08 - Hope for People Living with Metastatic Lung Cancer
Aditya Manna, India

P1.02-09 - Identifying Gaps in Messaging for Biomarker Testing in the Lung Cancer Community: Need for Consistent and Actionable Messaging
Upal Basu Roy, MD/USA
P1.02-10 - “We Are Ambassadors for Survivors:” Experiences of Lung Cancer Support Group Attendees and Facilitators  
Maureen Rigney, DC/USA

P1.02-11 - Lung Cancer Symptom Awareness: Findings from a Global Consumer Survey  
Maureen Rigney, DC/USA

P1.03
16:45 - 18:00  Biology  Exhibit Hall

P1.03-01 - Association of APC Mutations with Chinese Patients Molecular Spectrum in Non-Small-Cell Lung Cancer  
Shuitu Feng, China

P1.03-02 - Analysis of SMAD4 Aberrations in Chinese Patients with Non-Small-Cell Lung Cancer  
Jianhui Huang, China

P1.03-03 - Molecular Characteristics of Chinese Patients with TSC2-Mutated Non-Small-Cell Lung Cancer: A Retrospective Study  
Zhangzhou Huang, China

P1.03-04 - Molecular Characteristics of ALK Primary Point Mutations Non-Small-Cell Lung Cancer in Chinese Patients  
Chunwei Xu, China

P1.03-05 - Transcriptome Landscape of Lung Adenocarcinoma Patients Revealed Distinct Trajectory Patterns  
Yuqing Lou, China

P1.03-06 - Molecular Landscape of FGFR1 Point Mutations in Chinese Non-Small-Cell Lung Cancer Patients: A Retrospective Study  
Quxia Zhang, China

P1.03-07 - A Comparison of Consistency of Detecting HER2 Gene Mutations in Peripheral Blood and Tumor Tissue of Non-Small-Cell Lung Cancer Patients  
Chunwei Xu, China

P1.03-08 - Detection of PTCH1 Gene Variants in Non-Small Cell Lung Cancer Patients from China
Quxia Zhang, China

P1.03-09 - ROS1 Rearrangement in Pulmonary Sarcomatoid Carcinoma: A Retrospective Study of the Real World
Chunwei Xu, China

P1.03-10 - The Molecular Spectrum of NF1 Variants in Chinese Non-Small-Cell Lung Cancer Patients
Quxia Zhang, China

P1.03-11 - Analysis of T-Cell Repertoires in Benign and Malignant Solitary Pulmonary Nodules to Evaluate Tumor Immune Microenvironment
Min Li, China

P1.03-12 - PD-L1 Expression is Predominant in CD68+ Tumor-Associated Macrophages in Stage I-III Non-Small Cell Lung Cancers
Boris Sepesi, TX/USA

P1.03-13 - eIF2β, A Subunit of Translation-Initiation Factor EIF2, as a Potential Therapeutic Target for Non-Small Cell Lung Cancer
Daiki Goto, Japan

P1.03-14 - Interaction Between Celecoxib and Cisplatin is Dependent on the p53 Status in Human NSCLC Cell Lines
Weiying Li, China

P1.03-15 - TMS Reduced Gefitinib Resistance in NSCLCs Via Suppressing MAPK/Akt/Bcl-2 Pathway by Upregulation of miR-345 and miR-498
Ping Liu, China

P1.03-16 - Anlotinib Inhibits Angiogenesis of Refractory Advanced Non-Small Cell Lung Cancer via Blocking CCL2 Expression
Baohui Han, China

P1.03-17 - Functional Mechanism of GLDC Gene Alternative Splicing in Non-Small Cell Lung Cancer
Kewei Ma, China

P1.03-18 - Mechanobiology of Lung Cancer Cells: Regulation of PD-L1 Expression by Matrix Stiffness
Ayako Miyazawa, Japan
P1.03-19 - Antibody Blockade of Integrin Alpha-V-Beta-6 (avb6) as a Novel Treatment for NSCLC
Banu Rudran, UK

P1.03-20 - The Novel SFN Inhibitors Aprepitant and Ticagrelor Exert Anti-Tumor Effects Through Blocking of Oncoprotein Ubiquitination
Aya Shiba, Japan

P1.03-21 - Huaier Aqueous Extract Induces Lung Adenocarcinoma Cell Apoptosis Through Excessive Activation Of MEK/ERK Signaling Pathway
Zhao Shilei, China

P1.03-22 - MiR-125b Plays a Tumor Suppressor Role in Inflammation-Related Non-Small Cell Lung Cancer via Repressing IGF-1 Signal Pathway
Yanwei Zhang, China

P1.03-23 - The Molecular Landscape and Outcome of Chinese Patients with Non-Small Cell Lung Cancer Harboring NTRK1 Point Mutations: A Retrospective Study
Xiaohui Chen, China

P1.03-24 - TMPRSS4: A Novel Prognostic Biomarker and Therapeutic Target in NSCLC
Francisco Expósito, Spain

P1.03-25 - The Frequency and Prognosis of ATM Mutations in Chinese Non-Small-Cell Lung Cancer Patients
Quxia Zhang, China

P1.03-26 - Analysis of DDR2 Gene Aberrations in Chinese Non-Small-Cell Lung Cancer Patients and Evaluation of Their Prognosis
Chunwei Xu, China

P1.03-27 - Somatic Mutations in BRCA2 Genes Are Associated with Prognosis in Chinese Non-Small-Cell Lung Cancer Patients
Chunwei Xu, China

P1.03-28 - Association Between Molecular Characteristics of CTNNB1 Mutations and Prognosis in Patients with Nsclc in Chinese Patients
Chunwei Xu, China

P1.03-29 - An Intronic Variant in EGFR Regulates GBAS Expression and Predicts Survival in Early-Stage Non-Small Cell Lung Cancer
Eungbae Lee, Republic of Korea

P1.03-30 - The Number of Mutated Repair Genes as Predictor for Tumor Mutation Burden of Lung Adenocarcinoma
Yuqing Lou, China

P1.03-31 - Periostin is a Negative Prognostic Factor and Promotes Cancer Cell Proliferation in Non-Small Cell Lung Cancer
Toshimasa Okazaki, Japan

P1.03-32 - Molecular Characteristics and Prognosis FBXW7 Mutations in Chinese Non-Small-Cell Lung Cancer Patients
Chunwei Xu, China

P1.03-33 - Mutational Spectrum and Prognosis of Non-Small-Cell Lung Cancer Harboring MTOR Mutations in Chinese Population
Chunwei Xu, China

P1.03-34 - Combined Molecular and Radiological Evaluation Unveils Three Subtypes of Disease Progression to a Third Generation EGFR TKI
Yi-Chen Zhang, China

16:45 - 18:00 Immunooncology Exhibit Hall

P1.04-01 - Impact of Chromatin Remodeling Genes Including SMARCA2 and PBRM1 on Neoantigen and Immune Landscape of NSCLC
Young Chae, USA

P1.04-02 - Targeting Established Lung Cancer Through Combination of DNT Cellular Therapy with PD1 Checkpoint Blockade
Linan Fang, ON/Canada

P1.04-03 - Suppressive Immune Cell Profiling in Patients with Non-Small Cell Lung Cancer.
Jiae Koh, Republic of Korea

P1.04-04 - Efficient Uptake of Recombinant Lipidated Survivin by Antigen-Presenting Cells Initiates Antigen Cross-Presentation and Antitumor Immunity
Chih-Hsiang Leng, Taiwan
P1.04-05 - Elucidating the Role of Leukocyte-Associated Immunoglobulin-Like Receptor 2 (LAIR2) in Lung Cancer Development
Dalam Ly, Canada

P1.04-06 - Clinicopathological Analysis of Pulmonary Pleomorphic Carcinoma
Misa Noguchi, Japan

P1.04-07 - Pemetrexed Enhances Anti-Tumor Efficacy of PD-L1 blockade by Promoting Intra-Tumor Immune Response via Tumor and T Cell-Intrinsic Mechanisms
Nelusha Amaladas, NY/USA

P1.04-08 - Co-Residence of Patient-Derived Immune Cells in Patient-Derived Xenografts from Lung Cancer Patients
Xingxiang Pu, China

P1.04-09 - Immunomodulatory Effects of Afatinib and Pembrolizumab in EGFR-Mutant NSCLC with Progression on Prior EGFR-TKI
Jonathan Riess, CA/USA

P1.04-10 - The Importance of Suppressor and Cytotoxic T Lymphocyte Subsets and Cytotoxic Mechanisms in Non-Small Cell Lung Cancer
Akif Turna, Turkey

P1.04-11 - Exploring the Germ-Line Contribution to Exceptional Response to PD-1/PD-L1 Inhibition in Patients with NSCLC by Whole Genome Sequencing
Megan Barnet, NSW/Australia

P1.04-12 - Mass Spectrometry-Based Serum Proteomic Signature as a Potential Biomarker for Survival in NSCLC Patients with Immunotherapy
Young Chae, USA

P1.04-13 - Combining Clinical and Genomic Data for Predicting Response to Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer
Michelle Chiu, USA

P1.04-14 - HLA B44 Supertype Associated with Less Favorable Neoantigen Binding in Non-Small Cell Lung Cancer Treated with Immunotherapy
Amy Cummings, CA/USA

P1.04-15 - Computerized Tomography Texture Analysis as Biomarker of Benefit from Nivolumab in Advanced Non-Small Cell Lung Cancer
Carlo Genova, Italy
P1.04-16 - Comparison of Clinical Response to Checkpoint Inhibitors in Advanced NSCLC with High PD-L1 Expression Tested on Cytology Versus Biopsy Samples
Katie Guo, Canada

P1.04-17 - Tumour Burden as a Predictive Tool of Response to Immune Checkpoint Inhibitors (ICI) in Patients with Metastatic Non-Small-Cell Lung Cancer
Oded Icht, Israel

P1.04-18 - PD-L1 Expression and its Correlation with Tumor TNM Stage in Patients with Non-Small Cell Lung Cancer
Taewon Jang, Republic of Korea

P1.04-19 - Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios Predict Survival After Immunotherapy in Non-Small Cell Lung Cancer
Young Chae, USA

P1.04-20 - Computational Biological Model Prediction of PD-L1 Expression and Immunotherapy Response for KRAS Mutated Lung Cancer Based on Co-Mutations
Sukhmani Padda, CA/USA

P1.04-21 - The Utility of PD-L1/CD8 Dual Immunohistochemistry for Prediction of Response to Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)
Mari Mino-Kenudson, MA/USA

P1.04-22 - CD73 Immunohistochemical Expression in Malignant Cells and Correlation with Immune Infiltrate in Non-Small Cell Lung Carcinoma (NSCLC).
Ignacio Wistuba, AL/USA

P1.04-23 - Expression of Emerging Immunotherapy Targets in Early-Stage Squamous Lung Carcinoma
Hui Yu, CO/USA

P1.04-24 - Digital Core Needle-Biopsy to Assess PD-L1 Expression in Non-Small Cell Lung Cancer: Optimal Sampling and Need for Re-Biopsy
Alexander Haragan, UK

P1.04-25 - The Implication of Frameshift Mutation Burden in Neoantigen and Immune Cell Landscape in Non-Small Cell Lung Cancer (NSCLC)
Young Chae, USA

P1.04-26 - Prospective Immuno-Biobank in NSCLC
Alfredo Addeo, Switzerland

Maria Bluthgen, Argentina

P1.04-28 - Baseline Markers of Inflammation and Outcome with Nivolumab in Pretreated Non Small Cell Lung Cancers: A Retrospective Study.
Alessandro Russo, Italy

P1.04-29 - Second or Third Line Nivolumab Versus First Line Nivolumab in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)
Antonio Irigoyen Medina, Spain

P1.04-30 - A Potential Effect of Diabetes Mellitus and Metformin Use on Efficacy of Immune Checkpoint Inhibitors (ICI)
Oded Jacobi, Israel

P1.04-31 - Efficacy and Tolerance of Immune-Checkpoint Inhibitors in EGFR, ALK/ROS 1 Non-Small-Cell-Lung-Cancer (NSCLC): GFPC 03-2016 IMAD Study
Olivier Bylicki, France

P1.04-32 - Phase I/II Study of the A2AR Antagonist NIR178 (PBF-509), an Oral Immunotherapy, in Patients (pts) with Advanced NSCLC
Alberto Chiappori, FL/USA

P1.04-33 - Retrospective Descriptive Analysis of Metformin with Atezolizumab in Advanced Non-Small Cell Lung Cancer in The OAK Trial
Richard Pietras, CA/USA

P1.04-34 - Study on Treatment of Stage IV Solid Tumors with Mutant Neoantigen Specific T Cells
Song Qi, China

P1.04-35 - Quick Progression (QP) in Patients Treated by Nivolumab (IO) in 2nd Line or More for Non-Small Cell Lung Cancer: ERORECI Study (GFPC 2016-04)
Alain Vergnenegre, France

P1.04-36 - Tislelizumab Combined with Chemotherapy as First-Line Treatment in Chinese Patients with Advanced Lung Cancer
Jie Wang, China
**P1.05**

**Interventional Diagnostics/Pulmonology**

**Exhibit Hall**

**16:45 - 18:00**

**P1.05-01** - Incidence and Clinical Relevance of NSCLC Lymph Node Micro-Metastasis Detected by Staging EBUS-TBNA  
Adam Belanger, USA

**P1.05-02** - Endobronchial Ultrasound-Transbronchial Needle Aspiration for Lymphoma in Patients with Mediastinal Lymphadenopathy  
Yu-Deok Choi, Republic of Korea

**P1.05-03** - Significance of Lymph Node SUVmax In Predicting Nodal Metastasis By EBUS in Lung Cancer Patients  
Michael Gulak, ON/Canada

**P1.05-04** - Cone-Beam CT Confirms the Status of Transbronchial Biopsy Under Virtual Bronchoscopic Navigation for Peripheral Lung Lesions  
Naoya Kawakita, Japan

**P1.05-05** - Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for Suspected Malignancy; Current Status and Issues  
Hidenao Kayawake, Japan

**P1.05-06** - Bronchoscopic Image-Guided Microwave Ablation of Peripheral Lung Tumours - Early Results  
Kelvin Lau, UK

**P1.05-07** - Clinical Significance of Pleural Indentation of Lung Adenocarcinoma Presented as Ground Glass Opacities  
Choon-Taek Lee, Republic of Korea

**P1.05-08** - Spread Through Air Spaces (STAS) in Invasive Mucinous Adenocarcinoma of the Lung: Incidence, Prognostic Impact, and Predictive Factors  
Min A Lee, Republic of Korea

**P1.05-09** - Dielectric Property Test for the Rapid Differential Diagnosis of Lung Nodules/Mass  
Di Lu, China

**P1.05-10** - Usefulness of Respiratory Dilatation Balloon in Tracheobronchial Stenosis Requiring Silicone Y-Stent Treatment  
Shinjiro Mizuguchi, Japan
P1.05-11 - Role of EBUS-TBNA in Evaluation of Mediastinal Lymphadenopathy and Masses in Patients with Known or Suspected Extra-Pulmonary Malignancies
   Deepali Jain, India

P1.05-12 - ^18^F-FDG PET/CT Findings May Predict Postoperative Acute Exacerbation of Interstitial Pneumonia in Lung Cancer Patients
   Hisashi Oishi, Japan

P1.05-13 - The Demonstration of the Possibility of the Pleura Cryo Biopsy - A Preliminary Report
   Jaroslaw Pierog, Poland

P1.05-14 - Autofluorescence Mode of Thoracoscope Improves Visceral Pleural Invasion Diagnosis in Non-Small Cell Lung Cancer
   Toru Sawada, Japan

P1.05-15 - Benign Lung Nodule Resections in the Era of Advanced Imaging and Clinical Guidelines: Imaging Features and How we can Reduce the Resection Rate
   Mohamed Sayyouth, MI/USA

P1.05-17 - Clinicopathological Characteristics of Primary Lung Cancers Associated with Emphysematous Bullae
   Mikito Suzuki, Japan

P1.05-18 - Predictive Performance of Semi-Quantitative Metabolic Metrics on FDG-PET/CT for the Identification of EGFR Mutations
   Taimei Tachibana, Japan

P1.05-19 - CT and PET/CT Parameters of Lepidic Predominant Pattern Lung Adenocarcinoma and Invasiveness on Pathology
   Hiromitsu Takizawa, Japan

P1.05-20 - Therapeutic Condition of Photodynamic Therapy Using Taraporfin Sodium for Central Airway Stenosis
   Takaaki Tsuchida, Japan

P1.05-21 - CT-Guided Biopsy of Lung Lesions with Outer Cannula Washing Cytology
   Fumiyasu Tsushima, Japan

P1.05-22 - New Methods of Brachyradiotherapy Catheter Stabilization in the Airways
   Jiri Votruba, Czech Republic
P1.05-23 - Evaluation of the 8th Edition of the TNM Classification for Lung Cancer at a Single Institution  
Jia Wang, China

P1.05-24 - Clinical Characteristics and Prognostic Analysis of Multiple Primary Malignant Neoplasms in Patients with Lung Cancer  
Huijuan Wang, China

P1.09 - Pathology
16:45 - 18:00
Exhibit Hall

P1.09-01 - PD-L1 Testing on NSCLC Cytology Samples in a UK Teaching Hospital  
Haider Al-Najjar, UK

Dominique Arpin, France

P1.09-03 - Challenges in PD-L1 Immunoexpression in Liquid Based Cytology Samples of Advanced Stage Non-Small Cell Lung Carcinomas  
Deepali Jain, India

P1.09-04 - Optimization of PD-L1 Testing Specimen Flow in the Greater Hamilton, Ontario Region  
Rosalyn Juergens, Canada

P1.09-05 - Why does PD-L1 (22C3) expression rate show difference among regional hospitals?  
Yuko Minami, Japan

P1.09-06 - The Incidence of PD-L1 in NSCLC and its Correlation with Driver Mutations in Turkish Patients; A Single Center Experience.  
Buge Oz, Turkey

P1.09-07 - PD-L1 Protein Expression is a Predictor of Benefit from Adjuvant Chemotherapy in Resected Non-Small Cell Lung Carcinoma  
Naoki Yanagawa, Japan

P1.09-08 - Integrating NGS Information for Staging Multiple Lung Adenocarcinoma: A McGill University Health Centre Retrospective Study.  
Ayesha Baig, QC/Canada
P1.09-09 - Evaluation of a Novel ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in NSCLC Patients
Esther Conde, Spain

P1.09-10 - Targeted Sequencing of Pulmonary Enteric Adenocarcinoma Reveals Distinctive Mutation Profile from Conventional Type of Lung Adenocarcinoma
Likun Hou, China

P1.09-11 - Immunohistochemical Assessment of BRCA1 Associated Protein-1 (BAP1) in Pulmonary Mucoepidermoid Carcinomas
Deepali Jain, India

P1.09-12 - Simultaneous Platform of Genotyping EGFR, ALK, and ROS1 in Patients with NSCLC Highlights Correlation of ROS1 and PD-L1 Expression
Tae-Jung Kim, Republic of Korea

P1.09-13 - Detection of Actionable Mutations in Plasma cfDNA Samples from NSCLC Patients Using a Novel Amplicon-Based Firefly NGS Assay
Jiatao Lou, China

P1.09-14 - Analysis of Real-Word Mutations of Lung Cancer Driver Genes in 3081 Patients from China
Ye Guo, China

P1.09-15 - Preliminary Experience with Liquid Biopsies in a Resource Constrained Setting and its Impact on Treatment Decision Making
Valliappan Muthu, India

P1.09-16 - Novel Somatic Gene Mutation of SLC17A9, Detected in Early-Stage Lung Adenocarcinoma
Shingo Sakashita, Japan

P1.09-17 - CTNNB1 (Beta-Catenin) Mutations in Non-Small Cell Lung Carcinoma: A Clinicopathological Study of 18 Cases
Vincent Thomas De Montpréville, France

P1.09-18 - 15 Cases of Clinical and Molecular Features Analysis in Pulmonary Adenoid Cystic Carcinoma
Chunwei Xu, China

P1.09-19 - Positive Correlation Between Whole Genomic Copy Number Variant Scoring and the Grading System in Lung Non-Mucinous Invasive Adenocarcinoma
Zheng Wang, China

P1.09-20 - Correlation Between Whole Genomic Copy Number Variant Scoring and Pathological Classification, Staging in Lung Non-Mucinous Adenocarcinoma
Zheng Wang, China

P1.09-21 - Circulating Tumor DNA Improves Genotypification and Detection of Targetable Alterations in Selected Lung Cancer Patients
Zyanya Zatarain-Barrón, Mexico

P1.09-22 - Detection of ALK Gene Rearrangement in FFPE Tissues of Non-Small Cell Lung Cancer Using In Situ RNA Hybridization
Xuan Zeng, China

P1.09-23 - Effect of Plasma Input on the Clinical Sensitivity of a Real-Time PCR Assay for the Detection of EGFR Mutation in Plasma ctDNA From NSCLC Patients
Guanshan Zhu, China

P1.09-24 - The Effects of NLR and PLR of Effect on Prognosis in Patients with the Lung Cancer
Fazıl Aydın, Turkey

P1.09-25 - Invasive Size (Not Total Size) Predicts Overall Survival in Invasive Mucinous Adenocarcinomas
Wei-Chin Chang, Taiwan

P1.09-26 - A Case Report of Discordant Markers of Lung Cancer Tumor Cells: An Unusual Immunophenotype of Uncertain Significance
Lisa Giscombe, RI/USA

P1.09-27 - Clear Cell Adenocarcinoma Subtype is an Independent Predictor of Better Survival in Patients with Lung Adenocarcinoma
Takefumi Komiya, USA

P1.09-28 - Clinical Utility of Rapid Immunohistochemistry for Differentiation of Solitary Pulmonary Adenocarcinomas
Hayato Konno, Japan

P1.09-29 - In Situ Growth Pattern in Lung Adenocarcinoma Is Divisible into Distinct Categories with Divergent Biological and Survival Implications
John Le Quesne, UK
P1.09-30 - Heterotopic Expression of Ceruloplasmin in Lung Adenocarcinoma and its Possible Clinical Use as a Tumor Biomarker
Ryota Matsuoka, Japan

P1.09-31 - Preliminary Experience with Liquid Biopsies in a Resource Constrained Setting and Its Impact on Treatment Decision Making
Valliappan Muthu, India

P1.09-32 - Classification and Mutation Prediction from Non-Small Cell Lung Cancer Histopathology Images Using Deep Learning
Paolo Ocampo, USA

P1.09-33 - Validity of Non-Small Cell Lung Cancer Not Otherwise Specified to Use Immunohistochemistry on Treatment Outcome
Takahiro Ota, Japan

P1.09-34 - Prognostic Impact of Invasive Size, Actual Tumor Size, and Mucinous Tumor Size in Invasive Mucinous Adenocarcinoma of the Lung.
Tomohito Saito, Japan

P1.09-35 - Clinical Impact of Systematic Inflammation and Histologic Grade in Non-Small Cell Lung Carcinoma (NSCLC)
Nikolaos Tsoukalas, Greece

P1.09-36 - Clinical Significance of Cannabinoid Receptor CB2 Expression in Non-Small Cell Lung Cancer (NSCLC)
Nikolaos Tsoukalas, Greece

P1.09-37 - Tumor Spread Through Air Spaces (STAS) in Stage I Lung Squamous Cell
Hironori Uruga, Japan

P1.09-38 - Pulmonary Epithelioid Hemangioendothelioma (EHE) with Von Recklinghausen Disease
Satoshi Yamamoto, Japan

P1.09-39 - Spread Through Air Spaces Predicts a Worse Survival in Patients with Stage I Adenocarcinomas > 2.0cm After Radical Lobectomy
Lin Yang, China

P1.09-40 - Metastatic Endometrial Sarcoma Presenting as a Spontaneous Pneumothorax and Masquerading as a Pulmonary Blastoma.
Giselle Suero-Abreu, USA
P1.11

16:45 - 18:00

Screening and Early Detection

| Session | Title | Abstract
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>P1.11-01</td>
<td>The NELSON Triage Algorithm Applied to a Chinese Biopsied Population: A Pilot Study</td>
<td>Hubert Beaumont, France</td>
</tr>
<tr>
<td>P1.11-02</td>
<td>Pathologic Comparison of Prevalent vs. Incident CT Lung Screen Detected Cancer in NCCN High-Risk Subjects: Are They Different?</td>
<td>Eric Burks, MA/USA</td>
</tr>
<tr>
<td>P1.11-03</td>
<td>MicroRNA with Ability to Reciprocal Regulation of Dicer and Drosha - Plasma Expression Status and Diagnostic Value in Non-Small Cell Lung Cancer</td>
<td>Pawel Krawczyk, Poland</td>
</tr>
<tr>
<td>P1.11-04</td>
<td>Size Measurement Variability of Solid Component of Lung Adenocarcinoma</td>
<td>Kazutoshi Hamanaka, Japan</td>
</tr>
<tr>
<td>P1.11-05</td>
<td>Metabolomic Profiling for Second Primary Lung Cancer Among Lung Cancer Survivors</td>
<td>Summer Han, CA/USA</td>
</tr>
<tr>
<td>P1.11-06</td>
<td>Lung Cancer Probability in New Perifissural Nodules Detected in a Lung Cancer Screening Study</td>
<td>Marjolein Heuvelmans, Netherlands</td>
</tr>
<tr>
<td>P1.11-07</td>
<td>Utility of the Maximum CT Value in Predicting Invasiveness of Pure GGNs</td>
<td>Junji Ichinose, Japan</td>
</tr>
<tr>
<td>P1.11-08</td>
<td>AI Based Malignancy Prediction of Indeterminate Pulmonary Nodules: Robustness to CT Contrast Media</td>
<td>Timor Kadir, UK</td>
</tr>
<tr>
<td>P1.11-09</td>
<td>The Delay of Lung Cancer Diagnosis Due to Misdiagnosing as Pulmonary Tuberculosis</td>
<td>Ana Rima, Indonesia</td>
</tr>
<tr>
<td>P1.11-10</td>
<td>Optimizing Radiomics Features by Minimizing Boundary Effects and Normalizing with Opposite Lung Tissue Characteristics</td>
<td>Saeed Seyyedi, BC/Canada</td>
</tr>
</tbody>
</table>
P1.11-11 - Comparing Lung Cancer Diagnosed by Low Dose CT (LDCT), Incidental Lung Nodule Program (ILNP), and Non-Program-Based Detection
Matthew Smeltzer, TN/USA

P1.11-12 - Interrogation of an Exhaled MicroRNA Panel for Lung Cancer Risk Assessment
Simon Spivack, USA

P1.11-13 - Noninvasive Detection of Early Stage NSCLC EGFR Mutations Using Electric Field Induced Release and Measurement (EFIRM)
Charles Strom, USA

P1.11-14 - Radiological Pleura-Tumor Proximity in Pure-Solid Clinical Stage I Lung Cancer: Its Influence on Lymph Node Metastasis and Recurrence
Toshiki Tanaka, Japan

P1.11-15 - Application of Lung-RADS vs. PAN-CAN Nodule Risk Calculation in the Alberta Lung Cancer Screening Study
Alain Tremblay, Canada

P1.11-17 - Discriminating Less Invasive Lesions of Early-Stage Lung Adenocarcinoma by Three-Dimensional Computed Tomography Analysis
Nobuyuki Yoshiyasu, Japan

P1.11-18 - A Classification-Based Machine Learning Method Reveals Exosomal miRNA Biomarkers for Patients with Pulmonary Ground Glass Nodule
Jia-Tao Zhang, China

P1.11-19 - Expression of TNFRII in Serum is Correlated with the Significant Risk of Subcentimeter Lung Adenocarcinoma
Yanwei Zhang, China

P1.12

16:45 - 18:00   Small Cell Lung Cancer/NET

P1.12-01 - A Single-Arm Multi-Center Phase II Study of Apatinib in Patients with ES-SCLC After Second/Third-Line Chemotherapy
Yun Fan, China

P1.12-02 - Phase II Study of Amrubcin Monotherapy in Elderly or Poor-Risk Patients with Extensive Disease of Small Cell Lung Cancer
Satoshi Igawa, Japan
P1.12-03 - A Prospective Study of Apatinib in Advanced Small Cell Lung Cancer Patients Failed from Two or More Lines of Chemotherapy
Yutao Liu, China

P1.12-04 - A Ph3 Study of Niraparib as Maintenance Therapy in 1L Platinum Responsive Extensive Disease Small Cell Lung Cancer Patients
Shun Lu, China

P1.12-05 - Efficacy of Perioperative Chemotherapy for High-Grade Neuroendocrine Tumors
Hiroyuki Ogawa, Japan

P1.12-06 - Pulmonary Neuroendocrine (Carcinoid) Tumors: CommNETs/NANETS Endorsement and Update of the ENETs Best Practice Consensus
Simron Singh, ON/Canada

P1.12-06a - Rovalpituzumab Tesirine Maintenance Therapy Following 1st Line Platinum-Based Chemotherapy in Small Cell Lung Cancer
Ho-Jin Lee, USA

P1.12-06b - Rovalpituzumab Tesirine vs Topotecan in Patients with Advanced Small Cell Lung Cancer Following 1st Line Chemotherapy
Ho-Jin Lee, USA

P1.12-07 - Time to the End of Thoracic Radiotherapy Affects to Survival Outcomes Greater than Radiation Dose in Limited Stage Small Cell Lung Cancer
Sung-Ja Ahn, Republic of Korea

P1.12-08 - The Effect of Cisplatin Versus Carboplatin on Cancer Outcomes for Small Cell Lung Cancer Patients in a Population-Based Cohort
David Dawe, Canada

P1.12-09 - The Effect of Site of First Chemotherapy on Small Cell Lung Cancer Patient Outcomes
David Dawe, Canada

P1.12-10 - Patterns of Curative Chemo-Radiotherapy Regimen and Impacts on the Outcome of Limited Stage SCLC in a Canadian Institution: 2010 - 2015 Diagnoses
Anifat Elegbede, Canada

P1.12-11 - 2010 - 2015 Extensive Stage SCLC Diagnoses in a Canadian Institution: Baseline Characteristics That Impact on the Overall Survival
Anifat Elegbede, Canada

P1.12-12 - A Systematic Review and Meta-Analysis of Early and Late Survival Following Anti-Cancer Therapies for Small Cell Lung Cancer
Gavin Jones, UK

P1.12-13 - Impact of Chronic Obstructive Pulmonary Disease on the Survival of Patients with Extensive-Disease Small Cell Lung Cancer
Eun Joo Kang, Republic of Korea

P1.12-14 - Survival of Patients with Small-Cell Lung Cancer Undergoing Surgical Resection
Shinji Kikuchi, Japan

P1.12-15 - Distinctive Clinical Characteristics of SCLC in Never-Smokers
Idrees Mian, USA

P1.12-16 - Management of Elderly Small-Cell Lung Cancer Patients in a Romanian Tertiary Care Center
Lucian Miron, Romania

P1.12-17 - Overall Survival and Recurrence After Surgical Resection of Pure and Mixed Large Cell Neuroendocrine Tumors.
Brooks Udelsman, MA/USA

P1.12-18 - Outcome in Small Cell Lung Cancer Patients with Cerebral Recurrence After Prior Prophylactic Cranial Irradiation
Lei Zhao, China

P1.12-19 - Clinico-Pathological Characteristics and Treatment Outcome in Small Cell Lung Cancer: A Single Institutional Experience
Sandip Ganguly, India

P1.12-20 - Overall Survival with Lurbinectedin Plus Doxorubicin in Relapsed SCLC. Results from an Expansion Cohort of a Phase Ib Trial.
Martin Forster, UK

P1.12-21 - Developing a Real-World 3L Comparator to CheckMate 032: Overall Survival (OS) in Patients with Small Cell Lung Cancer (SCLC)
Lee Schwartzberg, PA/USA
P1.13 - Anti-EGF Antibodies Increase the Effect of ALK and MEK Inhibitors in ALK and KRAS NSCLC and CRC Cell Lines
Silvia Garcia - Roman, Spain

P1.13-02 - eXalt3: Phase 3 Randomized Study Comparing Ensartinib to Crizotinib in Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer Patients
Leora Horn, TN/USA

P1.13-03 - Ensartinib Treatment Beyond Disease Progression in Stage IV ALK+ Non-Small Cell Lung Cancer
Leora Horn, TN/USA

P1.13-04 - Integrin β3 Inhibition Enhances the Antitumor Activity of ALK Inhibitor in ALK Rearranged NSCLC
Mi-Sook Lee, Republic of Korea

P1.13-05 - Integrin β3 Inhibition Enhances the Antitumor Activity of Alk Inhibitor in Alk Rearranged NSCLC
Mi-Sook Lee, Republic of Korea

P1.13-06 - First-Line Lorlatinib Versus Crizotinib for Advanced Anaplastic Lymphoma Kinase-Positive (ALK+) Non-Small Cell Lung Cancer
Alice Shaw, USA

P1.13-07 - Epithelial-Mesenchymal Transition Induced the Acquired Resistance to ALK Inhibitor Brigatinib in Lung Cancer Cells Harboring with ALK Fusions
Keiko Tanimura, Japan

Xuefeng Xia, China

P1.13-09 - Efficacy and Tolerance of Osimertinib in Real Word Setting: Results of the French Early Access Program (EXPLORE T790M GFPC Study).
Jean Bernard Auliac, France

P1.13-10 - Aurora Kinase A Drives the Evolution of Resistance to Third Generation EGFR Inhibitors in Lung Cancer
Sourav Bandyopadhyay, United States Minor Outlying Islands
P1.13-11 - PRO-CTCAE Toxicities in Advanced NSCLC Patients with EGFR Mutations: A Real-World Assessment
Katrina Hueniken, USA

P1.13-12 - EGFR Therapy in ASCL1 Positive Lung Adenocarcinoma
Farhad Kosari, USA

P1.13-13 - Potent Anti-Tumor Effect of Ganetespib in Acquired EGFR-TKI Resistance NSCLC Cells
Eisuke Kurihara, Japan

P1.13-14 - The Molecular Landscape of Lung Adenocarcinomas with Activating EGFR Gene Mutations Determined by Targeted-Sequencing
Kamila Wojas-Krawczyk, Poland

P1.13-15 - Detection of EGFR Mutations in cfDNA and Development of Resistance
Grainne O'kane, Canada

P1.13-16 - The Diagnostic Accuracy of Circulating Tumor DNA for the Detection of EGFR-T790M Mutation in NSCLC: A Systematic Review and Meta-Analysis
Francesco Passiglia, Italy

P1.13-17 - Multicentre Phase II Trial of First-Line Afatinib in Patients with Suspected/Confirmed EGFR Mutant NSCLC: ctDNA & Long-Term Efficacy
Adam Januszewski, UK

Yuankai Shi, China

P1.13-19 - Treatment Cessation for Improved Detection of EGFR-Mutated Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer (aNSCLC)
Samer Tabchi, USA

P1.13-20 - MET Protein Expression and Activation During Targeted Therapy in EGFR Mutated Lung Adenocarcinoma
Silvia Novello, Italy

P1.13-21 - Clinical Efficacy and Safety of Apatinib Combined with EGFR - TKIs in Advanced Non-Small Cell Lung Cancer with EGFR - TKIs Resistance
Ruifen Tian, China
P1.13-22 - Clinical Features and Outcomes of NSCLC Patients with Uncommon EGFR Mutations Treated with EGFR-TKIs
Roxana Tudor, AB/Canada

P1.13-23 - TP53 Mutations as Mechanisms of Primary and Acquired Resistance to Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated NSCLC
Paola Ulivi, Italy

P1.13-24 - EGFR-KDD is Rare and Demonstrates Variable Anti-Tumor Response to Tyrosine Kinase Inhibitors in East Asian NSCLC Population
Yang Shao, Canada

P1.13-25 - Efficacy and Safety of Osimertinib in EGFR T790M-Positive Advanced NSCLC Patients with Brain Metastases (APOLLO Study)
Ligang Xing, China

P1.13-26 - First-Line Continual EGFR-TKI Plus LAT Demonstrated Survival Benefit in Egfr-Mutant Nsclc Patients with Oligoprogressive Disease
Qinghua Xu, China

P1.13-27 - A Randomized Study of Concurrent vs Sequential Alternating EGFR-TKIs and Chemotherapy for Advanced NSCLC with EGFR Mutations
He Yong, China

P1.13-28 - The Functional MDM4 Genetic Polymorphism as Prognostic Biomarker for Advanced Lung Adenocarcinoma Patients' Survival to EGFR-TKIs Therapy
Ming Yang, China

P1.13-29 - Overall Response Rate of Nintedanib and Docetaxel in Combination with the Nutraceutical Use of Silibinin in Advanced NSCLC
Joaquim Bosch Barrera, Spain

P1.13-30 - Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor and its Relationship to NSCLC Patient Outcomes in the REVEL Trial
Aafia Chaudhry, NY/USA

P1.13-31 - Safety and Tumour Hypoxia Modifying Effect of Buparlisib with Radiotherapy in NSCLC: A Phase I Dose Escalation Study
Michael Skwarski, UK

P1.13-32 - Comparison Between Immune-Mediated Pneumonitis and Pneumonia in Patients Treated with PD-1/PD-L1 Therapy
Mi Young Kim, Republic of Korea

P1.13-33 - Ex Vivo 2*2*2 Tumor Tissue Explant Culture for Precision Medicine in Immunotherapy and TKI progressors in Lung Cancer
Nir Peled, Israel

P1.13-34 - Changes in Radiomic Features Between Baseline and Two Weeks Post-Nivolumab Treatment Are Predictive of Pathologic Complete Response
Kaustav Bera, OH/USA

Ahmed Salem, UK

P1.13-36 - Randomized Phase 2 Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer
Lecia Sequist, MA/USA

P1.13-37 - Clinical Evaluation of Plasma-Based (cfDNA) Genomic Profiling in Over 1,000 Patients with Advanced Non-Small Cell Lung Cancer
Hai Tran, USA

P1.13-38 - Inter-Organ Heterogeneity on Mechanisms of Targeted Drug Resistance -Central Nervous System (CNS) vs Extra CNS-
Seiji Yano, Japan

P1.13-39 - Epidermal Growth Factor Receptor Mutation Among Non-Small Cell Lung Cancer Patients in Trinidad and Tobago: Frequency and Trends
Aaron Haralsingh, Trinidad And Tobago

P1.13-40 - Rapid, Robust and Durable Responses to Larotrectinib in Patients with TRK Fusion Non-Small Cell Lung Cancer
Anna Farago, MA/USA

P1.13-41 - In Vitro Evaluation for Optimal MET-TKI Selection in Lung Cancers with MET Mutations Including Exon 14 Skipping
Toshio Fujino, Japan

P1.13-42 - Activity of Novel HER2 Inhibitor, Poziotinib, for HER2 Exon 20 Mutations in Lung Cancer and Mechanism of Acquired Resistance
Takamasa Koga, Japan
P1.13-43 - Molecular and Imaging Predictors of Response to Ado-Trastuzumab Emtansine in Patients with HER2 Mutant Lung Cancers: An Exploratory Phase 2 Trial
Bob Li, NY/USA

P1.13-44 - Safety, PK, and Preliminary Antitumor Activity of the Oral EGFR/HER2 Exon 20 Inhibitor TAK-788 in NSCLC
Joel Neal, CA/USA

P1.13-45 - Coexistence of Activating BRAF and KRAS Mutations in Lung Cancer Patients
Yingyi Wang, China

P1.14
16:45 - 18:00  Thymoma/Other Thoracic Malignancies  Exhibit Hall

Edward Caruana, UK

P1.14-02 - Predicting Stent Failure in Malignant Esophageal Obstruction
Tommi Järvinen, Finland

P1.14-03 - Phase II Trial of Amrubicin and Cisplatin Chemotherapy for Invasive Thymoma: WJOG5509L
Keita Kudo, Japan

P1.14-04 - Stereotactic Body Radiation Therapy for Pleural Recurrences of Thymoma
Cecile Le Pechoux, France

P1.14-05 - The Association of Pulmonary Function with Survival After Treatment in Patients with Esophageal Cancer
Hsien-Chi Liao, Taiwan

P1.14-06 - Treatment Outcomes of Patients with Thymic Carcinoma: A Monocentric Experience of Sequential Regimens Modality
Margaret Ottaviano, Italy

P1.14-07 - Intraoperative Detection of Circulating Tumor Cells in Pulmonary Venous Blood During Metastasectomy for Colorectal Lung Metastases
Severin Schmid, Germany
P1.14-08 - The Usefulness of the Hemiclamshell Thoracotomy in Thoracic Surgery
Masanori Tsuchida, Japan

P1.14-09 - Outcome After Lung Resection for Primary Lung Carcinomas/Metastasis in Patients with Performed Total Laryngectomy for Laryngeal Carcinoma
Huseyin Melek, Turkey

P1.14-10 - Surgical Treatment of a Rare Case of Clear Cell Carcinomatous Transformation of a Diaphragmatic Endometriosis Focus
Angela De Palma, Italy

P1.14-11 - The Expression Pattern of Programmed Death-Ligand 1 According to the Pathological Type of Malignant Thymic Epithelial Tumors
Shunta Ishihara, Japan

P1.14-12 - GTF2I Mutation in Thymomas: Indian and German Study
Deepali Jain, India

P1.14-13 - PD-L1 Immuno-Expression Assay in Thymomas: A Study from India
Deepali Jain, India

P1.14-14 - Histotyping of Indian Thymomas: A Comprehensive Clinicopathologic Study
Deepali Jain, India

P1.14-15 - Prevalence of Mediastinal Tumors Using Low-Dose Spiral Computed Tomography in Healthy Population
Ikuma Kasuga, Japan

P1.14-16 - DNA Methylation of GNG4, GHSR, HOXD9 and SALL3 Genes Predict Malignant Behavior of Thymic Epithelial Tumors
Reina Kishibuchi, Japan

P1.14-17 - Identification of Molecular Subtypes of Thymic Epithelial Tumors and Novel Treatments Using a Computational Biological Model
Sukhmani Padda, CA/USA

P1.14-18 - The Promising Role of Sunitinib Rechallenge in Heavily Pre-Treated Thymic Carcinoma: A Case Report
Giovannella Palmieri, Italy

P1.14-19 - Hemagglutinating Virus of Japan Envelope (HVJ-E: Inactivated Viral Nanoparticles) Against Chemotherapy-Resistant Pleural Mesothelioma
Kazuma Sakura, Japan

P1.14-20 - The Expression of DNA Methylation of GAD1 Gene is an Indicator of Malignant Behavior in Thymic Epithelial Tumor.
Kazuya Kondo, Japan

P1.14-21 - Circulating Biomarkers in Thymic Epithelial Tumors
Clemens Aigner, Germany

P1.14-22 - The Prognostic Role of the Suppressor of Cytokine Signaling-5 (SOCS5) in Esophageal Squamous Cell Carcinoma
Pei-Wen Yang, Taiwan

Sandhya Acharya, Nepal

P1.14-24 - External Radiotherapy Concurrent with Cisplatin Plus 5-Flurouracil in Locally Advanced Carcinoma of Esophagus
Rashmey Pun, Nepal

P1.14-25 - Pulmonary Metastasis from Oral Cancer - Who Survive Without Recurrence After Pulmonary Metasectomy?
Chihiro Takasaki, Japan

P1.14-26 - Long Term Outcome and Clinicopathological Features of Thymic Carcinoma - A Retrospective Study of 25 Cases at a Single Institution
Hiroto Tanaka, Japan

P1.14-27 - Differentiation Between Each Thymic Epithelial Tumor According to WHO Classification Scheme by Using MDCT Findings
Yutthaphan Wannasopha, Thailand

P1.14-28 - Frequent Genetic Alterations and Their Clinical Significance in Patients with Thymic Epithelial Tumors
Song Xu, China

P1.14-29 - Surgical Treatment for Metastatic Lung Tumors from Various Sarcomas
Hiromasa Yamamoto, Japan

P1.14-30 - Prognostic Factors for Sarcoma Patients with Lung Metastasis Who Underwent Extended Pulmonary Resection
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1.15</td>
<td>Treatment in the Real World - Support, Survivorship, Systems Research</td>
<td>Exhibit Hall</td>
</tr>
<tr>
<td>P1.15-01</td>
<td>Radiotherapy (RT) and Nivolumab in Non-Small-Cell Lung Cancer (NSCLC): A Multicenter Real-Life Experience</td>
<td>Biagio Ricciuti, Italy</td>
</tr>
<tr>
<td>P1.15-02</td>
<td>Migration Differences in Small Cell vs Non-Small Cell Lung Cancer</td>
<td>Shruti Bhandari, KY/USA</td>
</tr>
<tr>
<td>P1.15-03</td>
<td>Clinical Characteristics of Long-Term Survivors with Nivolumab in Pretreated Advanced NSCLC from Real-World Data (RWD)</td>
<td>Antonio Calles, Spain</td>
</tr>
<tr>
<td>P1.15-04</td>
<td>Practice Patterns Regarding Multidisciplinary Cancer Management for NSCLC and Implemetantion: Results of National Survey in México</td>
<td>Saul Campos-Gomez, Mexico</td>
</tr>
<tr>
<td>P1.15-05</td>
<td>The Frequency and Spectrum of EGFR Exon 20 Insertions in NSCLC: A Global Literature Review</td>
<td>Victoria Crossland, UK</td>
</tr>
<tr>
<td>P1.15-06</td>
<td>Integrative Quality Improvement for Management of Lung Cancer in Uganda</td>
<td>Semujju David, Uganda</td>
</tr>
<tr>
<td>P1.15-07</td>
<td>Geriatric Oncology - Lung Cancer in Elderly Patients and Palliative Treatment: Prospective Analysis of A. C. Camargo Cancer Center</td>
<td>Mauro DS Donadio, Brazil</td>
</tr>
<tr>
<td>P1.15-08</td>
<td>Implementation and Feasibility of the Assessment of EGFR Mutation in NSCLC Using Liquid Biopsy at an Argentinean University Hospital</td>
<td>Carolina Gabay, Argentina</td>
</tr>
<tr>
<td>P1.15-09</td>
<td>Trends in Lung Cancer Survival in Lithuania</td>
<td>Vaida Gedvilaite, Lithuania</td>
</tr>
</tbody>
</table>
P1.15-10 - Comparison of Selected Colombian National Administrative Cancer Registry (NACR) Data in Lung Cancer with the U.S.
Robert Hsu, USA

P1.15-11 - Lung Cancer as One of Multiple Cancers: A Population-Based Study in Estonia 1995-2015
Jana Jaal, Estonia

P1.15-12 - Real World Applications of Next-Generation Sequencing of Non-Small Cell Lung Cancer in the Veteran Population
Jeremy Kratz, USA

P1.15-13 - Wait Times for Diagnosis and Treatment of Lung Cancer Across the Province of Quebec, Canada
Catherine Labbe, Canada

P1.15-14 - Pneumonia in Patients with Lung Cancer of South Korea: A Nationwide Population Based Study
Hyun Woo Lee, Republic of Korea

P1.15-15 - Real-world Experience with Afatinib after Failure of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor
Chong-Kin Liam, Malaysia

P1.15-16 - ALKConnect: An Anaplastic Lymphoma Kinase Positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Patient Insights Network
Huamao Lin, MA/USA

P1.15-17 - Risk Factors of Local Recurrence in EGFR-Mutant Stage III-pN2 Adenocarcinoma After Complete Resection: A Multi-Center Real-World Cohort Study
Hui Liu, China

P1.15-18 - The Impact of Patient Age on Clinical Outcomes in NSCLC: A National Study
Yanyan Lou, FL/USA

P1.15-19 - Treatment of Choice for First-Line Therapy of EGFR-Mutated Stage IIIb Lung Adenocarcinoma Based on the Real-World Data
Shun Lu, China

P1.15-20 - Diagnosis and Treatment Delay Among Patients with Lung Cancer in Mexican Population
Omar Macedo-Pérez, Mexico
P1.15-21 - Creating an Optimal Care Coordination Model to Improve Multidisciplinary Care for Lung Cancer Patients on Medicaid
Amanda Kramar, USA

P1.15-22 - Patterns of Palliative and Psychosocial Care in Stage IV Non-Small Cell Lung Cancer (NSCLC) Patients
Tahir Mehmood, Pakistan

P1.15-23 - Factors Affecting Treatment in Non-Small Cell Lung Cancer Patients
Phuong Ngo, KY/USA

P1.15-24 - Small Cell Lung Cancer: Clinical Characteristics and Survival of a Spanish Cohort of 221 Patients
Virginia Calvo, Spain

P1.15-25 - Has Lung Cancer Radiotherapy Utilisation Changed over Time in New South Wales, Australia?
Shalini Vinod, Australia

P1.15-26 - A Review of Colombian National Administrative Cancer Registry (NACR) Data to Evaluate Healthcare Delivery and Biologics Use
Brian Pico, FL/USA

P1.15-27 - Patient Characteristics, Treatment Patterns and Survival for Unresectable Stage III NSCLC in Ontario, Canada.
Soo Jin Seung, Canada

P1.15-28 - Real World Treatment Patterns and Survival of Stage IV Non-Small Cell Lung Cancer (NSCLC) in Ontario, Canada.
Soo Jin Seung, Canada

P1.15-29 - Impact of Radiation Therapy Quality Assurance on Progression-Free and Overall Survival in Randomized Trials of Lung Cancer
Yu Yang Soon, Singapore

P1.15-30 - Survival of Patients with Advanced NSCLC Treated with First-Generation EGFR-TKIs at a Cancer Hospital in Thailand, 2011-2016
Sitthi Sukauichai, Thailand

P1.15-31 - Survival and Patterns of Care Comparing Black and White Patients with All Stages of NSCLC: An NCDB Analysis
Melissa Vyfhuis, USA

P1.15-32 - Real World EGFR Mutation Profile from 1699 Non-Small Cell Lung Cancer Patients in Eastern China
Wei Wang, China

P1.15-33 - Real-World Data on Prognostic Factors for Overall Survival in NSCLC Patients Treated with Bevacizumab Combination Therapy
Shang-Gin Wu, Taiwan

P1.15-34 - Treatment Patterns and Outcomes of Stage III Non-Small Cell Lung Cancer (NSCLC): Real World Evidence of How our Patients Fare
Dimas Yusuf, Canada

P1.15-35 - Real World Outcome of Different Administrations Endostar Combined with Chemotherapy in Driver Gene Mutation Negative Advanced NSCLC
Yongchang Zhang, China

P1.15-36 - A Better Real-World Practice for Pemetrexed in First-Line Treatment of Advanced Mon-Squamous Non-Small Cell Lung Cancer
Yongchang Zhang, China

P3.15-36a - Assessment of Depression Among Advanced Stage Lung Cancer Patients in Developing Country
Guru Sah, Nepal

P1.16
16:45 - 18:00 Treatment of Early Stage/Localized Disease Exhibit Hall

P1.16-01 - Prognostic Variables Associated with Improved Outcomes in Stage III NSCLC Patients Treated with Consolidation Pembrolizumab
Bilal Anouti, IN/USA

P1.16-02 - Support and Information Needs for Patients with NSCLC Receiving Concurrent Chemo-Radiotherapy: Findings from the INSIGHT Study.
Jackie Fenemore, UK

P1.16-03 - Prognostic Significance of PD-L1 in Stage II/III Non-Small Cell Lung Cancer
Mustafa Karaca, Turkey
P1.16-04 - Outcomes of Patients <70 or ≥70 Years of Age in PACIFIC
Mark Socinski, FL/USA

P1.16-05 - Effect of Induction Chemotherapy in the PACIFIC Study
David Spigel, TN/USA

P1.16-06 - Expanded Efficacy and Safety Analysis of PACIFIC Based on a PD-L1 Cutpoint of 25%
Alexander Spira, VA/USA

P1.16-07 - Cost-Effectiveness of Pembrolizumab as 1st Line Treatment for Metastatic NSCLC
Patients with High PD-L1 Expression in Singapore
Wan Ling Tan, Singapore

P1.16-08 - Weekly Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy for IIIA-N2 Lung Squamous Cell Carcinoma: A Prospective Phase II Study
Changli Wang, China

P1.16-09 - Surgical Result of Pathologic Stage III a Non-Small Cell Lung Cancer: Have We Improved?
Ching-Yang Wu, Taiwan

P1.16-10 - Marginal Features Analyses of Lung Adenocarcinoma for Survival Prediction
Geewon Lee, Republic of Korea

P1.16-11 - Monitoring of Early Stage Lung Cancer Using Liquid Biopsies.
Alexander Dobrovic, VIC/Australia

P1.16-12 - Identification of a Biomarker Panel in Resected NSCLC That Predicts Patient Outcomes and Benefit from Adjuvant Chemotherapy
Stacy Grieve, Canada

P1.16-13 - Photo Dynamic Therapy (PDT) in Our Hospital
Fumihiko Hoshi, Japan

P1.16-14 - Impact of Smoking on Treatment Outcome in Early Squamous Cell Lung Cancer (T1N0)
Junghee Lee, Republic of Korea

P1.16-15 - Evaluation of Emphysema Severity by 3D-CT for Predicting Postoperative Respiratory Complications and Prognosis of Lung Cancer
Yojiro Makino, Japan
P1.16-16 - Automatic Intratumor Segmentation in CT of NSCLC: An Alternative to PET Metabolic Subregions
Qintao Qiu, China

P1.16-17 - The Role of Quantitative Metabolic Metrics on FDG-PET/CT in Predicting Pathological Invasive Factors in cN0 Lung Adenocarcinoma
Takehiko Tanaka, Japan

P1.16-18 - Role of ERCC1/2 Single Nucleotide Polymorphism (SNP) on Treatment Response in Patients with Lung Cancer Undergoing Radiation Therapy
Yaping Xu, China

P1.16-19 - Neither Maximum Tumor Size nor Solid Component Size Was the Best Prognosticator for Subsolid Nodule
Erjia Zhu, China

P1.16-20 - A Systematic Review and Meta-Analysis of Stereotactic Body Radiation Therapy Versus Surgery for Patients with Non-Small Cell Lung Cancer
Christopher Cao, NY/USA

P1.16-21 - Phase I / II Study of Carboplatin, Nab-Paclitaxel, and Concurrent Radiotherapy for Patients with Locally Advanced NSCLC
Yuko Kawano, Japan

P1.16-22 - Meta-Analysis of Stereotactic Ablative Radiotherapy Versus Surgery for Early Stage Lung Cancer.
Janusz Kowalewski, Poland

P1.16-23 - Long-Term Survival Analysis of Surgery in Potential Stereotactic Ablative Radiotherapy Candidates of Non-Small Cell Lung Cancer
Shaolei Li, China

P1.16-24 - Impact of Tumor Location & Dosimetric Predictors for Chest Wall Toxicity in Single Fraction SBRT for Stage I Non-Small Cell Lung Cancer
Gregory Videtic, OH/USA

P1.16-25 - A Propensity Score Model for Appropriate Treatment Selection (Sublobar Resection vs. SBRT) In Patients With cStage I NSCLC
Yukinori Matsuo, Japan
P1.16-26 - Safety of SABR (Stereotactic Ablative Body Radiotherapy) for Central Non-Small Cell Lung Cancers (cNSCLC) with 50 Gray in 5 Fractions (50Gy/5f)
Robert Rulach, UK

P1.16-27 - Using Rates of Clinical Brachial Plexopathy after Lung SBRT to Better Characterize the Tolerance of the Brachial Plexus
Kyle Verdecchia, OH/USA

P1.16-28 - The Impact of Spironolactone on the Lung Injury Induced by Concomitant Trastuzumab and Thoracic Radiotherapy
Guler Yavas, Turkey

P1.16-29 - Accelerated Hypofractionated Radiotherapy for Central Lung Tumors Unsuitable for Stereotactic Body Radiotherapy or Concurrent CRT
K Liang Zeng, Canada

P1.16-30 - Quality of Lymphadenectomy During Lobectomy for Non-small Cell Lung Cancer: VATS Versus Thoracotomy
Raquel Alves, QC/Canada

P1.16-31 - Surgically Resected Acinar Adenocarcinoma of the Lung: Analysis of Different Prognostic Groups.
Pietro Bertoglio, Italy

P1.16-32 - Lung Cancer Completeness of Resection in Uniportal Versus Multiportal Video-Assisted Thoracoscopic Surgery Lobectomy
Etienne Bourdages-Pageau, QC/Canada

P1.16-33 - Occult Lymph Node Metastases in Early Stage NSCLC Patients: Where Do We Stand Now? A Proposal for a Preoperative Risk Model
Giuseppe Cipollone, Italy

P1.16-34 - The Impact of Pathology, Staging and Operative Resection on Survival and CT Evidence of Recurrence of Early NSCLC
Richard Finley, Canada

P1.16-35 - Sleeve Lobectomy Versus Pneumonectomy for Non-Small Cell Lung Cancer, a Cumulative Updated Meta-Analysis
Zhihua Guo, China

P1.16-36 - Real-Time Ct Guided Video Assisted Thoracoscopic Partial Resection of Peripheral Small-Sized Lung Tumors.
Taisuke Kaiho, Japan
P1.16-37 - Clinicopathological Characteristics and Prognostic Factors of Operable Non-Small Cell Lung Cancer Patients with the Diabetes Mellitus
Kaoru Kaseda, Japan

P1.16-38 - Meta-Analysis of Unplanned Readmissions Following Thoracoscopic Versus Open Lung Cancer Resection
Janusz Kowalewski, Poland

P1.16-39 - A Nomogram for Predicting Survival of TNM8 Stage I Non-Small Cell Lung Cancer Patients to Tailor Potential Chemotherapy Candidates
Wenhua Liang, China

P1.16-40 - Evaluating the Tumor Heterogeneity in Lung Cancer by Constructing Tumor Heterogeneity Index (THI) from Magnetic Resonance Imaging
Hui Liu, China

P1.16-41 - The Role of Surgery in Pulmonary Large Cell Neuroendocrine Carcinoma: A Propensity-Score Matching Analysis of SEER Database
Zhichao Liu, China

P1.16-42 - Indocyanine Green Intersegmental Visualization During Fluorescence Imaging of Thoracoscopic Anatomic Segmentectomy: A Novel Approach
Takuya Matsui, Japan

P1.16-43 - Analyses of Long-Term Outcomes and Prognostic Factors in Surgically Resected ALK-Rearranged Lung Adenocarcinoma
Yosuke Matsuura, Japan

P1.16-44 - Minute Ventilation-To-Carbon Dioxide Slope is Associated with Early and Long-Term Survivals Following Anatomical Pulmonary Resection
Takuro Miyazaki, Japan

P1.16-45 - Thoracoscopic Stapler-Based Complex Segmentectomy Assisted by Virtual Assisted Lung Mapping
Jun-ichi Nitadori, Japan

P1.16-46 - A Population-Based Validation Study of the Proposed ‘R-Factor’ Classification in a Lung Cancer-Endemic Region of the US.
Raymond Osarogiagbon, TN/USA
P1.16-47 - Adjuvant Targeted Therapy Following Standard Adjuvant Therapy for Resected NSCLC: An Initial Report from ALCHEMIST (Alliance A151216)
Geoffrey Oxnard, AL/USA

P1.16-48 - The Impact of Segmentectomy Versus Lobectomy on Pulmonary Function of Patients with Non-Small Cell Lung Cancer: A Meta-Analysis
Guanping Qiu, China

P1.16-49 - Treatment of NSCLC Patients with Clinical N1 Disease: Is There an Advantage to Neoadjuvant Therapy?
Brendon Stiles, NY/USA

P1.16-50 - The Role of Adjuvant Therapy for Patients with Early Stage Large Cell Neuroendocrine Lung Cancer: A National Analysis
Vignesh Raman, USA

Lary Robinson, FL/USA

P1.16-52 - Long-Term Impact of Postoperative Complications Following Lung Resection Among Patients with Non-Small Cell Lung Cancer
Shuichi Shinohara, Japan

P1.16-53 - County-Level Variations and Contributing Factors in Receipt of Surgery for Early-Stage Non-Small Cell Lung Cancer in the US
Raymond Osarogiagbon, TN/USA

P1.16-54 - The Significance of Multiple Lung Cancer Occurrence in Surgically-Treated Clinical Stage I Lung Cancer
Hiroshi Sugimura, Japan

P1.16-55 - Surgical Treatment for Lung Cancer. Subaortic (Para-Aortic) Lymph Nodes Involvement - N1 or N2 Disease?
Magdalena Szczęsna, Poland

P1.16-56 - Prognostic Ability of New T1 Descriptors in the TNM Classification of Surgically Treated Non-Small Cell Lung Cancer
Tomoyoshi Takenaka, Japan

P1.16-57 - Outcomes of Pulmonary Resection in Elderly Non-Small Cell Lung Cancer Patient
Apichat Tantraworasin, Thailand
P1.16-58 - Hospital Lung Surgery Volume and Patient Outcomes in Victoria
Alesha Thai, Australia

P1.16-59 - A Phase II Study of Adjuvant Chemotherapy with Tegafur-Uracil for Vessel Invasion Positive Stage IA Non-Small Cell Lung Cancer (LOGIK0602)
Tomoshi Tsuchiya, Japan

P1.16-60 - A High Risk of Recurrence After the Resection of Lower Lobe Adenocarcinoma
Kazuhiro Ueda, Japan

P1.16-61 - Intermittent Chest Tube Clamping Shortens Chest Tube Duration After Lung Cancer Surgery: An Interim Analysis of Randomized Clinical Trial
Shi Yan, China

P1.16-62 - A Nomogram to Predict Disease-Free Survival After Curative Resection of Non-Small Cell Lung Cancer
Ziping Wang, China

P1.16-63 - The Value of Adjuvant Chemotherapy in Patients with Resected Stage IB Solid Predominant and Solid Non-Predominant Lung Adenocarcinoma
Shuhui Cao, China

P1.16-64 - The Histological Predominant Pattern Could Predict Site of Recurrence and Metastasis in Surgically Treated Stage I Adenocarcinoma of the Lung
Francesco Guerrera, Italy

P1.17
16:45 - 18:00 Treatment of Locoregional Disease - NSCLC Exhibit Hall

P1.17-01 - Robustness of an Image-Based Data Mining Approach in Lung Cancer Patients
Alan Mcwilliam, UK

P1.17-02 - Low Prognostic Nutritional Index Predicts Poor Survival in Stage IIIB Non-Small Cell Lung Cancer Patients Treated with Chemoradiotherapy
Ali Besen, Turkey

P1.17-03 - Potential Associated SNPs by GWAS with Radiation Pneumonitis (RP) in Patients with Lung Cancer Treated with Radiotherapy
Lehui Du, China
P1.17-04 - Curative Intent Treatment for Stage III NSCLC in England
Susan Harden, UK

P1.17-05 - Accelerated Radiotherapy for Non-Small Cell Lung Cancer: A 12 Year Retrospective Review of Two Dose Fractionation Schedules
Matthew Hatton, UK

P1.17-06 - Salvage Surgery After Chemotherapy and/or Radiotherapy Including SBRT and Proton: Consecutive Analysis of 46 Patients
Aki Kobayashi, Japan

P1.17-07 - The Prognostic Value of Volumetric Changes of the GTV Measured on CBCT During Radiotherapy for CCRT in NSCLC Patients
Jose Belderbos, Netherlands

P1.17-08 - Genetic Predictors of Response to Chemoradiation in Stage III Non-Small-Cell Lung Cancer
Leo Luo, USA

P1.17-09 - V30 May Better Predict Radiation Pneumonitis After Intensity-Modulated Radiation Therapy for Lung Cancer
Yinnan Meng, China

P1.17-10 - Consolidation Chemotherapy in Stage III Non-Small Cell Lung Cancer: Still a Critical Piece of the Puzzle
Pranshu Mohindra, MD/USA

P1.17-11 - Pattern and Survival Impact of Neoadjuvant Treatment of Non-Small Cell Lung Cancer (NSCLC) in a Prospective Lung Resection Cohort
Meredith Ray, USA

P1.17-12 - Colleague Peer Review of Radical Lung Radiotherapy Treatment Plans: The Impact on Interval from Decision to Treat to Treatment Delivery
Gerard Walls, UK

P1.17-13 - The Role of Post-Operative Radiation Therapy in Patients with Locally Advanced NSCLC after Nodal Down-Staging with Systemic Chemotherapy
Annemarie Shepherd, NJ/USA

P1.17-14 - Outcomes of Hypofractionated Radiation Therapy (HFRT) with Concurrent Chemotherapy in Patients with Stage III Non-Small Cell Lung Cancer (NSCLC)
Annemarie Shepherd, NJ/USA

**P1.17-15 - Perioperative Prognostic Nutrition Index for Induction Chemoradiotherapy Followed by Surgery in Locally Advanced Non-Small Lung Cancers**
Junichi Soh, Japan

**P1.17-16 - Correlation of Tumor Volume Reduction During Neoadjuvant Chemoradiotherapy with Pathological Complete Response of Lung Cancer**
Shigeo Takahashi, Japan

**P1.17-17 - The Impact of Induction Chemoradiotherapy Followed by Surgery for N1 Involved Non-Small Cell Lung Cancer**
Yuta Takahashi, Japan

**P1.17-18 - Treatment for Patients with T4 Superior Sulcus Non-Small Cell Lung Cancer: A Propensity-Matched Analysis of SEER Database**
Min Fan, China

**P1.17-19 - Correlation of Dosimetric and Clinical Factors with Radiation Pneumonitis in Lung Cancer Patients Received Involved-Field IMRT**
Lehui Du, China

**P1.17-20 - Excluding PTV From Lung Volume May Better Predict Radiation Pneumonitis for IMRT Treated Lung Cancer Patients**
Yinnan Meng, China

---

**ISS10**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:00 - 19:30</td>
<td>Symposium Supported by Boehringer Ingelheim: Overcoming Challenges in Thoracic Malignancies: Expert Insights</td>
<td>Plenary Hall</td>
</tr>
<tr>
<td>18:00 - 18:00</td>
<td>Overcoming Challenges in Thoracic Malignancies: Expert Insights</td>
<td></td>
</tr>
<tr>
<td>19:30 - 22:30</td>
<td>Faculty Dinner (By Invitation Only)</td>
<td>By Invitation Only</td>
</tr>
<tr>
<td>19:30 - 22:00</td>
<td>Faculty Dinner (By Invitation Only)</td>
<td></td>
</tr>
</tbody>
</table>
### Tuesday, September 25, 2018

**ISS11**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00 - 08:00</td>
<td>Symposium Supported by Pfizer: Future Options for ALK+ Metastatic NSCLC</td>
<td>Room 105</td>
</tr>
<tr>
<td>07:00 - 08:00</td>
<td>Future Options for ALK+ Metastatic NSCLC</td>
<td></td>
</tr>
</tbody>
</table>

**ISS12**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00 - 08:00</td>
<td>Symposium Supported by Roche: Selecting the Right Cancer Immunotherapy Regimen for the Right Patient in First-line Lung Cancer</td>
<td>Room 106</td>
</tr>
<tr>
<td>07:00 - 08:00</td>
<td>Selecting the Right Cancer Immunotherapy Regimen for the Right Patient in First-line Lung Cancer</td>
<td></td>
</tr>
</tbody>
</table>

**ISS13**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00 - 08:00</td>
<td>Symposium Supported by Medscape: Progress of the NSCLC Revolution: Questioning the Experts</td>
<td>Room 107</td>
</tr>
<tr>
<td>07:00 - 08:00</td>
<td>Progress of the NSCLC Revolution: Questioning the Experts</td>
<td></td>
</tr>
</tbody>
</table>

**MTE11**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00 - 08:00</td>
<td>Biology of Small Cell Lung Cancer (Ticketed Session)</td>
<td>Room 203 BD</td>
</tr>
<tr>
<td>07:00 - 07:30</td>
<td>MTE11.01 - Novel Therapeutic Targets in SCLC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Julien Sage, CA/USA</td>
<td></td>
</tr>
<tr>
<td>07:30 - 08:00</td>
<td>MTE11.02 - Biological Subsets of SCLC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Charles Rudin, NY/USA</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session Description</td>
<td>Location</td>
</tr>
<tr>
<td>--------</td>
<td>-------------------------------------------------------------------------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>07:00</td>
<td>IO in the Real World - High Risk Populations and Patient Support (Ticketed Session)</td>
<td>Room 206 AC</td>
</tr>
<tr>
<td>07:00</td>
<td>MTE12.01 - Is IO an Option for Patients with Contraindications (Auto-immune Disease, Pulmonary Fibrosis, HIV, Hepatitis, Transplant etc)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Andrew Robinson, Canada</td>
<td></td>
</tr>
<tr>
<td>07:40</td>
<td>MTE12.02 - How can we Minimize Toxicity for our High-Risk Patients?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Massey Nematollahi, Canada</td>
<td></td>
</tr>
<tr>
<td>07:00</td>
<td>Clonal Evolution and Targeted Therapy (Ticketed Session)</td>
<td>Room 201 BD</td>
</tr>
<tr>
<td>07:00</td>
<td>MTE13.01 - Clonal Evolution and Targeted Therapy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ramaswamy Govindan, MO/USA</td>
<td></td>
</tr>
<tr>
<td>07:30</td>
<td>MTE13.02 - Clonal Evolution and Targeted Therapy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Janessa Laskin, Canada</td>
<td></td>
</tr>
<tr>
<td>07:00</td>
<td>Nodule Management (Pro Con Debate and Case Presentations) (Ticketed Session)</td>
<td>Room 206 F</td>
</tr>
<tr>
<td>07:00</td>
<td>MTE14.01 - Nodule Management (Pro Con Debate and Case Presentations)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Stephen Lam, Canada</td>
<td></td>
</tr>
<tr>
<td>07:30</td>
<td>MTE14.02 - Nodule Management (Pro Con Debate and Case Presentations)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Matthijs Oudkerk, Netherlands</td>
<td></td>
</tr>
<tr>
<td>07:00</td>
<td>Who is Too High Risk for a VATS Resection? (Ticketed Session)</td>
<td>Room 205 B</td>
</tr>
<tr>
<td>07:00</td>
<td>MTE15 - Who is Too High Risk for a VATS Resection? (Ticketed Session)</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Title</td>
</tr>
<tr>
<td>--------------</td>
<td>---------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>07:00 - 07:30</td>
<td>MTE15.01</td>
<td>Identifying High Risk Patients: What Makes a Patient Too High Risk for Surgery and Who Decides?</td>
</tr>
<tr>
<td>07:30 - 08:00</td>
<td>MTE15.02</td>
<td>Who is Too High Risk for a VATS Resection?</td>
</tr>
</tbody>
</table>

**MTE16**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00 - 08:00</td>
<td>MTE16</td>
<td>What Is Changing in the Management of Pulmonary Neuroendocrine Tumours? (Ticketed Session)</td>
<td>Room 205 AC, Topics: Small Cell Lung Cancer/NET</td>
<td></td>
</tr>
<tr>
<td>07:00 - 07:30</td>
<td>MTE16.01</td>
<td>Proper Treatment of LCNEC; Chemotherapy or Targeted Therapy</td>
<td>Sumitra Thongprasert, Thailand</td>
<td></td>
</tr>
<tr>
<td>07:30 - 08:00</td>
<td>MTE16.02</td>
<td>The Management of Small Cell Lung Cancer following First Line Treatment Failure</td>
<td>Glenwood Goss, ON/Canada</td>
<td></td>
</tr>
</tbody>
</table>

**MTE17**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00 - 08:00</td>
<td>MTE17</td>
<td>Living with and Beyond Lung Cancer: An Education for Advocates (Ticketed Session)</td>
<td>Room 206 BD, Topics: Advocacy</td>
<td></td>
</tr>
<tr>
<td>07:00 - 08:00</td>
<td>MTE17.01</td>
<td>Living with and Beyond Lung Cancer: An Education for Advocates</td>
<td>Winfield Boerckel, NY/USA; Maureen Rigney, DC/USA</td>
<td></td>
</tr>
</tbody>
</table>

**MTE18**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00 - 08:00</td>
<td>MTE18</td>
<td>Case-Based Management of Patients with Inadequate Tissue for Molecular Tests (Ticketed Session)</td>
<td>Room 201 F, Topics: Advanced NSCLC</td>
<td></td>
</tr>
<tr>
<td>07:00 - 08:00</td>
<td>MTE18.01</td>
<td>Case-Based Management of Patients with Inadequate Tissue for Molecular Tests</td>
<td>Benjamin Levy, NY/USA; Adrian Sacher, Canada</td>
<td></td>
</tr>
</tbody>
</table>
### SH01

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00</td>
<td>Highlight of the Previous Day Sessions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>07:00  - 07:12</td>
<td>SH01.01 - Advances in Radiation</td>
<td>Robert MacRae</td>
<td>Canada</td>
</tr>
<tr>
<td>07:12  - 07:24</td>
<td>SH01.02 - Surgery</td>
<td>Masairo Tsuboi</td>
<td>Japan</td>
</tr>
<tr>
<td>07:24  - 07:36</td>
<td>SH01.03 - Access, Outcomes, Survivorship</td>
<td>Viola Zhu</td>
<td>USA</td>
</tr>
<tr>
<td>07:36  - 07:48</td>
<td>SH01.04 - Advanced Lung Cancer</td>
<td>Luis Raez</td>
<td>USA</td>
</tr>
<tr>
<td>07:48  - 08:00</td>
<td>SH01.05 - Q&amp;A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### SH02

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00</td>
<td>Highlight of the Previous Day Sessions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>07:00  - 07:12</td>
<td>SH02.01 - Targeted tx</td>
<td></td>
<td></td>
</tr>
<tr>
<td>07:12  - 07:24</td>
<td>SH02.02 - Mesothelioma</td>
<td>Anne Tsao</td>
<td>USA</td>
</tr>
<tr>
<td>07:24  - 07:36</td>
<td>SH02.03 - IO</td>
<td>Gregory Riely</td>
<td>USA</td>
</tr>
<tr>
<td>07:36  - 07:48</td>
<td>SH02.04 - Pathology/Biology/Diagnostics</td>
<td>Rafael Rosell</td>
<td>Spain</td>
</tr>
<tr>
<td>07:48  - 08:00</td>
<td>SH02.05 - Q&amp;A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Title</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>----------------------------------------------------------------------</td>
<td>--------------------------</td>
<td></td>
</tr>
<tr>
<td>08:15 - 09:45</td>
<td>Presidential Symposium - Top 5 Abstracts</td>
<td>Plenary Hall</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Topics: Advanced NSCLC, Mesothelioma, Screening and Early Detection, Small Cell Lung Cancer/NET, Treatment of Early Stage/Localized Disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderation: F. Shepherd, Canada; G. Scagliotti, Italy; M. Tsao, Canada</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:15 - 08:25</td>
<td>PL02.01 - Overall Survival with Durvalumab Versus Placebo After Chemoradiotherapy in Stage III NSCLC: Updated Results from PACIFIC</td>
<td>Scott Antonia, FL/USA</td>
<td></td>
</tr>
<tr>
<td>08:25 - 08:30</td>
<td>PL02.02 - Discussant - PL02.01</td>
<td>Everett Vokes, USA</td>
<td></td>
</tr>
<tr>
<td>08:30 - 08:40</td>
<td>PL02.03 - Brigatinib vs Crizotinib in Patients with ALK Inhibitor-Naive Advanced ALK+ NSCLC: First Report of a Phase 3 Trial (ALTA-1L)</td>
<td>Ross Camidge, USA</td>
<td></td>
</tr>
<tr>
<td>08:40 - 08:45</td>
<td>PL02.04 - Discussant - PL02.03</td>
<td>Fiona Blackhall, UK</td>
<td></td>
</tr>
<tr>
<td>08:45 - 08:55</td>
<td>PL02.05 - Effects of Volume CT Lung Cancer Screening: Mortality Results of the NELSON Randomised-Controlled Population Based Trial</td>
<td>Harry De Koning, Netherlands</td>
<td></td>
</tr>
<tr>
<td>08:55 - 09:00</td>
<td>PL02.06 - Discussant - PL02.05</td>
<td>John Field, UK</td>
<td></td>
</tr>
<tr>
<td>09:00 - 09:10</td>
<td>PL02.07 - IMpower 133: Primary PFS, OS and Safety in a PH1/3 Study of 1L Atezolizumab + Carboplatin + Etoposide in Extensive-Stage SCLC</td>
<td>Stephen Liu, DC/USA</td>
<td></td>
</tr>
<tr>
<td>09:10 - 09:15</td>
<td>PL02.08 - Discussant - PL02.07</td>
<td>Natasha Leighl, ON/Canada</td>
<td></td>
</tr>
<tr>
<td>09:15 - 09:25</td>
<td>PL02.09 - Nintedanib + Pemetrexed/Cisplatin in Patients with Unresectable MPM: Phase III Results from the LUME-Meso Trial</td>
<td>Giorgio Scagliotti, Italy</td>
<td></td>
</tr>
<tr>
<td>09:25 - 09:30</td>
<td>PL02.10 - Discussant - PL02.09</td>
<td>Ross Soo, Singapore</td>
<td></td>
</tr>
<tr>
<td>09:30 - 09:45</td>
<td>PL02.11 - Q&amp;A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Event Description</td>
<td>Location</td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>-----------------------------------------------------------------------------------</td>
<td>---------------------------------</td>
<td></td>
</tr>
<tr>
<td>09:45 - 11:00</td>
<td>Press Conference</td>
<td>Plenary Hall</td>
<td></td>
</tr>
<tr>
<td>09:45 - 11:15</td>
<td>Press Conference</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:55 - 10:25</td>
<td>AstraZeneca Exhibit Showcase Session - The Visions and Science for Earlier Treatment</td>
<td>Exhibit Showcase Theater</td>
<td></td>
</tr>
<tr>
<td>09:55 - 10:10</td>
<td>EXH01.01 - Developing and Preparing for Earlier Treatments in Lung Cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>David Berman, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:10 - 10:25</td>
<td>EXH01.02 - Early Detection and Monitoring of Lung Cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>J Carl Barrett, MA/USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30 - 12:00</td>
<td>Quality Care in Lung Cancer</td>
<td>Room 206 BD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Topics: Nursing and Allied Professionals</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderation: P. Labuc, UK; N. Nouriany, Canada</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30 - 10:45</td>
<td>ES02.01 - Expanding PROs in Daily Practice</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kahren White, NSW/Australia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:45 - 11:00</td>
<td>ES02.02 - PRO: To Medicate: Managing Breathlessness</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alexandre Chan, Singapore</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00 - 11:15</td>
<td>ES02.03 - CON: Not to Medicate: Managing Breathlessness</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Catherine Granger, Australia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:15 - 11:30</td>
<td>ES02.04 - Molecular Testing 101 for Nurses</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Beth Eaby-Sandy, PA/USA</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
11:30 - 11:45  ES02.05 - Structured Approach for Developing and Implementing and Advanced Practice Nursing Role in Lung Cancer  
Andrea Serena, Switzerland

11:45 - 12:00  ES02.06 - Q&A

GR01

10:30 - 12:00  Thymic Malignancies Tumor Board  
Topics: Thymoma/Other Thoracic Malignancies  
Moderation: V. Fang, China; G. Giaccone, USA

10:30 - 10:45  GR01.01 - Pathology  
Anja Roden, MN/USA

10:45 - 11:00  GR01.02 - Surgical Oncology  
Pier Luigi Filosso, Italy

11:00 - 11:15  GR01.03 - Surgical Oncology  
David Waller, UK

11:15 - 11:30  GR01.04 - Medical Oncology  
Nicolas Girard, France

11:30 - 11:45  GR01.05 - Radiation Oncology  
Anthony Brade, Canada

11:45 - 12:00  GR01.06 - Discussion

MA10

10:30 - 12:00  Considerations in Immunotherapy / Real World  
Topics: Advanced NSCLC, Treatment in the Real World - Support, Survivorship, Systems Research  
Moderation: K. Jao, Canada; R. Juergens, Canada

10:30 - 10:35  MA10.01 - Antibiotic Use and PD-1 Inhibitors: Shorter Survival in Lung Cancer, Especially When Given Intravenously. Type of Infection Also Matters  
Xabier Mielgo-Rubio, Spain
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker, Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:35 - 10:40</td>
<td>MA10.02</td>
<td>Impact of Antibiotics on Outcome of Metastatic Non Small Cell Lung Cancer Patients Treated with Immunotherapy</td>
<td>Giulia Galli, Italy</td>
</tr>
<tr>
<td>10:40 - 10:45</td>
<td>MA10.03</td>
<td>Plasmatic Evaluation of the Intestinal Barrier and Blood Microbiota, and Antibiotic Use in Non-Small Cell Lung Cancer Patients Treated with Nivolumab</td>
<td>Etienne Giroux Leprieur, France</td>
</tr>
<tr>
<td>10:45 - 11:00</td>
<td>MA10.04</td>
<td>Discussant - MA 10.01, MA 10.02, MA 10.03</td>
<td>Bertrand Routy, Canada</td>
</tr>
<tr>
<td>11:00 - 11:05</td>
<td>MA10.05</td>
<td>Effect of Early Steroids use in Advanced NSCLC Patients Treated with Immunotherapy</td>
<td>Giovanni Fucà, Italy</td>
</tr>
<tr>
<td>11:05 - 11:10</td>
<td>MA10.06</td>
<td>Impact of Immune-Related Adverse Events on Survival in Patients with Advanced Non-Small Cell Lung Cancer Treated with Nivolumab</td>
<td>Biagio Ricciuti, Italy</td>
</tr>
<tr>
<td>11:10 - 11:25</td>
<td>MA10.07</td>
<td>Discussant - MA 10.05, MA 10.06</td>
<td>Kenneth O’Byrne, ACT/Australia</td>
</tr>
<tr>
<td>11:25 - 11:30</td>
<td>MA10.08</td>
<td>Choice of Taxane and Outcomes in the KEYNOTE-407 Study of Pembrolizumab Plus Chemotherapy for Metastatic Squamous NSCLC</td>
<td>Balazs Halmos, NY/USA</td>
</tr>
<tr>
<td>11:30 - 11:35</td>
<td>MA10.09</td>
<td>NECPAL 2: A Multicentre Descriptive Study of Primary and Continuous Attention in Palliative Care in Argentina: Lung Cancer Cohort</td>
<td>Carolina Gabay, Argentina</td>
</tr>
<tr>
<td>11:40 - 11:55</td>
<td>MA10.11</td>
<td>Discussant - MA 10.08, MA 10.09, MA 10.10</td>
<td>Antoinette Wozniak, USA</td>
</tr>
<tr>
<td>11:55 - 12:00</td>
<td>MA10.12</td>
<td>Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session Title</td>
<td>Speaker(s)</td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>-------------------------------------------------------------------------------</td>
<td>-------------------------------------</td>
<td></td>
</tr>
<tr>
<td>10:30 - 10:35</td>
<td>MA11.01 - Comparative Efficacy of T-Cell Intrinsic Versus Extrinsic PD-1 Blockade to Overcome PD-L1+ Tumor-Mediated Exhaustion</td>
<td>Jordan Dozier, USA</td>
<td></td>
</tr>
<tr>
<td>10:35 - 10:40</td>
<td>MA11.02 - Increased CD3+ TIL Infiltration and Low FOXP3+/CD8+ TIL Ratio Can Predict Anti-PD-1 Therapeutic Response in Non-Small Cell Lung Cancer Patients</td>
<td>Hyojin Kim, Republic of Korea</td>
<td></td>
</tr>
<tr>
<td>10:40 - 10:45</td>
<td>MA11.03 - Interaction of Tumor Infiltrating Lymphocytes and Cancer Nuclei Predicts Response to Nivolumab in Non-Small Cell Lung Cancer (NSCLC)</td>
<td>Xiangxue Wang, OH/USA</td>
<td></td>
</tr>
<tr>
<td>10:45 - 11:00</td>
<td>MA11.04 - Discussant - MA 11.01, MA 11.02, MA 11.03</td>
<td>Donald Morris, AB/Canada</td>
<td></td>
</tr>
<tr>
<td>11:00 - 11:05</td>
<td>MA11.05 - Indoleamine 2,3-Dioxygenase Expression in Non-Small-Cell Lung Cancer: Analyses of Prevalence, Clinical Correlations and Prognostic Impact</td>
<td>Francesco Agustoni, USA</td>
<td></td>
</tr>
<tr>
<td>11:05 - 11:10</td>
<td>MA11.06 - Prognostic Value of Complement System in NSCLC and its Association with PD-1 and PD-L1 Expression</td>
<td>Luis Montuenga, Spain</td>
<td></td>
</tr>
<tr>
<td>11:10 - 11:15</td>
<td>MA11.07 - Expression of LAG-3 and NY-ESO-1 In Tumor Cells is Promising Biomarker Predicting Durable Clinical Benefit of PD-1 Blockade in Advanced NSCLC</td>
<td>Hee Ryeong Jang, Korea, Republic of</td>
<td></td>
</tr>
<tr>
<td>11:15 - 11:30</td>
<td>MA11.08 - Discussant - MA 11.05, MA 11.06, MA 11.07</td>
<td>Erin Schenk, MN/USA</td>
<td></td>
</tr>
<tr>
<td>11:30 - 11:35</td>
<td>MA11.09 - Single-Cell Characterization of the Immunologic Microenvironment in Advanced-Stage, Oncogene-Driven NSCLC</td>
<td>Julia Rotow, USA</td>
<td></td>
</tr>
</tbody>
</table>
MA11.10 - Identification of Mismatch Repair Deficient Lung Adenocarcinomas Using Targeted Next-Generation Sequencing
Navin Mahadevan, MA/USA

MA11.11 - Discrepancy of Tumor Neoantigen Burden Between Primary Lesions and Matched Metastases in Lung Cancer
Tao Jiang, China

MA11.12 - Discussant - MA 11.09, MA 11.10, MA 11.11
Ignacio Gil-Bazo, Spain

MA12

10:30 - 12:00 Mesothelioma Surgery and Novel Targets for Prognosis and Therapy Room 202 BD
Topics: Mesothelioma
Moderation: G. Zalcman, France; C. Pepe, Canada

MA12.01 - The Information Pathway to Randomisation: Patients Experience of the Mesothelioma and Radical Surgery (MARS2) Feasibility Trial
Angela Tod, UK

MA12.02 - Quality of Life Following Pleurectomy Decortication and Extrapleural Pneumonectomy for Pleural Malignant Mesothelioma
Wil Lieberman-Cribbin, USA

MA12.03 - The Impact of Malignant Pleural Mesothelioma Histology on the Use of Surgery and Survival in a Population-Based Analysis
Chi-Fu Yang, NC/USA

MA12.04 - Discussant - MA 12.01, MA 12.02, MA 12.03
Marc De Perrot, Canada

MA12.05 - Phase 1 Study of HSP90 Inhibitor Ganetespib with Pemetrexed and Cisplatin/Carboplatin Chemotherapy for Pleural Mesothelioma
Dean Fennell, UK

MA12.06 - STELLAR - Final Results of a Phase 2 Trial of TTFields with Chemotherapy for First-Line Treatment of Malignant Pleural Mesothelioma
Giovanni Ceresoli, Italy
<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:10 - 11:15</td>
<td>MA12.07 - gC1qR Expression is Independently Prognostic for Survival Benefit Following Chemotherapy in Mesothelioma</td>
<td>Xiaoyu Li, NY/USA</td>
</tr>
<tr>
<td>11:15 - 11:30</td>
<td>MA12.08 - Discussant - MA 12.05, MA 12.06, MA 12.07</td>
<td>Quincy Chu, Canada</td>
</tr>
<tr>
<td>11:30 - 11:35</td>
<td>MA12.09 - Preclinical Investigations of Folate Receptor Targeted Nanoparticles for Photodynamic Therapy of Malignant Pleural Mesothelioma</td>
<td>Tatsuya Kato, ON/Canada</td>
</tr>
<tr>
<td>11:35 - 11:40</td>
<td>MA12.10 - Long-Term Impact of Radiotherapy Before Surgery for Mesothelioma on the Distribution of Memory T Cell Subsets</td>
<td>Junichi Murakami, Japan</td>
</tr>
<tr>
<td>11:40 - 11:45</td>
<td>MA12.11 - Analysis of Angiogenic and Stromal Biomarkers in a Large Malignant Mesothelioma Cohort</td>
<td>Puey Ling Chia, Australia</td>
</tr>
<tr>
<td>11:45 - 12:00</td>
<td>MA12.12 - Discussant - MA 12.09, MA 12.10, MA 12.11</td>
<td>Masaki Anraku, Japan</td>
</tr>
</tbody>
</table>

### MA13

**Interventional Pulmonology**

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 - 12:00</td>
<td>Interventional Pulmonology</td>
<td>Room 206 AC</td>
</tr>
<tr>
<td></td>
<td>Topics: Interventional Diagnostics/Pulmonology</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderation: J. Agulnik, Canada; K. Fong, Australia</td>
<td></td>
</tr>
<tr>
<td>10:30 - 10:35</td>
<td>MA13.01 - CT-Guided Transthoracic Needle Biopsy for Evaluation of PD-L1 Expression: Comparison of 22C3 and SP263 Assays</td>
<td>Kyongmin Beck, Republic of Korea</td>
</tr>
<tr>
<td>10:35 - 10:40</td>
<td>MA13.02 - PD-L1 Expression in EBUS-Guided Cytology Specimens of Non-Small Cell Lung Cancer is Not Affected by Type of Fixation: A Study of Matched Pairs</td>
<td>Alexander Haragan, UK</td>
</tr>
<tr>
<td>10:40 - 10:45</td>
<td>MA13.03 - Heterogeneity Analysis of EBUS-TBNA-Derived Specimens for Evaluation of PD-L1 Expression and Copy Number Alterations in Patients with NSCLC</td>
<td>Katsuhiro Yoshimura, Japan</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Title</td>
</tr>
<tr>
<td>--------</td>
<td>---------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>10:45</td>
<td>MA13.04</td>
<td>Discussant - MA 13.01, MA 13.02, MA 13.03</td>
</tr>
<tr>
<td>11:00</td>
<td>MA13.05</td>
<td>The Canada Lymph Node Sonographic Score: National Validation of a Sonographic Score to Determine Mediastinal Lymph Node Malignancy</td>
</tr>
<tr>
<td>11:05</td>
<td>MA13.06</td>
<td>Endosonography with Lymph Nodes Sampling for Restaging the Mediastinum in Lung Cancer: A Systematic Review and Pooled-Data Analysis</td>
</tr>
<tr>
<td>11:10</td>
<td>MA13.07</td>
<td>Diagnostic Yield of N3 Hilar Staging by Endobronchial Ultrasonography (EBUS) in Lung Cancer</td>
</tr>
<tr>
<td>11:15</td>
<td>MA13.08</td>
<td>Discussant - MA 13.05, MA 13.06, MA 13.07</td>
</tr>
<tr>
<td>11:30</td>
<td>MA13.09</td>
<td>Electromagnetic Navigation Bronchoscopy as an Integrated Approach to Aid in Diagnosis and Treatment of Pulmonary Lesions</td>
</tr>
<tr>
<td>11:35</td>
<td>MA13.10</td>
<td>Comparison of Pulmonary Nodule Location Between Preprocedural CT and Intra-Procedural Cone-Beam CT During Guided Bronchoscopy</td>
</tr>
<tr>
<td>11:40</td>
<td>MA13.11</td>
<td>Photodynamic Therapy for Peripheral-Type Lung Cancer in a Multi-Center Clinical Trial</td>
</tr>
<tr>
<td>10:30</td>
<td>MA14</td>
<td>Survivorship, Socioeconomic and End-of-Life Considerations</td>
</tr>
<tr>
<td>10:30</td>
<td>MA14</td>
<td>Room 205 B</td>
</tr>
</tbody>
</table>

**Room 205 B**

**Topics:** Treatment in the Real World - Support, Survivorship, Systems Research

**Moderation:** T. Owonikoko, USA; P.M. Schuffenegger, Canada
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 - 10:35</td>
<td>MA14.01</td>
<td>Life Sustaining Procedures, Palliative Care and Hospital Cost Trends in Dying Lung Cancer Patients in U.S. Hospitals: 2005-2014</td>
<td>Jinwook Hwang, Republic of Korea</td>
</tr>
<tr>
<td>10:35 - 10:40</td>
<td>MA14.02</td>
<td>Use and impact of a systematic advanced care planning in hospitalized lung cancer patients: a prospective study.</td>
<td>Anne Claire Toffart, France</td>
</tr>
<tr>
<td>10:40 - 10:45</td>
<td>MA14.03</td>
<td>Aggressiveness of Cares on the Month Before Death of Patients with Lung Cancer: A French National Database Survey</td>
<td>Olivier Bylicki, France</td>
</tr>
<tr>
<td>10:45 - 11:00</td>
<td>MA14.04</td>
<td>Discussant - MA 14.01, MA 14.02, MA 14.03</td>
<td>Gouri Shankar Bhattacharyya, India</td>
</tr>
<tr>
<td>11:00 - 11:05</td>
<td>MA14.05</td>
<td>Social Isolation Increases Psychological Distress in Patients With NSCLC</td>
<td>Bonnie Leung, BC/Canada</td>
</tr>
<tr>
<td>11:05 - 11:10</td>
<td>MA14.06</td>
<td>Predictors of Financial Toxicity, an Under-Recognized Patient-Reported Outcome</td>
<td>Doreen Ezeife, Canada</td>
</tr>
<tr>
<td>11:10 - 11:15</td>
<td>MA14.07</td>
<td>The Impact of Socioeconomic Status and Geographic Location on Palliative Chemotherapy Uptake in Patients with Metastatic NSCLC</td>
<td>Zamzam Al-Hashami, Canada</td>
</tr>
<tr>
<td>11:15 - 11:30</td>
<td>MA14.08</td>
<td>Discussant - MA 14.05, MA 14.06, MA 14.07</td>
<td>Christos Chouaid, France</td>
</tr>
<tr>
<td>11:30 - 11:35</td>
<td>MA14.09</td>
<td>Mortality of Lung Cancer as a Second Primary Malignancy among Cancer Survivors: A Study of Surveillance, Epidemiology, and End Results Database</td>
<td>Lei Deng, NY/USA</td>
</tr>
<tr>
<td>11:35 - 11:40</td>
<td>MA14.10</td>
<td>QTc Interval-Prolonging Medications in Lung Cancer: Implications for Clinical Trial Eligibility and Routine Clinical Care</td>
<td>David Gerber, TX/USA</td>
</tr>
<tr>
<td>11:40 - 11:45</td>
<td>MA14.11</td>
<td>Factors Associated with Early Mortality in Non-Small Cell Lung Cancer Patients Following Systemic Anti-Cancer Treatment</td>
<td>Amanda Gibson, Canada</td>
</tr>
<tr>
<td>11:45 - 12:00</td>
<td>MA14.12</td>
<td>Discussant - MA 14.09, MA 14.10, MA 14.11</td>
<td></td>
</tr>
</tbody>
</table>
Amanda Tufman, Germany

### MS13

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
</table>
| 10:30 - 12:00 | Novel Mediators of Lung Cancer Metastasis | Topics: Biology  
Moderation: O. Arrieta, Mexico; K.-K. Wong, USA | Amanda Tufman, Germany | Room 201 F         |
| 10:30 - 10:45 | MS13.01 | Liquid Biopsy-mediated Identification of Metastatic Variants | Philip Mack, CA/USA |                     |
| 10:45 - 11:00 | MS13.02 | Capicua Inactivation Drives Lung Cancer Metastasis                  | Trever Bivona, CA/USA |                     |
| 11:00 - 11:15 | MS13.03 | Ubiquilin as a Novel Mediator of Lung Cancer Invasion and Metastasis | Levi Beverly, USA |                     |
| 11:15 - 11:30 | MS13.04 | Tracking the Evolution of Non-Small-Cell Lung Cancer                | Charles Swanton, UK |                     |
| 11:30 - 12:00 | MS13.05 | Discussant                                                           | David Beer, MI/USA |                     |
|               | MS13.06 | Q&A                                                                  |                   |                     |

### MS14

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
</table>
| 10:30 - 12:00 | IO in Early Stage NSCLC | Topics: Immunooncology  
Moderation: M. Kris, USA, J. Edwards, Canada | Amanda Tufman, Germany | Room 107   |
<p>| 10:30 - 10:45 | MS14.01 | Basic Science Rationale of IO in Early Stage NSCLC?                   | Johan Vansteenkiste, Belgium |           |
| 10:45 - 11:00 | MS14.02 | Adjuvant / Neoadjuvant IO Therapy                                     | Julie Brahmer, MD/USA |           |
| 11:00 - 11:15 | MS14.03 | Concerns About IO for the Thoracic Surgeon?                           |                     |           |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15 - 11:30</td>
<td><strong>MS14.04</strong> - IO - New Standards in Stage III NSCLC</td>
<td>Rafal Dziadziszko, Poland</td>
<td>Room 201 BD</td>
</tr>
<tr>
<td>11:30 - 11:45</td>
<td><strong>MS14.05</strong> - Do Biomarkers used in Metastatic Setting Apply in Earlier Stages</td>
<td>Naiyer Rizvi, NY/USA</td>
<td>Room 201 BD</td>
</tr>
<tr>
<td>11:45 - 12:00</td>
<td><strong>MS14.06</strong> - Q&amp;A</td>
<td></td>
<td>Room 201 BD</td>
</tr>
</tbody>
</table>

**MS15**

10:30 - 12:00 Disruptive Technology and Lung Cancer Risk

Topics: Prevention and Tobacco Control
Moderation: E. Bedard, Canada; D. Arenberg, USA

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 - 10:45</td>
<td><strong>MS15.01</strong> - Just Water Vapor? Toxicology Perspectives on Electronic Cigarettes</td>
<td>Maciej Goniewicz, USA</td>
<td>Room 201 BD</td>
</tr>
<tr>
<td>10:45 - 11:00</td>
<td><strong>MS15.02</strong> - PRO- Electronic Cigarettes: A Cessation Tool</td>
<td>K Michael Cummings, SC/USA</td>
<td>Room 201 BD</td>
</tr>
<tr>
<td>11:00 - 11:15</td>
<td><strong>MS15.03</strong> - CON- Electronic Cigarettes: Not Evidence Based Cessation</td>
<td>Alison Wallace, Canada</td>
<td>Room 201 BD</td>
</tr>
<tr>
<td>11:15 - 11:30</td>
<td><strong>MS15.04</strong> - The Rise of Heat-Not Burn Tobacco in Japan: A “Hot” Issue for Tobacco Control</td>
<td>Junji Yoshida, Japan</td>
<td>Room 201 BD</td>
</tr>
<tr>
<td>11:30 - 11:45</td>
<td><strong>MS15.05</strong> - Heat-Not-Burn Tobacco: Real Risk Reduction or Industry’s Next Promise</td>
<td>Carolyn Dresler, MD/USA</td>
<td>Room 201 BD</td>
</tr>
<tr>
<td>11:45 - 12:00</td>
<td><strong>MS15.06</strong> - Q&amp;A</td>
<td></td>
<td>Room 201 BD</td>
</tr>
</tbody>
</table>

**OA10**

10:30 - 12:00 Right Patient, Right Target & Right Drug - Novel Treatments and Research Partnerships

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 - 12:00</td>
<td>Right Patient, Right Target &amp; Right Drug - Novel Treatments and Research Partnerships</td>
<td></td>
<td>Room 106</td>
</tr>
</tbody>
</table>
Topics: Targeted Therapy
Moderation: H. West, USA; J. Patel, USA

10:30 - 10:40
OA10.01 - Patient Preferences for Tyrosine Kinase Inhibitor Treatments for EGFR Mutation Positive Metastatic NSCLC
John Bridges, USA

10:40 - 10:50
OA10.02 - Oncogene-Driven Patient Groups: A New Era for Research Partnerships
Janet Freeman-Daily, WA/USA

10:50 - 11:05
OA10.03 - Discussant - OA 10.01, OA 10.02
Zosia Piotrowska, MA/USA

11:05 - 11:15
OA10.04 - Afatinib With or Without Cetuximab for EGFR-Mutant Non-Small Cell Lung Cancer: Safety and Efficacy Results from SWOG S1403
Sarah Goldberg, CT/USA

11:15 - 11:25
OA10.05 - An Open-Label, Multicenter, Phase II Single Arm Trial of Osimertinib in NSCLC Patients with Uncommon EGFR Mutation (KCSG-LU15-09)
Jang Ho Cho, Republic of Korea

11:25 - 11:35
OA10.06 - A First-in-Human Phase 1 Trial of the EGFR-cMET Bispecific Antibody JNJ-61186372 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Keunchil Park, Republic of Korea

11:35 - 11:45
OA10.07 - Resistance Mechanisms of Osimertinib in Chinese Non-Small Cell Lung Cancer patients: Analysis from AURA17 Trial
Caicun Zhou, China

11:45 - 12:00
OA10.08 - Discussant - OA 10.04, OA 10.05, OA 10.06, OA 10.07
Linda Coate, Ireland

PC05

10:30 - 10:45
PC05.01 - Debate 1: Which is Most Important Efficacy Endpoint in First Line Trials in Advanced NSCLC PFS or OS - Point of View: PFS
Mary O'Brien, UK
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 10:45 - 11:00 | PC05.02 - Debate 1: Which is Most Important Efficacy Endpoint in First Line Trials in Advanced NSCLC PFS or OS - Point of View: OS  
Yu Shyr, TN/USA |
| 11:00 - 11:05 | PC05.03 - Discussion                                                      |
| 11:05 - 11:20 | PC05.04 - Debate 2: Patient Reported Outcomes Should Be the Most Important Endpoint in Trials in the Palliative Setting - YES  
Maurice Pérol, France |
| 11:20 - 11:35 | PC05.05 - Debate 2: Patient Reported Outcomes Should Be the Most Important Endpoint in Trials in the Palliative Setting - NO  
Rathi Pillai, USA |
| 11:35 - 11:40 | PC05.06 - Discussion                                                      |
| 11:40 - 11:50 | PC05.07 - Let's Not Forget Chemo-Regret  
Patricia Hollen, USA |
| 11:50 - 12:00 | PC05.08 - Discussion                                                      |

**ISS14**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 12:00 - 13:30 | Symposium Supported by Novartis: Expert Perspectives on the Management of NSCLC in Clinical Practice: Are Novel Approaches Realistic?  
Plenary Hall |

**MA15**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 13:30 - 15:00 | Colliding Approaches - EGFR and Immunotherapy  
Topics: Targeted Therapy  
Moderation: H. Wakelee, USA; N. Rizvi, USA |

Tuesday, September 25, 18
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30 - 13:35</td>
<td>MA15.01</td>
<td>Strong PD-L1 Expression Predicts Poor Response and de Novo Resistance to EGFR TKIs Among Non-Small Cell Lung Cancer Patients with EGFR Mutation</td>
<td>Shan Su, China</td>
</tr>
<tr>
<td>13:35 - 13:40</td>
<td>MA15.02</td>
<td>Long-Term Safety and Clinical Activity Results from a Phase Ib Study of Erlotinib Plus Atezolizumab in Advanced NSCLC</td>
<td>Charles Rudin, NY/USA</td>
</tr>
<tr>
<td>13:40 - 13:45</td>
<td>MA15.03</td>
<td>PD-L1 Expression in Untreated EGFRm Advanced NSCLC and Response to Osimertinib and SoC EGFR-TKIs in the FLAURA Trial</td>
<td>Suresh Ramalingam, USA</td>
</tr>
<tr>
<td>13:45 - 14:00</td>
<td>MA15.04</td>
<td>Discussant - MA 15.01, MA 15.02, MA 15.03</td>
<td>Adrian Sacher, Canada</td>
</tr>
<tr>
<td>14:00 - 14:05</td>
<td>MA15.05</td>
<td>The Mutational Profiles of EGFR 19 Exon Deletion and 21 Exon L858R Mutation and Their Association with Primary Response to EGFR-TKIs</td>
<td>Wenhua Liang, China</td>
</tr>
<tr>
<td>14:05 - 14:10</td>
<td>MA15.06</td>
<td>Circulating Tumor DNA Portrays the Resistance Landscape to a Novel Third Generation EGFR Inhibitor, AC0010</td>
<td>Yi-Chen Zhang, China</td>
</tr>
<tr>
<td>14:10 - 14:15</td>
<td>MA15.07</td>
<td>Different Responses to Osimertinib in Primary and Acquired EGFR T790M-Mutant NSCLC Patients</td>
<td>Shuyuan Wang, China</td>
</tr>
<tr>
<td>14:15 - 14:30</td>
<td>MA15.08</td>
<td>Discussant - MA 15.05, MA 15.06, MA 15.07</td>
<td>Charu Aggarwal, PA/USA</td>
</tr>
<tr>
<td>14:30 - 14:35</td>
<td>MA15.09</td>
<td>Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR Mutant Advanced NSCLC Patients Treated with First-Line EGFR-TKIs</td>
<td>Chunxia Su, China</td>
</tr>
<tr>
<td>14:35 - 14:40</td>
<td>MA15.10</td>
<td>Loss of T790M Mutation is Associated with Early Progression to Osimertinib in Chinese Advanced NSCLC Patients Harboring EGFR T790M</td>
<td>Sha Zhao, China</td>
</tr>
<tr>
<td>14:40 - 14:45</td>
<td>MA15.11</td>
<td>Real World Biomarker Testing and Treatment Patterns in Patients with Advanced NSCLC Receiving EGFR-TKIs</td>
<td>Anne Chiang, CT/USA</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Title</td>
<td>Speaker</td>
</tr>
<tr>
<td>----------</td>
<td>--------------------</td>
<td>----------------------------------------------------------------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>14:45 - 15:00</td>
<td>MA15.12 - Discussant - MA 15.09, MA 15.10, MA 15.11</td>
<td>Joel Neal, CA/USA</td>
<td></td>
</tr>
<tr>
<td>13:30 - 15:00</td>
<td>MA16</td>
<td>Novel Mechanisms for Molecular Profiling</td>
<td>Room 203 BD</td>
</tr>
<tr>
<td>Topics: Advanced NSCLC</td>
<td>Moderation: M. Tehfe, Canada; M. Nishio, Japan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30 - 13:35</td>
<td>MA16.01</td>
<td>Frequency and Genomic Context of Emerging Markers for Molecular Testing in Lung Adenocarcinoma in Cell-Free DNA NGS Analysis</td>
<td>Vincent Lam, TX/USA</td>
</tr>
<tr>
<td>13:35 - 13:40</td>
<td>MA16.02</td>
<td>Prospective Clinical Validation of the InVisionFirst™ ctDNA Assay for Molecular Profiling of Patients with Advanced NSCLC</td>
<td>Ramaswamy Govindan, MO/USA</td>
</tr>
<tr>
<td>13:40 - 13:55</td>
<td>MA16.03</td>
<td>Discussant - MA 16.01, MA 16.02</td>
<td>Geoffrey Oxnard, AL/USA</td>
</tr>
<tr>
<td>13:55 - 14:00</td>
<td>MA16.04</td>
<td>Clinical and Molecular Characteristics of EGFR Mutant Lung Cancers with Concurrent TP53 and RB1 Mutations.</td>
<td>Michael Offin, NY/USA</td>
</tr>
<tr>
<td>14:00 - 14:05</td>
<td>MA16.05</td>
<td>MET Kinase Domain Rearrangements (KDRE) in Non-Small Cell Lung Cancer (NSCLC) Identified Through Comprehensive Genomic Profiling (CGP)</td>
<td>Sai-Hong Ou, CA/USA</td>
</tr>
<tr>
<td>14:05 - 14:10</td>
<td>MA16.06</td>
<td>EGFR Clonality and Tumor Mutation Burden (TMB) by Circulating Tumor DNA (ctDNA) Sequencing in Advanced Non-Small Cell Lung Cancer (NSCLC)</td>
<td>Xinghao Ai, China</td>
</tr>
<tr>
<td>14:10 - 14:25</td>
<td>MA16.07</td>
<td>Discussant - MA 16.04, MA 16.05, MA 16.06</td>
<td>Ben Solomon, ACT/Australia</td>
</tr>
<tr>
<td>14:25 - 14:30</td>
<td>MA16.08</td>
<td>Clinical Utility of Detecting ROS1 Genetic Alterations in Plasma</td>
<td>Ibiayi Dagogo-Jack, MA/USA</td>
</tr>
<tr>
<td>14:30 - 14:35</td>
<td>MA16.09</td>
<td>Feasibility, Clinical Relevance of ALK/ROS1 Fusion Variant Detection by Liquid Biopsy in Advanced Non-Small Cell Lung Cancer</td>
<td>Aurélie Swalduz, France</td>
</tr>
</tbody>
</table>
14:35 - 14:40  MA16.10 - Clinical Utility of Cerebrospinal Fluid Cell-Free DNA for Clarifying Genetic Features of Leptomeningeal Metastases in ALK Rearrangement NSCLC
Meimei Zheng, China

14:40 - 14:55  MA16.11 - Discussant - MA 16.08, MA 16.09, MA 16.10
Robert Doebele, CO/USA

14:55 - 15:00  MA16.12 - Q&A

MA17

13:30 - 15:00  New Methods to Improve Lung Cancer Patients Outcomes
Room 205 AC
Topics: Nursing and Allied Professionals
Moderation: M. Nematollahi, Canada; R. Navon, Israel

13:30 - 13:35  MA17.01 - A Sense of Understanding and Belonging When Life Is at Stake - Operable Lung Cancer Patients’ Lived Experiences of Participation in Exercise
Malene Missel, Denmark

13:35 - 13:40  MA17.02 - Early Accrual to a Precision Lung Cancer Survivorship Intervention: The Kentucky LEADS Collaborative Lung Cancer Survivorship Care Program
Jamie Studts, USA

13:40 - 13:45  MA17.03 - Shared Decision-Making for Patients with Advanced Non-Small Cell Lung Cancer
Mette Jensen, Denmark

13:45 - 14:00  MA17.04 - Discussant - MA 17.01, MA 17.02, MA 17.03
Anne Fraser, New Zealand

14:00 - 14:05  MA17.05 - Development of a Telephone Clinic for Patients Undergoing Long Term Follow-Up After Thoracic Surgery
Jenny Mitchell, UK

14:05 - 14:10  MA17.06 - The Specialist Lung Cancer Nurse and Self-Management for People Living with Lung Cancer: A Model of Engagement
Vanessa Brunelli, Australia

14:10 - 14:15  MA17.07 - Nurse-Led Telehealth Clinic in Treatment Monitoring and Follow Up
Sarah Cubbin, UK
14:15 - 14:30  MA17.08 - Discussant - MA 17.05, MA 17.06, MA 17.07
Melissa Culligan, PA/USA

14:30 - 14:35  MA17.09 - Remote Symptom Reporting for Tele-Nursing Team in Thoracic Oncology Clinics: Environmental Scan and Stakeholder Engagement
Simranjit Kooner, Canada

14:35 - 14:40  MA17.10 - The Use of Technology in the Delivery of Supportive Care of Lung Cancer Patients After Treatment
Pamela Rose, UK

14:40 - 14:45  MA17.11 - Multi-Centred, Prospective, Audit to Identify Readmission Causes and Complications Within 30 of Primary Lung Cancer Surgery
Amy Kerr, UK

14:45 - 15:00  MA17.12 - Discussant - MA 17.09, MA 17.10, MA 17.11
Mary Duffy, Australia

MA18
13:30 - 15:00  Modelling, Decision-Making and Population-Based Outcomes
Topics: Treatment in the Real World - Support, Survivorship, Systems Research
Moderation: F. Moraes, Brazil; A. Louie, Canada
Room 201 F

13:30 - 13:35  MA18.01 - Non-Small Cell Lung Cancer Risk Assessment with Artificial Neural Networks
Tafadzwa Chaunzwa, MA/USA

13:35 - 13:40  MA18.02 - The Impact of Treatment Evolution in NSCLC (iTEN) Model: Development and Validation
Manjusha Hurry, Canada

13:40 - 13:45  MA18.03 - How in the Real World Are Lung Cancer Patients Treated? The Ontario, Canada Experience
William Evans, ON/Canada

13:45 - 14:00  MA18.04 - Discussant - MA 18.01, MA 18.02, MA 18.03
Shalini Vinod, Australia

14:00 - 14:05  MA18.05 - Characteristics and Long-Term OS of Non-Small Cell Lung Cancer Patients Receiving EGFR Tyrosine Kinase Inhibitor Treatment
14:05 - 14:10  MA18.06 - Patterns of Lung Cancer Care in the United States: Developments and Disparities  
Erik Blom, Netherlands

14:10 - 14:15  MA18.07 - Awareness of the Harms of Continued Smoking Among Lung Cancer (LC) Survivors  
Lawson Eng, ON/Canada

14:15 - 14:30  MA18.08 - Discussant - MA 18.05, MA 18.06, MA 18.07  
Vera Hirsh, Canada

14:30 - 14:35  MA18.09 - Predictors of Health Utility Scores (HUS) in Advanced EGFR-Mutated NSCLC.  
Shirley Jiang, Canada

14:35 - 14:40  MA18.10 - Evolving Immunotherapy Practice Patterns in Advanced NSCLC: Analysis of an Online Treatment Decision Tool  
David Gandara, CA/USA

14:40 - 14:45  MA18.11 - Implementing a Comprehensive National Audit of Lung Cancer Surgery: The English Lung Cancer Clinical Outcomes Publication (LCCOP) Project  
Doug West, UK

14:45 - 15:00  MA18.12 - Discussant - MA 18.09, MA 18.10, MA 18.11  
Martin Stockler, Australia

---

**MS16**

13:30 - 15:00  Implementation of Lung Cancer Screening  
Room 206 F  
Topics: Screening and Early Detection  
Moderation: G. Nicholas, Canada; H. Groen, Netherlands

13:30 - 13:45  MS16.01 - CMS Approved ACR Lung Cancer Screening Registry in the United States  
Ella Kazerooni, USA

13:45 - 14:00  MS16.02 - NELCIN B3 Screening Program in China  
Qinghua Zhou, China

14:00 - 14:15  MS16.03 - Recruitment Strategies for the Lung Cancer Screening  
Gail Darling, Canada
<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:15 - 14:30</td>
<td><strong>National Lung Screening Program in Taiwan</strong></td>
<td>Pan-Chyr Yang, Taiwan</td>
<td>Room 206 AC</td>
</tr>
<tr>
<td>14:30 - 14:45</td>
<td><strong>Optimal Approach to Integrate Smoking Cessation into Screening Program</strong></td>
<td>Matthew Callister, UK</td>
<td>Room 206 AC</td>
</tr>
<tr>
<td>14:45 - 15:00</td>
<td><strong>Q&amp;A</strong></td>
<td></td>
<td>Room 206 AC</td>
</tr>
</tbody>
</table>

**MS17**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30 - 15:00</td>
<td><strong>Life After Lung Cancer: Survivorship</strong></td>
<td></td>
<td>Room 206 AC</td>
</tr>
<tr>
<td></td>
<td>Topics: Treatment in the Real World - Support, Survivorship, Systems Research</td>
<td></td>
<td>Room 206 AC</td>
</tr>
<tr>
<td></td>
<td>Moderation: D. Dawe, Canada; J. Gray, USA</td>
<td></td>
<td>Room 206 AC</td>
</tr>
<tr>
<td>13:30 - 13:45</td>
<td><strong>Unmet needs and QOL of Lung Cancer Survivors</strong></td>
<td>Meredith Giuliani, AB/Canada</td>
<td>Room 206 AC</td>
</tr>
<tr>
<td>13:45 - 14:00</td>
<td><strong>Financial Toxicity and Out of Pocket Costs</strong></td>
<td>Bishal Gyawali, MA/USA</td>
<td>Room 206 AC</td>
</tr>
<tr>
<td>14:00 - 14:15</td>
<td><strong>Surveillance &amp; Second Primary Malignancies in Lung Cancer Survivors</strong></td>
<td>Virginie Westeel, France</td>
<td>Room 206 AC</td>
</tr>
<tr>
<td>14:15 - 14:30</td>
<td><strong>How Important Is Tobacco Cessation as Part of Lung Cancer Treatment?</strong></td>
<td>Clarissa Baldotto, Brazil</td>
<td>Room 206 AC</td>
</tr>
<tr>
<td>14:30 - 15:00</td>
<td><strong>Discussion</strong></td>
<td></td>
<td>Room 206 AC</td>
</tr>
</tbody>
</table>

**MS18**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30 - 15:00</td>
<td><strong>Management of SCLC Patients Not Represented in Clinical Trials</strong></td>
<td></td>
<td>Room 206 BD</td>
</tr>
<tr>
<td></td>
<td>Topics: Small Cell Lung Cancer/NET</td>
<td></td>
<td>Room 206 BD</td>
</tr>
<tr>
<td></td>
<td>Moderation: J. Wang, China; E. Vokes, USA</td>
<td></td>
<td>Room 206 BD</td>
</tr>
<tr>
<td>13:30 - 13:50</td>
<td><strong>Treatment of Patients with Poor Performance Status (ECOG 3-4)</strong></td>
<td>Luiz H Araujo, Brazil</td>
<td>Room 206 BD</td>
</tr>
</tbody>
</table>
13:50 - 14:10  MS18.02 - Treatment of Elderly Patients with SCLC  
Karen Kelly, CA/USA

14:10 - 14:30  MS18.03 - Treatment of SCLC transformed from EGFR Mutant Adenocarcinoma  
Nicolas Marcoux, USA

14:30 - 14:50  MS18.04 - Retreatment with Platinum and Etoposide and Treatment Beyond Second Line  
Charles Butts, Canada

14:50 - 15:00  MS18.05 - Q&A

---

MS19

13:30 - 15:00  Pulmonary Dilemmas with Immunotherapy  
Room 201 BD

Topics: Interventional Diagnostics/Pulmonology  
Moderation: S. Andarini, Indonesia; L. Raez, USA

13:30 - 13:50  MS19.01 - Drug-Induced Pneumonitis with IO: How worried should we be for our Lung Cancer Patients  
Desiree Hao, AB/Canada

13:50 - 14:10  MS19.02 - What Are the Clinical Features of IO Progression/Pseudoprogression and Radiation Fibrosis vs Recurrence  
Chong-Kin Liam, Malaysia

14:10 - 14:30  MS19.03 - Diagnostic Approaches Suspected IO Progression/Pseudoprogression and What/When to Rebiospy for TT Progression  
Kasia Czarnecka-Kujawa, Canada

14:30 - 15:00  MS19.04 - Q&A

---

OA11

13:30 - 15:00  Thymic and Other Thoracic Tumours: Targeted Therapies, Biomarkers and Neo/Adjuvant Radiotherapy  
Room 205 B

Topics: Thymoma/Other Thoracic Malignancies  
Moderation: M. Taremi, Canada; Y. Shargall, Canada
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30 - 13:40</td>
<td>OA11.01 - Role of Post-Operative Radiation in Different Histologic Subgroups of Thymoma: Result Based on National Cancer Data Base (NCDB)</td>
<td>Tithi Biswas, OH/USA</td>
</tr>
<tr>
<td>13:40 - 13:50</td>
<td>OA11.02 - A Population-Based Study of Incidence and Survival Trends of 1,588 Thymic Malignancies: Results from the California Cancer Registry</td>
<td>David Benjamin, USA</td>
</tr>
<tr>
<td>13:50 - 14:05</td>
<td>OA11.03 - Discussant - OA 11.01, OA 11.02</td>
<td>Andrew Hope, Canada</td>
</tr>
<tr>
<td>14:05 - 14:15</td>
<td>OA11.04 - A Comparative Study of PD-L1 Immunohistochemical Assays with Four Reliable Antibodies in Thymic Carcinoma</td>
<td>Tadashi Sakane, Japan</td>
</tr>
<tr>
<td>14:15 - 14:25</td>
<td>OA11.05 - Phase II Study of Sunitinib in Patients with Thymic Carcinoma Previously Treated with Platinum-Based Chemotherapy (KOSMIC Trial)</td>
<td>Se Hyun Kim, Republic of Korea</td>
</tr>
<tr>
<td>14:25 - 14:35</td>
<td>OA11.06 - Two BRM Promoter Polymorphisms Do Not Predict Susceptibility or Prognosis of Thymoma</td>
<td>Nathan Kuehne, ON/Canada</td>
</tr>
<tr>
<td>14:35 - 14:50</td>
<td>OA11.07 - Discussant - OA 11.04, OA 11.05, OA 11.06</td>
<td>Giuseppe Giaccone, OR/USA</td>
</tr>
<tr>
<td>14:50 - 15:00</td>
<td>OA11.08 - Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>

PC06

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30 - 15:00</td>
<td>Controversies in Immunobiomarker Testing</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Topics: Pathology</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderation: C. Couture, Canada; E. Thunnissen, Netherlands</td>
<td></td>
</tr>
<tr>
<td>13:30 - 13:50</td>
<td>PC06.01 - Laboratory Developed Test - PRO</td>
<td>Dara Aisner, CO/USA</td>
</tr>
<tr>
<td>13:50 - 14:10</td>
<td>PC06.02 - Laboratory Developed Test - CON</td>
<td>Mari Mino-Kenudson, MA/USA</td>
</tr>
<tr>
<td>14:10 - 14:30</td>
<td>PC06.03 - Tumor Mutation Burden - PRO</td>
<td>Lynette Sholl, USA</td>
</tr>
<tr>
<td>Time</td>
<td>Session Title</td>
<td>Speaker</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>--------------------------------------------</td>
</tr>
<tr>
<td>14:30 - 14:50</td>
<td>PC06.04 - Tumor Mutation Burden - CON</td>
<td>Lukas Bubendorf, Switzerland</td>
</tr>
<tr>
<td>14:50 - 15:00</td>
<td>PC06.05 - Q&amp;A</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30 - 15:00</td>
<td>PC07 - The Future of Cytotoxic Chemotherapy in Advanced NSCLC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Room 202 BD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Topics: Advanced NSCLC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderation: S. Brule, Canada; T. Kato, Japan</td>
<td></td>
</tr>
<tr>
<td>13:30 - 13:50</td>
<td>PC07.01 - Debate 1: Chemotherapy Will Become a Thing of the past in the Management of Advanced NSCLC - For</td>
<td>Suresh Ramalingam, USA</td>
</tr>
<tr>
<td>13:50 - 14:10</td>
<td>PC07.02 - Debate 1: Chemotherapy Will Become a Thing of the past in the Management of Advanced NSCLC - Against</td>
<td>Keunchil Park, Republic of Korea</td>
</tr>
<tr>
<td>14:10 - 14:30</td>
<td>PC07.03 - Debate 2: For Wild-Type NSCLC, Which Will Be the Preferred Strategy: IO alone versus Chemo + IO - IO alone</td>
<td>Leora Horn, USA</td>
</tr>
<tr>
<td>14:30 - 14:50</td>
<td>PC07.04 - Debate 2: For Wild-Type NSCLC, Which Will Be the Preferred Strategy: IO alone versus Chemo + IO - Chemo + IO</td>
<td>Federico Cappuzzo, Italy</td>
</tr>
<tr>
<td>14:50 - 15:00</td>
<td>PC07.05 - Q&amp;A</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30 - 15:00</td>
<td>PC08 - The Great Oligometastatic Debates</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Room 105</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Topics: Oligometastatic NSCLC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderation: S. Harrow, USA; M. Johnson, USA</td>
<td></td>
</tr>
<tr>
<td>13:30 - 13:40</td>
<td>PC08.01 - Debate #1: Locally Ablative Therapies Should Be Standard Treatment for Patients with NSCLC Oligometastese (PRO)</td>
<td>Howard (Jack) West, WA/USA</td>
</tr>
</tbody>
</table>
13:40 - 13:50  PC08.02 - Debate #1: Locally Ablative Therapies Should Be Standard Treatment for Patients with NSCLC Oligometastases (CON)
Puneeth Iyengar, USA

13:50 - 14:00  PC08.03 - Discussion

14:00 - 14:10  PC08.04 - Debate #2: Optimal Therapy for OM Disease: Thoracic Surgery Should Be the Treatment of Choice Whenever Possible
David Jones, USA

14:10 - 14:20  PC08.05 - Debate #2: Keep Calm and Beam On: Thoracic Radiation Obviates the Need for Surgery
Matthias Guckenberger, Switzerland

14:20 - 14:30  PC08.06 - Discussion

14:30 - 14:40  PC08.07 - Debate #3: Brain Metastases with a Driver Mutation Should Be Treated with Systemic Therapy First (PRO)
Mark Doherty, Canada

14:40 - 14:50  PC08.08 - Debate #3: Brain Metastases with a Driver Mutation Should Be Treated with Systemic Therapy First (CON)
Marta Scorsetti, Italy

14:50 - 15:00  PC08.09 - Discussion

ES03

15:15 - 16:45  How to Manage Pleural Plaques and Pleural Effusion with Negative Pleural Biopsy
Room 206 AC
Topics: Mesothelioma
Moderation: R. Stahel, Switzerland; M. De Perrot, Canada

15:15 - 15:30  ES03.01 - Diagnosis of Mesothelioma Based on Cytology Alone
Jennifer Sauter, NY/USA

15:30 - 15:45  ES03.02 - Role of CT Scan to Follow Pleural Plaques
Demetris Patsios, Canada

15:45 - 16:00  ES03.03 - When to Repeat Pleural Biopsies
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Description</th>
<th>Speaker</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00 - 16:15</td>
<td>ES03.04 - Role of Chemotherapy in Mesothelioma with Minimal Bulk Disease</td>
<td>Christopher Lee, Canada</td>
<td></td>
</tr>
<tr>
<td>16:15 - 16:30</td>
<td>ES03.05 - Role of Surgery in T0 Mesothelioma</td>
<td>Seiki Hasegawa, Japan</td>
<td></td>
</tr>
<tr>
<td>16:30 - 16:45</td>
<td>ES03.06 - Q&amp;A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Description</th>
<th>Speaker</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:15 - 16:15</td>
<td>ES04 - Liquid Biopsies in Lung Cancer</td>
<td></td>
<td>Room 203 BD</td>
</tr>
<tr>
<td></td>
<td>Topics: Targeted Therapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderation: S.-H. Ou, USA; I. Wistuba, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:15 - 15:35</td>
<td>ES04.01 - Liquid Biopsies in Lung Cancer</td>
<td>Ming Tsao, Canada</td>
<td></td>
</tr>
<tr>
<td>15:35 - 15:55</td>
<td>ES04.02 - Mechanisms of Resistance to Targeted Therapy</td>
<td>Christine Lovly, TN/USA</td>
<td></td>
</tr>
<tr>
<td>15:55 - 16:15</td>
<td>ES04.03 - Overcoming Resistance by Improving Treatment Compliance</td>
<td>Felipe Gomes, Brazil</td>
<td></td>
</tr>
<tr>
<td>16:15 - 16:35</td>
<td>ES04.04 - Guiding Second Line Treatment in ALK + Patients (Sequence of Drugs, Rebiopsy?)</td>
<td>Enriqueta Felip, Spain</td>
<td></td>
</tr>
<tr>
<td>16:35 - 16:45</td>
<td>ES04.05 - Q&amp;A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Description</th>
<th>Speaker</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:15 - 16:15</td>
<td>ES05 - Collaboration Between Stakeholders to Improve Lung Cancer Research</td>
<td></td>
<td>Room 205 AC</td>
</tr>
<tr>
<td></td>
<td>Topics: Advocacy</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderation: B. Addario, USA; T. Sawa, Japan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:15 - 15:35</td>
<td>ES05.01 - Linking the Stakeholders: Can Patient Groups, Clinical Researchers and the Pharmaceutical Industry Collaborate to Accelerate Research?</td>
<td>Janet Freeman-Daily, USA</td>
<td></td>
</tr>
</tbody>
</table>
15:35 - 15:55  ES05.02 - Can Patient Groups and Regulatory Bodies Work Together to Make Clinical Research Easier?
Andrea Ferris, USA

15:55 - 16:15  ES05.03 - Discrepancies and Sustainable Access to Innovative Therapies: Transforming Patient Experience in to Patient Voice
Jesme Fox, UK

16:15 - 16:35  ES05.04 - Challenges and Solutions in Engaging with the Health Technology Assessment Process in Canada
Christina Sit, Canada

16:35 - 16:45  ES05.05 - Q&A

GR02

15:15 - 16:45  Management of N2 NSCLC - A Case Based Discussion
Topics: Treatment of Locoregional Disease - NSCLC
Moderation: T. Grodzki, Poland; L. Coate, Ireland

15:15 - 15:25  GR02.01 - Case 1: Single Zone N2 (No Pneumonectomy Necessary)
Anna Wrona, Poland

15:25 - 15:45  GR02.02 - Panel Discussion
David Harpole, AL/USA; Hiroshi Date, Japan; Alexander Sun, Canada; Joop De Langen, Netherlands; Mary Duffy, Australia; Kathy Albain, USA

15:45 - 15:55  GR02.03 - Case 2: Multiple N2 Bulky Primary
Megan Daly, CA/USA

15:55 - 16:15  GR02.04 - Panel Discussion
David Harpole, AL/USA; Hiroshi Date, Japan; Alexander Sun, Canada; Joop De Langen, Netherlands; Mary Duffy, Australia; Kathy Albain, USA

16:15 - 16:25  GR02.05 - Case 3: Post Operative Management of Incidentally Found N2 Disease
Masaya Yotsukura, Japan

16:25 - 16:45  GR02.06 - Panel Discussion
### MA19

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:15 - 16:45</td>
<td>Genomic Markers of IO Response</td>
<td>Room 201 BD</td>
</tr>
<tr>
<td></td>
<td>Topics: Immunooncology</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderation: R. Rosell, Spain; P. Cheema, Canada</td>
<td></td>
</tr>
</tbody>
</table>

| 15:15 - 15:20 | MA19.01 - Efficacy and Genomic Correlates of Response to Anti-PD1/PD-L1 Blockade in Non-Small Cell Lung Cancers Harboring Targetable Oncogenes | Natalie Vokes, USA |
| 15:20 - 15:25 | MA19.02 - Prior Therapy and Increased Expression of PD-L1 in NSCLC Tumor Samples | Anne-Marie Boothman, UK |
| 15:25 - 15:40 | MA19.03 - Discussant - MA 19.01, MA 19.02 | Jonathan W Goldman, USA |
| 15:40 - 15:45 | MA19.04 - The Clinical Implication of Frameshift Indel Mutation Burden in Non-Small Cell Lung Cancer (NSCLC) | Young Kwang Chae, USA |
| 15:45 - 15:50 | MA19.05 - Difference of Tumor Mutational Burden Is Associated with Distinct Immune Microenviroment in the T Cell-Inflamed Lung Adenocarcinoma | Takahiro Karasaki, Japan |
| 15:50 - 15:55 | MA19.06 - Blood Based Biomarkers: RNA, KRAS and PD-L1 Strongly Matching with Tissue and Showing Correlation with Clinical Responses in NSCLC Patient’s | Luis Raez, FL/USA |
| 15:55 - 16:10 | MA19.07 - Discussant - MA 19.04, MA 19.05, MA 19.06 | Claudia Poleri, Argentina |
| 16:10 - 16:15 | MA19.08 - Detection of Primary Immunotherapy Resistance to PD-1 Checkpoint Inhibitors (PD1CI) in 2nd Line NSCLC | Joachim Aerts, Netherlands |
| 16:15 - 16:20 | MA19.09 - Concurrent Mutations in STK11 and KEAP1 is Associated with Resistance to PD-(L)1 Blockade in Patients with NSCLC Despite High TMB | Kathryn Arbour, NY/USA |
Ferdinandos Skoulidis, TX/USA

16:25 - 16:40  MA19.11 - Discussant - MA 19.08, MA 19.09, MA 19.10
Lynette Sholl, USA

16:40 - 16:45  MA19.12 - Q&A

MA20

15:15 - 16:45  Implementation of Lung Cancer Screening
Topics: Screening and Early Detection
Moderation: S. Lam, Canada; C. Berg, USA

15:15 - 15:20  MA20.01 - Lung Cancer Screenee Selection by USPSTF versus PLCOm2012 Criteria - Preliminary ILST Findings
Martin Tammemägi, Canada

15:20 - 15:25  MA20.02 - “Reduced” HUNT Lung Cancer Model for Predicting Lung Cancer in the Prospective Danish Lung Cancer Screening Study - Comparison with the NLST.
Oluf Røe, Norway

15:25 - 15:30  MA20.03 - Surprising Implications of Proposed Risk-Thresholds for Selecting US Ever-Smokers into CT Lung-Cancer Screening
Hormuzd Katki, MD/USA

15:30 - 15:45  MA20.04 - Discussant - MA 20.01, MA 20.02, MA 20.03
Amanda Tufman, Germany

Melinda Aldrich, USA

15:50 - 15:55  MA20.06 - Lung Cancer Screening Pilot for People at High Risk: Early Results on Cancer Detection and Staging
Martin Tammemagi, Canada

15:55 - 16:00  MA20.07 - Lung Cancer Screening for Limited-Resource Patients: Preliminary Findings from a Low-dose CT Pilot Program
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00 - 16:15</td>
<td>MA20.08 - Discussant - MA 20.05, MA 20.06, MA 20.07</td>
<td>Annette Mcwilliams, Australia</td>
<td></td>
</tr>
<tr>
<td>16:15 - 16:20</td>
<td>MA20.09 - Improved Lung Cancer and Mortality Prediction Accuracy Using Survival Models Based on Semi-Automatic CT Image Measurements</td>
<td>Anton Schreuder, Netherlands</td>
<td></td>
</tr>
<tr>
<td>16:25 - 16:30</td>
<td>MA20.11 - Automatic Nodule Size Measurements Can Improve Prediction Accuracy Within a Brock Risk Model</td>
<td>Timor Kadir, UK</td>
<td></td>
</tr>
<tr>
<td>16:30 - 16:45</td>
<td>MA20.12 - Discussant - MA 20.09, MA 20.10, MA 20.11</td>
<td>Heidi Schmidt, Canada</td>
<td></td>
</tr>
</tbody>
</table>

**MA21**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:15 - 16:45</td>
<td>15:15 - 16:45 Molecular Subtyping, CBL3, and Non-Coding RNA</td>
<td>Room 205 B</td>
<td></td>
</tr>
<tr>
<td>15:15 - 15:20</td>
<td>MA21.01 - Cbl Mutations (mt) as Important Mediators of Oncogenic RTK Signaling in NSCLC</td>
<td>Rebecca Feldman, AZ/USA</td>
<td></td>
</tr>
<tr>
<td>15:20 - 15:25</td>
<td>MA21.02 - Identification of an E2 Ubiquitin Conjugase CDC34 That Competes with E3 Ligase c-Cbl to Stabilize EGFR and Promotes Lung Carcinogenesis</td>
<td>Guangbiao Zhou, China</td>
<td></td>
</tr>
<tr>
<td>15:25 - 15:30</td>
<td>MA21.03 - Heterogeneity in MET Copy Number and Intratumoural Subsets in Pleomorphic Lung Carcinoma: Implications for MET Directed Therapy in NSCLC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Title</td>
<td>Speaker</td>
</tr>
<tr>
<td>--------</td>
<td>------------------</td>
<td>----------------------------------------------------------------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>15:30</td>
<td>MA21.04</td>
<td>Discussant - MA 21.01, MA 21.02, MA 21.03</td>
<td>Ravi Salgia, CA/USA</td>
</tr>
<tr>
<td>15:45</td>
<td>MA21.05</td>
<td>Comprehensive Genomic Characterization and Prognostic Nomogram Developed by 295-Gene Panel Targeted Sequencing</td>
<td>Bin Zhang, China</td>
</tr>
<tr>
<td>15:50</td>
<td>MA21.06</td>
<td>Proteins Associated with Survival Differ Depending on Molecular Subtypes, and Mutational- and Smoking-Status in NSCLC Biopsies</td>
<td>Ann Halvorsen, Norway</td>
</tr>
<tr>
<td>15:55</td>
<td>MA21.07</td>
<td>A Nation-Wide Population-Based Mapping of Targetable Alterations in Smoking-Independent Lung Cancer</td>
<td>Maria Planck, Sweden</td>
</tr>
<tr>
<td>16:00</td>
<td>MA21.08</td>
<td>Discussant - MA 21.05, MA 21.06, MA 21.07</td>
<td>Siddhartha Devarakonda, MO/USA</td>
</tr>
<tr>
<td>16:20</td>
<td>MA21.10</td>
<td>Large-Scale Discovery of Novel Human Oncofetal Transcripts in Lung</td>
<td>Brenda Minatel, BC/Canada</td>
</tr>
<tr>
<td>16:25</td>
<td>MA21.11</td>
<td>Epigenomic Mapping of Cell-Free DNA in Patients with Non-Small Cell Lung Cancer</td>
<td>Christine Bestvina, USA</td>
</tr>
<tr>
<td>16:30</td>
<td>MA21.12</td>
<td>Discussant - MA 21.09, MA 21.10, MA 21.11</td>
<td>Geoffrey Liu, Canada</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>MA22</strong></td>
<td></td>
</tr>
<tr>
<td>15:15</td>
<td>New Therapeutics, Pathology, and Brain Metastases for Small Cell and Neuroendocrine Tumour</td>
<td>Room 206 BD</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Topics: Small Cell Lung Cancer/NET</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Moderation: E. Richardet, Argentina; M. El-Mallah, Canada</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Title</td>
<td>Speaker</td>
</tr>
<tr>
<td>------------</td>
<td>-----------</td>
<td>-------------------------------------------------------------------------------------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>15:15 - 15:20</td>
<td>MA22.01</td>
<td>PARP Inhibitor Radiosensitization of Small Cell Lung Cancer Differs by PARP Trapping Potency</td>
<td>Benjamin Lok, Canada</td>
</tr>
<tr>
<td>15:20 - 15:25</td>
<td>MA22.02</td>
<td>Activation of MAPK Suppresses Neuroendocrine Transcription Factors and Causes Transdifferentiation of Small Cell Lung Cancer</td>
<td>Yusuke Inoue, Canada</td>
</tr>
<tr>
<td>15:30 - 15:45</td>
<td>MA22.04</td>
<td>Discussant - MA 22.01, MA 22.02, MA 22.03</td>
<td>Céline Mascaux, ON/Canada</td>
</tr>
<tr>
<td>15:45 - 15:50</td>
<td>MA22.05</td>
<td>Impact of Tumor Spread Through Air Spaces (STAS) in Lung Neuroendocrine Tumors (NETs)</td>
<td>Rania Aly, NY/USA</td>
</tr>
<tr>
<td>15:50 - 15:55</td>
<td>MA22.06</td>
<td>Preinvasive Multifocal Neuroendocrine Lesions with Primary Typical Carcinoid Lung Tumors: A Negative Prognostic Factor?</td>
<td>Niccolo Daddi, Italy</td>
</tr>
<tr>
<td>15:55 - 16:00</td>
<td>MA22.07</td>
<td>Prognostic Value of Distant Organ-Specific Metastases in Newly Diagnosed Lung Neuroendocrine Tumors: A Population-Based Study</td>
<td>Min Fan, China</td>
</tr>
<tr>
<td>16:00 - 16:15</td>
<td>MA22.08</td>
<td>Discussant - MA 22.05, MA 22.06, MA 22.07</td>
<td>Giuseppe Pelosi, Italy</td>
</tr>
<tr>
<td>16:15 - 16:20</td>
<td>MA22.09</td>
<td>Should Stereotactic Radiosurgery be Considered for Salvage of Intracranial Recurrence in Small Cell Lung Cancer?</td>
<td>Brooklyn Mazure, Canada</td>
</tr>
<tr>
<td>16:20 - 16:25</td>
<td>MA22.10</td>
<td>Prevalence and Risk Factors of Brain Metastases in Limited Stage Small Cell Lung Cancer Immediately Before Prophylactic Cranial Irradiation</td>
<td>Zhengfei Zhu, China</td>
</tr>
<tr>
<td>16:25 - 16:30</td>
<td>MA22.11</td>
<td>Risk of Hippocampal Metastases in Small Cell Lung Cancer: Implications for Hippocampal Sparing Cranial Irradiation</td>
<td>Rachel Effeney, Australia</td>
</tr>
<tr>
<td>Time</td>
<td>Session/Topic</td>
<td>Speaker/Facility</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>------------------------</td>
<td></td>
</tr>
<tr>
<td>16:30 - 16:45</td>
<td>MA22.12 - Discussant - MA 22.09, MA 22.10, MA 22.11</td>
<td>Houda Bahig, Canada</td>
<td></td>
</tr>
<tr>
<td>15:15 - 16:45</td>
<td>Innovative and Evolving Strategies in Diagnosis and Management of Stage I NSCLC</td>
<td>Room 202 BD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Topics: Treatment of Early Stage/Localized Disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderation: B. Li, USA; K. Yasufuku, Canada</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:15 - 15:30</td>
<td>MS20.01 - Robotic and Innovative Surgery</td>
<td>Waël Hanna, Canada</td>
<td></td>
</tr>
<tr>
<td>15:30 - 15:45</td>
<td>MS20.02 - The Future of Stereotactic Ablative Radiotherapy (SABR)</td>
<td>Billy Loo, CA/USA</td>
<td></td>
</tr>
<tr>
<td>15:45 - 16:00</td>
<td>MS20.03 - Immunotherapy and Surgery: Neoadjuvant or Adjuvant? Is It Safe?</td>
<td>Jamie Chaft, USA</td>
<td></td>
</tr>
<tr>
<td>16:00 - 16:15</td>
<td>MS20.04 - Prediction of Clinical Outcome in NSCLC Using Integrative Genomics: Implications for Adjuvant Chemotherapy</td>
<td>Phillippe Broet, France</td>
<td></td>
</tr>
<tr>
<td>16:15 - 16:30</td>
<td>MS20.05 - Beyond Surgery - Support of the Surgical Patient</td>
<td>Kate Kuhns, USA</td>
<td></td>
</tr>
<tr>
<td>16:30 - 16:45</td>
<td>MS20.06 - Less Is More: Segmentectomy in the Management of Early Stage NSCLC</td>
<td>Shun-ichi Watanabe, Japan</td>
<td></td>
</tr>
</tbody>
</table>

**MS21**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Topic</th>
<th>Speaker/Facility</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:15 - 17:00</td>
<td>Giants in Thoracic Oncology</td>
<td>Room 105</td>
</tr>
<tr>
<td></td>
<td>Moderation: R. Feld, Canada; M. Satouchi, Japan</td>
<td></td>
</tr>
<tr>
<td>15:15 - 15:25</td>
<td>MS21.01 - Surgery and its Evolution</td>
<td>Paul Van Schil, Belgium</td>
</tr>
<tr>
<td>15:25 - 15:35</td>
<td>MS21.02 - Chemotherapy through the 21st Century</td>
<td>David Johnson, USA</td>
</tr>
</tbody>
</table>
15:35 - 15:45  MS21.03 - Revolution in Radiation  
Ben Slotman, Netherlands

15:45 - 15:55  MS21.04 - Targeted Therapy - The Second Revolution  
Frances Shepherd, Canada

15:55 - 16:05  MS21.05 - Quality of Life - Are we Paying Enough Attention?  
Richard Gralla, NY/USA

16:05 - 16:15  MS21.06 - Immunotherapy - Sequence or Combination?  
Roy Herbst, CT/USA

Fred Hirsch, CO/USA

16:25 - 16:35  MS21.08 - Where will we be in 10 years?  
Paul Bunn, Jr., CO/USA

16:35 - 17:00  MS21.09 - Discussion

OA12  
15:15 - 16:45  Novel Therapies in MET, RET and BRAF  
Topics: Targeted Therapy  
Moderation: N. Pavlakis, Australia; Y. Kobayashi, Japan

15:15 - 15:25  OA12.01 - Phase II Data for the MET Inhibitor Tepotinib in Patients with Advanced NSCLC and MET Exon 14-Skipping Mutations  
Enriqueta Felip, Spain

15:25 - 15:35  OA12.02 - Updated Antitumor Activity of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer  
Alexander Drilon, NY/USA

15:35 - 15:45  OA12.03 - Activity of Crizotinib in MET or ROS1 Positive (+) NSCLC: Results of the AcSé Trial.
Denis Moro-Sibilot, France

15:45 - 16:00 OA12.04 - Discussant - OA 12.01, OA 12.02, OA 12.03
Mark Awad, MA/USA

16:00 - 16:10 OA12.05 - Vemurafenib in Patients Harboring V600 and Non V600 BRAF Mutations: Final Results of the NSCLC Cohort from the AcSé Trial.
Julien Mazieres, France

16:10 - 16:20 OA12.06 - Mutational Landscape of BRAF V600E Positive Lung Cancer Patients Following BRAF Directed Therapy Failure
Anastasios Dimou, CO/USA

16:20 - 16:30 OA12.07 - Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients with RET Fusion+ Non-Small Cell Lung Cancer
Geoffrey Oxnard, AL/USA

16:30 - 16:45 OA12.08 - Discussant - OA 12.05, OA 12.06, OA 12.07
Thomas Newsom-Davis, UK

P2.01

16:45 - 18:00 Advanced NSCLC Exhibit Hall

P2.01-01 - The Impact of Anlotinib on Brain Metastases of NSCLC: Post-Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303)
Wenhua Liang, China

P2.01-02 - Osimertinib for EGFR-Positive Advanced NSCLC with Brain Metastases: Preliminary Analysis of an Open-Label, Two-Arm, Phase 2 Study
Nir Peled, Israel

P2.01-03 - Quality of Life Outcomes for FDA-Approved Agents in Advanced Non-Small Cell Lung Cancer
Hamzeh Albaba, ON/Canada

P2.01-04 - Reducing Time to Molecular Diagnosis for Advanced NSCLC in the Context of a Reference Testing Center
Alla’a Ali, Canada

P2.01-05 - Adenocarcinoma of the Lung: The Woman’s Cancer?
Noor Alsaadoun, AB/Canada

P2.01-06 - HSP72 Expression Associates with Survival in EGFR Mutated NSCLC
Idoroenyi Amanam, CA/USA

P2.01-07 - Safety and Efficacy of LATTICE Radiotherapy in Voluminous Non-Small Cell Lung Cancer: A Retrospective Study of 10 Patients Over 7 Year Period
James Melotek, FL/USA

P2.01-08 - Conversion Surgery for Locally Advanced Lung Adenocarcinoma Harboring Driver Gene Mutation After TKI Followed by Cytotoxic Agent
Masaya Aoki, Japan

P2.01-09 - Targetable Genomic Alterations in KRAS Mutant Lung Adenocarcinoma by Targeted Next Generation Sequencing
Edurne Arriola, Spain

P2.01-10 - Prognostic Impact of Longitudinal Monitoring of Radiomic Features in Patients with Advanced Non-Small Cell Lung Cancer
So Hyeon Bak, Republic of Korea

P2.01-11 - Characteristics of Non-Small Cell Lung Cancer: Differences by Sex and Hormonal Status in a Hispanic Population
Feliciano Barron, Mexico

P2.01-12 - Ramucirumab+Docetaxel Usage Following Rapid Disease Progression in Real World Advanced Non-Small Cell Lung Cancer Patients
Marta Batus, IL/USA

P2.01-13 - Number, Rather Than Location of Metastases, Dictates Outcome in Stage IV, M1b, Non-Small Cell Lung Cancer
Amanda Gibson, Canada

P2.01-14 - Preferred and Achieved Goals of Patients with Metastatic Lung Cancer and Their Oncologists in End-of-Life Therapy
Annemarie Becker, Netherlands

Sean Brown, UK
P2.01-16 - Dynamic ctDNA Monitoring Revealed Novel Resistance Mechanisms and Response Predictors of Osimertinib Treatment in East Asian NSCLC Patients
Jianhua Chang, China

P2.01-17 - MALAT1-Mir-101-3p-SOX9 Feedback Loop Modulates the Chemo-Resistance of Lung Cancer Cell to DDP via Wnt Signaling Pathway
Wei Chen, China

P2.01-18 - Differential Molecular Mechanisms Associated with Dramatic and Gradual Progression in NSCLC Patients with Intrathoracic Dissemination
Ying Chen, China

P2.01-19 - Radiomics Features of Contrast Enhanced CT as Prognostic Factors in Resectable Adenocarcinoma of Lung
Jooae Choe, Republic of Korea

P2.01-20 - FLT-PET for Detection of Relapse Following Radiotherapy for Lung Cancer. Preliminary Results
Tine Christensen, Denmark

P2.01-21 - Antigen Cascade Triggering Correlates with Prolonged Survival in Advanced NSCLC Patients Undergone PD-1 Blockade with Nivolumab.
PIERPAOLO Correale, Italy

P2.01-22 - Increased Incidence, Morbidity and Mortality Rates for Lung Cancer in Women in Brazil Between 2000 and 2014
Guilherme Costa, Brazil

P2.01-23 - Baseline Plasma Biomarkers Predict Long-Term Responses to ALK-TKIs in ALK+ Advanced Non-Small Cell Lung Cancer (NSCLC)
Mathilde Couetoux Du Tertre, QC/Canada

P2.01-24 - MLPH Activates CDC42/PAK1 Signaling to Promote Epithelial-Mesenchymal Transition via TGF-β in Non-Small Cell Lung Cancer
Xiaorong Dong, China

P2.01-25 - MicroRNA-330-3p Promotes Brain Metastasis of Non-Small Cell Lung Cancer by Activating MAPK/MEK/ERK Signaling Through GRIA3
Xiaorong Dong, China

P2.01-26 - Association of Base Excision Repair Gene Polymorphisms with Response to Chemotherapy of Advanced Non Small-Cell Lung Cancer
Xu Wang, China

P2.01-27 - MR, CT and Cone-Beam CT for Lymph Node Visualisation in Locally-Advanced Lung Cancer
Sean Brown, UK

P2.01-28 - Gender and Systemic Treatment Patterns: Impacts on the Overall Survival of Stage IV NSCLC 2010 - 2014 Diagnoses
Anifat Elegbede, Canada

P2.01-29 - Economic Analysis of Osimertinib in Previously Untreated EGFR-Positive Advanced Non-Small Cell Lung Cancer
Doreen Ezeife, Canada

P2.01-30 - Applicability of Lung-molGPA Index in Non-Small Cell Lung Cancer Patients with Different Gene Alterations and Brain Metastases
Yun Fan, China

P2.01-31 - Updated EGFR Mutation Frequency in 1,689 NSCLC Brazilian Patients - A National-Wide Study
Carlos Gil Ferreira, Brazil

P2.01-32 - Economic Evaluation of Diagnostic Platforms for T790M Detection in Post EGFR-TKI NSCLC in Brazil
Carlos Gil Ferreira, Brazil

P2.01-33 - Open-Label, Biomarker-Directed Platform Study in NSCLC Patients Who Progressed on an Anti-PD-(L)1 Containing Therapy (HUDSON)
Patrick Forde, MD/USA

P2.01-34 - Prognostic Value of Neutrophil to Lymphocyte Ratio for Metastatic NSCLC Patients Treated with Immunotherapy and Ramucirumab Plus Docetaxel.
Marta Batus, IL/USA

P2.01-35 - Predicting Risk of Chemotherapy-Induced Severe Neutropenia in Patients with Advanced Lung Cancer
Apar Kishor Ganti, NE/USA

P2.01-36 - Real-World Treatment Patterns in Treatment-Naïve Advanced NSCLC Patients in North America: A Systematic Literature Review
Yong Yuan, NJ/USA
P2.01-37 - A Ph 1/2 Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) with Docetaxel in pts with Previously Treated NSCLC
David Gerber, TX/USA

P2.01-38 - Sarcopenia is Associated with Metastatic Burden and is a Negative Prognostic Factor in Metastatic Non-Small Cell Lung Cancer
Chad Glisch, WI/USA

P2.01-39 - Can Benefit or Futility in Treating Advanced NSCLC Be Determined Early Using the LCSS 3-Item Global Index (3-IGI) PRO?
Richard Gralla, NY/USA

P2.01-40 - Prognostic Importance of Sarcopenia and Inflammatory Statements in Stage III Non Small Cell Lung Carcinoma
Serap Akyürek, Turkey

P2.01-41 - The Role and Mechanism of FBW7 Deficiency in Advanced Non-Small Cell Lung Cancer with Docetaxel Resistance
Qisen Guo, China

P2.01-42 - Impact of Tobacco Smoking on Outcomes in Patients with Metastatic Non-Small Cell Lung Cancer in the Era of Targeted Therapy
Martin Gutierrez, NJ/USA

P2.01-43 - ADSCaN: A Randomised Phase II Study of Accelerated, Dose Escalated, Sequential Chemo-Radiotherapy in Non-Small Cell Lung Cancer (NSCLC)
Matthew Hatton, UK

P2.01-44 - Prognostic Value of TP53 Hot Exon Mutation in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Yong He, China

P2.01-45 - Mutational and Inflammatory Biomarkers for Lung Cancer Patients with Pleural Effusions
Balazs Hegedus, Germany

P2.01-46 - Investigating the Effects of Prior Malignancy on NSCLC Trial Eligibility
Michael Herman, Canada

P2.01-47 - Clinical Outcome After Surgical Resection of Clinical Single-station N2 Non-Small Cell Lung Cancer
Kwanyong Hyun, Republic of Korea
P2.01-48 - Predictive Factors in NSCLC Patients with Stage IIIIB/IV Treated with First Line Platinum-Doublet Chemotherapy  
Sofi Isaksson, Sweden

P2.01-49 - Comparision of Radiotheraphy Concurrent Weekly Treatment in Locally Advanced Unresectable Non Small Cell Lung Cancer  
Abdurrahman Isikdogan, Turkey

P2.01-50 - Thromboembolism in ROS1 Rearranged Non-Small Cell Lung Cancer  
Nick Pavlakis, Australia

P2.01-51 - Study of CD26/DPP4 Expression in a Large Series of Non-Small Cell Lung Cancer Patients  
Sven Hillinger, Switzerland

P2.01-52 - Identification of Leptomeningeal Metastasis-Specific Exosomal miRNA Signatures in Cerebrospinal Fluids of NSCLC Patients  
Yang W Shao, Canada

P2.01-53 - Local Treatment for Oligoprogression/Oligometastases After Failure to Crizotinib for ALK-Rearranged Stage IV Lung Cancer  
Tsz Yeung Kam, Hong Kong

P2.01-54 - Predictive Factors for Thromboembolism in Advanced Lung Cancer Patients on Platinum Chemotherapy: A Prospective Study  
Shruti Kate, India

P2.01-55 - Dual-Energy CT Scan to Evaluate Sarcopenia in Lung Cancer in Comparison with Conventional CT Scan  
Eun Young Kim, Republic of Korea

P2.01-56 - Metastases in Residual PET Uptake of Lymph Nodes After Treatment: Added Value of CT Radiomic Approach for Prediction  
Chu Hyun Kim, Republic of Korea

P2.01-57 - Prognostic Implication of Clinical, Imaging, and Pathologic Parameters in N2(+) Stage IIIA Lung Cancer Patients  
Yong Chan Ahn, Republic of Korea

P2.01-58 - Demographics, Clinical Characteristics and Treatment Sequencing in Stage III Unresectable NSCLC Patients: A Cancerlinq Cohort
Alyssa Klein, MD/USA

P2.01-59 - The Cost of Lung Cancer in the County of Gävleborg - Sweden
Hirsh Koyi, Sweden

P2.01-60 - Clinical Utility of Circulating Tumor Cell (CTC) Analysis Using Target Selector™ in Metastatic NSCLC Chemotherapy Patients
Lara Kujtan, USA

P2.01-61 - Body Mass Index over Time is Associated with Overall Survival in Advanced NSCLC Patients Treated with Immunotherapy.
Stephanie Labomascus, IL/USA

P2.01-62 - Extracellular Vesicle-Based Egfr Genotyping in Bronchoalveolar Lavage Fluid from Non-Small Cell Lung Cancer Patients
Jong Sik Lee, Republic of Korea

P2.01-63 - Are Heart Doses Associated with Survival in NSCLC Treated with Post-Operative Radiotherapy? A National Population-Based Study
Chia Ching Lee, Singapore

P2.01-64 - Prognostic Value of PET-CT after Induction Chemoradiotherapy and Curative Surgery in IIIA-N2 NSCLC: A Multi-Institutional Analysis
Jong Hoon Lee, Republic of Korea

P2.01-65 - Assessment of Individual and Combined of Five Serum Tumor Markers for Lung Cancer
Yuping Li, China

P2.01-66 - Comparison of EGFR Mutation Status in Tissue and Plasma Cell-Free DNA Detected by ARMS in Advanced Lung Adenocarcinoma Patients
Yuping Li, China

P2.01-67 - The Prognostic Analysis of Lung Cancer Patients with Occult Malignant Pleural Disease at Thoracotomy
Shaolei Li, China

P2.01-68 - Capture-Based Sequencing Depicts Evolution Characteristics of Pulmonary Sarcomatoid Carcinoma
Xuewen Liu, China
P2.01-69 - EZH2-Mediated Epigenetic Suppression of GDF15 Predicts a Poor Prognosis and Regulates Cell Proliferation in Non-Small Cell Lung Cancer
Xiyi Lu, China

P2.01-70 - Tumor Treating Fields and Radiosurgery for Supra- and/or Infratentorial Brain Metastases (1-10) from NSCLC in the Phase 3 METIS Study
Uri Weinberg, Switzerland

P2.01-71 - Clinical Outcome of Induction Chemoradiotherapy Followed by Surgery for the Patients with cN2 Non-Small Cell Lung Cancer
Akihiro Miura, Japan

P2.01-72 - Bronchial Sleeve vs Pneumonectomy: Complications, Recurrences and Survival
Marc Boada, Spain

P2.01-73 - Automated Image Analysis Tool for Tumor Volume Growth Rate to Guide Precision Cancer Therapy: EGFR-Mutant NSCLC as a Paradigm
Mizuki Nishino, USA

P2.01-74 - Docetaxel-Related Febrile Neutropenia (FN) And Patient Reported Symptoms/ QOL (PROs) in East Asian (EA) and Non-EA Patients
Sotaro Enatsu, Japan

P2.01-75 - Study of Molecular Alterations in Cytological Smears by FISH In Patients with Advanced Non Small Cell Lung Carcinoma (NSCLC).
Julieta Pandolfi, Argentina

P2.01-76 - The Impact of Concordance with a Lung Cancer Diagnosis Pathway Guideline on Treatment Access in Patients with Stage IV Lung Cancer
Luke Jeagal, ON/Canada

P2.01-77 - Interconversion of Two Commonly Used Performance Tools: An Analysis of 5844 Paired Assessments in 1501 Lung Cancer Patients
Kuruswamy Prasad, India

P2.01-78 - Validation of InVisionFirst ctDNA NGS Profiling via ddPCR Testing in Patients with Non-Small Cell Lung Cancer (NSCLC)
Michael Pritchett, NC/USA

P2.01-79 - Neurological Death is Common in Patients with EGFR Mutant Non-Small Cell Lung Cancer
Matthew Ramotar, Canada

P2.01-80 - Performance Status and Resource Utilization in Patients Receiving Palliative Care with Stage IV Non-Small Cell Lung Cancer
Candice Wilshire, USA

P2.01-81 - Treatment of Superior Sulcus Tumor: A Twelve-Year Single-Center Experience
Witold Rzyman, Poland

P2.01-82 - Neutrophil-to-Lymphocyte Ratio Complements the Prognostic Ability of PD-L1 in Non-Small Cell Lung Cancer Treated with PD-1/PD-L1 Inhibitors
Diana Saravia, USA

P2.01-83 - Evaluation of Dynamic Thiol/Disulphide Homeostasis in Advance Non-Small Cell Lung Cancer and Small Cell Lung Cancer
Mehmet Ali Sendur, Turkey

P2.01-84 - Patterns of Central Nervous System Metastases in EGFR Mutated or ALK Rearranged Non Small Cell Lung Cancer Patients
Mansi Sharma, India

P2.01-85 - The Efficacy of the Traditional Chinese Medicine as Maintenance Therapy for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
Peng Shen, China

P2.01-86 - Genetic Profiling of Circulating Cell-Free DNA from Cerebrospinal Fluid and Plasma in ALK-Positive Lung Cancer with Brain Metastases
Liang Shi, China

P2.01-87 - Profiling the Symptom Burden of Patients with Metastatic NSCLC Receiving Either Chemotherapy or Targeted Therapy: Real-World Data
Qiuling Shi, USA

P2.01-88 - C-Reactive Protein (CRP) as a Predictive Marker for Survival in Patients with Advanced NSCLC Treated with First Line Pembrolizumab Monotherapy
Yuji Shibata, Japan

P2.01-89 - Synergistic Cytotoxicity Through MAPK/ERK Pathway and ALK Inhibition in Crizotinib Resistant EML4-ALK-Positive Lung Cancer
Nensi Shrestha, New Zealand
P2.01-90 - PD-L1 Expression as a Predictive Biomarker in Advanced Non-Small Cell Lung Cancer Patients with or without EGFR Mutation
Teerada Siripoon, Thailand

P2.01-91 - Treatment Patterns in Patients with Stage IIIB-IV NSCLC in Clinical Practice: Retrospective Analysis of a UK Trust Database
Michael Snee, UK

P2.01-92 - “All-In-One” Window: A New Way of Looking at Chest CT Studies in Thoracic Oncology
Anнеме Snoeckx, Belgium

P2.01-93 - The Analysis of the Soluble Programmed Death-1 of Lung Cancer Patients with Different Characteristics
Xia Song, China

P2.01-94 - Diagnostic Patterns of Non-Small Cell Lung Cancer at Princess Margaret Cancer Centre
Mike Sung, Canada

P2.01-95 - Assessement the Fitness for Chemotherapy of NSCLC Patients using 6MWT
Zsuzsanna Szalai, Hungary

P2.01-96 - Dysgeusia Associated with Nutritional and Quality of Life Parameters in Non-Small Cell Lung Cancer Patients Naïve to Chemotherapy
Jenny Turcott, Mexico

P2.01-97 - Prognostic Factors in Resected Lung Mucinous Adenocarcinoma: Clinical and Pathological Features
Daisuke Ueda, Japan

P2.01-98 - Single-Isocenter Volumetric-Modulated Arc Radiosurgery for Non-Small-Cell Lung Cancer Patients with Multiple Brain Metastases
Megumi Uto, Japan

P2.01-99 - Can NGS NSCLC Testing Be Implemented Without in House Expertise? Clinical Utility of the First FDA-Approved Lung Cancer NGS End-To-End Solution
Anagh Vora, CA/USA

P2.01-100 - Different Genetic Mutations Enriched in Circulating Tumor DNA Predict Different Metastatic Sites in Lung Adenocarcinoma Patients
Liyun Miao, China

P2.01-101 - Dynamic Monitoring of Gene Alterations with ctDNA by NGS for EGFR Mutated Lung Adenocarcinoma Treated with Gefitinib in BENEFIT Study (CTONG 1405)
Jie Wang, China

P2.01-102 - Comprehensive Next-Generation Sequencing Guided Targeted Therapies Improve Clinical Outcomes of Lung Cancer Patients
Zhaoxia Wang, China

P2.01-103 - Neutrophil-to-Lymphocyte Ratio as a Predictor of Immunotherapy Treatment Outcomes in Advanced Non-Small Lung Cancer
Xiao Wang, USA

P2.01-104 - Plasma T-Cell-Derived Circulating DNA in Advanced NSCLC is Not Correlated with TIL but has a Potential of Prognostic Value
Chanida Vinayanuwattikun, Thailand

P2.01-105 - Tumor Treating Fields Plus Standard of Care for Non-Small Cell Lung Cancer Following Platinum Failure: Phase 3 LUNAR Study
Uri Weinberg, Switzerland

P2.01-106 - A Comparative Analysis of Genomic Alterations by Tumor Tissue and Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer
Go-un Woo, Republic of Korea

P2.01-107 - Analysis of Mutation Detection by ctDNA on the Basis of Metastatic Sites in Lung Adenocarcinoma Patients
Renhua Guo, China

P2.01-108 - Temporal Heterogeneity of Resistant Mutations in Sequential ALK TKI Treated Lung Cancer Revealed by NGS-Based Liquid Biopsy
Yu Yang, China

P2.01-109 - Treatment Duration—A More Reasonable Definition to Evaluate the Efficacy of Crizotinib in ALK Positive Advanced NSCLC
Guangjian Yang, China

P2.01-110 - Unique Genomic Profile Revealed by Malignant Pleural Effusion
Zhihua Guo, China
P2.01-111 - Clinical Features and Prognosis of Eighty-Five Patients with Primary Pulmonary Lymphoepithelioma-Like Carcinoma
Qin Yin, China

P2.01-112 - Prognostic Value of Changes in Neutrophil-To-Lymphocyte Ratio in Patients with Lung Cancer Treated with Nivolumab
Takashi Yokoi, Japan

P2.01-113 - Prognostic Roles of Neoadjuvant and Adjuvant Chemotherapy for Treating Patients with Operable Stage III-N2 Non-Small Cell Lung Cancer (NSCLC)
Luo-Sheng Yong, Taiwan

P2.01-114 - The Correlation Among PD-L1 Expression, TMB and Lung Immune Prognostic Index in Chinese Patients with Advanced Lung Adenocarcinoma
Pei Yuan, China

P2.01-115 - Evaluation of EGFR T790M of Cell Free Circulating DNA in Plasma by Droplet Digital PCR for Progressive Non-Small Cell Lung Cancer
Zhihong Zhang, China

P2.01-116 - The Potential of Assessing Blood Tumor Mutation Burden (bTMB) Using a Large Panel
Kai Zhang, China

P2.01-117 - Concurrent Gene Alterations in Treatment-Naïve EGFR-Mutant Advanced Non-Small Cell Lung Cancer
Xuefeng Xia, China

P2.01-118 - LINE-1 Retrotransposition Promotes the Occurrence and Progression of Lung Squamous Cell Carcinoma
Jinpu Yu, China

P2.01-119 - Phase III Randomized Trial of Palonosetron and Dexamethasone with Aprepitant to Prevent Full Dose Single-Day Cisplatin-Based CINV in Lung Cancer
Yongchang Zhang, China

P2.01-120 - First Study to Evaluate the Efficacy of SB Oral Solution to Prevent Neutropenia and FN Induced by Platinum-Based Chemotherapy in Lung Cancer
Yongchang Zhang, China

P2.01-121 - Genomic Profiling of Pulmonary Lymphoepithelioma-Like Carcinoma
Chengzhi Zhou, China

**P2.01-122 - Individual Precision Surgery for Locally Advanced Non-Small Cell Lung Cancer Based on Molecular Staging and Typing: The Chinese Experience.**
Qinghua Zhou, China

**P2.01-123 - Translational Medicine of Lung Cancer Metastasis: From Bench to Bedside**
Qinghua Zhou, China

**P2.01-124 - SIB-IMRT in Symptomatic Brain Metastases for NSCLC: A Randomized Controlled Study of WBRT Comparing 25Gy and 30Gy**
Jian Zhu, China

**P2.01-125 - EGFR Mutations by NGS in Advanced Squamous Cell Lung Cancer**
Govind Babu, India

**P2.01-126 - MicroRNA-330-3p Modulates Tumor Vascular Normalization After Hypofractionated Radiotherapy by Targeting p-STAT3/ HIF-1 Alpha Pathway**
Xiaorong Dong, China

**P2.01-127 - Efficacy of Endostar Combined with Whole Brain Radiotherapy in Patients with NSCLC Brain Metastases**
Xiaorong Dong, China

**P2.01-128 - Low Positivity Rate in T790M Detection with ctDNA in NSCLC and Post EGFR-TKI Progression - Timing or Sensitivity?**
Carlos Gil Ferreira, Brazil

**P2.01-129 - Potential Impact of KRAS Molecular Profiling of Non-Squamous Non-Small Cell Lung Cancer (NSCLC).**
Nagla Karim, OH/USA

**P2.01-130 - Detection of Actionable Mutation Status in Advanced Non-Small Cell Lung Cancer by Next-Generation Sequencing of Circulating Tumor DNA**
Xia Song, China

**P2.01-131 - Apatinib as an Alternative for Advanced Non-Small Cell Lung Cancer**
Jiexia Zhang, China

**P2.01-132 - Comparison Molecular Profiles in NSCLC by Using Different NGS Platforms and Different Variant Frequency Cutoff**
Thanyanan Reungwetwattana, Thailand
P2.03-01 - Prevalence of EGFR Alterations in Chilean Lung Cancer Patients: A Retrospective Study
Hector Galindo, Chile

P2.03-02 - Cell-Free DNA (cfDNA) Testing in Lung Adenocarcinoma (LUAC) Patients: Spanish Lung Liquid Versus Invasive Biopsy Program (SLLIP)
Ramon Palmero, Spain

P2.03-03 - Upfront Next Generation Sequencing in NSCLC: A Publicly Funded Perspective
Kirstin Perdrizet, Canada

P2.03-04 - Next Generation Sequencing in Lung Cancer Using the Oncomine Comprehensive Assay: The Canadian Publicly Funded Experience
Kirstin Perdrizet, Canada

P2.03-05 - Biologic Profiling of Brain Metastasis from Non-Small Cell Lung Cancer
Tomohito Saito, Japan

P2.03-06 - Serum Syndecan-1 Levels in Patients with Nonsmall Cell Lung Cancer
Ibrahim Tek, Turkey

P2.03-07 - Radiomic Signatures Linked to Genetic Alterations as Detected by Next-Generation Sequencing: A Radiogenomics Analysis of Early-Stage NSCLC
Sibo Tian, GA/USA

P2.03-08 - Molecular Spectrum of Patients with MSH2 Mutations in Chinese Non-Small Cell Lung Cancer
Chunwei Xu, China

P2.03-09 - The Real World of NTRK Fusion Data in the Chinese Lung Cancer Populations: A Multicenter Study
Chunwei Xu, China

P2.03-10 - Gene Mutational Profiling of Chinese TKI-Sensitizing EGFR Mutations NSCLC Patients Required Resistance to Icotinib Using NGS
Chunwei Xu, China

P2.03-11 - PDGFRα Defines a Unique Molecular Subtypes of Chinese Non-Small Cell Lung Cancer Patients
Chunwei Xu, China

P2.03-12 - EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer
Shun Lu, China

P2.03-13 - SWATH MS Analysis of Serine Hydrolase Activity in Human Lung Adenocarcinoma for Biomarker Discovery
Sven Hillinger, Switzerland

P2.03-14 - PKCι-PAK1 Pathway Modulates Sensitivity to Therapy in EGFR, KRAS Mutant and Squamous Cell Non-Small Cell Lung Cancer (NSCLC)
Masaoki Ito, Japan

P2.03-15 - Integrin-Linked Kinase (ILK), Protein Tyrosine Phosphatase SHP2 and B lymphoma Mo-MLV Insertion Region 1 Homolog (Bmi-1) in EGFR-Mutant NSCLC
Niki Karachaliou, Spain

P2.03-16 - TGF-β Induced EMT and Stemness Characteristics are Associated with Epigenetic Regulation in Lung Cancer
Seung Joon Kim, Republic of Korea

P2.03-17 - EGFR T790M Mutation may not be Generated through Selection by EGFR-TKI from Randomly Occurring Mutations In vitro Using ENU
Yoshihisa Kobayashi, Japan

P2.03-18 - X-Inactivation Specific Transcript (XIST)-Mediated miRNA Sequestration In NSCLC
Erin Marshall, BC/Canada

P2.03-19 - RET-Mediated Activation of Ezrin is Associated with Cell Motility and Survival in a Subset of Lung Adenocarcinomas
Serisha Moodley, Canada

P2.03-20 - Factor XIIIA-Expressing Inflammatory Monocytes Promote Lung Squamous Cancer through Fibrin Cross-Linking
Chad Pecot, USA

P2.03-21 - Mechanistic Investigation of DRD1 in Lung Cancer
Leila Toulabi, MD/USA

P2.03-22 - OCT4 & SOX2 Specific CTLs Plus PD-1 Inhibitor Had Synergistic Effect on Killing CSC And Treating Drug-Resistant Lung Cancer Mice
Fang Hu, China

P2.03-23 - MicroRNA-30e Inhibits Cell Proliferation and Invasion in Non-Small Cell Lung Cancer via Directly Targeting SOX9
Lei Zhao, China

P2.03-24 - CD90 Enhances Metastasis by Epithelial-Mesenchymal Transdifferentiation in Lung Adenocarcinoma
Xiangdong Zhou, China

P2.03-25 - Loss of Expression Rather Than Cytoplasmic Mislocalization of RUNX3 Predicts Worse Outcome in Non-Small Cell Lung Cancer
Xiaohui Chen, China

P2.03-26 - A Prospective Cohort Study of TMB and Determinants of ctDNA Detection by Comprehensive Genomic Profiling in Stage I Lung Adenocarcinomas
Kezhong Chen, China

P2.03-27 - Polymorphisms in Folate Metabolism Related Genes Affect the Survival Outcomes of Early-Stage Non-Small Cell Lung Cancer
Sun Ha Choi, Republic of Korea

P2.03-28 - Whole Exome Sequencing to Discover Lung Tumor Predisposition in Women with Previous Breast Cancer
Carlo Genova, Italy

P2.03-29 - Prognostic Significance of Phosphorylated Fyn in Patients with Lung Adenocarcinoma
Shigeto Nishikawa, Japan

P2.03-30 - Proteins Involved in Necroptosis and DNA Damage Repair and Survival of Stage I Non-Small-Cell Lung Cancer Patients
Jeong-Seon Ryu, Republic of Korea

P2.03-31 - LncRNA RGMB-AS1 Affects Lung Adenocarcinoma Prognosis by Regulating Microtube Associated Genes: A Genome-Wide Analysis in Silicon
Xiaoshun Shi, China
P2.03-32 - Genome-Wide Analysis of m6A-Modified RNA Binding Proteins Associated with Lung Cancer Survival
Xiaoshun Shi, China

P2.03-33 - Anti-Aging Gene, Klotho is a Predictive Factor of Pemetrexed for Lung Cancer Treatment
Kyoshiro Takegahara, Japan

P2.03-34 - The Relationship Between Treatment Response and Serum EGFR Level in Nonsmall Cell Lung Cancer
Ibrahim Tek, Turkey

P2.03-35 - Non-Small-Cell Lung Cancer with SMO Gene Variants of Uncertain Significance Share Distinct Molecular Features
Chunwei Xu, China

P2.03-36 - DNA Methylation: A More Sensitive Marker for Treatment Monitoring?
Yu Chen, China

P2.03-37 - The Efficiency of Octamer-4 Specific Cytotoxic T Cells Induce By CD40-B Cells in Killing Lung Cancer Stem-Like Cells
Fang Hu, China

---

P2.04

16:45 - 18:00 Immunooncology

P2.04-01 - Associations Histological Subtype of Lung Adenocarcinoma and Programmed Death Ligand 1 (PD-L1) Expression in Tumor Cells.
Luis Antonio Cabrera-Miranda, Mexico

P2.04-02 - Predictive Value of Circulating Tumor Cells and Circulating Free DNA in NSCLC Patients Treated with Nivolumab
Carlo Genova, Italy

P2.04-03 - NF-κB and HIF-1α Play Important Roles in Regulating PD-L1 Expression by EGFR or KRAS Mutants in Non-Small Cell Lung Cancer Cells
Jie Wang, China

P2.04-04 - Expression of Intratumoral Programmed Cell Death-Ligand 1 (PD-L1) and Intratumoral CD4^+ T Cell, CD8^+ T Cell and FOXP3^+ T Cell in Lung Cancer
Yasuto Jin, Japan

P2.04-05 - Correlation Between PD-L1 Gene Promoter Polymorphisms and Expression of PD-L1 mRNA and Protein in NSCLC Patients.
Pawel Krawczyk, Poland

P2.04-06 - Increased Plasma Cell % and Decreased B-Cells in Tumor Immune Infiltrates Are Associated with Worse Prognosis in Lung Adenocarcinomas
Hee Eun Lee, MN/USA

P2.04-07 - Effects of Neoadjuvant Chemotherapy on the Expression of Programmed Death Ligand-1 and Tumor Infiltrating Lymphocytes in Lung Cancer Tissues
Xu Wang, China

P2.04-08 - Platinum-Based Chemotherapy is Associated with Altered PD-L1 Expression in Lung Cancer
Judit Moldvay, Hungary

P2.04-09 - Driver Mutations are Associated with Distinct Patterns of Response to Immune Checkpoint Blockade in Non-Small Cell Lung Cancer
Marcelo Negrao, USA

P2.04-10 - Early Monitoring of Blood Biomarkers to Predict Nivolumab Efficacy in NSCLC Patients
Francesco Passiglia, Italy

P2.04-11 - An IL-8/IFN-gamma/NLR Plasma Score to Predict Nivolumab Efficacy in Patients with NSCLC
Francesco Passiglia, Italy

P2.04-12 - A Genomic Signature [JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2] Predicts Baseline Resistance to Nivolumab in Advanced NSCLC.
Sara Pilotto, Italy

P2.04-13 - The Immune Checkpoint, HVEM Contribute to Immune Escape in Non-Small Cell Lung Cancer of Lacking PDL1 Expression
Shengxiang Ren, China
P2.04-14 - Tumor Mutational Burden Assessed by a Targeted NGS Assay Predicts Benefit from Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Sacha Rothschild, Switzerland

P2.04-15 - Heterogeneity and Correlation Between Immune Markers in Lung Cancers: Analysis of Treatment-Naïve Lesions
Kenichi Suda, CO/USA

P2.04-16 - Correlation Between Programmed Death Ligand 1(PD-L1) Expression and Solid Component on HRCT in Stage I Lung Cancer Patients
Ryosuke Tsugitomi, Japan

P2.04-17 - Pre-Therapy Radiomic Features Can Distinguish Hyperprogression from Other Response Patterns to PD1/PD-L1 Inhibitors in NSCLC
Pranjal Vaidya, USA

P2.04-18 - The Association Between IDO Activity and Clinical Prognosis in Patients with Non-Small Cell Lung Cancer After Radiotherapy
Yaping Xu, China

P2.04-19 - Correlation of Clinicopathological Characteristics with Tumor Mutation Burden in Chinese Patients with NSCLC
Shun Lu, China

P2.04-20 - Immunologic Characterization of Fibrinous Pericarditis as an Immune Checkpoint Blockade Toxicity in NSCLC
Mehmet Altan, USA

P2.04-21 - Real World Experience of Immune Checkpoint Inhibitors In NSCLC: Our First 10 Months Experience at Leeds Cancer Centre, UK
Kathryn Ellenger, UK

Natalia Khranovska, Ukraine

P2.04-23 - Immune-Related Adverse Events: The Growing Pains of Immunooncology
Meghan Mooradian, MA/USA

P2.04-24 - Nivolumab in the "Real World": Are the Results of Clinical Trials Reproducible?
Inmaculada Ramos García, Spain
P2.04-25 - Randomized Clinical Trial Comparing Immunotherapy Plus SABR (i-SABR) Versus SABR Alone for Early Stage NSCLC
Joe Chang, USA

P2.04-26 - Interim Results from a Phase I/II Trial of Nivolumab in Combination with CIMAvax-EGF as Second-Line Therapy in Advanced NSCLC
Grace Dy, USA

P2.04-27 - Ph II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with Pembrolizumab in Patients with Advanced NSCLC
James Lorens, Norway

P2.04-28 - Use of Immune Checkpoint Inhibitors (ICIs) in Patients with Refractory Non-Small Cell Lung Cancer (NSCLC) and Poor Performance Status (PS)
Jonathan Thompson, WI/USA

P2.04-29 - Preliminary Results with Tislelizumab in Chinese Patients with Non-Small Cell Lung Cancer (NSCLC)
Yi-Long Wu, China

P2.04-30 - PD-1/PD-L1 Inhibition Might be an Option for the Treatment of Advanced Primary Pulmonary Lymphoepithelioma-Like Carcinoma
Xu-Chao Zhang, China

P2.06

16:45 - 18:00 Mesothelioma Exhibit Hall

P2.06-01 - Short-Term Outcome of Entire Pleural Intensity-Modulated Radiotherapy in a Neoadjuvant Setting for Malignant Mesothelioma
Ji Hyun Hong, Republic of Korea

P2.06-02 - Feasibility of Intensity Modulated Radiotherapy After Pleurectomy/Decortication for Malignant Pleural Mesothelioma Patients
Oscar Arrieta, Mexico

P2.06-03 - Can We Predict Pathological Nodal Positivity in Malignant Pleural Mesothelioma from Preoperative Clinical Variables?
Silviu Buderi, UK
P2.06-04 - Throughput of a Specialist Mesothelioma Multidisciplinary Team Meeting at a Radical Treatment Centre in the UK.
Edward Caruana, UK

P2.06-05 - TTFields Applied to the Torso and Upper Abdomen: Safety Meta-Analysis of 176 Patients from four Phase I-II Trials
Giovanni Ceresoli, Italy

P2.06-06 - Role of GITRL-GITR System in Promoting Proliferation of Malignant Mesothelioma
Mei-Lin Chan, ON/Canada

P2.06-07 - Genomic Deletion of BAP1 and CDKN2A are Better MM Diagnostic Biomarkers.
Yuen Yee Cheng, Australia

P2.06-08 - ABT-806 Derived Antibody Drug Conjugates (ADCs) Inhibit Growth of Malignant Mesothelioma In-Vivo
Puey Ling Chia, Australia

P2.06-09 - MiST3: A Phase II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with Pembrolizumab in pts with Malignant Mesothelioma
Dean Fennell, UK

P2.06-10 - Combination Chemotherapy with Cisplatin, Pemetrexed, and Nivolumab for Malignant Pleural Mesothelioma: A Trial in Progress
Nobukazu Fujimoto, Japan

P2.06-11 - A Phase I/II Study of Intrapleural Ad-SGE-REIC Administration in Patients with Refractory Malignant Pleural Mesothelioma
Yasushi Goto, Japan

P2.06-12 - Improving Quality of Care for Pleural Mesothelioma: 2018 National Mesothelioma Audit Results for England and Wales
Susan Harden, UK

P2.06-13 - Poor Nutritional Status Is a Poor Prognostic Factor in Malignant Pleural Mesothelioma
Isabelle Opitz, Switzerland

P2.06-14 - Does Size Matter? A Population-Based Analysis of Malignant Pleural Mesothelioma
Jiaxi He, China
P2.06-15 - Malignant Pleural Mesothelioma in Young Adult People in Uganda
Nehemiya Igulu Bandese, Uganda

P2.06-16 - YB-1: An Important Driver of Mesothelioma Drug Resistance and a Potential Novel Therapeutic Target
Karin Schelch, Australia

P2.06-17 - Real-World Accuracy of Malignant Pleural Mesothelioma (MPM) Preoperative Magnetic Resonance Imaging (MRI) for Staging the Diaphragm.
Sharyn Katz, USA

P2.06-18 - Comparison of Extubation Time of Pleulectomy/Decortication with Lobectomy Under General Anesthesia Using Desflurane
Keisuke Kawata, Japan

P2.06-19 - Targeting Polyamines as Potential Adjuvant Therapy in Malignant Pleural Mesothelioma Xenograft Models
Sze Kwan Lam, Hong Kong

P2.06-20 - Bacteria as Novel Anti-Mesothelioma Agents.
Sally Lansley, WA/Australia

P2.06-21 - Low Intratumoral Platinum Concentration is Associated with Unfavorable Clinical Outcome in Malignant Pleural Mesothelioma
Viktoria Laszlo, Austria

P2.06-22 - Proposal of a New Local Recurrence Score for Patients with Malignant Pleural Mesothelioma
Isabelle Opitz, Switzerland

P2.06-23 - Association of Two BRM Promoter Polymorphisms and Tobacco Exposure with Malignant Pleural Mesothelioma (MPM) Risk and Survival
Min Joon Lee, Canada

P2.06-24 - The Impact of Demographic and Socioeconomic Factors on Survival of Patients with Mesothelioma in the USA
Rami Manochakian, FL/USA

P2.06-25 - Combined Immune Checkpoint Blockade in Malignant Pleural Mesothelioma: In Vivo Validation of in Vitro Results
Jan Van Meerbeeck, Belgium
P2.06-26 - Ribonucleotide Reductase Subunit M1 but not M2 is Associated to Better PFS in Patients with Advanced Stage Mesothelioma
Saé Muñiz-Hernández, Mexico

P2.06-27 - Extrapleural Pneumonectomy, Radiation Therapy, and Chemotherapy for Epithelioid Malignant Pleural Mesothelioma
Kazunori Okabe, Japan

P2.06-28 - Assessment of Chest Wall Motion Using Structured Light Plethysmography (SLP) in Mesothelioma and Benign Pleural Disease
Nicola Oswald, UK

P2.06-29 - Expression of Estrogen Receptor Beta (ERb) and its Prognostic Value in the Pleural Mesothelioma.
Jeronimo Rodriguez-Cid, Mexico

P2.06-30 - Association of Histopathological Patterns of Mesothelioma and Response to Treatment with Chemotherapy
Jeronimo Rodriguez-Cid, Mexico

P2.06-31 - Inhibition of Heat Shock Protein 70 Function Suppresses Proliferation in Mesothelioma Cells
Kosuke Sakai, Japan

P2.06-32 - YB-1 - A Key Factor in Mesothelioma Aggressive Growth and Behaviour
Karin Schelch, Australia

P2.06-33 - Heterogeneity in Care Pathways for Patients with Malignant Pleural Mesothelioma Presenting at a Quaternary Thoracic Oncology Center in Quebec
Aya Siblini, Canada

P2.06-34 - Inhibition of the HGF/c-Met Pathway for Malignant Mesothelioma with an Intra-Thoracic Injection of the NK4 Expressing Adenoviral Vectors
Yuji Tada, Japan

P2.06-35 - Pleurectomy Decortication Versus Extrapleural Pneumonectomy in Malignant Pleural Mesothelioma: SPARCS Data
Maaike Van Gerwen, USA

P2.06-36 - EORTC 1205: Randomized Phase II Study of Pleurectomy/Decortication Preceded or Followed by Chemotherapy in Early Stage MPM
Jan Van Meerbeeck, Belgium
P2.06-37 - Four Immunohistochemical Assays to Measure the PD-L1 Expression in Malignant Pleural Mesothelioma
  Takuya Watanabe, Japan

P2.06-38 - Mesothelioma Stem Cells May Be the Critical Factor of Treatment Failure
  Licun Wu, ON/Canada

P2.06-39 - Next Generation Sequencing Reveals Genetic Landscape of Malignant Mesothelioma
  Xuefeng Xia, China

P2.06-40 - VISTA is Highly Expressed in Malignant Pleural Mesothelioma (MPM) and Independent of PD-L1 Expression
  Marjorie Zauderer, NY/USA

P2.06-41 - Differentiating Sarcomatoid Mesothelioma from Pleomorphic Carcinoma and Chest Wall Sarcoma Using GATA-3/MUC4/BAP1 IHC
  Yu Zhi Zhang, UK

P2.06-42 - AXL, c-MET and VEGFR2 Tyrosine Kinase Receptors as Therapeutic Targets in Malignant Pleural Mesothelioma.
  Federica Zito Marino, Italy

---

P2.09

16:45 - 18:00  Pathology

P2.09-01 - Tumor-Associated Immune Cell Infiltration Patterns in Early Stage Squamous Lung Carcinoma
  Hui Yu, CO/USA

P2.09-02 - Comprehensive Assessment of PD-L1 Immunohistochemistry on Paired Tissue and Cytology Specimens in Non-Small Cell Lung Cancer
  Andréanne Gagné, Canada

P2.09-03 - Rapid-Immunocytochemistry for Evaluation of Surgical Margin in Sublobar Pulmonary Resection
  Nobuyasu Kurihara, Japan
P2.09-04 - PD-L1 Expression in Primary Lung Adenocarcinoma and its Relation with EGFR / KRAS Mutation and Clinicopathological Features
Lin Li, China

P2.09-05 - Evaluation of PD-L1-Stained Tumor Cells via the 22C3 and SP-142 Antibodies in Cohort of Patients Treated on KEYNOTE-001
Aaron Lisberg, CA/USA

P2.09-06 - Expression of PD-L1 on Routine Non-Small Cell Lung Carcinoma Sections: Comparative Assessment of SP263 (Ventana) and 22C3 (DAKO pharmDx)
Anne Marie Quinn, UK

P2.09-07 - Does Metastatic Site Matter for PD-L1 Testing in Stage IV NSCLC?
Hangjun Wang, QC/Canada

P2.09-08 - Clinical Outcomes of Histology Versus Cytology PD-L1 22C3 Antibody Testing in Advanced Non-Small Cell Lung Cancer
Ying Wang, BC/Canada

P2.09-09 - Precision and Repeatability of VENTANA DLL3 (SP347) Assay Immunohistochemistry Assay in Fine Needle Aspirations of Small Cell Lung Cancer
Brittany Admire, AZ/USA

P2.09-10 - qRT-PCR as an Efficient and Reliable Diagnostic Screening Approach for the Detection of EML4-ALK Fusion Gene in NSCLC Samples: A Pilot Study
Anuradha Choughule, India

P2.09-11 - TMB Estimated with Targeted NGS in Early Stage Squamous Cell Carcinoma: Correlation with PD-L1 Expression and Lymphocyte Density
Susana Hernandez, Spain

P2.09-12 - EGFR Mutation Status in Squamous Cell Carcinoma or Non-Small Cell Carcinoma Favor Squamous Cell Carcinoma Diagnosed from Small Lung Biopsies
Hsiang-Ling Ho, Taiwan

P2.09-13 - Correlation of ROS1 (SP384) Immunohistochemistry with ROS1 Rearrangement Determined by Fluorescence in Situ Hybridization
Catherine Le, AZ/USA

P2.09-14 - The Detection of EGFR Gene Mutation from Washing Solution of Devices used for the Bronchoscopic Examination
Rie Nakahara, Japan
P2.09-15 - A Next Generation Sequencing (NGS) RNA-Scan Multiplex Panel (QIAseq) to Identify Gene-Rearranged Non-Small Cell Lung Cancer  
Rebecca Tay, UK

P2.09-16 - Heterogeneity Analyses of MSLCs—Especially in the EGFR Mutation-Positive Ones  
Yinghui Xu, China

P2.09-17 - A Call to Action: Rapid Collection of Post-Mortem Lung Cancer Tissue in the Community to Enable Lung Cancer Research  
Theresa Boyle, CO/USA

P2.09-18 - A Clinicopathologic Analysis of Pulmonary Sclerosing Pneumocytoma in Korea: A Multicenter Study  
Han Kyeom Kim, Republic of Korea

P2.09-19 - Utilising Heterogeneity: Using a Digital Database of Lung Cancers and Immune Profile to Complement Subjective Assessment  
Alexander Haragan, UK

P2.09-20 - Minor Components of Solid Pattern is a Significant Poor Prognostic Factor in Pathological Stage I Lung Adenocarcinoma  
Miao Huang, China

P2.09-21 - Women with Synchronous or Metachronous Lung and Ovarian Cancers: A Multi-Institutional Report  
Silvia Novello, Italy

P2.09-22 - Relevance of Results of Intraoperative Pleural Lavage Cytology and Histological Subtype in Lung Adenocarcinoma  
Masashi Mikubo, Japan

P2.09-23 - A Combination of Podoplanin and E-Cadherin Expression in Lung SqCC may be a Poor Prognostic Indicator: A Propensity Score-Matched Analysis.  
Ryo Miyata, Japan

P2.09-24 - MERS67 is a Novel anti-NaPi2b Antibody and Demonstrates Differential Expression Patterns in Lung Cancer Histologic Subtypes  
Rebecca Mosher, MA/USA

P2.09-25 - Abundant Tumor Promoting Stromal Cells in Lung Adenocarcinoma with Hypoxic Regions
Hiroshi Nakamura, Japan

P2.09-26 - Clinical Significance of Subcellular Localization of Maspin in Patients with Pathological Stage IA Lung Adenocarcinoma
Takashi Ohno, Japan

P2.09-27 - Prognostic Significance of Vascular Invasion in Pathological Stage IA Lung Adenocarcinoma According to the 8th Edition of the TNM Classification
Joji Samejima, Japan

P2.09-28 - Detection of Isolated Tumor Cells in Regional Lymph Nodes from pN0 Lung Cancer by Negative Selection Using Immunomagnetic Beads
Xizhao Sui, China

P2.09-29 - Automatic Lung Cancer Staging from Medical Reports Using Natural Language Processing
Xizhao Sui, China

P2.09-30 - Clinicopathological Investigation of Four Resected Cases for Pleomorphic Carcinoma of the Lung
Kenichi Taguchi, Japan

P2.09-31 - Cisplatinum Suppressed Metastasis of NSCLC by Inhibiting Macrophage M2-Like Polarization
Yanjun Xu, China

P2.09-32 - Detached Epithelial Cell Cluster Size in Lung Adenocarcinoma is a Marker of Poor Prognosis
Akihiko Yoshizawa, Japan

P2.10 - Prevention and Tobacco Control

16:45 - 18:00  Exhibit Hall

P2.10-01 - Success of a Pharmacy-Driven Smoking Cessation Program
Catherine Burdalski, USA

P2.10-02 - Variations in Smoking Cessation Activities at Ontario’s Regional Cancer Centres
William Evans, ON/Canada
P2.10-03 - Feasibility and Acceptability of E-Cigarettes as an Aid to Quitting Smoking in Lung Cancer Patients: A Pilot Study
Stephen Harrow, UK

P2.10-04 - Pattern and Factors Associated with Intention to Quit Tobacco Use in a Rural Community of Anambra State of Nigeria
Uzochukwu Ofonakara, Nigeria

P2.10-05 - Provider Medical Specialty Influences Smoking Cessation Counseling at an Academic Medical Center and Veterans Affairs in U.S. Mid-South
Jennifer Lewis, USA

P2.10-06 - The Risk of Lung Cancer Among Women Who Start Smoking as Teenagers
Malcolm Tagbarha, Nigeria

P2.10-07 - Health Professional's Perception Towards Smoking: A Cross-Sectional Study from Bangalore, India.
Satheesh Thungappa, India

P2.10-08 - Smoking Prevention Project in School Population: My Health Is in My Own Hands
Tomi Kovacevic, Serbia

P2.10-09 - The Beliefs, Orientation, Knowledge, Understanding, Attitudes And Treatment Access To Lung Cancer Amongst Rural Men In Nigeria
Malcolm Tagbarha, Nigeria

P2.10-10 - Lung Cancer Survival in Younger Patients (<40 Years): Analysis of Surveillance, Epidemiology and End Results Program Data
Marisa Bittoni, OH/USA

P2.10-11 - Impact of Smoking on Multiple Primary Cancers Survival - A Retrospective Analysis
Anna Doboszyńska, Poland

P2.10-12 - Prevalence, Pattern and Factors Associated with Dual Tobacco Use in a Rural Community in South Eastern Nigeria
Uzochukwu Ofonakara, Nigeria

P2.10-13 - When Lung Cancer Was Rare: An Historical Study of Prevalence from 1760
Luc Ollivier, France

P2.10-14 - The Evaluation of Relationship Between Radon Gas and Lung Cancers in Trabzon
Tuesday, September 25, 2018

P2.10 - RADON: #1 Cause of Lung Cancer in Non-Smokers
Kelley Bush, ON/Canada

P2.10 - Finding the Relations Between Lung Cancer and Associated Risk Factors in Pakistani Population
Arooj Fatima, Pakistan

P2.10 - Environmental Tobacco Smoke Exposure and EGFR Mutations in Non-Smokers with Lung Cancer: A Dose-Response Analysis of Published Data
Wenhua Liang, China

P2.11 - Blood Transcriptomics Enables Detection of Pre-Invasive & Minimally-Invasive Lung Adenocarcinoma
Baohui Han, China

P2.11 - Direct Comparison of New Solid Nodules Detected in Women and Men During Incidence Screening Rounds of the NELSON Trial
Joan Walter, Netherlands

P2.11 - Cardiovascular Risk Prediction in a Community-Based Lung Cancer Screening Programme
Haval Balata, UK

P2.11 - Treatment Capacity Required for Implementing Lung Cancer Screening in the United States
Erik Blom, Netherlands

P2.11 - Recruitment Strategies for the Lung Cancer Screening Pilot for People at High Risk
Gail Darling, Canada

P2.11 - A New Histoplasmosis Antibody Enzyme Immunoassay for the Diagnosis of Lung Benign Nodules
Stephen Deppen, TN/USA

P2.11 - Lung Cancer in a Tertiary Care Setting: So Near, Yet So Far
Kranti Garg, India

P2.11-08 - Tumor Autoantibody Panel Can Improve the Accuracy of Early Diagnosis in Lung Cancer Presenting with GGNs /Solid Nodules
Yayi He, China

P2.11-09 - Uncommon EGFR Mutation Analysis from Urine of Lung Cancer Patients
Prista Hikmawati, Indonesia

P2.11-10 - Potential Utility of a Positive EarlyCDT®-Lung Blood Biomarker Test in Indeterminate Pulmonary Nodules
James Jett, CO/USA

P2.11-11 - Identification of the Genetic Determinants of Susceptibility to Lung Cancer in a Moroccan Cohort
Houda Kaanane, Morocco

P2.11-12 - Metabolomic Analysis in Lung Cancer for Screening and Early Detection
Naohiro Kajiwara, Japan

P2.11-13 - Precise Early Detection of Lung Cancer and Blood Cell Circuit
Oleg Kshivets, Russian Federation

P2.11-14 - Malignancy Associated Change and The LuCED® Test for Detection of Early Stage Lung Cancer
Michael Meyer, AZ/USA

P2.11-15 - Identifying Patients for Whom Lung Cancer Screening is Preference-Sensitive: A Microsimulation Study
Rafael Meza, MI/USA

P2.11-16 - Comparison of Two Lung Cancer Screening Programs in One Medical Center - Does Experience of the Screening Team and Indications Affect the Results?
Marcin Ostrowski, Poland

P2.11-17 - MicroRNAs in Exhaled Breath Condensate and Bronchial Brushings as Biomarkers for Early Diagnosis of Lung Cancer
Bijay Pattnaik, India

P2.11-18 - A Comprehensive Lung Cancer Screening Program: 5 Years in Review
April Plank, NY/USA

P2.11-19 - MicroRNAs as Liquid Biopsy Biomarkers for Early Detection in Lung Cancer.
Patricia Reis, Brazil

P2.11-20 - Lung EpiCheck TM - Results of the Training and Test Sets of a Methylation-Based Blood Test for Early Detection of Lung Cancer
Joanna Chorostowska-Wynimko, Poland

P2.11-21 - Factors Predicting Attrition in Community-Based Healthcare Network Lung Cancer Screening Programs
Candice Wilshire, WA/USA

P2.11-22 - Use of Electronic Medical Records for Tobacco Use and Lung Cancer Screening Documentation in a Large Urban Academic Medicine Practice
Giselle Suero-Abreu, USA

P2.11-23 - Risk Perception Among a Lung Cancer Screening Population
John Goffin, ON/Canada

P2.11-24 - Impact of Screening Interval Length on New Nodules Detected in Incidence Rounds of CT Lung Cancer Screening: the NELSON Trial
Joan Walter, Netherlands

P2.11-25 - Lung Cancer Screening Implementation in Community Practice: Kaiser Permanente Washington Experience 2015-2018
Karen Wernli, USA

P2.11-26 - First of its Kind Multi-Pronged Training for PCPs in an Epicenter of Lung Cancer - What Was Achieved in Two Years?
Celeste Worth, KY/USA

P2.11-27 - A Rapid Access Lung Cancer Clinic Reduces Variation in Lung Cancer Diagnostic and Treatment Services.
Robert Zielinski, NSW/Australia

P2.11-28 - A Focus Group and Interview Study to Explore the Information-Needs of Lung Cancer Screening Participants
Mamta Ruparel, UK

P2.11-29 - Impact of an Information-Film to Promote Informed Decision-Making in Individuals Taking Part in a Lung Cancer Screening Demonstration Pilot
P2.11-29a - Modified Lung-RADS Improves Performance of Screening LDCT in a Population with High Prevalence of Non-Smoking-Related Lung Cancer
En-Kuei Tang, Taiwan

P2.12 - Small Cell Lung Cancer/NET

P2.12-01 - Efficacy of Belotecan as Second-Line Treatment for Recurrent Small Cell Lung Cancer: A Phase IIb Randomized Multicenter Study
Jin-Hyoung Kang, Republic of Korea

P2.12-02 - Phase II Study of Combination of Nab-Paclitaxel and Gemcitabine for Relapsed Small Cell Lung Cancer (SCLC)
Muhammad Furqan, USA

P2.12-03 - Phase I/II Trial Of 177Lu-DOTA0-Tyr3-Octreotate (Lutathera) And Nivolumab for Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Chul Kim, USA

P2.12-04 - Liposomal Irinotecan vs Topotecan in Patients with Small Cell Lung Cancer Who Have Progressed On/After Platinum-Based Therapy
Natalya Nazarenko, MA/USA

P2.12-05 - SUKSES (Small Cell Lung Cancer Umbrella Korea Studies): A Phase II Biomarker-Driven Umbrella Study in Relapsed or Refractory SCLC
Keunchil Park, Republic of Korea

P2.12-06 - The Efficacy of Apatinib Plus Topotecan as Laterline Therapy for Advanced Small Cell Lung Cancer
Haifeng Qin, China

P2.12-07 - Utility of Stereotactic Body Radiotherapy in Pulmonary Carcinoid Tumors
Robert Ramirez, USA

P2.12-08 - Network Meta-Analysis of Angiogenesis Inhibitors on Survival of Patients with Small Cell Lung Cancer
Xiaoshun Shi, China
P2.12-09 - Efficacy and Safety of Carboplatin and Paclitaxel for Patients Preexisting Interstitial Lung Disease with Small Cell Lung Cancer
Ayumi Uchiyama, Japan

P2.12-10 - Novel Prognostic Model for Limited-Stage Small-Cell Lung Cancer
Hanbo Chen, ON/Canada

P2.12-11 - A Prognostic Model Integrating Immunohistochemistry Markers for Extensive Disease Small-Cell Lung Cancer
Rui Fu, China

P2.12-12 - Plasma Vitamin D Level is an Independent Prognosis Factor in SCLC Patients Treated with Platinum Plus Etoposide as First-Line Chemotherapy
Xu Wang, China

P2.12-13 - Effectiveness of Hypofractionated Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: A Propensity Score Analysis
Hanbo Chen, ON/Canada

P2.12-14 - Stereotactic Radiosurgery for Brain Metastases in Small Cell Lung Cancer.
Elizabeth Dudnik, Israel

P2.12-15 - Prognostic and Predictive Covariates in Limited-Stage Small-Cell Lung Cancer: Analysis of the Phase 3 CONVERT Trial
Corinne Faivre-Finn, UK

P2.12-16 - Significant Tumor Regression and Toxicity with Nivolumab Plus Ipilimumab in Small Cell Lung Cancer Patients Following Radiation
Brendan Gilmore, IL/USA

P2.12-17 - Prophylactic Cranial Irradiation Can Not Provide Survival Benefits for Resected Small Cell Lung Cancer Without Lymph Node Involvement
Baohui Han, China

P2.12-18 - Interstitial Lung Abnormalities are a Risk Factor for Radiation Pneumonitis in Patients with Limited-Stage Small-Cell Lung Cancer
Fangjuan Li, China
**P2.13**

**16:45 - 18:00**  
Targeted Therapy

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2.13-01</td>
<td>Brigatinib Use in England - Where Next?</td>
<td>Fabio Gomes, UK</td>
</tr>
<tr>
<td>P2.13-02</td>
<td>ALK-Translocation and Brain Metastases: A Retrospective Study. Correlation Between Clinical Outcome, Disease Burden and Management.</td>
<td>Oscar Grundberg, Sweden</td>
</tr>
<tr>
<td>P2.13-03</td>
<td>Real-Life Experience with Brigatinib in Pretreated EML4-ALK Translocated NSCLC Patients</td>
<td>Maximilian Hochmair, Austria</td>
</tr>
<tr>
<td>P2.13-04</td>
<td>Outcomes of ALK-Positive Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Crizotinib: A Multicenter Cohort Retrospective Study.</td>
<td>Di Ma, China</td>
</tr>
<tr>
<td>P2.13-05</td>
<td>Real-World Clinical Benefit of Continuing Crizotinib Beyond Progression Disease (CBPD) in Patients with Advanced ALK-Positive NSCLC.</td>
<td>Di Ma, China</td>
</tr>
<tr>
<td>P2.13-06</td>
<td>TP53 Status in Relation to Response to Anti-ALK Agents in Patients with EML4-ALK-Translocated NSCLC</td>
<td>Paola Ulivi, Italy</td>
</tr>
<tr>
<td>P2.13-07</td>
<td>CUX1-ALK: A Novel ALK Rearrangement That Responds to Crizotinib in Non-Small-Cell Lung Cancer</td>
<td>Kaihua Lu, China</td>
</tr>
<tr>
<td>P2.13-09</td>
<td>Efficacy and Safety of Osimertinib After Prior EGFR TKI: Analysis of Patients Underrepresented in Randomized Clinical Trials</td>
<td>Luiz H Araujo, Brazil</td>
</tr>
<tr>
<td>P2.13-10</td>
<td>Ph I/II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with Erlotinib in pts with EGFRm NSCLC</td>
<td>Lauren Byers, TX/USA</td>
</tr>
<tr>
<td>P2.13-11</td>
<td>EGFR Amplification and Sensitizing Mutations Correlates with Survival from Erlotinib in Lung Adenocarcinoma Patients (MutP-CLICAP¶)</td>
<td>Andrés Cardona, Colombia</td>
</tr>
</tbody>
</table>
P2.13-12 - The deNovo T790M Mutation Recovered by ddPCR is Associated with a Poor Response to 1st and 2nd Generation EGFR-TKI in Lung Adenocarcinoma.
Yoon Soo Chang, Republic of Korea

P2.13-13 - Real-World Study of Osimertinib in EGFR T790M-Mutated Non-Small Cell Lung Cancer (NSCLC): ASTRIS Canadian Cohort Analysis
Parneet Cheema, Canada

P2.13-14 - The Clinical Usefulness of Liquid Biopsy for Detection and Dynamic Monitoring of EGFR T790M in NSCLC Patients on EGFR-TKI Therapy
Joanna Chorostowska-Wynimko, Poland

P2.13-15 - Short-Term Responders of NSCLC to EGFR-TKIs Display High Prevalence of TP53 Mutations and Primary Resistance Mechanisms
Yun Fan, China

P2.13-16 - Preference of Adjuvant Treatments for EGFR-Mutant Resected NSCLC Patients: Results of a National-Wide Survey in China
Wenhua Liang, China

P2.13-17 - Non-Small Cell Lung Cancer in the Very Young: More EGFR/ALK Mutation Rate Than the Elder
ChienHui He, Taiwan

P2.13-18 - A Multicenter Prospective Biomarker Study to Explore Mechanisms of Afatinib Resistance Based on Digita PCR and Next-Generation Sequencing
Eiji Iwama, Japan

P2.13-19 - Prognostic Value Inferred from the Quantitative Measurement of EGFR Mutation Using PNA-Clamping Method in Advanced EGFR Mutant NSCLC Patients
Mi-hyun Kim, Korea, Republic of

P2.13-20 - The Comparative Effectiveness of Gefitinib Versus Erlotinib on the Intracranial Progression-Free Survival in Patients with Brain Metastasis
Yao-Wen Kuo, Taiwan

P2.13-21 - MET Addiction Can be Circumvented Through EGFR Inhibition Via AXL in MET-Amplified Primary Resistant EGFR-Mutant NSCLC
Xue Lin Kwang, Singapore

P2.13-22 - Resistant Patterns to Osimertinib in Non-Small Cell Lung Cancer Patients with Both T790M and Sensitizing EGFR Mutation
Jae Cheol Lee, Republic of Korea

**P2.13-23 - Osimertinib Treatment Result of Plasma T790M Positive in Different Clinical Failure Modes After First-Line EGFR TKI for EGFR Mutant NSCLC**

Haiyan Li, China

**P2.13-24 - Prospective Efficacy of Osimertinib in Circulating Tumour DNA (ctDNA) T790M-Mutant NSCLC Patients**

Jordi Remon, France

**P2.13-25 - Analysis of EGFR Mutations Using Circulating Tumour DNA (ctDNA) in Non-Small Cell Lung Cancer Patients in North East Scotland**

Paula Scott, UK

**P2.13-26 - Impact of Concurrent Tumor Suppressor Gene Mutation on Clinical Outcomes in EGFR Mutated NSCLC Treated with First-Line TKI**

Sandhya Sharma, NY/USA

**P2.13-27 - Development, Internal Validation, and Calibration of a Risk Score to Predict Survival in Patients with EGFR Mutant NSCLC**

Ross Soo, Singapore

**P2.13-28 - Comparison of ddPCR and NGS in Liquid Biopsy to Pathology Results in EGFR-Mutated NSCLC**

Christi Steendam, Netherlands

**P2.13-29 - IL-22 Confers Resistance To EGFR-TKIs In Non-Small Cell Lung Cancer Bearing EGFR Gene Mutation and Amplification**

Xiyi Lu, China

**P2.13-30 - High-Dose Icotinib in Advanced Non-Small Cell Lung Cancer with EGFR 21 L858R Mutation: The Randomized, Open-Label INCREASE Study**

Shucai Zhang, China

**P2.13-31 - p. (Leu747Pro) Mutation Leads to Misdiagnosis in EGFR Mutation Assessment - Analysis in a Cohort of 1841 Polish NSCLC Patients**

Joanna Chorostowska-Wynimko, Poland

**P2.13-32 - TAK-788 is a Novel and Potent Tyrosine Kinase Inhibitor with Selective Activity Against EGFR/HER2**

Jouhara Chouitar, MA/USA
P2.13-33 - A Case Report of Exceptional Clinical Response to MEK Inhibition in a Patient with NRAS Mutation Positive NSCLC
Donna Graham, UK

P2.13-34 - Long Intergenic Non-Coding RNA 00665 Induces Acquired Resistance to Gefitinib in Non-Small-Cell Lung Cancer
Xiyi Lu, China

P2.13-35 - Inhibition of H3K27 Demethylation is Toxic in Poorly Differentiated Small Cell Lung Cancer
Timothy Lochmann, VA/USA

P2.13-36 - Analysis of CDK4/6 Pathway Activity in Lung Adenocarcinoma Patients with Oncogenic Driver Mutations in China
Shun Lu, China

P2.13-37 - Chloroquine overcomes acquired resistance to icotinib in vitro and in vivo through STAT3/STMN1 pathway
Xin Lyu, China

P2.13-38 - Impact of Tyrosine Kinase Inhibitor (TKI) Dose on Outcomes of Patients with Lung Cancer
Emily Miao, USA

P2.13-39 - A Phase Ib Trial of the HSP90 Inhibitor AUY922 in Combination with Pemetrexed in Metastatic Non-Squamous, Non-Small Cell Lung Cancer Patients
Zorawar Noor, CA/USA

P2.13-40 - ABP 215 and Bevacizumab in NSCLC Patients: Time Course and Magnitude of Response in the Phase 3 Comparative Trial (MAPLE)
Valdimir Hanes, CA/USA

P2.13-41 - A Novel Mitochondria-Based Targeting to Restore Therapeutic Response in Cisplatin- and Gefitinib-Resistant Human Lung Cancer Cells
Qinghua Zhou, China

P2.13-42 - Osimertinib Treatment for Patients with EGFR exon 20 Insertion Positive Non-Small-Cell Lung Cancer
Joop De Langen, Netherlands

P2.13-43 - Phase 1 Study of the Anti-HER3 Antibody Drug Conjugate U3-1402 in Metastatic or Unresectable EGFR-Mutant NSCLC
Pasi Jänne, MA/USA

P2.13-44 - Targeting NFE2L2 Mutations in Advanced Squamous Cell Lung Cancers with the TORC1/2 Inhibitor TAK-228
Paul Paik, NY/USA

P2.13-45 - SHERLOC: A Phase 2 Study of Seribantumab in Combination with Docetaxel in Patients with Heregulin Positive, Advanced NSCLC
Lecia Sequist, MA/USA

P2.13-46 - Comprehensive Investigation of ERBB2 Transmembrane Domain Mutations (V659/G660) in 12,833 Chinese Lung Cancer Patients
Shao W Yang, Canada

16:45 - 18:00  Treatment in the Real World - Support, Survivorship, Systems Research  Exhibit Hall

P2.15-01 - CANscript™ as a Patient-Derived Predictive Platform for individualizing Treatment in Lung Cancer
K Govind Babu, India

P2.15-02 - Gender-Associated Differences in Patients with Lung Cancer Treated at an Argentinean University Hospital in the Last 10 Years
Carolina Gabay, Argentina

P2.15-03 - Availability and Reimbursement of Diagnostic Testing and Novel Anti-Cancer Drugs for NSCLC in CEE: Results of a CECOG Survey
Luka Brcic, Austria

P2.15-04 - Costs of Cares on the Month Before Death of Patients with Lung Cancer: A French National Database Survey
Olivier Bylicki, France

P2.15-05 - Prescribing Patterns of Physicians and Financial Implications for Lung Cancer Treatment at the End of Life
Josephine Feliciano, MD/USA

P2.15-06 - Examination of Optimal Timing of Post-Surgical Surveillance for Early Stage Lung Cancer Patients and Association with Outcomes
Leah Backhus, USA
P2.15-07 - Lung Cancer in the Young
Marco Galvez Nino, Peru

P2.15-08 - Impact and Feasibility of a Support Group for Women with Lung Cancer
Paul Wheatley-Price, Canada

P2.15-09 - The Impact of Treatment Evolution in NSCLC (iTEN) Model: Survival and Cost of Treating Patients with Advanced NSCLC in 2017
Daniel Moldaver, Canada

P2.15-10 - Determinants of Health Utility Scores (HUS) in Patients with ALK Rearranged Non-Small Cell Lung Cancer.
Badr Id Said, Canada

P2.15-11 - Clinical Outcome of Pulmonary Resection for Non-Small Cell Lung Cancer in Extremely Elderly Patients (85-Year-Old or Over)
Hiroaki Inoue, Japan

P2.15-12 - Exparel vs. Bupivicaine for Postoperative Analgesia After VATS Lung Resection: Results of a Randomized Control Trial
Sandeep Khandhar, VA/USA

P2.15-13 - Implementation of a Democratized Approach to Multi-Omic Molecular Profiling Via the LungMATCH Program.
Jennifer King, DC/USA

P2.15-14 - Survivorship of Advanced Lung Cancer Patients with Psychiatric Disorders and Malnutrition Risk
Tomi Kovacevic, Serbia

Sara Hayes, USA

P2.15-16 - Clinical Economic Impact of Improved Genotyping in Patients with Advanced Non-Small Cell Lung Adenocarcinoma (NSCLC)
Victoria Raymond, USA

P2.15-17 - Patient Care in Advanced Lung Cancer: Unmet Needs
Jean-François Morere, France
P2.15-18 - Cost-Effectiveness Analysis of Second-Line Immune Checkpoint Inhibitors for Advanced NSCLC in Colombia
Aylen Vanessa Ospina Serrano, Colombia

P2.15-19 - Inequality of Access to Novel Lung Cancer Therapies in Europe
Hazel O’sullivan, Ireland

P2.15-20 - Educating the Multispecialty Team on Molecular Testing Related to Immunotherapy
Jeffrey Gregg, CA/USA

P2.15-21 - Post Resection Lung Cancer Surveillance: Comparisons of Practice Between STS, ESTS and JACS Members
Cecilia Pompili, UK

P2.15-22 - Optimal Glycemic Control Improves Prognosis for Lung Cancer Patients with Diabetes Mellitus
Baohui Han, China

P2.15-23 - Are there Ethnic Disparities in the Clinical Outcomes of Non-Small Cell Lung Cancer Hispanic Patients Treated with Immunotherapy?
Luis Raez, FL/USA

P2.15-24 - Comparison of Pemetrexed Administered q 3 Weeks vs q 4 Weeks as Maintenance Therapy in NSCLC: Analysis of Real World Data from a Single Institution
Sruthi Reddy, USA

Delvys Rodriguez-Abreu, Spain

P2.15-26 - Rates and Economic Burden of Adverse Events in Patients with Metastatic NSCLC Treated with EGFR-TKIs
Janakiraman Subramanian, MT/USA

P2.15-27 - Lung Volume Change After Lobectomy Estimated by Three-Dimensional Image Analysis System
Hirofumi Suzuki, Japan

P2.15-28 - Effect of Insurance Types on Tumor Recurrence and Overall Survival in Resectable Non-Small Lung Cancer Patients in Northern Thailand
Nirush Lertprasertsu, Thailand
P2.15-29 - Eligibility for Anti-Angiogenic Treatments in Patients with Squamous Non-Small Cell Lung Cancer (SQ-NSCLC): EPISQUAMAB Study (GFPC 2015-01)
Alain Vergnenegre, France

P2.15-30 - Marital Status and Survival in Patients with Lung Cancer
Buhai Wang, China

P2.15-31 - The Evolution of Costs in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Ontario, Canada Between 1999 to 2014
Ying Wang, BC/Canada

P2.15-32 - Novice Training: The Time Course for Developing Competence in Single Port Video-Assisted Thoracoscopic Lobectomy
Ching Feng Wu, Taiwan

16:45 - 16:45
P2.15-33 - Evaluation of Liquid Biopsies for Molecular Profiling in Patients (pts) with Advanced NSCLC: What Happens After Panel Testing by NGS?
Chunxia Su, China

P2.16
16:45 - 18:00 Treatment of Early Stage/Localized Disease Exhibit Hall

P2.16-01 - Prognostic Significance of Preoperative Consolidation to Maximum Tumor Diameter Ratio and Suv-Max in Pathological Stage I Lung Adenocarcinoma
Pınar Akın Kabalak, Turkey

P2.16-02 - Predicting Pathological Noninvasiveness in T1 Non-Small Cell Lung Cancer on Chest CT Scan Using Deep Learning Algorithm
Kyongmin Beck, Republic of Korea

P2.16-03 - CheckMate 816: A Phase 3 Trial of Neoadjuvant Nivolumab Plus Ipilimumab or Chemotherapy vs Chemotherapy in Early-Stage NSCLC
Enriqueta Felip, Spain

P2.16-04 - Prognostic Value of Lymphovascular Invasion and Its Effect on Patterns of Recurrence in T1-3N0 Non-Small Cell Lung Cancer
Yeon Sil Kim, Republic of Korea

P2.16-05 - Hypermethylation of SOX1, RASSF1A, HOXA9, CDH13 and DAPK Genes Plays a Role in NSCLC Pathogenesis
Milica Kontic, Serbia
P2.16-06 - Development and Validation of a Gene Expression-Based Nomogram to Predict Relapse in Stage I NSCLC: A Retrospective, Multi-Cohort Study
Qixing Mao, China

P2.16-07 - Impact of de Novo T790M on Outcome for Resected NSCLC from EGFR Mutant Cohort of Japan Molecular Epidemiology (JME) Study
Yoshiya Matsumoto, Japan

P2.16-08 - Influence of Tumour Location and Histological Sub-Type of Non-Small Cell Lung Cancer on Patient Survival
Alan Mcwilliam, UK

P2.16-09 - Patterns of Brain Metastases in Stage I-III Non-Small Cell Lung Cancer: An NCDB Analysis
Stephanie Rice, USA

P2.16-10 - Prognostic Impact of Postoperative C-Reactive Protein for Non-Small Cell Lung Cancer Following Lobectomy
Shuichi Shinohara, Japan

P2.16-11 - Prognostic Role of Combined Pulmonary Fibrosis and Emphysema (CPFE) in Patients with Clinical Stage I Lung Cancer.
Yasuhiro Tsutani, Japan

P2.16-12 - Expanded Data Confirm Molecular Testing Identifies Lung Adenocarcinoma Patients, Including Stage IA, Who Benefit from Adjuvant Chemotherapy
Gavitt Woodard, CA/USA

P2.16-13 - A Proposal of Classification for Subsolid Nodule: Prognostic Impact of T Descriptor
Erjia Zhu, China

P2.16-14 - Results of Stereotactic Radiation Therapy (SABR) in Early Stage Lung Cancer: Turkish Radiation Oncology Group (TROG) Study
Banu Atalar, Turkey

P2.16-15 - Toxicities and Survival after Stereotactic Ablative Radiotherapy (SABR) for Centrally Located Lung Tumors
Banu Atalar, Turkey

P2.16-16 - SABRTOOTH: A Fasibility Study of SABR Versus Surgery in Patients with Peripheral Stage I NSCLC Considered to be at Higher Risk for Surgery.
Kevin Franks, UK

P2.16-17 - Hypo-Fractionated Accelerated Radiotherapy in Central Early Non-Small Cell Lung Cancer: Leeds Cancer Centre Experience.
Kevin Franks, UK

P2.16-18 - Study of Interstitial Lung Disease and Acute Exacerbation in Patients Receiving Radiation Therapy for Lung Cancer in Japan.
Yasuhi Hagiwara, Japan

P2.16-19 - Feasibility and Outcomes of Radiofrequency Ablation as Salvage Modality After Hypofractionated Radiation/SBRT for Early NSCLC
Ritika Harjani Hinduja, Canada

P2.16-20 - Prognostic Utility of PET in Non-Small Cell Lung Cancer After Empiric Stereotactic Body Radiotherapy (SBRT)
Shaakir Hasan, PA/USA

P2.16-21 - Post-Treatment Survival Difference Between Lobectomy and Stereotactic Ablative Radiotherapy in Stage 1 Non-Small Cell Lung Cancer in England
Neal Navani, UK

P2.16-22 - Comparing Two Common Radiotherapy Regimens in Non-Small Cell Lung Cancer - A Retrospective Study
Stephen Harrow, UK

P2.16-23 - Focal Therapy for Small Lung Cancer with Ethanol Release Heat-Generating Polymer
Junichi Shimada, Japan

P2.16-24 - Racial Differences in Treatment and Survival of Stage I NSCLC: A Comparison of Veterans Affairs (VA) and SEER-Medicare Populations
Christina Williams, NC/USA

P2.16-25 - Lower Hiliiar Lymph Node Upstaging in Early NSCLC Vats Surgery is Related to Tumor Location and Does Not Affect Survival
Marc Boada, Spain

P2.16-26 - Lung Cancer Resection in Patients with Criteria for Lung Cancer Screening Provides Satisfactory Short-Term Results
David Boulate, France
P2.16-27 - Indocyanine Green Virtual Assisted Lung Mapping (ICG-VAL-MAP): Anyone Can Perform a Visible Preoperative Marking Successfully
Toyofumi Chen-Yoshikawa, Japan

P2.16-28 - Comparison of Outcomes of VATS Segmentectomy Versus Lobectomy for Non-Small Cell Lung Cancer Using a Propensity Score Matching Analysis
Yoohwa Hwang, Republic of Korea

P2.16-29 - Clinical Outcomes of Surgically Resected Extraabdominal Chest Wall Desmoid Tumors
Seok Kim, Republic of Korea

P2.16-30 - Surgical Strategy for Clinical Stage IA Non-Small Cell Lung Cancer Patients with Risk Factors of Pathological Invasion and/or Metastasis
Terumoto Koike, Japan

P2.16-31 - Examination of the Intersegmental Isolation Method in the Segmental Resection Considering Respiratory Function Preservation
Katsuo Kojima, Japan

P2.16-32 - Survival Implications and Factors Associated with the Anatomic Level of Incomplete Non-Small-Cell Lung Cancer (NSCLC) Resection
Yu-Sheng Lee, TN/USA

P2.16-33 - Adenosquamous Carcinoma of the Lung: Comparison of Surgical Outcomes with Squamous Cell and Adenocarcinoma
Huseyin Melek, Turkey

P2.16-34 - Visceral Pleural Invasion is Closely Associated with Nodal Spread in cStage IA Lung Adenocarcinoma
Tetsuya Mizuno, Japan

P2.16-35 - Analysis of Pre and Intra Operative Factors Related to the Operation Time of Lobectomy in VATS: Is the Shape of Thoracic Cavity a Predictive Factor?
Takuya Nagashima, Japan

P2.16-36 - Adjuvant Chemotherapy is Effective for Completely Resected Stage IB Non-Small Cell Lung Cancer
Masao Nakata, Japan

P2.16-37 - The Introduction of Robotic Lobectomy for Non-Small Cell Lung Cancer in South East Asia: A 5-Year Single Centre Study
Kingsfield Ong, Singapore

P2.16-38 - Characteristics of Preoperative N Staging in Patients with Optimal Pathologic N Staging of Non-Small Cell Lung Cancer (NSCLC)
Meredith Ray, USA

P2.16-39 - The Application of 3D Medical Image Analyzer and a Fluorescence Guided Surgery for Pulmonary Sublobar Resection
Yasu Sekine, Japan

P2.16-40 - Impact of Preoperative Pectoralis Muscle Quantity and Density on Outcome After Complete Resection of Non-Small Cell Lung Cancer
Changbo Sun, Japan

P2.16-41 - Intraoperative Computed Tomography After Tumor Marking with Metal Clips for Non-Palpable Lung Tumors
Yoshimasa Tokunaga, Japan

P2.16-42 - Standard Mediastinoscopy Versus Video-Assisted Mediastinoscopic Lymphadectomy in Clinical N1 Non-Small Cell Lung Cancer
Akif Turna, Turkey

P2.16-43 - Diabetes is a Negative Prognostic Factor in Non-Small Cell Lung Cancer Patients Undergoing Resectional Surgery
Akif Turna, Turkey

P2.16-44 - Long-Term Outcome of Pulmonary Segmentectomy for c-IA Non-Small Cell Lung Cancer
Hironobu Wada, Japan

P2.16-45 - Should Patients with Stage IB Non-Small Cell Lung Cancer Receive Adjuvant Chemotherapy?
Jia Wang, China

P2.16-46 - Clinical Outcomes and Treatment Strategies of Sarcomatoid Carcinoma of the Lung
Yan Wang, China

P2.16-47 - “Improved aBVA Method” and “Anterior VAB Method” Result in Analogous Survival Benefits During Right Upper Lobectomy
Jin Xia, China
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2.16-48</td>
<td>Outcomes of Stage I Lung Cancer Patients Treated with Segmentectomy via Three-Dimensional Uniportal VATS Versus Two-Dimensional Approach</td>
<td>Chengliang Yang, China</td>
</tr>
<tr>
<td>P2.16-49</td>
<td>Which Nomogram is More Reliable to Predict Recurrence of Pathological Stage IA Lung Adenocarcinoma Treated by Surgery?</td>
<td>Lu Yang, China</td>
</tr>
<tr>
<td>P2.16-50</td>
<td>Do Patients Have Preconceived Ideas on Various Surgical Approaches? Patient Perspective: Open vs. Minimally Invasive Surgery (PROMIS) Survey.</td>
<td>Ching Yeung, ON/Canada</td>
</tr>
</tbody>
</table>

**16:45 - 18:00** Treatment of Locoregional Disease - NSCLC

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2.17-01</td>
<td>Trimodality Therapy (TT) in the Treatment of Stage IIIA Non-Small Cell Lung Cancer (NSCLC)</td>
<td>Tahir Mehmood, Pakistan</td>
</tr>
<tr>
<td>P2.17-02</td>
<td>Cardiopulmonary Exercise Tests in Lung Cancer Patients Treated Radical Radiotherapy and Chemotherapy - Feasibility Study</td>
<td>Nazia Mohammed, UK</td>
</tr>
<tr>
<td>P2.17-03</td>
<td>A Propensity-Matched Analysis of Neoadjuvant Chemoradiotherapy and Adjuvant Chemoradiotherapy for IIIA(N2) Non-Small Cell Lung Cancer</td>
<td>Yaping Xu, China</td>
</tr>
<tr>
<td>P2.17-04</td>
<td>Imiquimod Attenuates Radiation-Induced Pulmonary Fibrosis</td>
<td>Guler Yavas, Turkey</td>
</tr>
<tr>
<td>P2.17-05</td>
<td>Consolidation Chemotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer After Concurrent Chemoradiotherapy</td>
<td>Fatma Basal, Turkey</td>
</tr>
<tr>
<td>P2.17-06</td>
<td>Functional Lung Imaging in Radiotherapy for Lung Cancer: A Systematic Review and Meta-Analysis</td>
<td>Nicholas Bucknell, Australia</td>
</tr>
</tbody>
</table>
P2.17-07 - Concurrent Chemoradiotherapy (ConCRT) using Cisplatin-Vinorelbine in Locally Advanced (LA) Non-Small Cell Lung Cancer (NSCLC)

Haris Charalambous, Cyprus

P2.17-08 - Heart Motion in Lung Radiotherapy: How Representative Are Delineations Based on 3DCT, Average and Maximum Projection Scans?

David Cobben, UK

P2.17-09 - Exploring the Impact of Age on the Efficacy of Adjuvant Chemotherapy After Radical Resection in Non-Small Cell Lung Cancer

Catherine Davidson, UK

P2.17-10 - Daily Low-Dose Cisplatin and High Dose Radiotherapy for Elderly Patients with Stage III NSCLC is Well Tolerated.

E M T Dieleman, Netherlands

P2.17-11 - Impact of Quantitatively Assessed Emphysema on Chest Tube Drainage After Lobectomy for Non-Small Cell Lung Cancer

Tomasz Gil, Poland

P2.17-12 - Eliminating Radiation Resistance of Non-Small Cell Lung Cancer By DHA Trough Abrogating Immunity Escaping via Inhibiting PD-L1 Expression

Xiaomei Gong, China

P2.17-13 - Genome-Wide Copy Number Alterations Profiling Predict Efficacy of Resected Stage II-III A Lung Adenocarcinoma

Xiaohong Han, China

P2.17-14 - How Should Positive Margin for Bronchial Stumps (R1) Be Evaluated in Patients Undergoing Bronchoplasty for Lung Cancer?

Kazunori Hata, Japan

P2.17-15 - Mediastinoscopic Assessment of N2 Disease and Optimisation of Surgical Treatment of N2 Disease in NSCLC

George Karimundackal, India

P2.17-16 - Radical en Bloc Resection for Lung Cancer Invading the Spine

Masato Kato, Japan

P2.17-17 - Multimodal Treatment in Pathologically Confirmed Single-Station Resectable IIIA-N2 Non-Small Cell Lung Cancer: A Single Center Experience

Margarita Majem, Spain
P2.17-18 - A Prognostic Score for Patients Receiving Multimodal Treatment for Locally-Advanced Non-Small Cell Lung Cancer
Maurice Dantes, Germany

P2.17-19 - Concurrent Chemoradiotherapy with Carboplatin-Paclitaxel Versus Cisplatin-Etoposide for Stage III NSCLC Patients - Review of Literature
Tahir Mehmood, Pakistan

P2.17-20 - Systematic Literature Review of Chemoradiotherapy Versus Radiotherapy Alone in Elderly Patients with Stage III Non-Small Cell Lung Cancer
Tahir Mehmood, Pakistan

P2.17-21 - Efficacy of Concurrent Carboplatin-Paclitaxel Chemoradiotherapy with 66 Gy for Elderly Patients with Stage III Non-Small Cell Lung Cancer
Sachiko Miura, Japan

P2.17-22 - Cardiac Biomarkers in CART Study (CARdiac Toxicity in Lung Cancer Patients After Chemo-Radiotherapy).
Nazia Mohammed, UK

P2.17-23 - Optimal Therapy of Stage III NSCLC: The Role of Surgery in the Era of Immunotherapy
Sara Moore, BC/Canada

P2.17-24 - Does the Change in Body Mass Index During Induction Chemo/Chemoradiotherapy Affect the Outcome of Surgery in Locally Advanced NSCLC?
Huseyin Melek, Turkey

P2.17-25 - Post-Treatment Neutrophil to Lymphocyte Ratio in Locally Advanced NSCLC Patients Treated with Concurrent Chemoradiotherapy
Eun Young Park, Korea, Republic of

P2.17-26 - Quantifying the Interfractional Motion of the Esophagus During Radiation Therapy for Locally Advanced Non-Small Cell Lung Cancer
Hui Liu, China

P2.17-27 - IMpower030: Phase III Study Evaluating Neoadjuvant Treatment of Resectable Stage II-IIIB NSCLC with Atezolizumab + Chemotherapy
Naiyer Rizvi, NY/USA
P2.17-28 - Real-World Data: Survival Outcomes of Chemotherapy Regimens Given Concurrently with Radiotherapy for Locally Advanced NSCLC
David Chun Cheong Tsui, Canada

P2.17-29 - Is Collagen Vascular Disease-Associated Interstitial Lung Disease a High Risk for Lung Cancer Surgery?
YUKIO Watanabe, Japan

P2.17-30 - Serum Lipoprotein(A) Correlates with the Effect of Endostar Combined with Concurrent Chemoradiotherapy in Patients with Locally Advanced LSCC
Haihua Yang, China

P2.17-31 - The Effect of the Extended Bilateral Mediastinal Lymph Node Dissection Through a Median Sternotomy for Non-Small-Cell Carcinoma of the Left Lung.
Toshiya Yokota, Japan

Chao Zhang, China

P2.17-33 - Role of Adjuvant Therapy in Pulmonary Adenosquamous Carcinoma
Jiaxi He, China

17:00 - 18:00 IASLC Business Meeting Room 202 BD

18:00 - 19:30 Symposium Supported by AstraZeneca: Stage III NSCLC: Combining Immunotherapies with Standard Treatments... Who, When, Why? Room 106

18:00 - 19:30 Stage III NSCLC: Combining Immunotherapies with Standard Treatments... Who, When, Why?

20:00 - 23:00 Conference Dinner (Ticketed Event) Plenary Hall
20:00 - 23:00  Conference Dinner (Ticketed Event)
**Wednesday, September 26, 2018**

**MTE19**  
07:00 - 08:00  
**How I Treat Advanced Stage Thymic Malignancy Patients (Ticketed Session)**  
Topics: Thymoma/Other Thoracic Malignancies  
Room 205 AC

07:00 - 08:00  
**MTE19.01 - How I Treat Advanced Stage Thymic Malignancy Patients**  
Heather Wakelee, CA/USA

**MTE20**  
07:00 - 08:00  
**Molecular Testing in Small Samples (Ticketed Session)**  
Topics: Pathology  
Room 202 BD

07:00 - 07:30  
**MTE20.01 - Molecular Testing in Small Samples**  
John Longshore, NC/USA

07:30 - 08:00  
**MTE20.02 - Molecular Testing in Small Samples**  
Jin-Haeng Chung, Republic of Korea

**MTE21**  
07:00 - 08:00  
**Can I Treat Brain Metastasis with Immunotherapy? (Ticketed Session)**  
Topics: Immunooncology  
Room 105

07:00 - 07:30  
**MTE21.01 - Can I Treat Brain Metastasis with Immunotherapy?**  
Sarah Goldberg, CT/USA

07:30 - 08:00  
**MTE21.02 - Can I Treat Brain Metastasis with Immunotherapy?**  
Caroline Chung, USA
### MTE22

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00 - 07:30</td>
<td>Incorporation of Smoking Cessation in Clinical Care (Ticketed Session)</td>
<td>Matthew Steliga, AR/USA</td>
</tr>
<tr>
<td>07:30 - 08:00</td>
<td>Cessation and Clinical Lung Cancer Care</td>
<td>Jamie Ostroff, CO/USA</td>
</tr>
</tbody>
</table>

### MTE23

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00 - 07:30</td>
<td>Surgical Considerations Following Induction Therapy for Stage IIIA Disease (Ticketed Session)</td>
<td>Eric Vallieres, WA/USA</td>
</tr>
<tr>
<td>07:30 - 08:00</td>
<td>Surgical Considerations Following Induction Therapy for Stage IIIA Disease</td>
<td>Jonathan Spicer, QC/Canada</td>
</tr>
</tbody>
</table>

### MTE24

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00 - 07:30</td>
<td>Surgery vs SABR for Early NSCLC</td>
<td>Thomas D'amico, USA</td>
</tr>
<tr>
<td>07:30 - 08:00</td>
<td>Small Lung Tumours: High Risk Lesions and Contraindications to Stereotactict Ablative Body Radiotherapy (SABR)</td>
<td>David Ball, Australia</td>
</tr>
</tbody>
</table>
### MTE25

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00 - 08:00</td>
<td>Enhancing the Care of Your Older Adult Population with Lung Cancer (Ticketed Session)</td>
</tr>
<tr>
<td></td>
<td>Topics: Nursing and Allied Professionals</td>
</tr>
<tr>
<td>07:00 - 08:00</td>
<td>MTE25.01 - Enhancing the Care of Your Older Adult Population with Lung Cancer</td>
</tr>
<tr>
<td></td>
<td>Martine Puts, Canada</td>
</tr>
</tbody>
</table>

### MTE26

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00 - 08:00</td>
<td>New Paradigms in Symptom Management in Lung Cancer (Ticketed Session)</td>
</tr>
<tr>
<td></td>
<td>Topics: Treatment in the Real World - Support, Survivorship, Systems Research</td>
</tr>
<tr>
<td>07:00 - 07:30</td>
<td>MTE26.01 - Treatment of Cancer Related Symptoms</td>
</tr>
<tr>
<td></td>
<td>Patricia Rivera, USA</td>
</tr>
<tr>
<td>07:30 - 08:00</td>
<td>MTE26.02 - Symptoms and IO Toxicity Management</td>
</tr>
<tr>
<td></td>
<td>Jarushka Naidoo, USA</td>
</tr>
</tbody>
</table>

### MTE27

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00 - 08:00</td>
<td>Controversies in Radiotherapy for SCLC (Ticketed Session)</td>
</tr>
<tr>
<td></td>
<td>Topics: Small Cell Lung Cancer/NET</td>
</tr>
<tr>
<td>07:00 - 08:00</td>
<td>MTE27.01 - Radiotherapy in ES-SCLC</td>
</tr>
<tr>
<td></td>
<td>Elizabeth Gore, USA</td>
</tr>
</tbody>
</table>

### MTE28

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00 - 08:00</td>
<td>Lessons from the Past-What I Would Not Do Again in Diagnostic and Therapeutic IP (Ticketed Session)</td>
</tr>
<tr>
<td></td>
<td>Topics: Interventional Diagnostics/Pulmonology</td>
</tr>
<tr>
<td>07:00 - 07:30</td>
<td>MTE28.01 - Lessons from the Past-What I Would Not Do Again in Diagnostic and Therapeutic IP</td>
</tr>
<tr>
<td></td>
<td>Navneet Singh, India</td>
</tr>
<tr>
<td>07:30 - 08:00</td>
<td>MTE28.02 - Lessons from the Past-What I Would Not Do Again in Diagnostic and Therapeutic IP</td>
</tr>
<tr>
<td></td>
<td>Jason Agulnik, Canada</td>
</tr>
</tbody>
</table>
### SH03

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00</td>
<td>Highlight of the Previous Day Sessions</td>
<td>Room 107</td>
</tr>
<tr>
<td></td>
<td>Moderation: C. Sit, Canada; A. Bang, Canada</td>
<td></td>
</tr>
<tr>
<td>07:00</td>
<td>SH03.01 - Thymoma &amp; Outcomes</td>
<td>Shirish Gadgeel, USA</td>
</tr>
<tr>
<td>07:12</td>
<td>SH03.02 - Targeted</td>
<td>Alice T. Shaw, USA</td>
</tr>
<tr>
<td>07:24</td>
<td>SH03.03 - Biology</td>
<td>Glen Reid, Australia</td>
</tr>
<tr>
<td>07:36</td>
<td>SH03.04 - Screening</td>
<td>Stephen Lam, Canada</td>
</tr>
<tr>
<td>07:48</td>
<td>SH03.05 - Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>

### SH04

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00</td>
<td>Highlight of the Previous Day Sessions</td>
<td>Room 106</td>
</tr>
<tr>
<td></td>
<td>Moderation: P. Garrido, Spain; S. Singh, Canada</td>
<td></td>
</tr>
<tr>
<td>07:00</td>
<td>SH04.01 - SCLC/NET</td>
<td>Melissa Johnson, USA</td>
</tr>
<tr>
<td>07:12</td>
<td>SH04.02 - Surgery</td>
<td>Biniam Kidane, Canada</td>
</tr>
<tr>
<td>07:24</td>
<td>SH04.03 - Locally Advanced/IO</td>
<td>Edgardo Santos, USA</td>
</tr>
<tr>
<td>07:36</td>
<td>SH04.04 - Survivorship &amp; Radiation</td>
<td>Chad Rusthoven, USA</td>
</tr>
<tr>
<td>07:48</td>
<td>SH04.05 - Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>
## PL03

### 08:15 - 09:45  Call to Action - Challenges Ahead  
**Plenary Hall**
Moderation: G. Darling, Canada; N. Saijo, Japan

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15</td>
<td>PL03.01 - From Bench to Bedside</td>
<td>Charles Swanton, UK</td>
</tr>
<tr>
<td>08:30</td>
<td>PL03.02 - Host Immunity - No Longer a Passive Bystander</td>
<td>Julie Brahmer, MD/USA</td>
</tr>
<tr>
<td>08:45</td>
<td>PL03.03 - Beaming into the Future</td>
<td>David Palma, Canada</td>
</tr>
<tr>
<td>09:00</td>
<td>PL03.04 - A Cut Above</td>
<td>Yolonda Colson, USA</td>
</tr>
<tr>
<td>09:15</td>
<td>PL03.05 - It's All in The Tissue</td>
<td>Keith Kerr, UK</td>
</tr>
<tr>
<td>09:30</td>
<td>PL03.06 - The Future of Targeted Therapy</td>
<td>Tetsuya Mitsudomi, Japan</td>
</tr>
</tbody>
</table>

## ES06

### 10:30 - 12:00  Oligometastatic Disease  
**Room 202 BD**
Topics: Oligometastatic NSCLC
Moderation: R. Martins, USA; G. Rocco, Italy

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30</td>
<td>ES06.01 - Current Clinical Trials in Oligometastases</td>
<td>Anne-Marie Dingemans, Netherlands</td>
</tr>
<tr>
<td>10:50</td>
<td>ES06.02 - Integrating New Systemic Therapy into Trials in OMD</td>
<td>Sanjay Popat, UK</td>
</tr>
<tr>
<td>11:10</td>
<td>ES06.03 - Developments in SBRT in the Oligometastatic Paradigm in NSCLC</td>
<td>Patrick Cheung, ON/Canada</td>
</tr>
<tr>
<td>11:30</td>
<td>ES06.04 - Surgical Considerations in OMD</td>
<td>Jessica Donington, NY/USA</td>
</tr>
</tbody>
</table>
MA23
Early Stage Lung Cancer: Present and Future
Room 105

10:30 - 10:35
MA23.01 - Buffy Coat Immunooncologic Diagnosis and Prognosis of pStage I Lung Adenocarcinoma
Harvey Pass, NY/USA

10:35 - 10:40
MA23.02 - Circulating Tumor DNA Analysis with a Novel Variant Classifier for Recurrence Detection in Resected, Early-Stage Lung Cancer
Vincent Lam, TX/USA

10:40 - 10:45
MA23.03 - Risk Assessment for Indeterminate Pulmonary Nodules Using a Novel, Plasma-Protein Based Biomarker Assay
Anil Vachani, PA/USA

10:45 - 11:00
MA23.04 - Discussant - MA 23.01, MA 23.02, MA 23.03
Scott Bratman, Canada

11:00 - 11:05
MA23.05 - Post-Operative Radiation Improves Overall Survival in Patients with Node-Positive Non-Small Cell Lung Cancer Undergoing Sublobar Resections
Karl Fabian Uy, MA/USA

11:05 - 11:10
MA23.06 - Small Residual Setup Errors After Image-Guided Radiotherapy Affect Heart Dose and Are Linked to Overall Survival
Alan Mcwilliam, UK

11:10 - 11:15
MA23.07 - Defining the Role of Adjuvant Therapy for Early Stage Large Cell Neuroendocrine Lung Cancer
Elliot Wakeam, Canada

11:15 - 11:30
MA23.08 - Discussant - MA 23.05, MA 23.06, MA 23.07
Kevin Franks, UK
11:30 - 11:35  MA23.09 - Minimally Invasive Approaches Do Not Compromise Outcomes for Pneumonectomy, a Comparison Utilizing the National Cancer Database  
Mark Hennon, NY/USA

11:35 - 11:40  MA23.10 - Cone-Beam Computed Tomography-Guided Microcoil Localization of Pulmonary Nodules During Video-Assisted Thoracic Surgery  
Hideki Ujiie, ON/Canada

11:40 - 11:45  MA23.11 - Lobe-Specific Nodal Dissection for Clinical Stage I and II Non-Small Cell Lung Cancer: Japanese Multi-Institutional Retrospective Study  
Tomoyuki Hishida, Japan

11:45 - 12:00  MA23.12 - Discussant - MA 23.09, MA 23.10, MA 23.11  
Giulia Veronesi, Italy

10:30 - 10:35  MA24.01 - Genomic Evolution Trajectory Depicts Invasiveness Acquisition from Pre-invasive to Invasive Adenocarcinoma  
Chao Zhang, China

10:35 - 10:40  MA24.02 - Genomic Alterations in Lung Adenocarcinoma Precursor Lesions  
Dennis Wigle, USA

10:40 - 10:45  MA24.03 - Biologic Profiling of Pre-Metastatic Niche in Completely Resected Pathological Stage I Non-Small Cell Lung Cancer  
Tomohito Saito, Japan

10:45 - 11:00  MA24.04 - Discussant - MA 24.01, MA 24.02, MA 24.03  
Udayan Guha, USA

11:00 - 11:05  MA24.05 - Baseline Spatial Heterogeneity of T790M in Tyrosine Kinase Inhibitor Naïve EGFR-Mutant Lung Adenocarcinomas  
Michael Cabanero, ON/Canada
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:05 - 11:10</td>
<td><strong>MA24.06</strong> - Long Non-Coding RNA Expression Patterns Delineate Infiltrating Immune Cells in the Lung Tumour Microenvironment</td>
<td>Adam Sage, BC/Canada</td>
</tr>
<tr>
<td>11:10 - 11:15</td>
<td><strong>MA24.07</strong> - A Novel Cis-Acting IncRNA Controls HMGA1 Expression in Lung Adenocarcinoma</td>
<td>Adam Sage, BC/Canada</td>
</tr>
<tr>
<td>11:15 - 11:30</td>
<td><strong>MA24.08</strong> - Discussant - MA 24.05, MA 24.06, MA 24.07</td>
<td>Alice Berger, USA</td>
</tr>
<tr>
<td>11:30 - 11:35</td>
<td><strong>MA24.09</strong> - Synergy Between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small Cell Lung Cancer with an Altered Metabolism</td>
<td>Sarah Best, VIC/Australia</td>
</tr>
<tr>
<td>11:35 - 11:40</td>
<td><strong>MA24.10</strong> - Interrogating the Metabolic Effects of Keap1 Inactivation in Adenocarcinoma</td>
<td>Sarah Best, VIC/Australia</td>
</tr>
<tr>
<td>11:40 - 11:45</td>
<td><strong>MA24.11</strong> - Loss of Tumour Suppressors is Adequate and Sufficient to Drive Lung Cancer in CRISPR/Cas9 Mice.</td>
<td>Paola Marignani, Canada</td>
</tr>
<tr>
<td>11:45 - 12:00</td>
<td><strong>MA24.12</strong> - Discussant - MA 24.09, MA 24.10, MA 24.11</td>
<td>Vladmir Cordeiro De Lima, Brazil</td>
</tr>
</tbody>
</table>

**MS22**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 - 12:00</td>
<td><strong>Biology of the Lung and Lung Cancer</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Topics:</strong> Biology</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Moderation:</strong> M. Meyerson, USA; G. Liu, Canada</td>
<td></td>
</tr>
<tr>
<td>10:30 - 10:45</td>
<td><strong>MS22.01</strong> - Lung Development and Stem Cells</td>
<td>Samuel Rowbotham, USA</td>
</tr>
<tr>
<td>10:45 - 11:00</td>
<td><strong>MS22.02</strong> - Epigenetic Alterations in Lung Cancer Development</td>
<td>Wan Lam, Canada</td>
</tr>
<tr>
<td>11:00 - 11:15</td>
<td><strong>MS22.03</strong> - Non-Coding RNA in Lung Cancer</td>
<td>Sven Diederichs, Germany</td>
</tr>
</tbody>
</table>
MS22.04 - Genomics of Resistance and Response in Lung Cancer
Marc Ladanyi, NY/USA

MS22.05 - Inflammation in Lung Cancer
Katerina Politi, USA

MS22.06 - Transcriptomic-Metabolomic Reprograming as Resistant Mechanism
Patrick Ma, WV/USA

MS23

10:30 - 12:00 What's New in Targeted Therapy?
Topics: Targeted Therapy
Moderation: V. Hirsh, Canada; A. Drilon, USA

10:30 - 10:45 MS23.01 - Novel Combinations of Targeted Therapies
Pasi Jänne, MA/USA

10:45 - 11:00 MS23.02 - Emerging or Rare Targets - Fusions, Mutational Burden Etc
Luis Paz-Ares, Spain

11:00 - 11:15 MS23.03 - Management of CNS Mets in the Era of CNS-Penetrant TKIs (Med Onc and Rad Onco Perspectives)
Marina Garassino, Italy

11:15 - 11:30 MS23.04 - Targeting Driver Oncogenes in Stage 1-3 NSCLC
Helena Yu, NY/USA

11:30 - 11:45 MS23.05 - Role of Immunotherapy in Patients with Molecular Driven NSCLC
Benjamin Besse, France

11:45 - 12:00 MS23.06 - Q&A

MS24

10:30 - 12:00 Global Perspectives on Tobacco Control
Topics: Prevention and Tobacco Control
Moderation: R. Haddad, Brazil; D. Carney, Ireland
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Code</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 - 10:45</td>
<td>MS24.01</td>
<td>Tobacco Control Impacting the Effectiveness and Cost of Cancer Care</td>
<td>Graham Warren, USA</td>
</tr>
<tr>
<td>10:45 - 11:00</td>
<td>MS24.02</td>
<td>Legal Action Against the Tobacco Industry in Europe</td>
<td>Paul Baas, Netherlands</td>
</tr>
<tr>
<td>11:00 - 11:15</td>
<td>MS24.03</td>
<td>The Importance of Physician Involvement in Tobacco Control</td>
<td>Jacek Jassem, Poland</td>
</tr>
<tr>
<td>11:15 - 11:30</td>
<td>MS24.04</td>
<td>Challenges of Tobacco Control in China</td>
<td>Caicun Zhou, China</td>
</tr>
<tr>
<td>11:30 - 12:00</td>
<td>MS24.05</td>
<td>Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>

**MS25**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Code</th>
<th>Topic</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 - 12:00</td>
<td>MS25</td>
<td>Genetic and Prognostic Markers in Mesothelioma; Going Beyond the Histology Subtypes</td>
<td></td>
<td>Room 206 AC</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Topics: Mesothelioma</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Moderation: D. Fennell, UK; A. Mansfield, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30 - 10:45</td>
<td>MS25.01</td>
<td>Impact of Tumor Volume on Outcome: What Are the Limitations?</td>
<td>Anna Nowak, Australia</td>
<td></td>
</tr>
<tr>
<td>10:45 - 11:00</td>
<td>MS25.02</td>
<td>How Should P16, BAP1, and NF2 Mutations Be Integrated in Therapeutic Algorithms?</td>
<td>Francoise Galateau-Salle, France</td>
<td></td>
</tr>
<tr>
<td>11:00 - 11:15</td>
<td>MS25.03</td>
<td>Impact of Innate and Adaptive Tumor Infiltrating Cells on Prognosis</td>
<td>Thomas John, Australia</td>
<td></td>
</tr>
<tr>
<td>11:15 - 11:30</td>
<td>MS25.04</td>
<td>Biomarkers in Clinical Practice: Is It Prime Time?</td>
<td>Harvey Pass, NY/USA</td>
<td></td>
</tr>
<tr>
<td>11:30 - 11:45</td>
<td>MS25.05</td>
<td>Targeting the Micro-RNA: A New Therapeutic Venture</td>
<td>Nick Pavlakis, Australia</td>
<td></td>
</tr>
<tr>
<td>11:45 - 12:00</td>
<td>MS25.06</td>
<td>Q&amp;A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session Name</td>
<td>Topic</td>
<td>Speaker Country</td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>--------------------------------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>------------------</td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td><strong>MS26</strong></td>
<td>From Textbook to Practice Around the World</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Room 205 AC</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Topics: Treatment in the Real World - Support, Survivorship, Systems Research</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Moderation: J. Naidoo, USA; F. Moraes, Brazil</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td>MS26.01 - Translation of Clinical Data to Real World - Asia</td>
<td></td>
<td>Dae Ho Lee, Republic of Korea</td>
<td></td>
</tr>
<tr>
<td>10:45</td>
<td>MS26.02 - Translation of Clinical Data to Real World - North America</td>
<td></td>
<td>Cheryl Ho, BC/Canada</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>MS26.03 - Translation of Clinical Data to Real World - Europe</td>
<td></td>
<td>Fabrice Barlesi, France</td>
<td></td>
</tr>
<tr>
<td>11:15</td>
<td>MS26.04 - Translation of Clinical Data to Real World - Latin America/Africa</td>
<td></td>
<td>Luis Ubillos, Uruguay</td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td>MS26.05 - Panel Discussion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td><strong>MS27</strong></td>
<td>Therapeutic Implications of Staging Issues</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Room 201 BD</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Topics: Treatment of Early Stage/Localized Disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Moderation: J. Edwards, Canada; M. Ito, Japan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td>MS27.01 - Staging of Lymph Nodes in Early Stage NSCLC: Therapeutic Implications</td>
<td></td>
<td>Raymond Osarogiagbon, TN/USA</td>
<td></td>
</tr>
<tr>
<td>10:45</td>
<td>MS27.02 - Invasive Staging in Medically Inoperable Patients Treated with SBRT: Is It Necessary?</td>
<td></td>
<td>Anand Swaminath, Canada</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>MS27.03 - Multiple Lung Nodules: M1, T4 or T3? Are They Really Different?</td>
<td></td>
<td>Frank Detterbeck, CT/USA</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Speaker</td>
<td>Location</td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>-------------------------------------------------------------------------</td>
<td>----------------------------------------------</td>
<td>-------------------</td>
<td></td>
</tr>
<tr>
<td>11:15 - 11:30</td>
<td>MS27.04 - Therapeutic Implications of AJCC 8th Edition T1 Subsets</td>
<td>Laura Donahoe, Canada</td>
<td>Room 203 BD</td>
<td></td>
</tr>
<tr>
<td>11:30 - 11:45</td>
<td>MS27.05 - The Future of Precision Therapy for Localized Lung Cancer</td>
<td>Takashi Seto, Japan</td>
<td>Room 203 BD</td>
<td></td>
</tr>
<tr>
<td>11:45 - 12:00</td>
<td>MS27.06 - Q&amp;A</td>
<td></td>
<td>Room 203 BD</td>
<td></td>
</tr>
</tbody>
</table>

**OA13**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 - 12:00</td>
<td>Therapeutics and Radiation for Small Cell Lung Cancer</td>
<td></td>
<td>Room 203 BD</td>
</tr>
<tr>
<td></td>
<td><strong>Topics:</strong> Small Cell Lung Cancer/NET</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Moderation:</strong> S. Snow, Canada; T. Tsakiridis, Canada</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30 - 10:40</td>
<td>OA13.01 - The Impact of $[^{18}F]$ fludeoxyglucose PET/CT in Small-Cell Lung Cancer: Analysis of the Phase 3 CONVERT Trial</td>
<td>Corinne Faivre-Finn, GB</td>
<td>Room 203 BD</td>
</tr>
<tr>
<td>10:40 - 10:50</td>
<td>OA13.02 - Two Novel Immunotherapy Agents Targeting DLL3 in SCLC: Trials in Progress of AMG 757 and AMG 119</td>
<td>Taofeek Owonikoko, GA/USA</td>
<td>Room 203 BD</td>
</tr>
<tr>
<td>10:50 - 11:00</td>
<td>OA13.03 - Anlotinib as Third-Line or Further-Line Treatment in Relapsed SCLC: A Multicentre, Randomized, Double-Blind Phase 2 Trial</td>
<td>Ying Cheng, China</td>
<td>Room 203 BD</td>
</tr>
<tr>
<td>11:00 - 11:15</td>
<td>OA13.04 - Discussant - OA 13.01, OA 13.02, OA 13.03</td>
<td>Normand Blais, QC/Canada</td>
<td>Room 203 BD</td>
</tr>
<tr>
<td>11:15 - 11:25</td>
<td>OA13.05 - Prophylactic Cranial Irradiation (PCI) for Limited-Stage Small-Cell Lung Cancer: Results from the Phase 3 CONVERT Trial</td>
<td>Cecile Le Pechoux, France</td>
<td>Room 203 BD</td>
</tr>
<tr>
<td>11:25 - 11:35</td>
<td>OA13.06 - Final Report of a Prospective Randomized Study on Thoracic Radiotherapy Target Volumes with Radiation Dosimetric and Pathologic Analyses</td>
<td>Xiao Hu, China</td>
<td>Room 203 BD</td>
</tr>
<tr>
<td>11:35 - 11:45</td>
<td>OA13.07 - Survival Outcomes After Whole Brain Radiotherapy for Brain Metastases in Elderly Patients with Newly Diagnosed Metastatic Small Cell Carcinoma.</td>
<td>Paul Renz, PA/USA</td>
<td>Room 203 BD</td>
</tr>
</tbody>
</table>
11:45 - 12:00  OA13.08 - Discussant - OA 13.05, OA 13.06, OA 13.07
Inga Grills, USA

PC09
10:30 - 12:00  Approaches to Management of Advanced NSCLC  Room 107
Topics: Advanced NSCLC
Moderation: G. Bebb, Canada; Y. Goto, Japan

10:30 - 10:45  PC09.01 - Debate 1: Early vs Delayed Treatment of Asymptomatic Brain Metastases in Wild-Type NSCLC - Early
Qing Zhou, China

10:45 - 11:00  PC09.02 - Debate 1: Early vs Delayed Treatment of Asymptomatic Brain Metastases in Wild-Type NSCLC - Delayed
Walter Curran Jr., USA

11:00 - 11:15  PC09.03 - Discussion

11:15 - 11:30  PC09.04 - Debate 2: Large Cell Neuroendocrine Carcinoma Should Be Treated like NSCLC or SCLC? - NSCLC
Noemi Reguart, Spain

11:30 - 11:45  PC09.05 - Debate 2: Large Cell Neuroendocrine Carcinoma Should Be Treated like NSCLC or SCLC? - SCLC
Scott Laurie, Canada

11:45 - 12:00  PC09.06 - Discussion

ISS16
12:00 - 13:30  Symposium Supported by AbbVie: Biomarker Driven SCLC Treatment: Fact or Fiction?  Plenary Hall

12:00 - 13:30  Biomarker Driven SCLC Treatment: Fact or Fiction?
P3.01
12:00 - 13:00  Advanced NSCLC  Exhibit Hall

P3.01-02 - Patients with a Smaller Primary Tumor and Fewer Metastases Could be Cured Even in Advanced Non-Small Cell Lung Cancer
Takuya Aoki, Japan

P3.01-03 - The Cost Benefit from Second Line Immunotherapy in Metastatic NSCLC: ASCO Value Framework Prospective
Ahmed Badawy, Egypt

P3.01-04 - Immune Checkpoint Inhibitors (ICIs) in NSCLC: Immune Related Adverse Events (irAEs) and Outcomes. A Canadian Single Institution Experience.
Kiran Virik, ON/Canada

P3.01-05 - Mature Progression-Free Survival in Stage IV Non-Small Cell Lung Cancer Patients Treated with Pemetrexed Maintenance Therapy
Marta Batus, IL/USA

P3.01-06 - Concomitant Plasma-Genotyped T790M Positivity and Small Cell Carcinoma Transformation in EGFR-Mutated NSCLC
Sourin Bhuniya, India

P3.01-07 - Outcome and Prognostic Factors in ALK+ve Metastatic Adenocarcinoma of Lung: Single Center Experience from Eastern India
Bivas Biswas, India

P3.01-08 - Gender Differences in Lung Cancer Survival
Marko Jakopovic, Croatia

P3.01-09 - Impact of Urban or Rural Residence on Overall Survival for Patients with Metastatic Non-Squamous NSCLC
Jacqueline Brown, VA/USA

P3.01-10 - Dyspnea as a Prognostic Factor in Hispanic Patients with Non-Small Cell Lung Cancer Cohort
Saul Campos-Gomez, Mexico
P3.01-11 - Depression and Inflammation in Patients with EGFR-Mutated Non-Small Cell Lung Cancer
Andrés Cardona, Colombia

P3.01-12 - EGFR Mutation and Targeted Therapies: Difficulties and Disparities in Access to NSCLC Treatment in Brazil.
Gilberto Castro Jr, Brazil

P3.01-13 - Prognosis of Non-driver, Never Smoker Metastatic Non-Small Lung Cancer (NSCLC)
Anna Chalmers, USA

P3.01-14 - mTORC1 Regulates the Radiosensitivity of NSCLC Cells with Wildtype PI3KCA and KRAS Genes by Affecting EMT
Yuan Chen, China

P3.01-15 - Efficacy of Paclitaxel Plus TS1 Against Non-Small Cell Lung Cancer Previously Treated
Yuh-Min Chen, Taiwan

P3.01-16 - Low Dose Apatinib Combined with EGFR-TKI in Treating Advanced NSCLC After First-Generation EGFR-TKIs Treatment Failure
Mingda Chen, China

P3.01-17 - Long Survivors with Advanced Lung Cancer - Efficacy and Tolerability of Nivolumab
Ewa Chmielowska, Poland

P3.01-18 - Comparison of PD-L1 Immunohistochemical Assays and Clinical Response to Anti PD-1 Checkpoint Inhibitors in Patients with Lung Cancer
Jang Ho Cho, Republic of Korea

P3.01-19 - Sequencing of Ramucirumab+Docetaxel Post-Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer Patients
Cliff Molife, USA

P3.01-20 - Advanced NSCLC Treatment and Outcomes After Nivolumab
Girish Mallesara, NSW/Australia

P3.01-21 - Metastatic Lung Carcinoma – An Institutional Experience from Eastern India
Saroj Das Majumdar, India

P3.01-22 - An Exploratory Analysis of PD-L1 Expression and Smoking History in a Cohort of Advanced Non-Small Cell Lung Cancer Patients
Marios Decatris, UK

**P3.01-23 - Imaging Modalities for Surveillance and Follow-Up of Patient with Lung Cancer After Adjuvant Chemotherapy**
Aya El Helali, UK

**P3.01-24 - The Importance to Switch from EGFR-TKI to Cytotoxic Chemotherapy for EGFR Mutation-Positive Adenocarcinoma**
Daisuke Eriguchi, Japan

**P3.01-25 - Feasibility of Moderate Hypofractionated Thoracic Irradiation for Non-Small Cell Lung Cancer Patients with Very Limited Lung Function**
Maurice Dantes, Germany

Corinne Faivre-Finn, UK

**P3.01-27 - Characterization and Sensitization of Non-Small Cell Lung Cancer Cell Line Variants Selected for Resistance to Osimertinib**
Peter Ferguson, Canada

**P3.01-28 - The Clinical Impact of Comprehensive cfDNA Genomic Testing in Lung Cancer**
Laila Roisman, Israel

**P3.01-29 - St. Iv Lung Adenocarcinoma Treated by First-Line EGFR-Tyrosine Kinase Inhibitors-Survival, EGFR Mutation, Histologic Subtype**
Tomasz Gil, Poland

**P3.01-30 - Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) in Japan**
Yasushi Goto, Japan

**P3.01-31 - Prognostic Factors in Patients with Resected Pathological N2 Non-Small Cell Lung Cancer**
Tatsuya Goto, Japan

**P3.01-33 - EGFR Mutation in Patients with NSCLC and Its Relationship Between Survival and Clinicopathological Features: An Update Analysis**
Mahmut Gumus, Turkey
P3.01-34 - Short Hydration Regimen with a Modified Dose of Magnesium Supplementation for Lung Cancer Patients Receiving Cisplatin-Based Chemotherapy
Tetsunari Hase, Japan

P3.01-35 - Outcomes in Advanced Non-Small Cell Lung Cancer After Discontinuation of PD-1 Checkpoint Inhibitor Due to Toxicity. A Retrospective Study
Jonathon Hill, Australia

P3.01-36 - Prognostic Factors in Elderly Patients with Advanced Non-Small Cell Lung Cancer
Marta Honorio, Portugal

P3.01-37 - Phase II Study of Amrubicin Plus Erlotinib in Previously Treated, Advanced Non-Small Cell Lung Cancer Patients with Wild-Type EGFR: TORG 1320
Shinobu Hosokawa, Japan

P3.01-38 - Therapeutic Effects of FMNP-MSC for Hyperthermia on Lung Cancer A549 in Nude Mice
Runlei Hu, China

P3.01-39 - Analysis of Acquired EGFR T790M Mutation in Patients with Non-Small Cell Lung Cancer Who Received Icotinib Progress
Chunwei Xu, China

P3.01-40 - Treatment of Super Elderly Patients for Non-Small Cell Lung Cancer in Japan
Tatsuya Ibe, Japan

P3.01-41 - Anatomical and Clinical Basis of #11 LN by Systematic Bilateral Mediastinal Nodal Dissection for Left Lung Cancer through Median Sternotomy
Shingo Ikeda, Japan

P3.01-42 - Phase II Trial Allowed Surgery After Induction Chemotherapy of CBDCA+PTX, Bevacizumab in Patients with Stages IIIA-IV Nonsquamous NSCLC
Kazuhiro Imai, Japan

P3.01-43 - Predictive Value of Computed Tomography Characteristics for Nivolumab Response in Pretreated Non-Small Cell Lung Cancer
Hisao Imai, Japan

P3.01-44 - CYFRA 21-1 As a Predictor to Response to Chemotherapy and Overall Survival in Patients with Advanced NSCLC
Kashif Iqbal, Pakistan
P3.01-45 - Multifactorial Gene Alterations in EGFR Bypass Pathway are Induced by Afatinib in T790M-Mutant NSCLC Resistant to Osmertinib
Hidenobu Ishii, Japan

P3.01-46 - Prognostic Utility of Advanced Lung Cancer Inflammation Index (ALI) in Thoracic Malignancies: A Meta-Analysis
Syed Jafri, TX/USA

P3.01-47 - Clinical Characteristics and Outcome for Patients with Advanced Lung Adenocarcinoma Treated with First-Line Pemetrexed Plus Platinum
Xue Ji, China

P3.01-48 - The Efficiency of Low-Dose Apatinib in Treatment of Advanced Lung Squamous Cell Carcinoma
Yu-Ming Jia, China

P3.01-49 - Efficiency of Low-Dosage Apatinib Monotherapy in Treatment of Advanced Lung Squamous Cell Carcinoma
Hua Jiang, China

P3.01-50 - Identification of EGFR Mutational Profile in Lung Cancer Moroccan Cohort
Houda Kaanane, Morocco

P3.01-51 - Outcomes with Systemic Chemotherapy in Advanced NSCLC Patients with Performance Status 2 and Above and without Driver Mutation
Harish Kancharla, India

P3.01-52 - The Role of Serum Carcinoembryonic Antigen to Predict the Response of Treatment in Non-Small Cell Lung Cancer Patients
Muhammed Ali Kaplan, Turkey

P3.01-53 - Comparison of the Treatment Efficacy of Osimertinib in Young and Elderly Patients with T790M-Positive NSCLC
Yasuhiro Kato, Japan

P3.01-54 - A Historical Comparison of Patients with Advanced NSCLC Harboring Uncommon EGFR Mutations Before and After the Approval of Afatinib in Japan
Takahisa Kawamura, Japan

P3.01-55 - SF2: A PCYT-2 Inhibitor Prototype is Capable of Inducing Citotoxicity in NSCLC
Bárbara Kawamura, Brazil
P3.01-56 - Hyperprogression and Pseudoprogression in Patients with Non-Small Cell Lung Cancer on Checkpoint Blocking Immunotherapy
Seoree Kim, Republic of Korea

P3.01-57 - Real-World (RW) Predictors of Immuno-Oncology (IO) vs Chemotherapy (C) Use in Advanced Non-Small Cell Lung Cancer (aNSCLC)
Bruce Feinberg, OH/USA

P3.01-58 - Relative Abundance of EGFR Mutations in Plasma Predicts Tumor Response to EGFR-TKI in Advanced Lung Adenocarcinoma
Yuping Li, China

P3.01-59 - Comparison of Lobectomy, Segmentectomy and Wedge Resection for Early Stage NSCLC: A Direct and Network Meta-Analysis
Wang Liang, China

P3.01-60 - A Novel MET D1246H Mutation After Progression of EGFR-TKI/MET Inhibitor Combined Therapy in a NSCLC Patient with Acquired MET Amplification
Ying Liang, China

P3.01-61 - EGFR and KRAS Mutational Status and Significance in Greek Patients with Advanced Non-Small Cell Lung Cancer
George Fountzilas, Greece

P3.01-62 - A New Method for Non-Invasive Prediction of Radiotherapy: SDH5 Depletion Enhances Radiosensitivity by Regulating P53
Jun Liu, China

P3.01-63 - Baseline Biomarkers for Outcome of Advanced NSCLC Patients Receiving Anti-PD1/PD-L1 Treatment—Data from a Chinese Population
Shun Lu, China

P3.01-64 - Preliminary Data of Diverse Therapies in Patients with Advanced Non-Small-Cell Lung Cancer Harbouring RET-Rearrangement
Chang Lu, China

P3.01-65 - First-Line Radical Local Therapy May Provide Additional Survival Gain for Patients with EGFR-Mutant Metastatic NSCLC Receiving TKIs
Jingbo Wang, China

P3.01-66 - Clinicopathological Characteristics and Mutation Status of Pulmonary Invasive Mucinous Adenocarcinoma
Fangliang Lu, China
P3.01-67 - Integrated Network Analysis to Understand the Potential Mechanisms of Hydroxychloroquine in Non-Small Cell Lung Cancer Treatment
Jingyun Chen, China

P3.01-68 - Early SBRT to the Primary Tumor May Overcome the Icotinib Resistance in Patients with Advanced NSCLC Harboring EGFR Mutations
Dongqing Lv, China

P3.01-69 - Stereotactic Ablative Radiotherapy Improves Progression-Free Survival & Local Control in Oligometastatic Lung Cancer Patients
Federico Maldonado, Mexico

P3.01-70 - Meta-Analysis of Metformin in Combination with Platinum Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer
Kristen Marrone, USA

P3.01-71 - Results of Extended Resection in T4 Non-Small Cell Lung Cancer
Takeshi Matsunaga, Japan

P3.01-72 - Pulmonary Resection in a Prone Position for Lung Cancer Invading the Spine: Two Cases Report
Shunsaku Miyauchi, Japan

P3.01-73 - Talc Versus Minocycline and OK-432 Pleurodesis for Malignant Pleural Effusion.
EISUKE Mochizuki, Japan

P3.01-74 - Clinical and Radiological Predictors of Efficacy to Nivolumab in NSCLC: A Multi-Institutional, Retrospective Cohort Study.
Rebecca Moor, QLD/Australia

P3.01-75 - RELAY+, an Exploratory Study of Gefitinib with Ramucirumab in Untreated Patients with EGFR Mutation-Positive Metastatic NSCLC
Makoto Nishio, Japan

P3.01-76 - Clinical Background and Response to Chemotherapy in NSCLC Patients with MET Exon14 Skipping Mutation or High MET Gene Copy Number
Kaname Nosaki, Japan

P3.01-77 - Clinical Characteristics of Korean Lung Cancer Patients with Programmed Death-Ligand 1 Expression
In-Jae Oh, Republic of Korea

P3.01-78 - The Cytology Samples and Plasma Specimens were Feasible for the EGFR Molecular Testing.
Tatsuo Ohira, Japan

P3.01-79 - Intracerebral Efficacy of Immune Check-Point Inhibitors in NSCLC Patients with Brain Metastases
Fumiyoshi Ohyanagi, Japan

P3.01-80 - Retrospective Analysis of the Impact of EGFR T790M Mutation Detection by Re-Biopsy in Patients with NSCLC Harboring EGFR Mutations.
Naoko Okura, Japan

P3.01-81 - Long-Term Outcome of Surgically Resected Unsuspected N2 Lung Adenocarcinoma
Byung Jo Park, Republic of Korea

P3.01-82 - Survival Impact of Surgery in the Treatment of Stage IIIB-IVA Non-Small Cell Lung Cancer
Ji Young Park, Republic of Korea

P3.01-83 - Use of Blood Outgrowth Endothelial Cells as a Cellular Carrier for Oncolytic Vesicular Stomatitis Virus in Preclinical Models of NSCLC
Manish Patel, MN/USA

P3.01-84 - The Association of CDKN2A Gene Mutation with Clinicopathological Features and Prognosis in Advanced Lung Cancer Patients
Xiujuan Qu, China

P3.01-85 - Real-World Gefitinib 1st Line Treatment of Patients with Advanced NSCLC and EGFR Mutations - Serbian Single Center Experience
Davorin Radosavljevic, Serbia

P3.01-86 - Treatment Outcomes with Reduced Frequency of Nivolumab Dosing as Second-Line Therapy in Patients with Advanced NSCLC
Shabnam Rehman, USA

P3.01-87 - Efficacy and Safety of Pembrolizumab in Non-Small Cell Lung Cancer in Our Institution: A Retrospective Study
Nobuhiko Saijo, Japan
P3.01-88 - Clinical and Molecular Analysis of Long-Term Survivors with Advanced Non-Small Cell Lung Cancer: A Multicenter Experience in Madrid
Maria Sereno Moyano, Spain

P3.01-89 - Upfront Surgery Versus Neoadjuvant Treatment Followed by Surgery in Pathologic N2 Non-Small Cell Lung Cancer
Byoung Yong Shim, Republic of Korea

P3.01-90 - A Phase II Study Evaluating Continuation of EGFR-TKIs Beyond Progressive Disease Followed by the Addition of CDDP+PEM+Bev
Satoshi Shoji, Japan

P3.01-91 - Computing the Impact of Immuno therapy on the Non-Small Cell Lung Cancer (NSCLC) Therapeutic Landscape
George Simon, TX/USA

P3.01-92 - Blood Test Parameters as Prognostic Factors In EGFR-Mutated Non-Small Cell Lung Cancer Treated with TKIs
Jelena Spasic, Serbia

P3.01-93 - Osimertinib-Related Hematological and Pulmonary Toxicities in Advanced NSCLC Patients: Combined Analysis of Phase III Trials
Sriman Swarup, TX/USA

P3.01-94 - Safety and Efficacy of First-Line Pemetrexed Versus Bevacizumab-Containing Regimens in Advanced Non-Small Cell Lung Cancer
Konstantinos Syrigos, Greece

P3.01-95 - EGFR Genotype as a Predictor of Survival in EGFR Mutant Non-Small Cell Lung Cancer
Konstantinos Syrigos, Greece

P3.01-96 - Clinical Characteristics of Non-Small Cell Lung Cancer Harboring Mutations in Exon 20 Of EGFR or HER2
Masayuki Takeda, Japan

P3.01-97 - Which is Better Prognostic Factor, PS, Inflammatory Marker, or PD-L1 Expression in Treating NSCLC with Nivolmab; A Retrospective Analysis
Akihiro Tamiya, Japan

P3.01-99 - Effect of Pembrolizumab on Patients Harboring Uncommon Epidermal Growth Factor Receptor Mutations
Yoshihiko Taniguchi, Japan
P3.01-100 - Risk of Gastrointestinal and Hepatic Toxicities in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Osimertinib
Kyaw Thein, TX/USA

P3.01-101 - A Retrospective Study of Lung Cancer that has Progressed to Brain Metastasis Alone
Kenjiro Tsuruoka, Japan

P3.01-102 - Potential Predictors of Unexpected Readmission After Lung Resection
Shinsuke Uchida, Japan

P3.01-103 - Efficacy of Crizotinib in Chinese Non-Small Cell Lung Cancer Patients with Brain Metastasis: A Multicenter Retrospective Study
Shouzheng Wang, China

P3.01-104 - EGFR-RAD51 Fusion Variant in Lung Adenocarcinoma and Response to Erlotinib: A Case Report
Chunwei Xu, China

P3.01-105 - Retrospective Analysis of Efficacy and Safety in Chinese Elderly Patients Treated with Nab-Paclitaxel
Shuhang Wang, China

P3.01-106 - Real-World Data to Evaluate the Clinical Benefit of NGS for Directing Lung Adenocarcinoma Treatment
Zhaoxia Wang, China

P3.01-107 - Correlation Study of Bone Metastasis and Cholesterol Level in Patients with Lung Adenocarcinoma
Yan Wang, China

P3.01-108 - Oncologist Treatment Considerations and Selection in EGFR M+ NSCLC
Thomas Wehler, Germany

P3.01-109 - Real-World Patient-Reported Outcome Assessment of Patients with Metastatic Non-Small Cell Lung Cancer
Loretta Williams, USA

P3.01-110 - Defining Aggressive Disease in Patients with Advanced NSCLC Receiving Second-Line Treatment: A Systematic Review
Cliff Molife, USA

P3.01-111 - Efficacy and Safety of Cytotoxic Drug Chemotherapy After First-Line EGFR-TKI in Elderly Patients with NSCLC Harboring Sensitive EGFR Mutations
Yutaka Yamada, Japan

P3.01-112 - The Prognosis of Lung Cancer Patients with Unexpected Malignant Pleural Effusion and Without Pleural Dissemination Detected at Thoracotomy
Takashi Yamamichi, Japan

P3.01-113 - A Multicenter Survey of One Year Survival Among Chinese Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer (CTONG1506)
Qing Zhou, China

P3.01-114 - Dissociation of Heart and Great Vessels for Long Tracheal Tumors and Lung Cancer Invaded Trachea: The Chinese Experience.
Qinghua Zhou, China

P3.01-115 - Liposomal Paclitaxel Versus Gemcitabine: Which is Better?
Xiangdong Zhou, China

P3.01-116 - Randomized Clinical Trial on Three Different Platinum Based Chemotherapy in Advanced NSCLC in Bangladeshi Population
Ferdous Begum, Bangladesh

P3.03

12:00 - 13:00 Biology

P3.03-01 - BRAF V600 and Non-V600 Mutations in Chinese Lung Cancer
Yang Gao, China

P3.03-02 - Single-Cell RNA-Seq in Human Lung Cancer
Jinhong Kim, NS/Canada

P3.03-03 - Differential Microbiota Features in Lung Tumor and Adjacent Normal Tissues in Lung Cancer Patients
Qixing Mao, China

P3.03-04 - Is the Ciliary Function of the Lesion Bronchus Maintained in Patients with Lung Cancer?
Toshiyuki Sawa, Japan

P3.03-05 - Comparative Transcriptomic Analysis of Lung-iPSC, NSCLC, and SCLC: Potential Implications for iPSC Modeling of Lung Cancer
Vivek Shukla, MD/USA

P3.03-06 - Differentially Expressed microRNAs in Lung Adenocarcinoma Invert Effects of Copy Number Aberrations of Prognostic Genes
Tomas Tokar, Canada

P3.03-07 - Co-Occurring Genomic Alterations in EGFR Altered Chinese Lung Adenocarcinoma Patients
Minghui Wang, China

P3.03-08 - Analysis of ESR1 Mutation Spectrum from Non-Small-Cell Lung Cancer in Chinese Patients
Chunwei Xu, China

P3.03-09 - Molecular Spectrum of KIT Mutations Detection in Chinese Non-Small Cell Lung Cancer Patients
Chunwei Xu, China

P3.03-10 - Transcriptomic Differences Between Early and Late Stage Lung Adenocarcinoma
Dongsheng Yue, China

P3.03-11 - Lung Cancer Stem Cells on Immune Modulation in Tumorous Microenvironment
Huei-Wen Chen, Taiwan

P3.03-12 - Cyclic Mechanical Strain and Myoferlin Modulates Lung Adenocarcinoma Cell Proliferation and Erlotinib Resistance
YouJin Cho, USA

P3.03-13 - Downregulation of miRNA-506 Mediates EGFR-TKI Resistance Through Inducing Sonic Hedgehog Signaling in Non-Small-Cell Lung Cancer Cell Lines
Inamul Haque, KS/USA

P3.03-14 - Downregulation of FOXM1 Inhibits Tumor Proliferation, Colony Formation and Spheroid Formation of Non-Small Cell Lung Cancer
Yoichi Otaki, Japan

P3.03-15 - Lung Cancer Regulation of Glucose Metabolic Stress Response
Laila Roisman, Israel
P3.03-16 - 3D Morphometric Detection of Mismatch Repair Deficiency in Human Lung Adenocarcinoma Cell Lines using the Cell-CT® Platform
Daniel Sussman, AZ/USA

P3.03-17 - Roles of α7nAchR Signaling in Lung Cancer
Yu-Feng Wei, Taiwan

P3.03-18 - Collagen Type XI Promotes Lung Adenocarcinoma Dissemination Via Integrin α2 and DDR1
Cédric Zeltz, ON/Canada

P3.03-19 - The Lysyl Oxidase like-1 Promotes NSCLC Tumorigenecity Through Increased Matrix Reorganization and Stiffness
Cédric Zeltz, ON/Canada

P3.03-20 - Circulating Tumor Cell Clustering in Vitro Short-Term Culture Correlates with Poor Survival and Allows Monitoring Response to Treatment
Govind Babu, India

P3.03-21 - CXCR4 Overexpression is Associated with Poor Survival Outcome After Recurrence in Early Stage Non-Small Cell Lung Cancer Patients
Andrea Fung, Canada

P3.03-22 - IL-1β as a New Early Predictive Biomarker for Non-Small Cell Lung Cancers Outcome
Carlotta Giorgi, Italy

P3.03-23 - A Propensity Score Matching Cohort Study on Prognosis of the Diversity of MUC1 Expression in Patients with Lung Adenocarcinoma
Chundong Gu, China

P3.03-24 - Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer Staging
Greg Haro, USA

P3.03-25 - Squamous Cell Carcinoma-Associated Bronchial Dysplasias Demonstrate Altered T-helper Lymphocyte Differentiation
Daniel Merrick, CO/USA

P3.03-26 - Tumor Immune Microenvironment in NSCLC is Predictive of Prognosis After Surgery
Åsa Öjlert, Norway
P3.03-27 - Somatic BRCA1/2 Mutations in Advanced NSCLC Patients: Description of a Sub-Population from the Ongoing Unicancer SAFIR02-Lung / IFCT-1301 Trial
Jordi Remon, France

P3.03-28 - LKB1 Mutation Status is Associated with Poor Radiation Outcome in Patients with Non-Small Cell Lung Cancer
Piyada Sitthideatphaiboon, TX/USA

P3.03-29 - The Prognostic Effect of Tumor Mutation Burden and Smoking History in Resected EGFR Mutant Non-Small Cell Lung Cancer
Hadas Sorotsky, ON/Canada

P3.03-30 - Clinical Significance of Urothelial Carcinoma Associated 1 in Lung Cancer
Hongyu Wu, China

P3.04

12:00 - 13:00 Immunooncology

P3.04-01 - Combined Plasma cfDNA Mutations and a Serum Proteomic Signature may Identify Non-Responders to Anti PD-1 Treatment in NSCLC
Arno Amann, Austria

P3.04-02 - Early Plasma ctDNA Response Anticipates Clinical Response to First-Line Immunotherapy in Advanced NSCLC
Mark Awad, MA/USA

P3.04-03 - Association of Functional Polymorphism in CTLA-4 Gene with Survival in Non-Small Cell Lung Cancer: A Brazilian Study
Marcelo Balancin, Brazil

P3.04-04 - Prognostic Value of MHC-I, PD-L1 and CD8+ TILs Expressions in Patients with Surgically Resected Non-Small Cell Lung Cancer
Xu Wang, China

P3.04-05 - Programmed Death-Ligand 1 of Cytology Specimens as a Promising Method for Maker Evaluation in Patients of Non-Small Cell Lung Cancer
Zhengwei Dong, China

P3.04-06 - Prognostic Significance of Serum CXCL12 Level in Patients with Surgical Resected Lung Adenocarcinoma
Jung-Jyh Hung, Taiwan
P3.04-07 - Correlation Between PD-L1 Expression and Expression of CDK4 and SPOP in Non-Small Cell Lung Cancer
Masaaki Inoue, Japan

P3.04-08 - Identifying Resistance to Immune Checkpoint Inhibitors by Screening for PD-L1 and MHC I Expression on CTCs in Pts with NSCLC
Ticiana Leal, USA

P3.04-09 - Analysis of Repertoire Features of T Cell Receptor in Treat-Naïve EGFR Wild-Type Lung Cancer Patients by High-Throughput Sequencing
Yangyang Liu, China

P3.04-10 - Monocytes and Neutrophils as Predictive Markers of Response to Immune Checkpoint Inhibitors in Metastatic Non-Small Cell Lung Cancer
Kaushal Parikh, USA

P3.04-11 - The Influence of Circulating Tumor DNA Analysis on Response to Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)
Nir Peled, Israel

P3.04-12 - Prognostic and Predictive Role of Peripheral Blood Biomarkers in NSCLC Patients Treated with Checkpoint, a Single-Center Experience.
Domenico Galetta, Italy

P3.04-13 - PD-L1-Gene Expression by nCounter Correlates with PD-L1 Protein Expression in Advanced Non-Small Cell Lung Cancer (NSCLC)
Noemi Reguart, Spain

P3.04-14 - TMB and Immune Checkpoint Inhibitor Gene Expression are Unrelated in NSCLC Patients
Christopher Szeto, CA/USA

P3.04-15 - IDO and Tim3 Gene Expression is Correlated in NSCLC Patients with Low PDL1 Gene Expression
Christopher Szeto, USA

P3.04-16 - A Seven-Gene Expression Signature Reveals Unique Immune-Phenotypes Related to Major Oncogenic-Drivers in NSCLC
Cristina Teixidó, Spain

P3.04-17 - Cost-Effectiveness of Atezolizumab for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) in Canada
Umang Ondhia, ON/Canada

P3.04-18 - The Efficacy and Safety of Solid Tumors Combination Therapy with Immune Checkpoint Inhibitor: A Systematic Review and Meta-Analysis
YiMing Weng, China

P3.04-19 - Do Advanced Lung Cancer Patients Derive Similar Survival Benefits from Immunotherapy? A Systematic Review and Meta-Analysis
Jacques Raphael, ON/Canada

P3.04-20 - Correlation of Immune-Related Adverse Events and Response from Immune Checkpoint Inhibitors in Patients with Advanced NSCLC
Mike Sung, Canada

P3.04-21 - Antibiotics Attenuate the Clinical Benefit of Anti-PD-(L)1 Immunotherapies in Chinese Patients with Advanced Non-Small Cell Lung Cancer
Sha Zhao, China

P3.04-22 - Response of Brain Metastases in Patients with Non-Small Cell Lung Cancer Treated with Immunotherapy and Brain Directed Radiotherapy
Alessandra Curioni Fontecedro, Switzerland

P3.04-23 - Phase 1b/2 Study to Evaluate Novel Combinations with Oleclumab (MEDI9447) in Previously Treated Advanced EGFRm NSCLC
Naiyer Rizvi, NY/USA

P3.04-24 - EMPOWER-Lung 2: Cemiplimab and Ipilimumab ± Chemotherapy vs Pembrolizumab in Advanced NSCLC with PD-L1 ≥50%, a Phase 3 Study
Naiyer Rizvi, NY/USA

P3.04-25 - EMPOWER-Lung 3: A Phase 3 Study of Cemiplimab, Ipilimumab and Chemotherapy in Advanced NSCLC with PD-L1 <50%
Naiyer Rizvi, NY/USA

P3.04-26 - EMPOWER-Lung 4: A Phase 2 Study of Cemiplimab Plus Ipilimumab in the Second-Line Treatment of Advanced NSCLC with PD-L1 <50%
Naiyer Rizvi, NY/USA

P3.04-27 - An Allogeneic Tumor Cell Lysate Vaccine Induces Immune Responses to Lung Cancer Associated Antigens: Preliminary Results of a Phase II Study
David Schrump, USA
P3.04-28 - Can Ipilimumab Restore Immune Response in Advanced NSCLC After Progression on Anti PD1/PDL1 Agents?
Michal Sternschuss, Israel

P3.04-29 - Efficacy of Re-Treatment with Immune Checkpoint Inhibitors in Patients with Pretreated Advanced Non-Small Cell Lung Carcinoma
Takayuki Takahama, Japan

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Presenter, Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00</td>
<td>Nursing and Allied Professionals</td>
<td>Telephone Preassessment Clinic Incorporating Holistic Needs</td>
<td>Vanessa Beattie, UK</td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td>Expectations, Standards and Performance Framework to Support the Lung Cancer Support Nurse in Lung Foundation Australia</td>
<td>Vanessa Brunelli, Australia</td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td>Lung Cancer Clinical Nurse Specialist &amp; Palliative Care Nurse Specialist - A Dual Role</td>
<td>Karen Clayton, UK</td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td>Massage Chair Encounters Favorably Impact Outpatient Oncology RN’s Perceived Level of Stress, BP, HR</td>
<td>Mary Ellen Hand, USA</td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td>Can Improving Working Partnerships with Primary Care Prevent Avoidable Emergency Admissions for Patients with Lung Cancer?</td>
<td>June Morley, UK</td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td>Receiving a Diagnosis of MESOthelioma (RADIO Meso): Recommendations for Practice to Improve the Patient Experience</td>
<td>Bethany Taylor, UK</td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td>Multidisciplinary Supportive Care Assessment in Lung Cancer - A Case Study Example</td>
<td>Faye Dickinson, UK</td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td>Pain Management in Lung Cancer</td>
<td>Abdallah El Meziane, Morocco</td>
</tr>
</tbody>
</table>

Wednesday, September 26, 2018
P3.07-09 - Characterization of the Nutritional Status in Lung Cancer Patients: A Retrospective Study
Henrique Queiroga, Portugal

P3.07-10 - What Do People Living with Lung Cancer Want and Need from the Recovery Package
Josie Roberts, UK

P3.07-11 - Survivorship After Lung Cancer Surgery - SOLACE - A Macmillan Funded Project
Charlotte Merriman, UK

P3.07-12 - Improving Cardiac Tamponade Outcomes Through Less Invasive Interventions and Earlier Recognition
Kristie Murphy, NY/USA

P3.07-13 - Non-Oncology Provider Immunotherapy Needs Assessment
Enza Nguyen, CA/USA

P3.07-14 - Collaborations of Pharmacists with Lung Cancer Treatment by Prepared Patients Controlled Analgesia (PCA) for Perioperative Pain Control
Kumiko Tani, Japan

P3.08 - Oligometastatic NSCLC

12:00 - 13:00

P3.08-01 - Treatment Outcomes in Oligometastatic Disease of Non-Small Cell Lung Cancer: A Single Center Experience
Pınar Akın Kabalak, Turkey

P3.08-02 - Oligometastatic Non-Small Cell Lung Cancer Patients Treated with Stereotactic Body Radiotherapy (SBRT), a Single Institution Experience
Davide Franceschini, Italy

P3.08-03 - Stereotactic Radiotherapy of Lung Cancer with Synchronous Bilateral Noduli or Oligometastatic Disease
Tine Schytte, Denmark

P3.08-04 - OMEGA, A Randomized Trial of Local Ablative Therapy Vs. Conventional Treatment in Oligometastatic NSCLC - Trial in Progress
Maurizio Infante, Italy
P3.08-05 - Stereotactic Body Radiation Therapy (SBRT) Outcomes in Elderly Patients with Lung Oligometastases
Luis Larrea, Spain

P3.08-06 - Long-Term Survival for Brain-Only Oligometastatic NSCLC Patients Treated with Ablative Therapy (AT): Prognostic Factors
Oscar Juan-Vidal, Spain

P3.08-07 - An Institution Review of Outcomes of Lung Stereotactic Body Radiotherapy in Various Oligometastatic Disease States
Brendan Chia, Singapore

P3.08-08 - Outcomes of Pulmonary Metastasectomy in Breast Cancer: Prognosis Based on the Metastatic Lung Tumor Study Group of Japan
Makoto Endoh, Japan

P3.08-09 - Surgical Resection of Pulmonary Oligo-Recurrence of Non-Small Cell Lung Cancer
Yoshitaka Kitamura, Japan

P3.08-10 - A Retrospective Study of Oligo-Recurrence in Patients with Resected Non-Small Cell Lung Cancer
Taku Nakagawa, Japan

P3.08-11 - Differences in Evaluations of Early Thorax CT’s Post Lung Stereotactic Body Radiotherapy (SBRT)
Fazilet Oner Dincbas, Turkey

P3.08-12 - Long-Term Outcome After Adrenalectomy for Isolated Adrenal Metastasis in Otherwise Operable Patients with NSCLC - Two Institutions Study
Danail Petrov, Bulgaria

P3.08-13 - Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Lung Nodules: A Single Institution Series
Rodney Wegner, USA

P3.08-14 - Long-Term Survival Following Surgical Resection of Isolated Brain Metastasis in Non-Small Cell Lung Cancer.
Wen-jui Wu, Taiwan

P3.08-15 - Lung Squamous Cell Carcinoma with Solitary Ocular Metastasis, Successful Treatment: An Interesting and Rare Case Report
Ye Guo, China
P3.08-16 - Prognostic Value of PDL-1 Expression and Correlation Between Primary Tissue and Brain Metastases in Oligometastatic NSCLC
Vimal Krishnan, Canada

P3.08-17 - Paediatric Motion Management Solutions for Particle Therapy Based Thoracic Stereotactic Ablative Body Radiotherapy (SABR)
Fiona Hegi-Johnson, Australia

P3.08-18 - Changing Resistance Mechanisms in Rebiopsies of ALK-Positive NSCLC During Multiple Lines of Therapy: ALK/BRAF-Mutations Followed By EMT
Edyta Urbanska, Denmark

P3.08-18a - MR Perfusion and Spectroscopy to Distinguish Radiation Necrosis from Tumor Progression for Brain Metastases Treated with SRS
Christel de Pooter, Belgium

P3.09-01 - PDL1 Profile of Filipino Lung Adenocarcinoma Patients Show Moderate Positivity and Low EGFR Correlation
Francisco III Heralde, Philippines

P3.09-02 - Utilization of Laboratory Developed Tests for PD-L1 Evaluation is Dependent on Tumor Type
Jingxin Qiu, NY/USA

P3.09-03 - Alteration of Gut Microbiome in Lung Cancer Patients
Jun Chen, China

P3.09-04 - Assessment of PD-L1 Expression in Cytology Samples: An Analysis of 263 Consecutive NSCLC Biopsies.
Peter Illei, MD/USA

Cristian Ortiz-Villalón, Sweden

P3.09-06 - The Link Between Tumor Promoting Fibrous Microenvironment and Immunosuppressive Microenvironment in Stage I Lung Adenocarcinoma
P3.09-07 - Immunohistochemical Expression of Programmed Death-Ligand 1 in Diabetic Patients vs Non-Diabetics with Non-Small Cell Lung Cancer
Negar Rassaei, USA

P3.09-08 - Tumor Heterogeneity and Molecular Profile of NSCLC in Thai Population
Thanayan Reungwetwattana, Thailand

P3.09-10 - Circulating Cell-Free DNA (cfDNA) Molecular Profile of Thai NSCLC Patients Using Difference Variant Frequency of NGS
Nareenart Iemwimangsa, Thailand

P3.09-11 - Genomic Organization at Large Scales (GOALS) within Nuclei and Cell Sociology for Predicting Lung Cancer Outcomes
Calum Macaulay, Canada

P3.09-12 - Molecular and Immunohistochemical Correlates of RB1 Inactivation in Small Cell Lung Carcinoma
Navin Mahadevan, MA/USA

P3.09-13 - Molecular Profiling Suggests the Different Mechanisms Among Local Invasiveness in Resected Human Lung Adenocarcinoma
Toshi Menju, Japan

P3.09-14 - Pathobiology of Notch2 in Lung Cancer
Yamato Motooka, Canada

P3.09-15 - Genetic Profiling of Idiopathic Pulmonary Fibrosis Associated Non-Small Cell Lung Cancer by Targeted Next-Generation Sequencing
Kohei Otsubo, Japan

P3.09-16 - Transcriptome Profiling for Subtyping NSCLC: Off the Beaten Path (Ologist)
Lars Petersen, Canada

P3.09-17 - Molecular Profile in Lung Adenocarcinoma. A Multicenter Study in Cordoba, Argentina.
Norma Pilnik, Argentina

P3.09-18 - Identification of MET exon 14 Skipping Mutations by FusionPlex™ Solid Tumor Panel
Laura Tafe, NH/USA
P3.09-19 - Matched Thai Lung Cancer Patients Tissue and cfDNA Molecular Profile by NGS  
Narumol Trachu, Thailand

P3.09-20 - A Simple and Versatile Next-Generation Sequencing Technology for Co-Detection of RNA Structural Variants and DNA Mutations in Lung Cancer  
Huiping Zhu, USA

P3.09-21 - Mixed Mucoepidermoid Carcinoma and Adenocarcinoma of the Lung: A Case Report and a Literature Review  
Yu-Deok Choi, Republic of Korea

P3.09-22 - Correlation Between Maximum Tumour Diameter Measurement on CT-Scan and Histopathological Specimen: An Indian Experience  
Manoj Gowda, India

P3.09-23 - Accuracy and Reproducibility of Touch Imprint Cytology in Resected Lung Cancer  
Masatoshi Kakihana, Japan

P3.09-24 - The Concordance of Histological Diagnosis from Transbronchial Biopsy and Resected Specimen of Lung Cancers  
Yoshiteru Kidokoro, Japan

P3.09-25 - Survival Analysis in Young Adults with Lung Carcinoma  
Jessica Nicolau, USA

P3.09-26 - Concordance of Surgical Resections and Fine Needle Biopsy-Derived Cell Block Sections for PD-L1 22C3 Immunohistochemistry  
Joerg Schwock, Canada

P3.09-27 - Histopathologic Parameters Define Features of Treatment Response to Neoadjuvant Chemotherapy in Non-Small Cell Lung Cancer  
Annikka Weissferdt, TX/USA

P3.11 - Methylation Markers That Correlate with Occult Lymph Node Metastases of NSCLC and a Preliminary Prediction Model  

12:00 - 13:00  
Screening and Early Detection  
Exhibit Hall
Wenhua Liang, China

P3.11-02 - Lung Cancer Screening in a High Incidence Population: Results of Low-Dose CT Screenings in a Northern Kentucky Community Healthcare System
Royce Calhoun, KY/USA

P3.11-03 - Implementing Lung Cancer Screening in Canada: Evidence on Adherence and Budget Impact from the Pan-Canadian Early Detection Study
Sonya Cressman, BC/Canada

P3.11-04 - Trends and Barriers in Lung Cancer Screening Implementation Across the United States.
Jennifer King, DC/USA

P3.11-05 - Use of Electronic Medical Record (EMR)-Embedded Clinical Decision Support Tools Improves Lung Cancer Screening Rates
John Doty, NC/USA

P3.11-06 - Improving Lung Cancer Screening Completion Rates in a Primary Care Practice in Large Urban Academic Medical Center
Linda Dowling, IL/USA

P3.11-07 - The Quality of Screening: Comparing the Rush Lung Cancer Screening Program to the NLST and the VA Lung Cancer Screening Demonstration Project
Linda Dowling, IL/USA

P3.11-08 - Lung Cancer Screening at an Academic Medical Center: Early Patterns of Practice
Linda Dowling, IL/USA

P3.11-09 - Shared Decision Making; A Decision Aid for the Primary Practitioner
Fred Grannis, CA/USA

P3.11-10 - Lung Cancer Screening Shared Decision Making: Decision-Aid for the Patient
Fred Grannis, CA/USA

P3.11-11 - Improving Timeliness of Lung Cancer Diagnostic Services with the Implementation of Coordinated Care via a “Navigation Day”
Michael Gulak, ON/Canada

P3.11-12 - Comparison of Cancer Screening Adherence According to Smoking Status: Korea National Health and Nutrition Examination Survey 2010-2012
Yong Saing Kim, Republic of Korea
P3.11-13 - Liverpool Identifies the Hard to Reach Population at Risk of Developing Lung Cancer.
Martin Ledson, UK

P3.11-14 - Low Rates of Lung Cancer Screening Among Doctors in Mexico
Omar Macedo-Pérez, Mexico

P3.11-15 - Lung Cancer Symptom Perception and Intervention Preferences in the UK’s Most Deprived Communities: A Qualitative Study
Kate Brain, UK

P3.11-16 - Comparative Analysis of Health-Care Resources and Economic Costs of Lung Cancer Patients Treated Medically or Surgically in Catalunya
Laureano Molins, Spain

P3.11-17 - Gender Comparison in Lung Cancer Screening
Simran Randhawa, PA/USA

P3.11-18 - Implementing One Stop Lung Clinic to Improve Diagnostic Timeliness in Lung Cancer Patients in the North of England
Vytis Dudzevicius, UK

P3.11-19 - Improving Lung Cancer Screening Rates in an Underserved Outpatient Clinic
Carlos Rodriguez, USA

P3.11-20 - Patterns and Predictors of Adherence to Recommended Follow-Up After Low-Dose Computed Tomography Screening for Lung Cancer
Lori Sakoda, CA/USA

P3.11-21 - The Development of a Robust Radiology Quality Assurance (QA) Program in a Provincial High-Risk Lung Cancer Screening Pilot (HRLCSP)
Heidi Schmidt, Canada

P3.11-22 - The Path to National Lung Cancer Screening Program in Israel
Shani Shilo, Israel

P3.11-23 - Adherence to Annual Low-Dose CT Lung Cancer Screening at a Large Academic Institution
Lucy Spalluto, TN/USA
P3.11-24 - “To Know or Not to Know …?” Push and Pull in Ever Smokers Lung Screening Uptake Decision Making Intentions
Janet Tonge, UK

P3.11-25 - Analysis Indicates Low Incremental Cost-Effectiveness Ratio for Implementation of Lung Cancer Screening in Italy
Giulia Veronesi, Italy

P3.11-26 - Results of Initial Low-Dose Computed Tomographic Screening for Lung Cancer from a Single-Institution in China
Wei Wang, China

P3.11-27 - Lung Cancer Diagnosed at Age 50-54 Years: Survival as Poor as Older Patients
Ping Yang, AZ/USA

P3.12

12:00 - 13:00  Small Cell Lung Cancer/NET  Exhibit Hall

P3.12-01 - Targeting Mitochondrial Metabolism as a Selective Therapeutic Approach in Small Cell Lung Cancer (SCLC)
Shantanu Banerji, MB/Canada

P3.12-02 - Dynamics of DLL3 and ASCL1 Expression in SCLC Over Disease Course
Anna Farago, MA/USA

P3.12-03 - Targeting DLL3 with AMG 757, a BiTE® Antibody Construct, and AMG 119, a CAR-T, for the Treatment of SCLC
Michael Giffin, CA/USA

P3.12-04 - Linc00173 Modulates Chemoresistance of Small Cell Lung Cancer by Binding hnRNPAB1 and hnRNPI to Regulate CHK2 Level
Linlang Guo, China

P3.12-05 - The Pattern of PD-L1 Expression in Thoracic Neuroendocrine Tumors
Nagla Karim, OH/USA

P3.12-06 - SLFN11 Expression and Efficacy of PARP Inhibitor Therapy in Extensive Stage Small Cell Lung Cancer: ECOG-ACRIN 2511 Study
Taofeek Owonikoko, GA/USA
Ana Seneda, Brazil

P3.12-08 - The Role of Contactin 1 on Acquired Resistance to Pegylated Arginase in Small Cell Lung Cancer
Sheng Yan, Hong Kong

P3.12-09 - Smad4 Mutation Confers Acquired Neuroendocrine Phenotype in Transformation of Lung Adenocarcinoma to Small Cell Lung Cancer
Jie Zhang, China

P3.12-10 - Immunogenomic Characteristics of SCLC and LCNEC Redefined Molecular Subgroups
Xue-Tao Li, China

P3.12-11 - Association of the Lung Immune Prognostic Index (LIPI) with Outcomes for Immune Checkpoint Inhibitors in Diffuse SCLC Patients
Laura Mezquita, France

P3.12-12 - Genomic Profiling of Pulmonary Large-Cell Neuroendocrine Carcinoma (LCNEC) Reveals Distinct Mutational Landscape
Lin Wu, China

Hui Yu, CO/USA

P3.12-14 - Genomic Profiling of Chinese Small Cell Lung Cancer and the Implications for Therapy
Hong Zhong, China

P3.12-15 - 68 Ga DOTA PET/CT in Staging of Broncho-Pulmonary Carcinoid Tumors. Is there a Real Benefit?
George Karimundackal, India

P3.12-16 - Prognostic Impact of M Descriptors of the 8th Edition of TNM Classification for Extensive Disease-Small Cell Lung Cancer
Masayuki Shirasawa, Japan

P3.12-17 - A Retrospective Study Examining the Role of PET-CT in the 8th TNM Staging System of SCLC
Salomon Tendler, Sweden
### P3.13 - Targeted Therapy

**12:00 - 13:00**  
**Exhibit Hall**

<table>
<thead>
<tr>
<th>Paper ID</th>
<th>Title</th>
<th>Presenter, Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>P3.13-01</td>
<td>Detecting ALK Rearrangements in NSCLC Patients: IHC, FISH or NGS Fusion?</td>
<td>Alfredo Addeo, Switzerland</td>
</tr>
<tr>
<td>P3.13-02</td>
<td>Lymphocytic Plevral Effusion Due to Crizotinib Usage: First Case in Literature</td>
<td>Pınar Akın Kabalak, Turkey</td>
</tr>
<tr>
<td>P3.13-04</td>
<td>Lorlatinib in Anaplastic Lymphoma Kinase and Proto-Oncogene Tyrosine-Protein Kinase ROS-Positive Non-Small Cell Lung Cancer</td>
<td>Marthe Paats, Netherlands</td>
</tr>
<tr>
<td>P3.13-05</td>
<td>Use of Crizotinib in a Patient with a Ros Mutation Causing Elevated CPK and Resulting in Dose Limiting: Case Report</td>
<td>Ana Cecilia Vasconcelos, Brazil</td>
</tr>
<tr>
<td>P3.13-06</td>
<td>Analysis of ALK Rearrangement Non-Small Cell Lung Cancer Cell Blocks from Pleural Effusion</td>
<td>Chunwei Xu, China</td>
</tr>
<tr>
<td>P3.13-07</td>
<td>The Effect of Crizotinib in Patients of Non-Small Cell Lung Cancer with Brain Metastases: A Retrospective Analysis</td>
<td>Jiexia Zhang, China</td>
</tr>
<tr>
<td>P3.13-08</td>
<td>Assessment of EGFR Gene Mutations In cf-DNA in Monitoring of Response to EGFR TKIs in Patients with Lung Adenocarcinoma</td>
<td>Kamila Wojas-Krawczyk, Poland</td>
</tr>
<tr>
<td>P3.13-09</td>
<td>ALTER-0303 Study: Tumor Mutation Index (TMI) For Clinical Response to Anlotinib in Advanced NSCLC Patients at 3rd Line</td>
<td>Baohui Han, China</td>
</tr>
<tr>
<td>P3.13-10</td>
<td>Factors Associated with Long-Term Survival of Stage IV NSCLC Patients on First-Line EGFR-Targeting Therapy</td>
<td></td>
</tr>
</tbody>
</table>
Amanda Gibson, Canada

P3.13-11 - Advanced Nsclc Treated with Gefitinib or Erlotinib for Five Years or Longer - Retrospective Slovakian Study
Peter Berzinec, Slovak Republic

P3.13-12 - A Lung Adenocarcinoma with Concomitant EGFR and de novo MET Amplification Response Well to Combination of TKI and Bevacizumab
Qian Chu, China

Marcos Costa, Brazil

P3.13-14 - Identification of Novel Mutations by High-Throughput Sequencing in T790M Wildtype/cMET Unamplified NSCLC with Acquired Resistance to EGFR TKIs
Chenguang Li, China

P3.13-15 - First-Line Afatinib Dose Initiation and Adjustment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer
Chong-Kin Liam, Malaysia

P3.13-16 - Concomitant EML4-ALK Rearrangement and EGFR Mutation in Non-Small Cell Lung Cancer Patients: Data from Eastern Indian Hospital.
Prasanta Mohapatra, India

P3.13-17 - A Retrospective Study: Central Nervous System Response to Osimertinib in Patients with Advanced NSCLC
Yuxin Mu, China

P3.13-18 - Mechanisms of Acquired Resistance to Afatinib Clarified with Liquid Biopsy
Tomomi Nakamura, Japan

P3.13-19 - Surgery for cIIIB Lung Adenocarcinoma After Response to Erlotinib, Survival and Management of Postoperative Oligoproggressions
Danail Petrov, Bulgaria

P3.13-20 - Frequency of EGFR Mutations in Patients with Adenocarcinoma Lung Cancer. Comparative Study Between Public and Private Mexican Health Services
Jeronimo Rodriguez-Cid, Mexico

P3.13-21 - Apatinib Plus Icotinib as First-Line Therapy for EGFR Co-Mutations NSCLC in Chinese Patients: An Exploratory Study
Yanhong Shang, China

P3.13-22 - Real World Study of Afatinib in First-Line or Re-Challenge Setting for Patients with EGFR Mutant Non-Small Cell Lung Cancer.
Hisashi Tanaka, Japan

Xiyi Lu, China

Huijuan Wang, China

P3.13-24 - Efficacy of EGFR-TKIs Compared with Chemotherapy as First-Line Therapy in Patients with EGFR Rare Mutation Advanced Lung Adenocarcinoma

Francesca Cavallo, USA

P3.13-25 - Development of a Comprehensive Genomic Profiling System to Detect Actionable Genetic Alterations and Tumor Mutation Burden

Lisa Chu, CA/USA

P3.13-26 - Outcomes of Patients with Metastatic Lung Cancer Presented in a Multidisciplinary Molecular Tumor Board

Marcos Costa, Brazil

P3.13-27 - Clinical Outcomes of Patients with Lung Adenocarcinoma Harboring Concomitant Driver Mutations in a Brazilian Cancer Center

Michelle Dean, AB/Canada

P3.13-28 - Heterogeneity, Prevalence and Prognostic Significance of PDL1 Expression in Early Resected NSCLC

Tae Ho Kim, Republic of Korea

P3.13-29 - Patient-Derived Xenograft Models (PDX) of Lung Squamous Cell Carcinoma (SCC) for Preclinical Studies

Bárbara Maria Luz, Brazil

P3.13-30 - Driver Mutation in Heavy Smoker Patient with Squamous Cell Carcinoma Metastatic Lung Cancer: Case Report

Paola Marignani, Canada
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker, Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>P3.13-32</td>
<td>Drug Sensitivity of Lung Adenocarcinoma Towards Inducers of Epigenetic Modifications</td>
<td>Isabelle Moneke, Germany</td>
</tr>
<tr>
<td>P3.13-33</td>
<td>Lung Adenocarcinoma Harboring RET Fusion and Dramatic Response to Combination of Vandetanib (VAN) and Everolimus (EVE): A Case Report from Brazil</td>
<td>Carolina Haddad, Brazil</td>
</tr>
<tr>
<td>P3.13-34</td>
<td>RET Gene, a New Choice for NSCLC</td>
<td>Yinghui Xu, China</td>
</tr>
<tr>
<td>P3.13-35</td>
<td>Antitumor Effect of Neratinib Targeting HER2-Altered Lung Cancer</td>
<td>Yusuke Ogoshi, Japan</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker, Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>P3.15-01</td>
<td>Long-Term Outcomes of Pulmonary Metastasectomy: A 12-Year Dual Centre Experience</td>
<td>Phillip Antippa, Australia</td>
</tr>
<tr>
<td>P3.15-02</td>
<td>Carboplatin Dose Calculated Using Different Formula for eGFR and Their Comparison with Actual Dose Administered in Lung Cancer Patients</td>
<td>Digambar Behera, India</td>
</tr>
<tr>
<td>P3.15-03</td>
<td>Capturing the Patient Experience for the Treatment of EGFR Exon 20 Mutations in Non-Small Cell Lung Cancer</td>
<td>Aaron Galaznik, MA/USA</td>
</tr>
<tr>
<td>P3.15-04</td>
<td>An Interdisciplinary Educational Program Dedicated to Non-Small Cell Lung Cancer Patients to Improve their Quality of Life</td>
<td>Laurence Bigay-Gamé, France</td>
</tr>
<tr>
<td>P3.15-05</td>
<td>Patient Reported Outcomes (PROs) as Performance Measures After Surgery for Lung Cancer</td>
<td>Majken Brønserud, Denmark</td>
</tr>
<tr>
<td>P3.15-06</td>
<td>Capillary Leak Syndrome in a Primary Lung Adenocarcinoma Patient with Thrombocytopenia from Interleukin-11 Treatment</td>
<td>Huafei Chen, China</td>
</tr>
</tbody>
</table>
P3.15-07 - A Literature Review and Assessment of Lung Cancer Quality Indicators
Kim-Lin Chiew, NSW/Australia

P3.15-08 - Patient-Reported Outcomes (PROs) in Patients with Lung Resection: Open Versus Minimal Invasive Surgery
Qiuling Shi, USA

P3.15-09 - Are Lung Cancer Patients Receiving Education Materials? The Healthcare Provider Perspective on Distribution Gaps and Possible Solutions
Andrea Ferris, USA

P3.15-10 - Survival Impact of Peripheral Blood Ratios in Lung Cancer According Clinical Stage
Claudio Flores, Peru

P3.15-11 - Association Between Peripheral Blood Ratios and Clinical Stage Disease in Lung Cancer.
Claudio Flores, Peru

P3.15-12 - Survival Impact of Patient Enrollment in Antineoplastic Drug Trials for Stage IV Non-Small Cell Lung Cancer (NSCLC)
Bernardo Goulart, WA/USA

P3.15-13 - Surgical Management of Huge Pulmonary Arteriovenous Malformations: Our Experience
Fadil Gradica, Albania

P3.15-14 - Using Creative Co-Production to Develop a Treatment Decision Support Tool for People with Malignant Pleural Effusion
Angela Tod, UK

P3.15-15 - ALI Could Be a One of Prognostic Survival Factor for Non-Small Cell Lung Cancer Patients
Yoichiro Hamamoto, Japan

P3.15-16 - Management of Patients with ALK-Translocated NSCLC: A Simulation-Based Assessment of Medical Oncologists’ Practice Decisions
Emily Van Laar, USA

P3.15-17 - Lung Cancer Symptom Burden and Quality of Life: Findings from the Cancer Experience Registry
Julie Olson, USA
P3.15-18 - Comparison of Pain Control Effects and Side Effects Early After VATs Lobectomy Between IV-PCA, Epidural-PCA and On-Q
Joonho Jung, Republic of Korea

P3.15-19 - Risk Factors for Osteoporosis in Lung Cancer Patients
Kyung Ho Kang, Republic of Korea

P3.15-20 - Palliative Sedation in Lung Cancer Patients Whom Needs Immediate or Elective Intractable Symptom Control
Fatih Kose, Turkey

P3.15-21 - Real-World Experience of First-Line Afatinib Treatment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer
Chong-Kin Liam, Malaysia

Akihiro Nagoya, Japan

P3.15-23 - Data Mining the Internet and Crowdsourcing in Guiding Patient Decision-Making.
Shaneel Pathak, Canada

P3.15-24 - Ramathibodi Lung Cancer Consortium (RLC) Model: Multidisciplinary Team Approach Improves Lung Cancer Patients’ Survival Outcome
Thanyanan Reungwetwattana, Thailand

P3.15-26 - Safety of Nivolumab in Thoracic Malignancies: Results from a Single Institution in Bangladesh
Md Shuayb, Bangladesh

P3.15-27 - Initial Response to First Line Treatment is the Best Predictor of the Patient Survival in Advanced NSCLC
Nazim Turhal, Turkey

P3.15-28 - Prognostic Nutritional Index for Predicting Postoperative Complications After Surgery Thoracic Tumor Involving the Neighboring Structures
Isamu Watanabe, Japan

P3.15-29 - Defining the Symptom Burden of Non-Small Cell Lung Cancer
Meagan Whisenant, USA
<table>
<thead>
<tr>
<th>Session (P3.15-30)</th>
<th>Title</th>
<th>Speaker, Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>P3.15-30</td>
<td>Treatment Patterns and Survival of Patients with Stage IV Non-Small Cell Lung Cancer (NSCLC) in the Era of Novel Therapies</td>
<td>Dimas Yusuf, Canada</td>
</tr>
<tr>
<td>P3.15-31</td>
<td>Better Clinical Outcomes and Resistance Mechanisms of Crizotinib in ALK-Positive Non-Small Cell Lung Cancer</td>
<td>Yongchang Zhang, China</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Session (P3.16)</th>
<th>Title</th>
<th>Speaker, Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>P3.16</td>
<td>Treatment of Early Stage/Localized Disease</td>
<td>Exhibit Hall</td>
</tr>
<tr>
<td>P3.16-01</td>
<td>A Multi-Omic Study Reveals BTG2 as a Reliable Prognostic Marker for Early-Stage Non-Small Cell Lung Cancer</td>
<td>David Christiani, MA/USA</td>
</tr>
<tr>
<td>P3.16-02</td>
<td>Phase III Study of Canakinumab (ACZ885) as Adjuvant Therapy in Patients with Surgically Resected NSCLC</td>
<td>Edward Garon, CA/USA</td>
</tr>
<tr>
<td>P3.16-03</td>
<td>Uncommon EGFR Mutations as a Worse Prognostic Factor for Surgically Resected Lung Adenocarcinoma</td>
<td>Kazuki Hayasaka, Japan</td>
</tr>
<tr>
<td>P3.16-04</td>
<td>Comparison of 2D and 3D Consolidation to Tumor Ratios to Predict Less Invasive Lung Adenocarcinoma</td>
<td>Toshihiro Ikeda, Japan</td>
</tr>
<tr>
<td>P3.16-05</td>
<td>A Nanotechnology-Enabled Strategy for Image-Guided Transbronchial and Transpleural Photothermal Therapy of Peripheral Lung Cancer</td>
<td>Tomonari Kinoshita, ON/Canada</td>
</tr>
<tr>
<td>P3.16-06</td>
<td>Does Comprehensive Mutation Analysis Add Prognostic Value in Resected Early Stage Lung Adenocarcinoma?</td>
<td>Peter Kneuertz, OH/USA</td>
</tr>
<tr>
<td>P3.16-07</td>
<td>The Impact of Clinical and Molecular Profile of Resected EGFR-Mutant Non-Small Cell Lung Cancer on the Risk of Developing Brain Metastases</td>
<td>Mor Moskovitz, Israel</td>
</tr>
<tr>
<td>P3.16-08</td>
<td>Baseline Quality of Life is Influenced by the Duration of Abstinence from Smoking in Candidates to Lung Cancer Surgery</td>
<td>Cecilia Pompili, UK</td>
</tr>
</tbody>
</table>
P3.16-09 - High Preoperative D-Dimer Level Predicts Early Recurrence After Surgery for Non-Small Cell Lung Cancer
Yuki Shiina, Japan

P3.16-10 - Radiomic Features on CT are Prognostic of Recurrence as well as Predictive of Added Benefit of Adjuvant Chemotherapy in ES-NSCLC
Pranjal Vaidya, USA

P3.16-11 - Pattern of Recurrence of Completely Resected Lung Adenocarcinoma Varies According to EGFR Mutation Status
Katsuya Watanabe, Japan

P3.16-12 - Standard Conventional Lobectomy vs Stereotactic Body Radiotherapy in Patients with Early Stage Non-Small Cell Lung Cancer (NSCLC) - A Review
Prakash Balakrishnan, New Zealand

P3.16-13 - Long-Term Outcomes of Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer in Patients Less Than 70 Years of Age
Zhe Chen, Japan

P3.16-14 - SBRT in Early Stages of Lung Cancer
Luis Fernández Fornos, Spain

P3.16-15 - Kinetic Energy Distribution for Gated Technique at Lung Ablative Body Radiotherapy (SABR)
Kaile Li, USA

P3.16-16 - Long Term Outcomes of Body Gamma-Ray Stereotactic Ablative Radiotherapy for Patients with Stage I/II Non-Small Cell Lung Cancer
Hongqi Li, China

P3.16-17 - Cardiac Sparing in Stereotactic Body Radiotherapy of Early Stage NSCLC Patients
Barbara Stam, Jose Belderbos; Netherlands

P3.16-18 - Modern Radiotherapy Increases Patient Access to Curative Intent Radiotherapy in Non-Small Cell Lung Cancer
Karen Tumelty, UK

P3.16-19 - Clinical Outcomes of Stereotactic Body Radiation Therapy for T2N0M0 Non-Small Cell Lung Cancer
Yaping Xu, China
P3.16-20 - Feasibility of Limited Resection for Peripheral Small-Sized Non-Small Cell Lung Cancer According to FDG Accumulation and Imaging Findings
Masato Aragaki, Japan

P3.16-21 - Robotic Thoracic Surgery in Lung Cancer Resection - A Comprehensive Review
Prakash Balakrishnan, New Zealand

P3.16-22 - Wedge Resection for Small Pulmonary Lesions with Preoperative Bronchoscopic Barium Marking
Tatsuo Furuya, Japan

Fadil Gradica, Albania

P3.16-24 - Prognostic Value of Positive Lymph Node Ratio in Non-Small Cell Lung Cancer
Jiaxi He, China

P3.16-25 - Impact of Diabetes Mellitus on Survival Outcome in Patients with Pathological Stage IA Non-Small Cell Lung Cancer
Shunki Hirayama, Japan

P3.16-26 - Anatomic Segmentectomy in Stage I Non-Small-Cell Lung Cancer Reveals Equivalent Long-Term Outcomes Compared to Lobectomy
Alireza Hoda, Austria

P3.16-27 - Clinical Outcome of Preoperative Intervention Bronchoscopy Followed by Surgery
Yasufumi Kato, Japan

P3.16-28 - Surgery of Stage I Non-Small Cell Lung Cancer in Patients Aged 70 Years or Older
Osamu Kawamata, Japan

P3.16-29 - Prediction of Lymph Node Metastases in Clinical T1aN0M0 Non-Small Cell Lung Cancer
Tung-Ming Tsai, Taiwan

P3.16-30 - The Impact of the Surgical Approach on Lymph Node Upstaging in Curative Intent Lung Cancer Surgery
Khaled Mardanzai, Germany
P3.16-31 - Younger Patients Operated for Lung Cancer Have Better Overall Survival
Tomasz Marjanski, Poland

P3.16-32 - A Study of Postoperative Recurrence in Pathological Stage 1 Non-Small Cell Lung Cancer Patients
Kotaro Mizuno, Japan

P3.16-33 - Characteristics and Risk Factors of Recurrence After Segmentectomy in Patients With Clinical Stage I Non-Small Cell Lung Cancer
Akihiro Nakamura, Japan

P3.16-34 - The Impact of Preoperative Exercise Therapy on the Surgical Outcomes of Patients with Lung Cancer and COPD: A Systematic Review and Meta-Analysis
Wu Nan, China

P3.16-35 - Stair Climbing Exercise May Ameliorate Pulmonary Function Impairment in Patients at One Month After Lung Cancer Resection
Wu Nan, China

P3.16-36 - Adjuvant Chemotherapy May Improve the Outcome of Patients with Non-Small-Cell Lung Cancer with Metastasis of Intrapulmonary Lymph Nodes.
Wu Nan, China

P3.16-37 - Comparison of Long-Term Outcomes Between VATS and Open Lobectomies for Stage I NSCLC: Propensity Score-Matching Analysis
Risa Oda, Japan

P3.16-38 - Systematic Review and Meta-Analysis of Methods to Predict Postoperative Lung Function Following Lung Cancer Resection
Nicola Oswald, UK

P3.16-39 - Which Surgery for Ground Glass Opacity Lung Nodules?
Sara Ricciardi, Italy

P3.16-40 - Delayed Cut-End Recurrence After Wedge Resection for Pulmonary Ground-Glass Opacity Adenocarcinoma
Keigo Sekihara, Japan

P3.16-41 - Postoperative Pembrolizumab for the Patients with Pathologic Stage I Adenocarcinoma with Solid or Micropapillary Pattern
Sumin Shin, Republic of Korea
P3.16-42 - Early Stage Non-Small Cell Lung Cancer Survival in a Chilean Private Teaching Hospital
Francisco Suárez, Chile

P3.16-43 - Is Sublobar Resection for Stage I Invasive Adenocarcinoma (≤2-cm) Feasible?
Yuriko Terada, Japan

P3.16-44 - Robotic-Assisted Thoracic Surgery for Early-Stage Non-Small-Cell Lung Cancer: Initial Experience in Brazil
Ricardo Terra, Brazil

P3.16-45 - The Rates and Survival of Surgically-Resected Second Primary Lung Cancers in Patients Undergoing Resection of an Initial Primary Lung Cancer.
John Varlotto, MA/USA

P3.16-46 - The Comparison Between Non-Intubated and Intubated Thoracoscopic Resection for Pulmonary Nodule: A Meta-Analysis
Yaokai Wen, China

P3.16-47 - Analysis of The Novel Chest Tube (Coaxial Drain) for Lung Cancer Surgery
Masashi Yanada, Japan

P3.16-48 - Is Preoperative SUV(Max) of Primary Tumor a Predictor of Relapse for Operable Non-Small Cell Lung Cancer?
Perran Yumuk, Turkey

P3.17 - Treatment of Locoregional Disease - NSCLC

12:00 - 13:00

P3.17-01 - PD-L1 Expression, EGFR Mutations and ALK Expression in Non-Small Cell Lung Cancer (NSCLC) Patients from Brazil
Marclesson Alves, Brazil

P3.17-02 - Increasing Radiation Dose to Central Structures is Associated with Worse Survival Following Thoracic Proton Reirradiation
Jessika Contreras, USA

P3.17-03 - Survival and Side Effects in Non-Small Cell Lung Cancer Patients Treated with Combination of Chemotherapy and Conformal Radiotherapy
Simonida Crvenkova, Macedonia

P3.17-04 - Dealing with the N2 Disease in Non-Small Cell Lung Cancer- on the Edge.
Soo-Youn Ham, Republic of Korea

P3.17-05 - Multimodality Treatment for Superior Sulcus Non-Small-Cell Lung Carcinomas
Masahiko Harada, Japan

P3.17-06 - Impact of Integrating PET-CT in Radiotherapy Planning of Non Small Cell Carcinoma Lung: Dosimetric and Radiobiological Comparison
Rakesh Kapoor, India

P3.17-07 - The Beneficial Effect of the High Dose Irradiation During Concurrent Chemoradiotherapy in Locoregional Advanced Non-Small Cell Lung Cancer
Chul Seung Kay, Republic of Korea

P3.17-08 - Assessing Primary Lung Cancer Lesion Using Ratio Metrics of T1 and T2-Weighted Images in Magnetic Resonance Imaging
Hui Liu, China

P3.17-09 - Retrospective Analysis of the Efficacy and Safety of Multimodal Treatment for Locally-Advanced NSCLC in Elderly Patients
Francesca Mazzoni, Italy

P3.17-10 - Outcome of Surgical Resection for Superior Sulcus Tumor: Experience at a Single Institution.
Seiji Omura, Japan

P3.17-11 - Duo Synchronous Primary Lung Tumours Mimicking a Solitary Spiculated Cavitatory Mass on Computed Tomographic Imaging
Kingsfield Ong, Singapore

P3.17-12 - Phase II Trial of Atezolizumab Before and After Chemoradiation for Unresectable Stage III NSCLC (AFT-16): Trial in Progress
Helen Ross, AZ/USA

P3.17-13 - SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients with Stage IIIA(N2) NSCLC — A Multicenter Single-Arm Phase II Trial.
Sacha Rothschild, Switzerland

P3.17-14 - A Case of a Patient Harboring an EGFR -T790M Mutation Positive in Squamous Cell Lung Cancer
Carlos Carracedo Gonzales, Peru

P3.17-15 - Therapeutic Outcome of Surgery for Superior Sulcus Tumor
Akira Sakurada, Japan

P3.17-16 - Adenocarcinoma or Epidermoid? The Importance of the Histological Subdivision
Silvia Sequero, Spain

P3.17-17 - Stage III: Analysis to Assist in the Decision of Surgery Against Quimio-Radiotherapy
Silvia Sequero, Spain

P3.17-18 - Towards Individualizing Patient Selection in Proton Therapy for Lung Cancer Using the Model-Based Approach
Suliana Teoh, UK

P3.17-19 - First Relapse and Survival Five Years After Radical Radiotherapy for Lung Cancer.
Gerard Walls, Ireland

P3.17-20 - Impact of Significant Primary Tumor Size Reduction on Radiation Dose to Normal Structures in Patients Receiving Definitive Chemoradiotherapy
Meng Welliver, OH/USA

P3.17-21 - Surgical Treatment for Centrally Located or Hilar Invasive Locally Advanced Lung Cancer.
Motohiro Yamashita, Japan

P3.17-22 - Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable NSCLC
Ralph Zinner, PA/USA

P3.17-23 - Role of Surgery in Locoregional Advanced NSCLC; A Case of Aggressive Salvage Surgery After Definitive Chemoradiation
Ryuichi Waseda, Japan

P3.CR
12:00 - 13:00 Case Reports Exhibit Hall
Topics: Advanced NSCLC, Advocacy, Biology, Immunooncology, Interventional Diagnostics/Pulmonology, Small Cell Lung Cancer/NET, Thymoma/Other Thoracic Malignancies
P3.CR-01 - To Better Understand the Anatomical Proximity of Cardiac Plexus to Prevent Lethal Arrhythmias Associated with Lung Cancer Surgery
Kurumi Fukui, Japan

P3.CR-02 - SBRT of Lung Primary After Complete Resolution of Metastatic Disease in Case of EGFR Mutated Adenocarcinoma Lung: A Case Report
Saroj Majumdar, India

P3.CR-03 - Pulmonary Spindle Cell Neoplasm - Neoadjuvant Treatment and Response
Kyaw Thein, TX/USA

P3.CR-04 - Lung Cancer with Concurrent ROS1 Rearrangement and KRAS Mutation: A Case Report
Youcai Zhu, China

P3.CR-05 - The Role of Patient Engagement in Improved Outcomes in Lung Cancer Care
Anne Marie Cerato, ON/Canada

P3.CR-06 - Effect of Palliative Care and Cancer Rehabilitation on Lung Cancer Survivorship - Patient's Perspective
Satoko Kono, Japan

P3.CR-07 - Comprehensive Genomic Profiles for a Mediastinal Tumor Suspected of Synovial Sarcoma: A Case Report
Kota Araki, Japan

P3.CR-08 - Clonally Related Primary ALK Rearrangement Adenocarcinoma and Associated Metastatic Lesions: A Case Report
Chunwei Xu, China

P3.CR-09 - MET-UBE2H fusion as a novel mechanism of acquired EGFR resistance in lung adenocarcinoma with MET fusion as a novel mechanism of acquired EGFR resistance in lung adenocarcinoma
Chunwei Xu, China

P3.CR-10 - HIP1-ALK Fusion Variant in Non-Small-Cell Lung Cancer and Response to Crizotinib
Chunwei Xu, China

P3.CR-11 - ROS1 Fusion and MET Amplification Dual Drive Coexistence in Lung Adenocarcinoma and Response to Crizotinib: A Case Report
Chunwei Xu, China
P3.CR-12 - A Novel Oncogenic Driver in a Lung Adenocarcinoma Patient Harboring an EGFR-KDD and Response to Afatinib
Chunwei Xu, China

P3.CR-13 - Dual Drive Coexistence of EML4-ALK Fusion and TPM3-ROS1 Fusion Lung Adenocarcinoma: A Case Report
Youcai Zhu, China

P3.CR-14 - A Case of EGFR Tyrosine Kinase Inhibitor (TKI), Osimertinib Induced Pneumonitis in a Patient with Recurrent Fevers of Unknown Origin
Young Chae, USA

Marta Soares, Portugal

P3.CR-16 - A Case of Toxic Hepatic Event Occurring in Combination Treatment with Nivolumab and Anti-Tuberculosis in Advanced Lung Cancer
Tae Hoon Kim, Republic of Korea

P3.CR-17 - An Interesting Case of Long-Term Immunotherapy Response in Metastatic NSCLC
Swati Kulkarni, ON/Canada

P3.CR-18 - Central Nervous System Activity of Checkpoint Inhibitor in Non-Small-Cell Lung Cancer
Marta Pereira-Lima, Brazil

Leticia Maria Neves De Carvalho, Brazil

P3.CR-20 - The Effect of Pembrolizumab In EGFR Mutated Lung Adenocarcinoma Patients With PD-L1 Overexpression: Two Cases Report
Takeshi Uenami, Japan

P3.CR-21 - Utility of Thoracoscopy in Diagnosis of Lung Tumour in Pleural Effusion
Naveen Pandhi, India

P3.CR-22 - Pulmonary Tuberculosis - A Chameleon; Mimicking Lung Cancer on Imaging
Srijna Rana, India
J Turner, TN/USA

P3.CR-24 - Surgical Resection of 30 Years’ Recurring Pneumonia: 1 Case of Giant Bronchopulmonary Sequestration
Jun Zhang, China

P3.CR-25 - Finding the Ways to Determine the Prognosis of Pulmonary Carcinoids with Certain Genes/Markers in Pakistan
Arooj Fatima, Pakistan

P3.CR-26 - Mediastinal Lipoma in Adult: A Case Report
Amira Anwar, Indonesia

P3.CR-27 - Surgical Treatment of a Rare Case of Mediastinal Masson's Tumor Mimicking a Thymoma
Angela De Palma, Italy

P3.CR-28 - Simultaneous Presentation of Mediastinal Malignant Peripheral Nerve Sheath Tumor with Intrapulmonary Metastasis, an Extremely Rare Case
Akif Turna, Turkey

P3.CR-29 - En-Bloc Excision of Intrapericardial Thymoma Using Single Port Video-Assisted Thoracoscopic Surgery. A Rare Case
Akif Turna, Turkey

P3.CR-30 - Pleural Diseases on Single Lung After Pneumonectomy for Cancer
Veronica Manolache, Romania

P3.CR-31 - A Case of Thymoma with Autoimmune Hepatitis Following Preoperative Chemotherapy
Tomoki Nishimura, Japan

Kyung Joo Park, Republic of Korea

P3.CR-33 - Trichoptysis, Hemoptysis and Chest Pain: A Very Rare Presentation of Anterior Mediastinal Teratoma in a Young Patient
Asma Saidane, Tunisia
P3.CR-34 - A Giant Ganglioneuroma of the Thoracic Spine
Asma Saidane, Tunisia

P3.CR-35 - A Rare Giant Thoracic Desmoid Tumor /A Case Report
Asma Saidane, Tunisia

P3.CR-36 - Intrapericardial Thymoma: A Case Report
Akif Turna, Turkey

P3.CR-37 - Extensive Resection for Invasive Atypical Carcinoid of Thymus: 1 Case Report
Jun Zhang, China

ES07

13:30 - 15:00 Beyond the Diagnosis - Collaborative Care for Change
Topics: Nursing and Allied Professionals
Moderation: M. Guerin, USA; D. Zawisza, Canada

13:30 - 13:50 ES07.01 - A Moment in Time for the Unplanned Conversations
Kelly Mcguigan, Canada

13:50 - 14:00 ES07.02 - Special Needs and Wellness in Lung Cancer Patients - Australian Perspective
Maria Ftanou, VIC/Australia

14:00 - 14:10 ES07.03 - Special Needs and Wellness in Lung Cancer Patients - European Perspective
Rossie Navon, Israel

14:10 - 14:30 ES07.04 - Leveraging Social Media to Change the Public Conversation on Lung Cancer Stigma
Lisa Carter-Harris, USA

14:30 - 14:50 ES07.05 - Research Update: Patient’s Perspective on Living with Malignant Pleural Mesothelioma
Angela Tod, UK

14:50 - 15:00 ES07.06 - Q&A
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
</table>
| 13:30 - 15:00 | The Pathologist - An Essential Member of the Patient Care Team | Room 206 AC | The Pathologist - An Essential Member of the Patient Care Team  
Topics: Pathology  
Moderation: C. Poleri, Argentina; P. Pal, Canada |
| 13:30 - 13:50 | ES08.01 - Targeted Therapy                   | Yasushi Yatabe, Japan    | ES08.01 - Targeted Therapy  
Yasushi Yatabe, Japan |
| 13:50 - 14:10 | ES08.02 - Immunotherapy                      | Sylvie Lantuejoul, France| ES08.02 - Immunotherapy  
Sylvie Lantuejoul, France |
| 14:10 - 14:30 | ES08.03 - Mesothelioma, Thymic Epithelial Tumors and Others | Andrew Nicholson, UK | ES08.03 - Mesothelioma, Thymic Epithelial Tumors and Others  
Andrew Nicholson, UK |
| 14:30 - 14:50 | ES08.04 - Neoadjuvant Therapy                | Ignacio Wistuba, AL/USA  | ES08.04 - Neoadjuvant Therapy  
Ignacio Wistuba, AL/USA |
| 14:50 - 15:00 | ES08.05 - Q&A                                |                         | ES08.05 - Q&A |

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30 - 15:00</td>
<td>IASLC Lectureship Award Session</td>
<td>Room 105</td>
<td>IASLC Lectureship Award Session</td>
</tr>
</tbody>
</table>
| 13:30 - 13:40 | LA01.01 - Clifton F. Mountain Lectureship Award for Staging - Is There Still a Stage for Improvements in Staging? | Johan Vansteenkiste, Belgium | LA01.01 - Clifton F. Mountain Lectureship Award for Staging - Is There Still a Stage for Improvements in Staging?  
Johan Vansteenkiste, Belgium |
| 13:40 - 13:50 | LA01.02 - IASLC Lectureship Award for Radiation Oncology - Defining the Role of Radiotherapy for Lung Cancer: Past, Present and Future | Hak Choy, TX/USA | LA01.02 - IASLC Lectureship Award for Radiation Oncology - Defining the Role of Radiotherapy for Lung Cancer: Past, Present and Future  
Hak Choy, TX/USA |
| 13:50 - 14:00 | LA01.03 - Heine H. Hansen Lectureship Award for Small Cell Lung Cancer - New Opportunities in Small Cell Lung Cancer | Charles Rudin, NY/USA | LA01.03 - Heine H. Hansen Lectureship Award for Small Cell Lung Cancer - New Opportunities in Small Cell Lung Cancer  
Charles Rudin, NY/USA |
| 14:00 - 14:10 | LA01.04 - Adi F. Gazdar Lectureship Award for Translational Research - Genomic Alterations in Human Lung Cancers | Matthew Meyerson, MA/USA | LA01.04 - Adi F. Gazdar Lectureship Award for Translational Research - Genomic Alterations in Human Lung Cancers  
Matthew Meyerson, MA/USA |
| 14:10 - 14:20 | LA01.05 - Tsuguo Naruke Lectureship Award for Surgery - The Value of Naruke Lymph Node Chart and the Creation of IASLC Chart in Lung Cancer |                         | LA01.05 - Tsuguo Naruke Lectureship Award for Surgery - The Value of Naruke Lymph Node Chart and the Creation of IASLC Chart in Lung Cancer |
Hisao Asamura, Japan

14:20 - 14:30 LA01.06 - Daniel C. Ihde Lectureship Award for Medical Oncology - The Intersection of Science and Medicine
David Carbone, OH/USA

14:30 - 14:40 LA01.07 - Robert J. Ginsberg Lectureship Award for Surgery - Honoring the Tradition of Surgically-Based Clinical Trials
Valerie Rusch, NY/USA

14:40 - 14:50 LA01.08 - IASLC Lectureship Award for Nursing and Allied Health Professionals - The Right Hand: The Art of Collaboration
Kimberly Rohan, IL/USA

14:50 - 15:00 LA01.09 - Q&A

MA25

13:30 - 15:00 Oligometastasis: Defining, Treating, and Evaluating
Topics: Oligometastatic NSCLC, Biology
Moderation: J. Laba, Canada; Z. Allibhai, Canada
Room 203 BD

13:30 - 13:35 MA25.01 - EORTC Lung Cancer Group Survey to Define Synchronous Oligometastatic Disease in NSCLC
Lizza Hendriks, Netherlands

13:35 - 13:40 MA25.02 - Searching for a Definition of Synchronous Oligometastatic (sOMD)-NSCLC: A Consensus from Thoracic Oncology Experts
Anne-Marie Dingemans, Netherlands

Lizza Hendriks, Netherlands

13:45 - 14:00 MA25.04 - Discussant - MA 25.01, MA 25.02, MA 25.03
Abraham Wu, NY/USA

14:00 - 14:05 MA25.05 - Characteristics & Survival of Resected Stage IV Non-Small Cell Lung Cancer (NSCLC) in the Mid-South Quality of Surgical Resection Cohort
Nicholas Faris, TN/USA
MA25.06 - RPA Analysis for Oligometastatic Non-Small Cell Lung Cancer: Smoking Combine T3/4 Patients May Not Be Benefit from Local Consolidative Treatment
Jia-Tao Zhang, China

MA25.07 - Effectiveness of Systemic Therapy Combined with Thoracic Radiotherapy for Patients with Oligometastatic NSCLC: A Pooled Analysis
Jingbo Wang, China

MA25.08 - Discussant - MA 25.05, MA 25.06, MA 25.07
Alysa Fairchild, Canada

MA25.09 - M1b Disease in the 8th Edition of IASLC Staging of Lung Cancer: Pattern of Single Extrathoracic Metastasis and Clinical Outcome
Hyesun Park, MA/USA

MA25.10 - Complete Response by PET-CT After Radical Treatment in Oligometastatic Non-Small Cell Lung Cancer Predicts Longer Survival
Oscar Arrieta, Mexico

MA25.11 - Clinical and Molecular Predictors of Outcome in Patients with EGFR mutant NSCLC Brain Metastases treated with RT
Fabio Moraes, Brazil

MA25.12 - Discussant - MA 25.09, MA 25.10, MA 25.11
Michael Macmanus, Australia

MA26

13:30 - 15:00 New Therapies and Emerging Data in ALK, EGFR and ROS1
Room 201 BD
Topics: Targeted Therapy, Advanced NSCLC, Pathology
Moderation: A. Shaw, USA; G. Simon, USA

MA26.01 - Accumulation of Concomitant Mutations Involved in Drug Resistance in the Sequential ALK TKI Treatments of ALK-Positive NSCLC
Shun Lu, China

Elisa Gobbini, Italy
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Discussant</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:45-14:00</td>
<td>MA26.04</td>
<td>Discussant - MA 26.01, MA 26.02, MA 26.03</td>
<td>Caroline Mccoach, USA</td>
</tr>
<tr>
<td>14:00-14:05</td>
<td>MA26.05</td>
<td>Comprehensive Analysis of Treatment Response and Progression Pattern in Chinese Patients with Different ALK Fusion-Variants</td>
<td>Meng Qiao, China</td>
</tr>
<tr>
<td>14:05-14:10</td>
<td>MA26.06</td>
<td>Crizotinib-Treated ALK Immunopositive Metastasized NSCLC is Associated with an Unfavorable Prognosis when FISH Negative</td>
<td>Erik Thunnissen, Netherlands</td>
</tr>
<tr>
<td>14:10-14:15</td>
<td>MA26.07</td>
<td>ROS1 (SP384) Immunohistochemistry Inter-Reader Precision Between 12 Pathologists</td>
<td>Keith Kerr, UK</td>
</tr>
<tr>
<td>14:15-14:30</td>
<td>MA26.08</td>
<td>Discussant - MA 26.05, MA 26.06, MA 26.07</td>
<td>Dong-Wan Kim, Republic of Korea</td>
</tr>
<tr>
<td>14:30-14:35</td>
<td>MA26.09</td>
<td>Lazertinib, a Third Generation EGFR-TKI, in Patients with EGFR-TKI-Resistant NSCLC: Updated Results of a Phase I/II Study</td>
<td>Byoung Chul Cho, Republic of Korea</td>
</tr>
<tr>
<td>14:35-14:40</td>
<td>MA26.10</td>
<td>CNS Activity of Ramucirumab in Combination with Osimertinib in Patients with Advanced T790M-Positive EGFR-Mutant NSCLC</td>
<td>Luis Paz-Ares, Spain</td>
</tr>
<tr>
<td>14:40-14:45</td>
<td>MA26.11</td>
<td>Effects of Dose Modifications on the Safety and Efficacy of Dacomitinib for EGFR Mutation-Positive NSCLC</td>
<td>Yi-Long Wu, China</td>
</tr>
<tr>
<td>14:45-15:00</td>
<td>MA26.12</td>
<td>Discussant - MA 26.09, MA 26.10, MA 26.11</td>
<td>Liza Villaruz, PA/USA</td>
</tr>
<tr>
<td>Time</td>
<td>Presentation</td>
<td>Author(s)</td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>---------------------------------------------------------------------------------------------------</td>
<td>-----------------------------------</td>
<td></td>
</tr>
<tr>
<td>13:30 - 13:35</td>
<td><strong>MA27.01</strong> - Establishment of PDX From Tumors Characterized by EGFR Mutations or ALK Fusion Genes from Resections, Biopsies and Pleural Fluids</td>
<td>Sebastiao Martins-Filho, Canada</td>
<td></td>
</tr>
<tr>
<td>13:35 - 13:40</td>
<td><strong>MA27.02</strong> - Hypofractionated Radiotherapy Normalizes Tumor Vasculature in Non-Small Cell Lung Cancer Xenografts Through p-STAT3/HIF-1 Alpha Pathway</td>
<td>Xiaorong Dong, China</td>
<td></td>
</tr>
<tr>
<td>13:40 - 13:45</td>
<td><strong>MA27.03</strong> - Multi-Omic Characterization of TKI-Treated Drug-Tolerant Cell Population in an EGFR-Mutated NSCLC Primary-Derived Xenograft</td>
<td>Erin Stewart, Canada</td>
<td></td>
</tr>
<tr>
<td>13:45 - 14:00</td>
<td><strong>MA27.04</strong> - Discussant - MA 27.01, MA 27.02, MA 27.03</td>
<td>Byoung Chul Cho, Republic of Korea</td>
<td></td>
</tr>
<tr>
<td>14:00 - 14:05</td>
<td><strong>MA27.05</strong> - Drug Loaded Mesenchymal Stem Cells for Targeted Lung Cancer Treatment in Mice</td>
<td>Yaojiong Wu, China</td>
<td></td>
</tr>
<tr>
<td>14:05 - 14:10</td>
<td><strong>MA27.06</strong> - Therapeutic Silencing of Oncogenic KRAS With a Mutant-Specific Short Interfering RNA</td>
<td>Chad Pecot, USA</td>
<td></td>
</tr>
<tr>
<td>14:10 - 14:15</td>
<td><strong>MA27.07</strong> - Lung Adenocarcinoma Harboring BRAF G469V Mutation is Uniquely Sensitive to EGFR Tyrosine Kinase Inhibitors</td>
<td>Hirotugu Notsuda, ON/Canada</td>
<td></td>
</tr>
<tr>
<td>14:15 - 14:30</td>
<td><strong>MA27.08</strong> - Discussant - MA 27.05, MA 27.06, MA 27.07</td>
<td>Gwyn Bebb, Canada</td>
<td></td>
</tr>
<tr>
<td>14:30 - 14:35</td>
<td><strong>MA27.09</strong> - Dual Inhibition of BCL-XL and MCL-1 is Required to Induce Tumour Regression in Lung Squamous Cell Carcinomas Sensitive to FGFR Inhibition</td>
<td>Marie-Liesse Asselin-Labat, OR/USA</td>
<td></td>
</tr>
<tr>
<td>14:35 - 14:40</td>
<td><strong>MA27.10</strong> - EGFR-Targeted Therapy Alters the Tumor Microenvironment In EGFR-Driven Lung Tumors: Rationale for Combination Therapies</td>
<td>Yijun Jia, China</td>
<td></td>
</tr>
<tr>
<td>14:40 - 14:45</td>
<td><strong>MA27.11</strong> - Genomic Sequencing and Editing Revealed the GRM8 Signaling Pathway as Potential Therapeutic Targets of Squamous Cell Lung Cancer</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### MS28

**IO Combinations in Advanced NSCLC**

*Room 106*

**Topics:** Immunooncology  
**Moderation:** C. Langer, USA; E. Santos, USA

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30 - 13:45</td>
<td><strong>MS28.01</strong> - Understanding the Rationale for Combining IO Agents</td>
<td>Edward Garon, CA/USA</td>
</tr>
<tr>
<td>13:45 - 14:00</td>
<td><strong>MS28.02</strong> - Combination IO+IO</td>
<td>Myung-Ju Ahn, Republic of Korea</td>
</tr>
<tr>
<td>14:00 - 14:15</td>
<td><strong>MS28.03</strong> - Combinatorial IO + Chemo</td>
<td>Rosalyn Juergens, Canada</td>
</tr>
<tr>
<td>14:15 - 14:30</td>
<td><strong>MS28.04</strong> - Combination with Targeted Therapies</td>
<td>Ross Soo, Singapore</td>
</tr>
<tr>
<td>14:30 - 14:45</td>
<td><strong>MS28.05</strong> - Combining IO with Radiation</td>
<td>Corinne Faivre-Finn, UK</td>
</tr>
<tr>
<td>14:45 - 15:00</td>
<td><strong>MS28.06</strong> - Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>

### MS29

**Selection into Screening Programs: Interplay of Risk Algorithms, Genetic Markers and Biomarkers**

*Room 206 F*

**Topics:** Screening and Early Detection  
**Moderation:** J. Goffin, Canada; B. Tong, USA

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30 - 13:45</td>
<td><strong>MS29.01</strong> - Assessment of Risk Prediction Algorithms for Entry into Screening Programs</td>
<td>Martin Tammemagi, Canada</td>
</tr>
</tbody>
</table>
13:45 - 14:00  MS29.02 - Defining Screening Frequency & Duration Using Risk Prediction Algorithms and CT Image Findings
Kevin Ten Haaf, Netherlands

14:00 - 14:15  MS29.03 - Polygenic Risk Score for Risk Assessment
Rayjean Hung, Canada

14:15 - 14:30  MS29.04 - LuCID Exhaled Breath Analysis
Marc Van Der Schee, UK

14:30 - 14:45  MS29.05 - Early Detection Biomarker Development: Is Success on the Horizon?
Peter Mazzone, USA

14:45 - 15:00  MS29.06 - Q&A

MS30

13:30 - 15:00  Modern Day RT in LA NSCLC: Where Is the Evidence?
Room 202 BD
Topics: Treatment of Locoregional Disease - NSCLC
Moderation: F. Hegi-Johnson, Australia; Y. Nakayama, Japan

13:30 - 13:45  MS30.01 - Overview of RT Technology in LA NSCLC (IMRT, VMAT, IGRT)
Gerard Hanna, UK

13:45 - 14:00  MS30.02 - What Evidence Is Available to Support RT Technology in LA NSCLC (including Protons)?
Yong Chan Ahn, Republic of Korea

14:00 - 14:15  MS30.03 - What Evidence Is Available to Support RT Treatment Intensification in LA NSCLC?
Jeffrey Bradley, MO/USA

14:15 - 14:30  MS30.04 - Perspective
Maria Werner-Wasik, USA

14:30 - 14:45  MS30.05 - Nutritional Management During Radical Radiotherapy
Rhys White, UK

14:45 - 15:00  MS30.06 - Q&A
### MS31

**Clinical Science in Mesothelioma**  
Topics: Mesothelioma  
Moderation: H. Yang, USA; M. De Perrot, Canada

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30</td>
<td><strong>MS31.01</strong> - Mechanisms and Targets for BAP1 Activity</td>
<td>Michele Carbone, HI/USA</td>
</tr>
<tr>
<td>13:45</td>
<td><strong>MS31.02</strong> - Clinical Implementation of BAP1 Inhibitors</td>
<td>Paul Baas, Netherlands</td>
</tr>
<tr>
<td>14:00</td>
<td><strong>MS31.03</strong> - Targeting the Hippo Pathway</td>
<td>David Jablons, USA</td>
</tr>
<tr>
<td>14:15</td>
<td><strong>MS31.04</strong> - CAR-T and ADC's in MPM</td>
<td>Prasad Adusumilli, NY/USA</td>
</tr>
<tr>
<td>14:30</td>
<td><strong>MS31.05</strong> - Vaccination and Antibody-Based Therapy in Mesothelioma</td>
<td>Joachim Aerts, Netherlands</td>
</tr>
<tr>
<td>14:45</td>
<td><strong>MS31.06</strong> - Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>

### MS32

**SCLC - From Benchside to Bedside - Clinical Science Session**  
Topics: Small Cell Lung Cancer/NET  
Moderation: A. Adjei, USA; J. Pantarotto, Canada

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30</td>
<td><strong>MS32.01</strong> - Genetic Mouse Models (GEMMS)</td>
<td>Trudy Oliver, USA</td>
</tr>
<tr>
<td>13:45</td>
<td><strong>MS32.02</strong> - Patient Derived Models (PDX &amp; CTC-Derived)</td>
<td>Anna Farago, MA/USA</td>
</tr>
<tr>
<td>14:00</td>
<td><strong>MS32.03</strong> - Liquid Biopsies for Drug Development in SCLC</td>
<td>Caroline Dive, UK</td>
</tr>
<tr>
<td>14:15</td>
<td><strong>MS32.04</strong> - Molecular Phenotypes of SCLC</td>
<td>Adi Gazdar, TX/USA</td>
</tr>
<tr>
<td>14:30</td>
<td><strong>MS32.05</strong> - Targeting DNA Damage and Repair</td>
<td></td>
</tr>
</tbody>
</table>
Lauren Byers, TX/USA

14:45 - 15:00  MS32.06 - Epigenetic Targets
John Poirier, NY/USA

PL04

15:15 - 16:30  Take Action - Key Messages from WCLC 2018 and Goals for 2019
Plenary Hall
Moderation: N. Leighl, Canada; R. Pirker, Austria

15:15 - 15:25  PL04.01 - Immunotherapy
David Gandara, CA/USA

15:25 - 15:35  PL04.02 - Biomarkers
Fred Hirsch, CO/USA

15:35 - 15:45  PL04.03 - Surgery
Ramon Rami-Porta, Spain

15:45 - 15:55  PL04.04 - Radiation Oncology
Jose Belderbos, Netherlands

15:55 - 16:05  PL04.05 - Clinical Research in Latin America
Clarissa Mathias, Brazil

16:05 - 16:15  PL04.06 - Targeted Therapy
Michael Boyer, ACT/Australia

16:15 - 16:25  PL04.07 - Discussion and Q&A

16:25 - 16:30  PL04.08 - Invitation to WCLC 2019 Barcelona, Spain